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Preface to “Fatty Acids and Cardiometabolic Health” 
When we initially planned the Special Issue “Fatty Acids and Cardiometabolic Health” for 
Nutrients, we strived for a multidisciplinary collection of manuscripts with a common focus of the 
link between fatty acids in the diet and in our bodies with disease development and health 
outcomes. Thus, we formulated our call for papers to attract a wide array of high-quality studies and 
stated the following. “The impact of fat intake on hypercholesterolemia and related atherosclerotic 
cardiovascular diseases has been studied for decades. However, the current evidence base 
suggests that fatty acids also influence cardiometabolic diseases through other mechanisms 
including effects on glucose metabolism, body fat distribution, blood pressure, inflammation, 
and heart rate. Furthermore, studies evaluating single fatty acids have challenged the 
simplistic view of shared health effects within fatty acid groups categorized by the degree of 
saturation. In addition, investigations of endogenous fatty acid metabolism, including genetic 
studies of fatty acid metabolizing enzymes, and the identification of novel metabolically derived 
fatty acids have further increased the complexity of fatty acids’ health impacts.” This approach 
proved successful and allowed us to include 13 highly significant works in the Special Issue. 
The studies included represent a wide range of research disciplines and consisted of both original 
research studies and comprehensive reviews. Sissener et al. reported the content of the 
potentially cardiotoxic erucic acid in fish and seafood products, while three other studies 
utilized rodent models to 1) investigate the effects of medium-chain triglycerides on 
cardiometabolic risk factors (Sung et al.), 2) study the effect of fish oil supplementation on 
renal function (Henao Agudelo et al.), and 3) evaluate the atherosclerotic effects of weight loss 
driven by conjugated linoleic acid supplementation (Kanter et al.).  Beulen et al. reported 
beneficial effects on body weight and obesity, from replacing saturated fatty acids, proteins, and 
carbohydrates with unsaturated fats in a secondary analysis of the PREDIMED trial. In three 
observational studies, the authors 1) evaluated associations of polyunsaturated fatty acid 
metabolites with cardiometabolic risk factors in overweight and obese children (Bonafini et al.); 
2) identified genetic variants associated genome-wide with fatty acid metabolizing enzyme activity
estimated in serum and adipose tissue, and subsequently evaluated associations of these genetic
variants with insulin sensitivity (Marklund et al.); and 3) assessed prospective associations of
erythrocyte n-6 polyunsaturated fatty acids with incident cardiovascular disease and all-cause
mortality in 2500 participants of the Framingham Heart Study (Harris et al.). These original
studies were accompanied by five review articles that provided extensive summaries of diverse
research topics. While Billingsley et al. extensively synthesized evidence related to unsaturated
fats in the diet and non-communicable diseases, other reviews focused more specifically on
certain fatty acids (i.e., long-chain n-3 polyunsaturated fatty acids (Bird et al.) or less 
commonly studied fatty acids (Li et al.)) or health outcomes (i.e., coronary artery disease among
individuals with chronic obstructive pulmonary disease (Pizzini et al.)). Another review (Lankinen
et al.) summarized how dietary and genetic factors influence and interact with the fatty acid
composition in plasma lipids and cell membranes. This book combines exciting findings
from novel original studies and comprehensive summaries of the current state of research
on fatty acids and cardiometabolic health. We are grateful for all of the excellent contributions to
the Special Issue and this book. Finally, we want to express our gratitude to the Nutrients editorial
team, for their enthusiasm, expertise, and invaluable support. 





The Role of n-3 Long Chain Polyunsaturated Fatty
Acids in Cardiovascular Disease Prevention,
and Interactions with Statins
Julia K. Bird 1,*, Philip C. Calder 2,3 and Manfred Eggersdorfer 1
1 DSM Nutritional Products, 4303 Kaiseraugst, Switzerland; manfred.eggersdorfer@dsm.com
2 Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton,
Southampton SO16 6YD, UK; pcc@soton.ac.uk
3 NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation
Trust and University of Southampton, Southampton SO16 6YD, UK
* Correspondence: julia.bird@dsm.com; Tel.: +31-15-279-3998
Received: 25 May 2018; Accepted: 13 June 2018; Published: 15 June 2018
	

Abstract: Decreases in global cardiovascular disease (CVD) mortality and morbidity in recent decades
can be partly attributed to cholesterol reduction through statin use. n-3 long chain polyunsaturated
fatty acids are recommended by some authorities for primary and secondary CVD prevention, and for
triglyceride reduction. The residual risk of CVD that remains after statin therapy may potentially be
reduced by n-3 long chain polyunsaturated fatty acids. However, the effects of concomitant use of
statins and n-3 long chain polyunsaturated fatty acids are not well understood. Pleiotropic effects
of statins and n-3 long chain polyunsaturated fatty acids overlap. For example, cytochrome P450
enzymes that metabolize statins may affect n-3 long chain polyunsaturated fatty acid metabolism
and vice versa. Clinical and mechanistic study results show both synergistic and antagonistic effects
of statins and n-3 long chain polyunsaturated fatty acids when used in combination.
Keywords: omega-3; cardiovascular disease; statins
1. Introduction
Cardiovascular diseases (CVDs) are the leading cause of global mortality, accounting for 32% of
the 56 million deaths in 2015 [1]. Despite declines in age-adjusted mortality rates of 22% over the last
few decades, mostly in high income countries [2], mortality rates are expected to rise again due to shifts
from infectious to chronic disease over the next decades [3]. CVDs contribute not only to mortality, but
cause a considerable disease burden in healthy life years lost [4]. Reductions in cardiovascular risk
factors such as smoking have contributed to half the drop in mortality, whereas the other half can be
attributed to medical therapies that include the use of medications such as statins, niacin and fibrates
in both primary and secondary prevention [5].
Statins are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors and are
currently considered standard of care in both primary and secondary prevention of CVD. Their
main mode of action is to lower circulating cholesterol, mainly low-density lipoprotein (LDL)
cholesterol, concentrations, thereby slowing or even reversing the development of atherosclerotic
plaques [6]. A recent meta-analysis found that statins used as primary prevention reduced all-cause
mortality by 14%, CVD by 25% and stroke events by 22% [7]. While lipid-lowering monotherapy has
reduced overall cardiovascular mortality risk, even patients with a successful, aggressive reduction
in LDL-cholesterol levels have a residual risk of myocardial infarction [8]. Risk factors other than
elevated LDL-cholesterol have a marked influence on CVD incidence and mortality.
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n-3 polyunsaturated fatty acids (PUFAs) have cardioprotective effects, particularly the two n-3
long chain (LC) PUFAs eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) [9]. A landmark
study comparing the diets and CVD rates of Greenland Inuit to the Danish population triggered
the initial interest in the role of marine-derived n-3 PUFAs in CVD [10], and this was supported by
epidemiological research associating fish consumption with a reduction in CVD mortality in other
populations [11,12]. Various mechanisms have been proposed to explain the modest reductions in
cardiovascular risk by n-3 LC PUFAs: these include preventing cardiac arrhythmias, lowering plasma
triglycerides, reducing blood pressure, decreasing platelet aggregation, and reducing inflammation.
Early randomized, controlled trials showed a reduction in risk of cardiovascular mortality after
increasing consumption of fatty fish or n-3 LC PUFA dietary supplements [13–15]. However, some more
recent intervention studies did not show significant effects of EPA and/or DHA supplementation [16].
One reason postulated for the lack of effect of n-3 LC PUFA supplements in the more recent
secondary prevention studies conducted is the frequent use of statin therapy in study patients [17].
The mechanisms of action of n-3 LC PUFAs overlap with the pleiotropic effects of statins, such
as improving endothelial function, and anti-thrombotic and antioxidant effects [18]. In addition,
statins may affect PUFA concentrations and the production of eicosanoids through interactions with
cytochrome P450 (CYP) enzymes. The use of statins may therefore interfere with the effects of n-3 LC
PUFAs. The aim of this review is to explore the interrelationship between statins and n-3 LC PUFAs in
the context of CVD.
2. Statins: Mode of Action
Statins decrease LDL-cholesterol levels and are classed as anti-dyslipidemic drugs. The mode
of action common to all statins is the competitive inhibition of the activity of HMG-CoA reductase
(HMGCR), the rate-limiting step in the endogenous production of cholesterol. The structure of statins
mimics that of the cholesterol precursor HMG-CoA. Statins compete for binding sites on the HMGCR
enzyme, slowing the rate of mevalonate production from HMG-CoA in the liver, which leads to a
reduction in overall cholesterol production and also of other products downstream of mevalonate [19].
Statins consist of a HMG-like moiety with chemical side groups that affect their pharmacokinetics,
lipophilicity, affinity to HMGCR, rate of entry into the liver and non-target cells, and associated
side effects.
Pleiotropic effects of statins include improving endothelial function, inhibiting vascular
inflammation, and the stabilization of atherosclerotic plaques [20]. Plaque stabilization and regression
through statins may be caused by activation of peroxisome proliferator-activated receptors (PPARs).
These effects may be related to the inhibition of isoprenoid synthesis by statins, which ultimately
inhibits various intracellular signaling molecules.
Seven statins are approved for use in the United States and Europe for primary prevention of
CVD in patients with hypercholesteremia or an elevated risk of CVD, and in secondary prevention in
pre-existing CVD. Table 1 provides an overview of these statins and their classification. Of the marketed
statins, fluvastatin, atorvastatin, rosuvastatin, and pitavastatin are synthetic molecules, while lovastatin,
pravastatin and simvastatin are derived from compounds found in nature. Statin types have differing
effects on LDL-cholesterol reduction and may be further classified as “weak” statins (pravastatin,
simvastatin) and “strong” statins (rosuvastatin, pitavastatin, atorvastatin), loosely based on their
ability to lower the concentration of LDL-cholesterol. Weak statins lower cholesterol by up to 25%,
with strong statins achieving a greater reduction [21]. The degree of hydrophilicity is a further point
of differentiation between statins as it affects their absorption, tissue selectivity, and metabolism by
CYP enzymes in the liver [22]. The choice of statin is generally guided by the desired reduction in
LDL-cholesterol concentration.
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Table 1. Statin classifications.
Statin Name Origin [23] Structure [23] Lipophilicity [23] Generation [23] CYP Metabolism [22,24,25]
Fluvastatin Synthetic Fluorophenyl group Lipophilic I CYP2C9
Atorvastatin Synthetic Fluorophenyl group Lipophilic II CYP3A4
Rosuvastatin Synthetic Fluorophenyl group Lipophobic III CYP2C9
Pitavastatin Synthetic Fluorophenyl group Lipophilic II Marginal [26]
Lovastatin Fungal Butyryl group Lipophilic I CYP3A4
Pravastatin Fungal Butyryl group Lipophobic I CYP2C9
Simvastatin Fungal Butyryl group Lipophilic II CYP3A4
Cytochrome P450 (CYP).
The effectiveness of statins for both cholesterol-lowering and prevention of cardiovascular
mortality was recently confirmed once again with a systematic review and meta-analysis [27]. There
was a dose-dependent reduction in CVD with LDL-cholesterol lowering. Across 27 trials, all-cause
mortality was reduced by 10% per 1.0 mmol/L (approximately 40 mg/dL) LDL-cholesterol lowering,
with LDL-cholesterol lowering largely reflecting a significant decrease in deaths due to coronary heart
disease [27].
Even so, a residual CVD risk remains after statins are used, particularly in high-risk patients
such as type II diabetics. Cardiovascular events occur even in patients that are adherent to intensive
statin therapy and who achieve a large reduction in LDL-cholesterol to below 100 mg/dL [28]. CVD is
multifactorial, and various risk factors that work through numerous mechanisms in the cardiovascular
system affect the severity of disease risk. Statins mainly affect circulating concentrations of
LDL-cholesterol, but other parameters of the lipid profile or markers of inflammation independently
affect CVD progression and outcomes, such as HDL-cholesterol, LDL-cholesterol particle distribution,
and elevated C-reactive protein and triglyceride concentrations [28,29]. The remaining risk of CVD
outcomes in statin-treated patients is related to the independent effects of these risk factors and residual
atherosclerosis. Combination therapy offers a means to treat other atherogenic components of the lipid
profile, and also other risk factors. Common combinations include treatment with a fibrate to
simultaneously lower triglyceride concentrations or with niacin to increase HDL-cholesterol [28].
3. Epidemiology of Statin Use
Since the introduction of lovastatin into clinical practice in 1987, statins have become one of
the most widely prescribed classes of drugs in the world. The extensive use of statins has lowered
LDL-cholesterol levels in the general population in high-income countries, and statins are considered
to be one of the direct causes of the global reduction in cardiovascular events and mortality that has
taken place in recent decades [30].
The largest markets for statins globally are the United States and Europe; however, the loss of
patent exclusivity of the major brands since 2001 has opened the market for developing countries.
In the United States, 93% of users of cholesterol-lowering prescription medication used a statin. 25%
of adults aged 45 years and over used a statin in the period 2005–2008, equivalent to around 30 million
adults [31], but usage varied widely depending on age and existence of CVD or diabetes [32]. Statin
use varies greatly within Europe, with usage in countries such as Sweden, Ireland and the Netherlands
four times greater than that in Austria or Italy [33]. The pattern of statin types prescribed also shows
considerable variation among countries in the European Union [33]. In the United Kingdom, statins
accounted for 94% of all prescriptions in the anti-dyslipidemic class in 2010: this corresponds to
55.1 million statin prescriptions dispensed in primary care. 72% of these prescriptions were for generic
simvastatin [31]. Even so, treatment rates are still considered sub-optimal, and there is a considerable
opportunity to reduce CVD through greater use in populations [30,32].
4. n-3 LC PUFAs: Mode of Action in CVD Prevention
The PUFAs linoleic acid (LA, n-6) and alpha-linolenic acid (ALA, n-3) are essential fatty acids: they
are unable to be synthesized de novo by humans and must therefore be provided by the diet [34]. Intakes
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of LA and ALA less than 0.5% of energy are associated with deficiency symptoms, which include
impaired barrier function and wound healing, failure to thrive, and can lead to poor neurological
and visual development in infants [34]. Most vegetable oils are a good source of LA, and ALA may
be obtained from selected vegetable oils including flaxseed, canola and soybean [34]. Dietary LA can
function as a precursor for arachidonic acid (ARA). Likewise, ALA is a precursor for EPA and DHA,
although conversion is rather poor in humans. Pre-formed EPA and DHA from fatty fish remains
a more important dietary source of n-3 LC-PUFAs [35,36]. The n-3 LC PUFA DHA is regarded as
conditionally essential for neonates for normal visual and cognitive development [34]. For adults,
intakes of 250–2000 mg per day of EPA + DHA contribute to coronary heart disease prevention,
and possibly to prevention of other chronic, degenerative diseases [34].
n-3 LC PUFAs are incorporated into triglycerides, phospholipids, and cholesteryl esters in plasma
after absorption. There is a high correlation between EPA + DHA in erythrocytes, whole blood
and plasma [37]. DHA is the most abundant n-3 fatty acid in cell membranes, being present in
all organs, particularly in the cerebral cortex, the retina and in sperm [38]. EPA is also present in
cells and tissues, albeit at considerably lower concentrations than DHA [36]. Both human plasma
and tissues respond dose-dependently to supplementation with ALA, EPA and DHA [36]. Steady-state
concentrations are reached after 1 month in plasma, and after 4–6 months in red blood cells; higher
doses also lead to a faster response [36]. Interconversion from ALA to EPA and DHA is achieved
in the liver via the sequential addition of 2-carbon units to the fatty acid backbone using elongation
and desaturation enzymes until the chain length reaches 24 carbon units (Figure 1). The final step of
conversion to DHA requires peroxisomal beta-oxidation. This last step is highly inefficient, particularly
for men, with less than 1% of ALA intake ultimately converted to DHA [36]. Increasing doses of
ALA will increase ALA and EPA concentrations in plasma but result in no discernable change in
DHA concentrations [36]. The same enzyme system is also used for the elongation of n-6 PUFAs,
therefore high background n-6 PUFA intakes reduce interconversion of n-3 PUFAs through competition
(see Figure 1). Retroconversion of DHA to shorter chain n-3 PUFAs also occurs, albeit at a low rate of
approximately 1.4% of a single dose [39]. Higher rates of retroconversion above 10% are suggested in
individuals with high chronic intakes of DHA [40,41].
Figure 1. Pathway of metabolic interconversion of omega-6 and omega-3 polyunsaturated fatty acids.
Abbreviation used: Δ, delta.
The ratio of EPA + DHA to total fatty acids is considered to be important as supplementation with
EPA + DHA displaces ARA from plasma and tissues [36]. The saturation of the fatty acids and their
4
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chain length in the phospholipid bilayer of cell membranes affect its permeability, and physical state
which in turn influences receptor function and the efficiency of signaling pathways [37]. The chain
length of incorporated PUFAs affects membrane order; transmembrane protein activity is conferred by
longer molecules with a greater number of double bonds. Of importance to CVD prevention, n-3 LC
PUFAs reduce blood triglycerides, modulate the excitability of myocytes to reduce arrhythmias after
damage to the heart, slow the progression of atherosclerosis, are mildly hypotensive, anti-inflammatory
and promote endothelial relaxation, are anti-thrombotic, and are associated with a modest reduction
in risk of cardiac death [17,34,42,43].
The effect of both EPA and DHA on lowering blood triglyceride concentrations is well established
and is the basis for the use of ethyl esters of both molecules as a prescription medication for patients
with hypertriglyceridemia [44]. The mechanisms of action are not completely understood; however, it is
thought that a combination of reduced triglyceride synthesis and increased oxidation of triglycerides
induced by n-3 LC PUFAs act to lower circulating triglyceride concentrations. n-3 LC PUFAs inhibit
the hepatic synthesis and secretion of VLDL-triglycerides, mediated by decreases in transcription factors
controlling the expression of enzymes involved in the assembly of triglycerides. Some studies link
the down-regulation of sterol regulatory element-binding proteins (SREBPs), transcription factors required
for the biosynthesis of both cholesterol and fatty acids, with reduced triglyceride synthesis in animal
models seen following fish oil feeding. An increase in acyl-coenzyme A oxidase gene expression induced
by PPAR-α may increase rates of peroxisomal β-oxidation of fatty acids. While both EPA and DHA lower
triglycerides, head-to-head studies find that supplementation with DHA alone can raise LDL-cholesterol
to a small extent but EPA does not [45]. The atherogenic potential of this increase in LDL-cholesterol
may be mitigated by a shift in LDL particle size towards larger, more buoyant LDL particles after DHA
supplementation [46,47]. On the other hand, DHA supplementation was associated with a modest
increase in HDL-cholesterol, while increases due to EPA were comparatively minor [45].
The reduction in mortality found in some supplementation studies with n-3 LC PUFAs is
attributed primarily to reductions in sudden cardiac deaths from decreased arrhythmogenesis [9,17,42].
Specifically, n-3 LC PUFAs are incorporated into the phospholipids of myocyte plasma membranes,
where they have the ability to modulate cellular ion currents. EPA reduced myocyte excitability by
increasing the time taken to return sodium channels in the membrane to their active state; however,
this only occurs in cells that have become hyper-excitable due to damage such as ischemia [43].
Small to medium-sized intervention studies with n-3 LC PUFAs in secondary prevention support this
mechanism by showing a reduction in both atrial fibrillation and ventricular arrhythmias in patients
with frequent premature ventricular complexes or after coronary artery bypass surgery [42]. This may
explain why a reduced risk of coronary heart disease with EPA + DHA from food or supplements was
found in a recent meta-analysis, particularly in people with a higher risk of CVD [48]. n-3 LC PUFAs
may therefore be most effective in reducing sudden cardiac death when cardiac tissue has already
been injured.
A reduction in the risk of stroke is a clinically relevant outcome of the anti-thrombogenic
and hypotensive effects of n-3 LC PUFAs [49,50], although results from some intervention studies
have been indeterminate or only applicable to certain sub-groups [51–53]. Anti-thrombotic effects
are thought to be primarily caused by the exchange of ARA with EPA in membrane phospholipids
of blood platelets, causing favorable reductions in thrombogenicity due to enhanced production of
non-aggregatory eicosanoids from EPA. The promotion of endothelial relaxation through stimulating
nitric oxide synthesis in the endothelium has been demonstrated [54], but other effects on vascular
reactivity independent of the endothelium are considered to be important contributors to the reduction
in blood pressure found in intervention trials with n-3 LC PUFAs [55]. The slowing of atherosclerosis
progression is related to the modulation of the expression and transcription of genes involved in
the inflammatory response. Both EPA and DHA affect the nuclear factor-κB signal transduction
pathway to reduce inflammation: EPA decreases the expression of tumor necrosis factor-α by impeding
phosphorylation of nuclear factor-κB, while DHA reduces the ability of nuclear factor-κB to bind to
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DNA in an ischemia–reperfusion model [54]. It is likely that synergy between anti-inflammatory
mechanisms, triglyceride lowering, improving membrane order, anti-thrombotic and anti-arrhythmic
effects contributes to the overall reduction in CVD risk from n-3 LC PUFAs.
5. Use of n-3 LC PUFAs as Dietary Supplements in the General Population
Dietary supplements containing n-3 LC PUFAs are used widely in North America, Europe,
and the Asia-Pacific region. The main sources of these products include fatty fish, krill,
and fermentation-derived microalgal oils. Demand for n-3 LC PUFAs for human nutrition is projected
to grow 4.1% annually on a volume basis over the coming decade [56]. An international survey of n-3
LC PUFA supplement users in ten countries (U.S., U.K., Germany, Italy, China, South Korea, Russia,
Australia, Brazil, Mexico) found that usage varied from 14% of the adult population in Germany
to 38% in Australia [57]. A high proportion of n-3 LC PUFA supplement use has also been found
by other researchers [58]. In most countries, users started taking supplements due to advice from a
physician. The main reasons given for taking supplements are for overall or cardiovascular health [57].
n-3 LC PUFA supplements are taken by 10% of the U.S. adult population aged 20 years or more, most
commonly for heart health [59].
6. Interactions between LC PUFAs and Statins, and Effects on Dyslipidemia, CVD and Mortality
In addition to distinct effects on dyslipidemia, the pleiotropic effects of statins overlap with those
of n-3 LC PUFAs. Similar mechanisms include enhancing endothelial nitric oxide synthesis, inhibiting
the production of pro-inflammatory cytokines, and the lowering of LDL-cholesterol via repression in
activity and mRNA expression of the HMG-CoA reductase enzyme [60,61]. Given these commonalities
in actions, statins and n-3 LC PUFAs may interact, either competing with or complementing each other.
Statins may also augment the metabolism of LC PUFAs and their metabolites [60]. These interactions
are summarized in Figure 2.
 
Figure 2. Overview of the interaction between statins and n-3 LC PUFAs on cardiovascular risk factor.
6.1. Effects of Dietary Fatty Acids and Statin Co-Administration on Dyslipidemia
There is a well-established link between dietary fat type and the blood lipid profile. Dietary
manipulation of fatty acid unsaturation affects both total circulating cholesterol concentration
and various cholesterol fractions. For example, replacement of saturated fats in the diet
with polyunsaturated and monounsaturated fats lowers total cholesterol and LDL-cholesterol
concentrations [25,34]. The LDL-cholesterol lowering effect is thought to be due to the increased
expression of LDL-cholesterol receptors in response to a higher concentration of unsaturated
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fatty acids. In contrast, saturated fatty acids maintain a lower expression of LDL-cholesterol
receptors and thus LDL-cholesterol concentrations remain high [25], with the notable exception
of LDL-cholesterol-lowering stearic acid [62].
Cholesterol levels may also be affected by EFA status through the modulation of HMG CoA
reductase activity. In animal models, EFA deficiency increased the activity of HMG CoA reductase,
possibly to help maintain barrier function and integrity when the supply of EFA is low [63]. Reversing
deficiency normalized HMG CoA reductase activity [63]. Likewise, feeding studies in rodents show
reduced HMG CoA reductase activity or expression after n-3 LC PUFA administration [64–67].
Dietary fatty acids can influence statin pharmacokinetics. When combined with simvastatin
treatment, patients consuming a diet using olive oil as the primary culinary fat had a more favorable
change in calculated risk of CVD, based on serum lipid and lipoprotein concentrations, than patients
using sunflower oil. The higher concentrations of linoleic acid in sunflower oil compared to olive oil
was postulated to cause a comparatively greater activation of cytochrome P450 enzymes, leading to a
reduction in statin half-life, affecting its ability to lower cholesterol [25].
In clinical studies investigating the effect of various statins with n-3 LC PUFAs on cardiovascular
risk factors, predominantly performed in patients with elevated cholesterol and triglycerides,
combined treatment resulted in decreases in triglycerides, total cholesterol, and thrombotic potential
compared to statin-only [25]. In general, concomitant therapy with statin medication and n-3 LC
PUFAs is considered to be complementary, and alongside a reduction in both elevated triglycerides
and LDL-cholesterol, there is a trend to lower LDL-cholesterol particle size and a more favorable
lipoprotein distribution [68].
6.2. Effects of Statins on n-3 LC PUFA Concentrations
Statins and EFAs interact to modulate fatty acid synthesis and metabolism. In particular,
statins have the ability to alter n-3 LC PUFA concentrations [69]. Statins have differential effects
on the activities of the Δ6- and Δ5-desaturase enzymes, and studies indicate increases in activity
(simvastatin, rosuvastatin and pitavastatin [70,71]) or decreases (atorvastatin [72]), and PPARs can be
activated [20]. This can lead to changes in the relative proportions of longer chain PUFAs.
In vitro studies show that statins increase concentrations of ARA and other LC PUFAs, possibly
because elongation activity is enhanced [73,74]. A dietary intervention study conducted in 120
hypercholesterolemic men found marked changes in the fatty acid profile after treatment with
simvastatin, notably ARA, which suggested that there were changes in the activity of enzymes
involved in the elongation and desaturation of fatty acids [71]. Another clinical trial in 57 men with
coronary heart disease found that simvastatin treatment increased circulating concentrations of ARA,
with no effect on n-3 LC PUFAs or saturated fatty acids [75].
A rat model was used to determine the effect of atorvastatin on n-3 PUFAs in plasma, blood,
and erythrocyte membranes [72]. While n-3 LC PUFA concentrations remained the same or increased
in plasma and erythrocyte membranes, there were significant reductions in liver n-3 LC PUFA
concentrations as a result of atorvastatin treatment. These changes in n-3 LC PUFAs in the liver
coincided with decreases in the mRNA expression of fatty acid desaturase (FADS) 1 and 2 genes, which
encode Δ5-desaturase and Δ6-desaturase, respectively, and of ELOVL5 gene, which encodes a key fatty
acid elongation enzyme [76].
A study of 1723 Japanese cardiology patients showed that use of any statin increased
circulating ARA and reduced circulating concentrations of DHA relative to ARA, without affecting
EPA [77]. Differential effects were seen with simvastatin compared to rosuvastatin or pitavastatin.
In 106 hypercholesterolemic adults and in in vitro experiments, simvastatin appeared to enhance
the conversion of linoleic acid and EPA to ARA and DHA, respectively [69,78]. On the other hand,
rosuvastatin or pitavastatin decreased serum DHA levels without affecting ARA or EPA, and thereby
increased the ARA/DHA ratio in 46 dyslipidemic patients [70]. A further study in 46 coronary artery
disease (CAD) patients found that atorvastatin, rosuvastatin or pitavastatin reduced EPA and DHA
7
Nutrients 2018, 10, 775
concentrations in serum, in proportion to reductions in LDL-cholesterol, while concentrations of
ARA were unchanged [79]. There was a correlation between reduction in serum EPA + DHA
and LDL-lowering, producing counteractive effects on risk factors for atherosclerosis. This has led
some researchers to conclude that “weak” statins (simvastatin, pravastatin) increase the ARA/EPA
ratio, while “strong” statins (atorvastatin, rosuvastatin or pitavastatin) increase the ARA/DHA
ratio. Hydrophilic statins may require a higher dose to affect linoleic acid conversion than lipophilic
statins [74]. In any case, statin use in general appears to favor n-6 over n-3 LC PUFA content [77],
which may result in a net increase in inflammation and thrombogenesis [80].
6.3. Interactions between Statins and n-3 LC PUFAs on Mitochondrial Function
There may be a counteracting effect of statins and n-3 LC PUFAs on mitochondrial function [80].
Myocardial mitochondria provide energy for ischemic pre-conditioning in cardiomyocytes prior to
myocardial infarction, which may reduce the size of the infarction, reduce post-ischemic arrhythmias
and result in better patient survival. Dietary n-3 LC PUFAs are able to induce a chronic state of cardiac
preconditioning, associated with increases in n-3 LC PUFA accumulation in plasma as well as cardiac
mitochondria [80]. On the other hand, a known side-effect of statin usage is muscle pain and weakness,
linked to disrupted mitochondria in muscles [22]. Endogenous production of ubiquinone, used
primarily to generate energy in mitochondria, is decreased by statin administration, as its biosynthesis
requires the HMG-CoA reductase enzyme [81]. Therefore, in the presence of statins, n-3 LC PUFAs
may not be able to precondition cardiomyocytes due to a reduction in mitochondrial function arising
from intrinsic ubiquinone deficiency.
6.4. Inhibition of CYP Enzymes by Statins and Effects on Eicosanoid Production
An important biological function of LC PUFAs is the production of eicosanoids, lipid mediators
with cardioprotective, vasodilatory, inflammatory and allergic properties [82]. ARA is considered
the traditional precursor of eicosanoids; however the CYP enzymes responsible for metabolizing
ARA have broad substrate specificities and accept most n-3 and n-6 LC PUFAs [82]. Increasing
the availability of EPA and DHA to the CYP enzymes shifts eicosanoid production to EPA-
and DHA-derived metabolites, possibly having a favorable effect on CVD risk [83]. However, statins
can inhibit or induce the activity of particular CYP enzymes [22,24,84], and thus the production of
CYP-derived eicosanoids. For example, fluvastatin is both a substrate for, and potent inhibitor of,
CYP2C9 [84]. CYP2C9 is found in human cardiovascular tissue [85], where it catalyzes the conversion
of ARA, EPA and DHA to epoxyeicosatrienoic acids (EETs), epoxyeicosatetraenoic acids (EpETE)
and epoxydocosapentaenoic acids (EpDPE), respectively [86]. EpETE and EpDPE show in vitro
anti-inflammatory and cardioprotective properties [82]. Use of fluvastatin may reduce the overall
production of PUFA-derived eicosanoids, with differential effects on CVD risk depending on
the ultimate shift in PUFA-derived eicosanoids that occurs. When underlying n-3 LC PUFA
concentrations are high, statins may lower the effectiveness of EPA or DHA in reducing CVD risk by
inhibiting the production of EpETEs and EpDPE. On the other hand, when n-6 LC PUFA concentrations
are high, a reduction in the production of ARA-derived inflammatory metabolites through CYP2C9
inhibition by certain statins may be beneficial. As a complicating factor, different statins affect different
CYP enzymes, and some have no effect. In populations using a range of different statins, disparate
effects on eicosanoid production may increase variability in the effect of PUFA on cardiovascular risk.
Clearly, further work is needed in this area.
6.5. Effects of Statins and n-3 LC PUFAs on Clinical and Mechanistic Endpoints
The effect of n-3 LC PUFAs and statins on various clinically relevant endpoints has been addressed
in several observational and interventional studies. Clinical study results are summarized in Table 2.
Three large studies contrasted the effects of n-3 LC PUFAs in statin users compared to non-users.
The Southern Cohort Community study is a prospective cohort investigation into risk factors for chronic
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disease in the Southwestern USA [87]. Among 69,559 participants, there was a statistically significant
reduction in all-cause mortality across quintiles of increasing n-3 fatty acid intakes in non-statin users
only; there was no effect in statin users. The Alpha Omega clinical trial in the Netherlands tested
the effect of margarines that provided 4153 participants with a randomly-selected dose of 400 mg EPA
+ DHA, 2 g ALA, a combination, or placebo on major cardiovascular events [88]. There was no effect
of the fatty acid type on risk of composite cardiovascular endpoints in statin users. In non-users, there
were non-significant decreases in cardiovascular events in all treatment groups compared to placebo,
and the reduction bordered on significance in the adjusted model for the combined EPA + DHA + ALA
group (p = 0.051). On the other hand, in a retrospective cohort study conducted in 11,269 survivors of
acute myocardial infarction from five Italian Local Health Units, a significant reduction in recurrent
myocardial infarction was only seen in users of concurrent n-3 LC PUFA supplements and statins [89].
Statin use did not affect all-cause mortality in this study, however; there was a significant reduction
in both statin users (HR 0.52 [0.40–0.68]) and statin non-users (HR 0.39 [0.20–0.75]) who were taking
the n-3 LC PUFA supplements.
Table 2. Clinical studies with a combination of n-3 LC PUFAs and statins.





Modest inverse associations between n-3 PUFA
and n-6 PUFA intake with mortality among
non-statin users but not among statin users.
[87]
(n = 14,704) Retrospective cohort study
As compared with statins alone, combined treatment
with statins and n-3 LC PUFAs was associated with
an adjusted higher survival rate, survival free of
atrial fibrillation and survival free of new heart





Treatment: 1800 mg EPA + statin
Control: statin alone
The incidence of MCE was significantly lower in
the EPA group.
Compared to patients with normal serum TG
and HDL-C levels, those with abnormal had
significantly higher CAD hazard ratio. In this higher





Post hoc analysis of RCT
Treatments:




In statin users, n-3 fatty acids did not reduce
cardiovascular events. In statin non-users, only 9%
of those who received EPA-DHA plus ALA







1,800 mg EPA + 4 mg pitavastatin
Control: Pitavastatin (Pitavastatin) 4 mg
The prevalence rate of plaque regression was
significantly higher in Pitavastatin/EPA group than





Prospective, open-label, randomized trial
Treatment:
1,800 mg EPA + 2 mg Pitavastatin
Control: 2 mg Pitavastatin
Significant reduction in composite endpoint of
cardiovascular death, MI, stroke, or coronary
revascularization at 1 year: 9.2% in the EPA group
and 20.2% in the control group (absolute risk
reduction, 11.0%; HR, 0.42; 95% CI, 0.21–087;
p = 0.02), in acute coronary syndrome patients.
[94]
(n = 11,269) Retrospective cohort study
n-3 LC PUFA supplement users had a reduced risk of
all-cause mortality (HR 0.76 [0.59 to 0.97]). Statin use
did not affect all-cause mortality reduction, however
a reduction in recurrent myocardial infarction was
only seen in statin users.
[89]
(n = 77,776) Meta-regression
Lower control group statin use and higher
DHA/EPA ratio was associated with higher




RCT in patients with stable statin therapy
Treatment: 1860 mg EPA + 1500 mg DHA
Control: Placebo
EPA + DHA in addition to low-dose statin treatment
prevented progression of atherosclerotic plaques,
compared to low-dose statin treatment alone.
[95]
Abbreviations: coronary artery disease (CAD), alpha-linolenic acid (ALA, n-3), randomized clinical trial (RCT),
major coronary event (MCE), triglycerides (TG), coronary artery disease (CAD), myocardial infarction (MI),
eicosapentaenoic acid (EPA), hazard ratio (HR), docosahexaenoic acid (DHA).
Further clinical studies have investigated the effect of combined treatment with n-3 LC PUFAs
and statins compared to treatment with statins alone on cardiovascular events. In a large retrospective
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cohort study conducted across Italy, combined treatment with a statin and n-3 LC PUFAs (non-specified)
after acute myocardial infarction was associated with improved survival in both crude and adjusted
estimates for major outcomes compared to treatment with only a statin [90]. The large randomized
controlled study JELIS, conducted in Japanese patients with hypercholesterolemia, tested the effect of
adding 1800 mg EPA daily to existing statin treatment (10 mg pravastatin or 5 mg simvastatin) [91].
Compared to statin treatment alone, patients randomized to additional EPA had a lower incidence of
major coronary events. In a recent open-label, randomized, controlled trial, acute coronary syndrome
patients who were randomized to EPA + statin (1800 mg EPA ethyl ester and 2 mg pitavastatin daily)
had approximately half the rate of a composite endpoint consisting of cardiovascular death, MI, stroke,
or coronary revascularization at 1 year, compared to patients randomized to the statin treatment
alone [94].
Several studies conducted in patients taking statins show that n-3 LC PUFA use in addition to
statins affects CVD mechanisms. In 20 adults with familial hypercholesterolemia on stable statin
therapy, an 8-week intervention with 4 g per day n-3 LC PUFAs (46% EPA and 38% DHA) resulted in
improved arterial elasticity, and reduced blood pressure, apolipoprotein B and triglycerides, compared
to statin therapy alone. In this risk group for premature CVD, n-3 LC PUFAs improved several
independent predictors of CVD in addition to the normalization of cholesterol from statins [96]. In a
small study that explored the mechanisms of cardiovascular risk factors in 200 patients treated with
pitavastatin both alone and combined with 1800 mg EPA, there was a significantly higher rate of
plaque regression in the combination group compared to pitavastatin alone [93]. In a similar recent
RCT of patients with stable coronary artery disease on statin therapy, adherent patients randomized to
3.4 g EPA + DHA per day had less progression of fibrous coronary plaques, compared to statin therapy
alone [95]. Both these studies show that atherosclerotic plaques regressed when a combination of n-3
LC PUFAs and statins were used.
Combination therapy of n-3 LC PUFAs and statins has shown some potential for patients who
show poor tolerability or a lack of response to statin treatment. For example, in patients with moderate
hypertriglyceridemia despite statin treatment, a combination of low dose rosuvastatin (10 mg) and n-3
LC PUFAs (2 g EPA + DHA) reduced total cholesterol and triglycerides compared to baseline [97].
While this reduction was not as great as for high dose rosuvastatin (40 mg), it showed clinical benefit
and may be an option for patients with poor tolerability for high dose rosuvastatin. Another small
clinical trial investigating the use of n-3 LC PUFAs and phytochemicals as complementary therapy to
reduce statin dose used a personalized approach. In the first phase of the study, patients responding
to treatment with 1.7 g n-3 LC PUFAs were identified and assigned to receive a halved statin dose in
the second phase of the study. Despite a marked reduction in dose, there were no significant changes
in the lipid profile in responders taking the combination therapy [98].
The research involving clinical and mechanistic endpoints is equivocal: some studies show
that the combination of n-3 LC PUFAs and statins is beneficial, while others show no difference
in outcomes, and yet others find that n-3 LC PUFAs only affect outcomes in statin non-users. Yet,
in the period in which statin use has transitioned to becoming a first-line medication for reducing
mortality derived from hypercholesterolemia, the results of supplementation studies with n-3 LC
PUFAs have changed from showing a significant reduction in all-cause mortality increasingly to a
null-effect [52], although a modest reduction in cardiac death or coronary heart disease risk has been
found in two recent meta-analyses [17,48]. The disparate results of meta-analyses arise at least partly
from variations in inclusion criteria, with Maki et al. reporting that their inclusion of smaller trials
contributed to the robustness of the meta-analysis results [17]. Differences in n-3 LC PUFA doses
used and the formulation or dosage form may be important: lower doses are less effective in raising
circulating fatty acid concentrations, and the bioavailability from a food matrix may be subject to
greater variability than from a dietary supplement. In addition, the distinct effects of DHA compared
to EPA cannot be elucidated due to a paucity of comparative studies [55]. Furthermore, the effect
size of n-3 LC PUFAs on mortality may have become smaller against a background of increasing
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statin use in the general population, leading to a higher likelihood of type I error. Overlapping or
even counteractive effects of combined treatment with statins and n-3 LC PUFAs may be confounding
outcomes of clinical trials.
7. Conclusions
Both statins and n-3 LC PUFAs are recommended for CVD prevention. While each treatment
has a distinct mode of action, pleiotropic effects of the two overlap. In addition, statins and n-3
LC PUFAs interact, potentially affecting net cardiovascular risk (Figure 2). Statins may cause a
mitochondrial ubiquinone deficiency, which blocks the ability of n-3 LC PUFAs to precondition
myocytes, reducing their effectiveness in reducing cardiac arrhythmias. Statins appear to increase
concentrations of LC PUFAs: when LA intakes are high, this could lead to a rise in concentrations
of pro-inflammatory eicosanoids from ARA. The main effect of statins is to block the activity of
HMG-CoA reductase; however n-3 LC PUFAs are also capable of HMG-CoA reductase inhibition,
albeit less effectively, resulting in a smaller effect size for the combination. Both competition for,
and activation of, CYP enzymes could be a further confounding factor in the metabolism of statins
and the production of eicosanoids from n-3 LC PUFAs, but this may depend on the type of statin used.
Post hoc analyses of clinical studies have yielded mixed results, with some results indicating that n-3
LC PUFA supplementation is only beneficial in statin non-users and others showing combined use of
n-3 LC PUFA and statins is beneficial. Prospective intervention studies that stratify for statin use are
warranted to explore the interaction further.
Author Contributions: Conceptualization, M.E.; Writing-Original Draft Preparation, J.K.B.; Writing-Review
and Editing, J.K.B. and P.C.C.
Funding: This research received no external funding.
Acknowledgments: We acknowledge the critical reviews of the manuscript by Norman Salem Jr, Karin
Yurko-Mauro and Mary van Elswyk.
Conflicts of Interest: J.K.B. and M.E. are employed by DSM Nutritional Products, a manufacturer of omega-3
fatty acids. P.C.C. is an adviser to DSM Nutritional Products.
References
1. GBD Mortality Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause
mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global
Burden of Disease Study 2015. Lancet 2016, 388, 1459–1544. [CrossRef]
2. Bowry, A.D.; Lewey, J.; Dugani, S.B.; Choudhry, N.K. The Burden of Cardiovascular Disease in Low-
and Middle-Income Countries: Epidemiology and Management. Can. J. Cardiol. 2015, 31, 1151–1159.
[CrossRef] [PubMed]
3. Institute of Medicine. Promoting Cardiovascular Health in the Developing World: A Critical Challenge to Achieve
Global Health; National Academies Press (US): Washington, DC, USA, 2010.
4. Vos, T.; Barber, R.M.; Bell, B.; Bertozzi-Villa, A.; Biryukov, S.; Bolliger, I.; Charlson, F.; Davis, A.;
Degenhardt, L.; Dicker, D.; et al. Global, regional, and national incidence, prevalence, and years lived
with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: A systematic
analysis for the Global Burden of Disease Study 2013. Lancet 2015, 386, 743–800. [CrossRef]
5. Ford, E.S.; Ajani, U.A.; Croft, J.B.; Critchley, J.A.; Labarthe, D.R.; Kottke, T.E.; Giles, W.H.; Capewell, S.
Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. N. Engl. J. Med. 2007, 356,
2388–2398. [CrossRef] [PubMed]
6. Koskinas, K.C.; Windecker, S.; Raber, L. Regression of coronary atherosclerosis: Current evidence and future
perspectives. Trends Cardiovasc. Med. 2016, 26, 150–161. [CrossRef] [PubMed]
7. Taylor, F.; Huffman, M.D.; Macedo, A.F.; Moore, T.H.; Burke, M.; Davey Smith, G.; Ward, K.; Ebrahim, S.
Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst. Rev. 2013, 1, CD004816.
[CrossRef] [PubMed]
11
Nutrients 2018, 10, 775
8. Superko, H.R.; King, S., 3rd. Lipid management to reduce cardiovascular risk: A new strategy is required.
Circulation 2008, 117, 560–568. [CrossRef] [PubMed]
9. Breslow, J.L. n-3 fatty acids and cardiovascular disease. Am. J. Clin. Nutr. 2006, 83, 1477S–1482S. [CrossRef]
[PubMed]
10. Bang, H.O.; Dyerberg, J.; Sinclair, H.M. The composition of the Eskimo food in north western Greenland.
Am. J. Clin. Nutr. 1980, 33, 2657–2661. [CrossRef] [PubMed]
11. Daviglus, M.L.; Stamler, J.; Orencia, A.J.; Dyer, A.R.; Liu, K.; Greenland, P.; Walsh, M.K.; Morris, D.;
Shekelle, R.B. Fish consumption and the 30-year risk of fatal myocardial infarction. N. Engl. J. Med. 1997,
336, 1046–1053. [CrossRef] [PubMed]
12. Kromhout, D.; Bosschieter, E.B.; de Lezenne Coulander, C. The inverse relation between fish consumption
and 20-year mortality from coronary heart disease. N. Engl. J. Med. 1985, 312, 1205–1209. [CrossRef]
[PubMed]
13. Burr, M.L.; Fehily, A.M.; Gilbert, J.F.; Rogers, S.; Holliday, R.M.; Sweetnam, P.M.; Elwood, P.C.;
Deadman, N.M. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction:
Diet and reinfarction trial (DART). Lancet 1989, 2, 757–761. [CrossRef]
14. Singh, R.B.; Niaz, M.A.; Sharma, J.P.; Kumar, R.; Rastogi, V.; Moshiri, M. Randomized, double-blind,
placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction:
the Indian experiment of infarct survival—4. Cardiovasc. Drugs Ther. 1997, 11, 485–491. [CrossRef] [PubMed]
15. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Dietary supplementation with
n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione
trial. Lancet 1999, 354, 447–455. [CrossRef]
16. Kromhout, D.; Yasuda, S.; Geleijnse, J.M.; Shimokawa, H. Fish oil and omega-3 fatty acids in cardiovascular
disease: do they really work? Eur. Heart J. 2012, 33, 436–443. [CrossRef] [PubMed]
17. Maki, K.C.; Palacios, O.M.; Bell, M.; Toth, P.P. Use of supplemental long-chain omega-3 fatty acids and risk
for cardiac death: An updated meta-analysis and review of research gaps. J. Clin. Lipidol. 2017, 11,
1152.e2–1160.e2. [CrossRef] [PubMed]
18. Sethi, A.; Bajaj, A.; Khosla, S.; Arora, R.R. Statin Use Mitigate the Benefit of Omega-3 Fatty Acids
Supplementation-A Meta-Regression of Randomized Trials. Am. J. Ther. 2016, 23, e737–e748. [CrossRef]
[PubMed]
19. Istvan, E. Statin inhibition of HMG-CoA reductase: A 3-dimensional view. Atheroscler. Suppl. 2003, 4, 3–8.
[CrossRef]
20. Zhou, Q.; Liao, J.K. Pleiotropic effects of statins—Basic research and clinical perspectives. Circ. J. 2010, 74,
818–826. [CrossRef] [PubMed]
21. Grundy, S.M. Primary prevention of cardiovascular disease with statins: Assessing the evidence base behind
clinical guidance. Clin. Pharm. 2016, 8, 57.
22. Neuvonen, P.J. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP
enzymes, transporters and pharmacogenetics. Curr. Opin. Investig. Drugs 2010, 11, 323–332. [PubMed]
23. Maji, D.; Shaikh, S.; Solanki, D.; Gaurav, K. Safety of statins. Indian J. Endocrinol. Metab. 2013, 17, 636–646.
[CrossRef] [PubMed]
24. Shitara, Y.; Sugiyama, Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in
transporter and metabolic enzyme functions. Pharmacol. Ther. 2006, 112, 71–105. [CrossRef] [PubMed]
25. Vaquero, M.P.; Sanchez Muniz, F.J.; Jimenez Redondo, S.; Prats Olivan, P.; Higueras, F.J.; Bastida, S. Major
diet-drug interactions affecting the kinetic characteristics and hypolipidaemic properties of statins. Nutr.
Hosp. 2010, 25, 193–206. [PubMed]
26. Corsini, A.; Ceska, R. Drug-drug interactions with statins: Will pitavastatin overcome the statins’ Achilles’
heel? Curr. Med. Res. Opin. 2011, 27, 1551–1562. [CrossRef] [PubMed]
27. Fulcher, J.; O’Connell, R.; Voysey, M.; Emberson, J.; Blackwell, L.; Mihaylova, B.; Simes, J.; Collins, R.;
Kirby, A.; Colhoun, H.; et al. Efficacy and safety of LDL-lowering therapy among men and women:
meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015, 385,
1397–1405. [CrossRef] [PubMed]
28. Cziraky, M.J.; Watson, K.E.; Talbert, R.L. Targeting low HDL-cholesterol to decrease residual cardiovascular
risk in the managed care setting. J. Manag. Care Pharm. 2008, 14, S3–S28; quiz S30–S21. [CrossRef] [PubMed]
12
Nutrients 2018, 10, 775
29. Nishikido, T.; Oyama, J.; Keida, T.; Ohira, H.; Node, K. High-dose statin therapy with rosuvastatin reduces
small dense LDL and MDA-LDL: The Standard versus high-dose therApy with Rosuvastatin for lipiD
lowering (SARD) trial. J. Cardiol. 2016, 67, 340–346. [CrossRef] [PubMed]
30. Mann, D.; Reynolds, K.; Smith, D.; Muntner, P. Trends in statin use and low-density lipoprotein
cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines.
Ann. Pharmacother. 2008, 42, 1208–1215. [CrossRef] [PubMed]
31. Falkingbridge, S. The Cardiovascular Market Outlook to 2017: Competitive Landscape, Global Market Analysis, Key
Trends, and Pipeline Analysis; Informa: London, UK, 2012; pp. 58–61.
32. Robinson, J.G.; Booth, B. Statin use and lipid levels in older adults: National Health and Nutrition
Examination Survey, 2001 to 2006. J. Clin. Lipidol. 2010, 4, 483–490. [CrossRef] [PubMed]
33. Walley, T.; Folino-Gallo, P.; Stephens, P.; Van Ganse, E. Trends in prescribing and utilization of statins
and other lipid lowering drugs across Europe 1997-2003. Br. J. Clin. Pharmacol. 2005, 60, 543–551. [CrossRef]
[PubMed]
34. Food and Agriculture Organization of the United Nations. Fats and Fatty Acids in Human Nutrition: Report
of an Expert Consultation; Food and Agriculture Organization of the United Nations: Rome, Italy, 2010;
Available online: http://www.fao.org/3/a-i1953e.pdf (accessed on 5 April 2016).
35. Stark, K.D.; Van Elswyk, M.E.; Higgins, M.R.; Weatherford, C.A.; Salem, N., Jr. Global survey of the omega-3
fatty acids, docosahexaenoic acid and eicosapentaenoic acid in the blood stream of healthy adults. Prog.
Lipid Res. 2016, 63, 132–152. [CrossRef] [PubMed]
36. Arterburn, L.M.; Hall, E.B.; Oken, H. Distribution, interconversion, and dose response of n-3 fatty acids in
humans. Am. J. Clin. Nutr. 2006, 83, 1467S–1476S. [CrossRef] [PubMed]
37. Stark, K.D.; Aristizabal Henao, J.J.; Metherel, A.H.; Pilote, L. Translating plasma and whole blood fatty
acid compositional data into the sum of eicosapentaenoic and docosahexaenoic acid in erythrocytes.
Prostaglandins Leukot. Essent. Fatty Acids 2016, 104, 1–10. [CrossRef] [PubMed]
38. Brenna, J.T.; Salem, N., Jr.; Sinclair, A.J.; Cunnane, S.C.; for the International Society for the Study of
Fatty Acids and Lipids; ISSFAL. alpha-Linolenic acid supplementation and conversion to n-3 long-chain
polyunsaturated fatty acids in humans. Prostaglandins Leukot. Essent. Fatty Acids 2009, 80, 85–91. [CrossRef]
[PubMed]
39. Brossard, N.; Croset, M.; Pachiaudi, C.; Riou, J.P.; Tayot, J.L.; Lagarde, M. Retroconversion and metabolism
of (13C)22:6n-3 in humans and rats after intake of a single dose of (13C)22:6n-3-triacylglycerols.
Am. J. Clin. Nutr. 1996, 64, 577–586. [CrossRef] [PubMed]
40. Conquer, J.A.; Holub, B.J. Supplementation with an algae source of docosahexaenoic acid increases (n-3)
fatty acid status and alters selected risk factors for heart disease in vegetarian subjects. J. Nutr. 1996, 126,
3032–3039. [CrossRef] [PubMed]
41. Conquer, J.A.; Holub, B.J. Dietary docosahexaenoic acid as a source of eicosapentaenoic acid in vegetarians
and omnivores. Lipids 1997, 32, 341–345. [CrossRef] [PubMed]
42. Calo, L.; Martino, A.; Tota, C. The anti-arrhythmic effects of n-3 PUFAs. Int. J. Cardiol. 2013, 170, S21–S27.
[CrossRef] [PubMed]
43. Leaf, A.; Kang, J.X.; Xiao, Y.F.; Billman, G.E. Clinical prevention of sudden cardiac death by n-3
polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation
2003, 107, 2646–2652. [CrossRef] [PubMed]
44. Weintraub, H. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3
treatment options. Atherosclerosis 2013, 230, 381–389. [CrossRef] [PubMed]
45. Jacobson, T.A.; Glickstein, S.B.; Rowe, J.D.; Soni, P.N. Effects of eicosapentaenoic acid and docosahexaenoic
acid on low-density lipoprotein cholesterol and other lipids: A review. J. Clin. Lipidol. 2012, 6, 5–18.
[CrossRef] [PubMed]
46. Davidson, M.H. Omega-3 fatty acids: New insights into the pharmacology and biology of docosahexaenoic
acid, docosapentaenoic acid, and eicosapentaenoic acid. Curr. Opin. Lipidol. 2013, 24, 467–474. [CrossRef]
[PubMed]
47. Ryan, A.S.; Keske, M.A.; Hoffman, J.P.; Nelson, E.B. Clinical overview of algal-docosahexaenoic acid: effects
on triglyceride levels and other cardiovascular risk factors. Am. J. Ther. 2009, 16, 183–192. [CrossRef]
[PubMed]
13
Nutrients 2018, 10, 775
48. Alexander, D.D.; Miller, P.E.; Van Elswyk, M.E.; Kuratko, C.N.; Bylsma, L.C. A Meta-Analysis of Randomized
Controlled Trials and Prospective Cohort Studies of Eicosapentaenoic and Docosahexaenoic Long-Chain
Omega-3 Fatty Acids and Coronary Heart Disease Risk. Mayo Clin. Proc. 2017, 92, 15–29. [CrossRef]
[PubMed]
49. Saber, H.; Yakoob, M.Y.; Shi, P.; Longstreth, W.T., Jr.; Lemaitre, R.N.; Siscovick, D.; Rexrode, K.M.;
Willett, W.C.; Mozaffarian, D. Omega-3 Fatty Acids and Incident Ischemic Stroke and Its Atherothrombotic
and Cardioembolic Subtypes in 3 US Cohorts. Stroke 2017, 48, 2678–2685. [CrossRef] [PubMed]
50. Woodman, R.J.; Mori, T.A.; Burke, V.; Puddey, I.B.; Barden, A.; Watts, G.F.; Beilin, L.J. Effects of
purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in
hypertensive type 2 diabetic patients. Atherosclerosis 2003, 166, 85–93. [CrossRef]
51. Casula, M.; Soranna, D.; Catapano, A.L.; Corrao, G. Long-term effect of high dose omega-3 fatty acid
supplementation for secondary prevention of cardiovascular outcomes: A meta-analysis of randomized,
placebo controlled trials (corrected). Atheroscler. Suppl. 2013, 14, 243–251. [CrossRef]
52. Rizos, E.C.; Ntzani, E.E.; Bika, E.; Kostapanos, M.S.; Elisaf, M.S. Association between omega-3 fatty acid
supplementation and risk of major cardiovascular disease events: A systematic review and meta-analysis.
JAMA 2012, 308, 1024–1033. [CrossRef] [PubMed]
53. Cheng, P.; Huang, W.; Bai, S.; Wu, Y.; Yu, J.; Zhu, X.; Qi, Z.; Shao, W.; Xie, P. BMI Affects the Relationship
between Long Chain n-3 Polyunsaturated Fatty Acid Intake and Stroke Risk: A Meta-Analysis. Sci. Rep.
2015, 5, 14161. [CrossRef] [PubMed]
54. Mollace, V.; Gliozzi, M.; Carresi, C.; Musolino, V.; Oppedisano, F. Re-assessing the mechanism of action of
n-3 PUFAs. Int. J. Cardiol. 2013, 170, S8–S11. [CrossRef] [PubMed]
55. Innes, J.K.; Calder, P.C. The Differential Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on
Cardiometabolic Risk Factors: A Systematic Review. Int. J. Mol. Sci. 2018, 19. [CrossRef] [PubMed]
56. Frost and Sullivan. The State of the Global Omega-3 Ingredients Market in 2015. A Market at a Crossroad; Frost
and Sullivan: New York, NY, USA, 2015; pp. 4–33.
57. DSM Nutritional Products; TNS Canada Market Research. 2014 Omega-3 Usage & Attitude Study; DSM
Nutritional Products: Heerlen, The Netherland, 2015; pp. 5–35.
58. Burnett, A.J.; Livingstone, K.M.; Woods, J.L.; McNaughton, S.A. Dietary Supplement Use among Australian
Adults: Findings from the 2011–2012 National Nutrition and Physical Activity Survey. Nutrients 2017, 9,
1248. [CrossRef] [PubMed]
59. Bailey, R.L.; Gahche, J.J.; Miller, P.E.; Thomas, P.R.; Dwyer, J.T. Why US adults use dietary supplements.
JAMA Intern. Med. 2013, 173, 355–361. [CrossRef] [PubMed]
60. Das, U.N. Essential fatty acids as possible mediators of the actions of statins.
Prostaglandins Leukot. Essent. Fatty Acids 2001, 65, 37–40. [CrossRef] [PubMed]
61. Mori, T.A.; Woodman, R.J. The independent effects of eicosapentaenoic acid and docosahexaenoic acid
on cardiovascular risk factors in humans. Curr. Opin. Clin. Nutr. Metab. Care 2006, 9, 95–104. [CrossRef]
[PubMed]
62. Hunter, J.E.; Zhang, J.; Kris-Etherton, P.M. Cardiovascular disease risk of dietary stearic acid compared with
trans, other saturated, and unsaturated fatty acids: a systematic review. Am. J. Clin. Nutr. 2010, 91, 46–63.
[CrossRef] [PubMed]
63. Proksch, E.; Feingold, K.R.; Elias, P.M. Epidermal HMG CoA reductase activity in essential fatty
acid deficiency: barrier requirements rather than eicosanoid generation regulate cholesterol synthesis.
J. Investig. Dermatol. 1992, 99, 216–220. [CrossRef] [PubMed]
64. Notarnicola, M.; Messa, C.; Refolo, M.G.; Tutino, V.; Miccolis, A.; Caruso, M.G. Polyunsaturated fatty
acids reduce fatty acid synthase and hydroxy-methyl-glutaryl CoA-reductase gene expression and promote
apoptosis in HepG2 cell line. Lipids Health Dis. 2011, 10, 10. [CrossRef] [PubMed]
65. Oh, H.T.; Chung, M.J.; Kim, S.H.; Choi, H.J.; Ham, S.S. Masou salmon (Oncorhynchus masou) ethanol
extract decreases 3-hydroxy-3-methylglutaryl coenzyme A reductase expression in diet-induced obese mice.
Nutr. Res. 2009, 29, 123–129. [CrossRef] [PubMed]
66. Shirai, N.; Suzuki, H. Effect of docosahexaenoic acid on brain 3-hydroxy-3-methylglutaryl
-coenzyme A reductase activity in male ICR mice. J. Nutr. Biochem. 2007, 18, 488–494. [CrossRef] [PubMed]
14
Nutrients 2018, 10, 775
67. Ihara-Watanabe, M.; Umekawa, H.; Takahashi, T.; Furuichi, Y. Effects of dietary alpha- or gamma-linolenic
acid on levels and fatty acid compositions of serum and hepatic lipids, and activity and mRNA abundance
of 3-hydroxy-3-methylglutaryl CoA reductase in rats. Comp. Biochem. Physiol. Part A Mol. Integr. Physiol.
1999, 122, 213–220. [CrossRef]
68. Wang, H.; Blumberg, J.B.; Chen, C.Y.; Choi, S.W.; Corcoran, M.P.; Harris, S.S.; Jacques, P.F.; Kristo, A.S.;
Lai, C.Q.; Lamon-Fava, S.; et al. Dietary modulators of statin efficacy in cardiovascular disease and cognition.
Mol. Aspects Med. 2014, 38, 1–53. [CrossRef] [PubMed]
69. Harris, J.I.; Hibbeln, J.R.; Mackey, R.H.; Muldoon, M.F. Statin treatment alters serum n-3 and n-6 fatty acids
in hypercholesterolemic patients. Prostaglandins Leukot. Essent. Fatty Acids 2004, 71, 263–269. [CrossRef]
[PubMed]
70. Nozue, T.; Michishita, I. Statin treatment alters serum n-3 to n-6 polyunsaturated fatty acids ratio in patients
with dyslipidemia. Lipids Health Dis. 2015, 14, 67. [CrossRef] [PubMed]
71. Jula, A.; Marniemi, J.; Ronnemaa, T.; Virtanen, A.; Huupponen, R. Effects of diet and simvastatin on fatty
acid composition in hypercholesterolemic men: a randomized controlled trial. Arterioscler. Thromb. Vasc. Biol.
2005, 25, 1952–1959. [CrossRef] [PubMed]
72. Al Mamun, A.; Hashimoto, M.; Katakura, M.; Tanabe, Y.; Tsuchikura, S.; Hossain, S.; Shido, O.
Effect of dietary n-3 fatty acids supplementation on fatty acid metabolism in atorvastatin-administered
SHR.Cg-Leprcp/NDmcr rats, a metabolic syndrome model. Biomed. Pharmacother. 2017, 85, 372–379.
[CrossRef] [PubMed]
73. Risé, P.; Pazzucconi, F.; Sirtori, C.R.; Galli, C. Statins enhance arachidonic acid synthesis in
hypercholesterolemic patients. Nutr. Metab. Cardiovasc. Dis. 2001, 11, 88–94. [PubMed]
74. Risé, P.; Ghezzi, S.; Galli, C. Relative potencies of statins in reducing cholesterol synthesis and enhancing
linoleic acid metabolism. Eur. J. Pharmacol. 2003, 467, 73–75. [CrossRef]
75. De Lorgeril, M.; Salen, P.; Guiraud, A.; Zeghichi, S.; Boucher, F.; de Leiris, J. Lipid-lowering
drugs and essential omega-6 and omega-3 fatty acids in patients with coronary heart disease.
Nutr. Metab. Cardiovasc. Dis. 2005, 15, 36–41. [CrossRef] [PubMed]
76. Green, C.D.; Ozguden-Akkoc, C.G.; Wang, Y.; Jump, D.B.; Olson, L.K. Role of fatty acid elongases in
determination of de novo synthesized monounsaturated fatty acid species. J. Lipid Res. 2010, 51, 1871–1877.
[CrossRef] [PubMed]
77. Takahashi, M.; Ando, J.; Shimada, K.; Nishizaki, Y.; Tani, S.; Ogawa, T.; Yamamoto, M.; Nagao, K.;
Hirayama, A.; Yoshimura, M.; et al. The ratio of serum n-3 to n-6 polyunsaturated fatty acids is associated
with diabetes mellitus in patients with prior myocardial infarction: A multicenter cross-sectional study.
BMC Cardiovasc. Disord. 2017, 17, 41. [CrossRef] [PubMed]
78. Risé, P.; Colombo, C.; Galli, C. Effects of simvastatin on the metabolism of polyunsaturated fatty acids
and on glycerolipid, cholesterol, and de novo lipid synthesis in THP-1 cells. J. Lipid Res. 1997, 38, 1299–1307.
[PubMed]
79. Kurisu, S.; Ishibashi, K.; Kato, Y.; Mitsuba, N.; Dohi, Y.; Nishioka, K.; Kihara, Y. Effects of lipid-lowering
therapy with strong statin on serum polyunsaturated fatty acid levels in patients with coronary artery
disease. Heart Vessels 2013, 28, 34–38. [CrossRef] [PubMed]
80. De Lorgeril, M.; Salen, P.; Defaye, P.; Rabaeus, M. Recent findings on the health effects of omega-3 fatty acids
and statins, and their interactions: Do statins inhibit omega-3? BMC Med. 2013, 11, 5. [CrossRef] [PubMed]
81. Banach, M.; Serban, C.; Ursoniu, S.; Rysz, J.; Muntner, P.; Toth, P.P.; Jones, S.R.; Rizzo, M.; Glasser, S.P.;
Watts, G.F.; et al. Statin therapy and plasma coenzyme Q10 concentrations—A systematic review
and meta-analysis of placebo-controlled trials. Pharmacol. Res. 2015, 99, 329–336. [CrossRef] [PubMed]
82. Schunck, W.H.; Konkel, A.; Fischer, R.; Weylandt, K.H. Therapeutic potential of omega-3 fatty acid-derived
epoxyeicosanoids in cardiovascular and inflammatory diseases. Pharmacol. Ther. 2018, 183, 177–204.
[CrossRef] [PubMed]
83. Fleming, I. The pharmacology of the cytochrome P450 epoxygenase/soluble epoxide hydrolase axis in
the vasculature and cardiovascular disease. Pharmacol. Rev. 2014, 66, 1106–1140. [CrossRef] [PubMed]
84. Cohen, L.H.; van Leeuwen, R.E.; van Thiel, G.C.; van Pelt, J.F.; Yap, S.H. Equally potent inhibitors of
cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450
enzymes. Biopharm. Drug Dispos. 2000, 21, 353–364. [CrossRef] [PubMed]
15
Nutrients 2018, 10, 775
85. Jamieson, K.L.; Endo, T.; Darwesh, A.M.; Samokhvalov, V.; Seubert, J.M. Cytochrome P450-derived
eicosanoids and heart function. Pharmacol. Ther. 2017, 179, 47–83. [CrossRef] [PubMed]
86. Spector, A.A.; Kim, H.Y. Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism.
Biochim. Biophys. Acta 2015, 1851, 356–365. [CrossRef] [PubMed]
87. Kiage, J.N.; Sampson, U.K.; Lipworth, L.; Fazio, S.; Mensah, G.A.; Yu, Q.; Munro, H.; Akwo, E.A.; Dai, Q.;
Blot, W.J.; et al. Intake of polyunsaturated fat in relation to mortality among statin users and non-users
in the Southern Community Cohort Study. Nutr. Metab. Cardiovasc. Dis. 2015, 25, 1016–1024. [CrossRef]
[PubMed]
88. Eussen, S.R.; Geleijnse, J.M.; Giltay, E.J.; Rompelberg, C.J.; Klungel, O.H.; Kromhout, D. Effects of n-3 fatty
acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction.
Eur. Heart J. 2012, 33, 1582–1588. [CrossRef] [PubMed]
89. Greene, S.J.; Temporelli, P.L.; Campia, U.; Vaduganathan, M.; Degli Esposti, L.; Buda, S.; Veronesi, C.;
Butler, J.; Nodari, S. Effects of Polyunsaturated Fatty Acid Treatment on Postdischarge Outcomes After Acute
Myocardial Infarction. Am. J. Cardiol. 2016, 117, 340–346. [CrossRef] [PubMed]
90. Macchia, A.; Romero, M.; D'Ettorre, A.; Tognoni, G.; Mariani, J. Exploratory analysis on the use of statins
with or without n-3 PUFA and major events in patients discharged for acute myocardial infarction: an
observational retrospective study. PLoS ONE 2013, 8, e62772. [CrossRef] [PubMed]
91. Matsuzaki, M.; Yokoyama, M.; Saito, Y.; Origasa, H.; Ishikawa, Y.; Oikawa, S.; Sasaki, J.; Hishida, H.;
Itakura, H.; Kita, T.; et al. Incremental effects of eicosapentaenoic acid on cardiovascular events in
statin-treated patients with coronary artery disease. Circ. J. 2009, 73, 1283–1290. [CrossRef] [PubMed]
92. Saito, Y.; Yokoyama, M.; Origasa, H.; Matsuzaki, M.; Matsuzawa, Y.; Ishikawa, Y.; Oikawa, S.; Sasaki, J.;
Hishida, H.; Itakura, H.; et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients
with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention
Study (JELIS). Atherosclerosis 2008, 200, 135–140. [CrossRef] [PubMed]
93. Watanabe, T.; Ando, K.; Daidoji, H.; Otaki, Y.; Sugawara, S.; Matsui, M.; Ikeno, E.; Hirono, O.; Miyawaki, H.;
Yashiro, Y.; et al. A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart
disease on statins. J. Cardiol. 2017, 70, 537–544. [CrossRef] [PubMed]
94. Nosaka, K.; Miyoshi, T.; Iwamoto, M.; Kajiya, M.; Okawa, K.; Tsukuda, S.; Yokohama, F.; Sogo, M.; Nishibe, T.;
Matsuo, N.; et al. Early initiation of eicosapentaenoic acid and statin treatment is associated with better
clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a
randomized controlled study. Int. J. Cardiol. 2017, 228, 173–179. [CrossRef] [PubMed]
95. Alfaddagh, A.; Elajami, T.K.; Ashfaque, H.; Saleh, M.; Bistrian, B.R.; Welty, F.K. Effect of Eicosapentaenoic
and Docosahexaenoic Acids Added to Statin Therapy on Coronary Artery Plaque in Patients With Coronary
Artery Disease: A Randomized Clinical Trial. J. Am. Heart Assoc. 2017, 6. [CrossRef] [PubMed]
96. Chan, D.C.; Pang, J.; Barrett, P.H.; Sullivan, D.R.; Mori, T.A.; Burnett, J.R.; van Bockxmeer, F.M.;
Watts, G.F. Effect of omega-3 fatty acid supplementation on arterial elasticity in patients with familial
hypercholesterolaemia on statin therapy. Nutr. Metab. Cardiovasc. Dis. 2016, 26, 1140–1145. [CrossRef]
[PubMed]
97. Ballantyne, C.M.; Braeckman, R.A.; Bays, H.E.; Kastelein, J.J.; Otvos, J.D.; Stirtan, W.G.; Doyle, R.T., Jr.;
Soni, P.N.; Juliano, R.A. Effects of icosapent ethyl on lipoprotein particle concentration and size in
statin-treated patients with persistent high triglycerides (the ANCHOR Study). J. Clin. Lipidol. 2015,
9, 377–383. [CrossRef] [PubMed]
98. Scolaro, B.; Nogueira, M.S.; Paiva, A.; Bertolami, A.; Barroso, L.P.; Vaisar, T.; Heffron, S.P.; Fisher, E.A.;
Castro, I.A. Statin dose reduction with complementary diet therapy: A pilot study of personalized medicine.
Mol. Metab. 2018, 11, 137–144. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Medium-Chain Triglycerides Lower Blood Lipids and
Body Weight in Streptozotocin-Induced Type 2
Diabetes Rats
Ming-Hua Sung 1, Fang-Hsuean Liao 1 and Yi-Wen Chien 1,2,3,*
1 School of Nutrition and Health Sciences, Taipei Medical University, Taipei 11031, Taiwan;
Glycine1016@hotmail.com (M.-H.S.); function0727@gmail.com (F.-H.L.)
2 Research Center of Geriatric Nutrition, College of Nutrition, Taipei Medical University, Taipei 11031, Taiwan
3 Graduate Institute of Metabolism and Obesity Sciences, Taipei Medical University, Taipei 11031, Taiwan
* Correspondence: ychien@tmu.edu.tw; Tel.: +886-227-361-661; Fax: +886-227-373-112
Received: 2 July 2018; Accepted: 24 July 2018; Published: 26 July 2018
	

Abstract: Medium-chain triglycerides (MCTs) are distinguished from other triglycerides in that
each fat molecule consists of 6 to 12 carbons in length. MCTs and long-chain triglycerides (LCTs)
are absorbed and utilized in different ways. The aim of this study was to assess the effects
of replacing soybean oil with MCT oil, in a low- or high-fat diet, on lipid metabolism in rats
with streptozotocin-induced type 2 diabetes mellitus (T2DM). There were, thirty-two T2DM
Sprague-Dawley rats divided into low-fat-soybean oil (LS), low-fat-MCT oil (LM), high-fat-soybean
oil (HS), and high-fat-MCT oil (HM) groups. After 8 weeks, blood sugar, serum lipids, liver lipids,
and enzyme activities related to lipid metabolism were measured. Under a high-fat diet condition,
replacement of soybean oil with MCT oil lowered serum low-density lipoprotein cholesterol (LDL-C),
non-esterified fatty acids, and liver total cholesterol; whilst it increased serum high-density lipoprotein
cholesterol (HDL-C) and the HDL-C/LDL-C ratio. A low-fat diet with MCT oil resulted in lower
body weight and reproductive white adipose tissues compared to the HS groups, and higher hepatic
acyl-CoA oxidase activities (the key enzyme in the peroxisomal beta-oxidation) compared to the
LS group in T2DM rats. In conclusion, MCTs showed more protective effects on cardiovascular
health in T2DM rats fed a high-fat diet, by improving serum lipid profiles and reducing hepatic
total cholesterol.
Keywords: type 2 diabetes mellitus; medium-chain triglyceride; long-chain triglyceride; lipid metabolism
1. Introduction
Type 2 diabetes mellitus (T2DM) is the predominant form of diabetes worldwide and is
accompanied with a heavy economic burden [1]. From a pathophysiological standpoint, persons with
T2DM consistently show three cardinal abnormalities: (1) resistance to the action of insulin in peripheral
tissues particularly muscles and fat; (2) defective insulin secretion, particularly in response to a glucose
stimulus; and (3) increased glucose production by the liver. The pathogenesis of T2DM is complex and
involves diet imbalances, life stresses, and obesity [2].
The prevalence rates of being overweight and obese in Taiwan, defined by the Taiwanese definition
(body-mass index = 24~26.99 and ≥27 kg/m2, respectively), were 22.9% and 10.5% for men and 20.3%
and 13.2% for women, respectively [3]. Obesity reduces life expectancy and increases the risks of
several non-communicable diseases (i.e., T2DM, hypertension, and dyslipidemia).
Medium-chain triglycerides (MCTs) are distinguished from other triglycerides in that each fat molecule
is between 6 and 12 carbons in length. Medium-chain fatty acids (MCFAs) are transported in the portal
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blood directly to the liver, unlike low-chain fatty acids (LCFAs), which are incorporated into chylomicrons
and transported through lymph [4]. Moreover, MCFAs do not require a carnitine shuttle system to penetrate
mitochondria [5]. In β-oxidation, MCFAs cause the greatest induction of medium-chain acyl coenzyme
A (CoA) dehydrogenase and increase the oxidation rate. Overall, the MCT transport pathway and
the oxidation rate, differ from those of long-chain triglycerides (LCTs) [6]. The weight gain of rats
fed an MCT-containing diet was 30% less than that of rats fed an LCT-containing diet [7]. MCTs have
a reductive effect on body fat stores [8]. Body weight was significantly reduced (17%) in weanling
rats fed high-MCT diets [9]. The decreased deposition of fat in MCT-overfed rats may result from
obligatory oxidation of MCT-derived fatty acids in the liver [10]. MCT may decrease fat accumulation
in adipocytes by increasing thermogenesis and satiety [11]. MCTs also improved plasma triglyceride
and total cholesterol concentrations in rats [12].
Previous research, has verified that MCT oil has acceptable effects on body weight, fat, and blood
lipids [7–10]. The aim of this study was to assess the effects of replacing soybean oil with MCT oil,
in a low- or high-fat diet, on lipid metabolism and enzyme activities in rats with T2DM. The study
had two hypotheses: (1) that MCTs improve cardiovascular health in T2DM, shown by loss of body
weight and fat; and (2) that MCTs reduce serum and liver lipids accompanied by regulation of liver
lipid metabolic enzyme activities.
2. Materials and Methods
MCT oil (lot no. 1959) was obtained from Kao Corporation (Tokyo, Japan). The fatty acid component
percentages of the MCT and soybean oils were analyzed via gas chromatography [13]. The medium-chain
fatty acid (MCFA) and long-chain fatty acid (LCFA) proportions of the MCT oil were 87.1% (containing
32.1 ± 0.5% caprylic acids, 37.9 ± 0.2% capric acids, and 17.2 ± 0.1% lauric acid) and 12.9%, respectively.
There were no MCFAs in the soybean oil.
2.1. Animals and Diets
Male Sprague-Dawley rats (n = 60; aged 5 weeks with a body weight (BW) of 126~150 g) were
obtained from Lasco (Taipei, Taiwan). Rats were housed individually in wire-bottomed stainless-steel
cages, in an air-conditioned room (21 ± 2 ◦C and 50~70% relative humidity) with a 12-h light: dark cycle
and free access to a basic diet and water for 1 week before diabetes was induced. Diabetes was induced
via a high-fat diet (58% of calories as fat) for a period of 2 weeks, and an intraperitoneal injection of
a low dose of streptozotocin (STZ) (35 mg/kg). After 2 weeks, a rat was considered diabetic when
its fasting blood glucose concentration was ≥180 mg/dL [14]. At this point, baseline blood samples
were collected from the tail vein of rats after anesthetization with ether gas. We then began to feed the
rats with the experimental diets. Thirty-two T2DM Sprague-Dawley rats were divided into 4 groups,
with similar average initial body weights. T2DM rats were divided into low-fat with soybean oil (LS),
low-fat with MCT oil (LM), high-fat with soybean oil (HS), and high-fat with MCT oil (HM) groups.
The LS diet per kilogram contained 70 g soybean oil (16% of calories as fat); the LM diet contained
35 g soybean oil (8% of calories as fat) and 38 g MCT oil (8% of calories as fat); the HS diet contained
254.4 g soybean oil (58% of calories as fat); and the HM diet contained 127.2 g soybean oil (29% of
calories as fat) and 137.9 g MCT oil (29% of calories as fat). All diets contained 200 g casein and 50 g
a-cellulose as fiber/kg of diet. Choline, cysteine, minerals, and vitamins were added as described
in AIN-93 [15]. Calorie densities of low-fat diets and high-fat diets were 4 kcal/g and 5.1 kcal/g,
respectively. The weight of animal diets was adjusted to fix total caloric intake and all rats received
109 kcal/day for 8 weeks. Calories from the daily food intake, during the experimental period did
not differ among the groups (data not shown). After consuming the diets for 8 weeks, the rats were
deprived of food overnight (~14 h); then they were anesthetized with ester. Blood was centrifuged
at 3500 g at 4 ◦C for 10 min, and serum was collected. The livers and reproductive white adipose
tissue (RDWAT) were removed. All samples were frozen at −80 ◦C until being analyzed. All animal
18
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experimental procedures followed published guidelines and were approved by the Institutional
Animal Care and Use Committee of Taipei Medical University (Taipei, Taiwan).
2.2. Intraperitoneal Glucose Tolerance Test (IPGTT)
At 0 and 8 weeks, all rats were fasted for approximately 16 h and intraperitoneally injected with
50% glucose solution (0.1 mL/100 g), and venous blood samples were obtained at 0, 15, 30, 60, 90, 120
and 180 min to determine plasma glucose.
2.3. Assay of Serum and Hepatic Lipids
Blood glucose, triglyceride, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C),
low-density lipoprotein cholesterol (LDL-C), and non-esterified fatty acid (NEFA) concentrations
were determined spectrophotometrically using kits from Randox (Taipei, Taiwan). The serum insulin
concentration was measured with a rat insulin enzyme-linked immunosorbent assay (ELISA) kit
(Mercodia, Taipei, Taiwan). Triglycerides, cholesterol, and NEFAs in liver samples were extracted [16],
and levels were measured using kits from Randox.
2.4. Enzyme Assay
The fatty acid synthase (FAS) activity assay, was based on measuring the initial rates of total
NADP+ formation from NADPH, by cytosomes by an ELISA. The cytosomes in the medium were
incubated with 2 M potassium phosphate, 20 mM dithiothreitol, 0.25 mM acetyl-CoA, 60 mM
EDTA-2Na, and 0.39 mM malonyl-CoA, and the reaction was monitored at 340 nm [17,18].
The acyl-CoA oxidase (ACO) activity assay, was based on the method of Small et al. by an ELISA
reader [19]. Liver postnuclear supernatant medium, were taken at 1% of total reaction volume and
incubated with 11 mM potassium phosphate, 8 μg/μL horseradish peroxidase type II, and the 5% LAT
mixture (contained 2.5 mM DCFH-DA, 4 M aminotriazole, and 20% Triton X-100). After 6 min (30 ◦C),
3 mM palmitoyl CoA was added. The reaction was monitored at 502 nm every minute for a total of
10 min, and the rate of H2O2 formation was calculated.
The acetyl-CoA carboxylase (ACC) activity assay [20], was based on measuring the initial rates
of total NADP+ formation from NADPH, by cytosomes by an ELISA. Cytosomes in the medium,
were incubated with 20 mM Tris-HCl, 10 mM MgCl2, 10 mM potassium citrate, 3.75 mM glutathione,
12.5 mM KHCO3, 0.675 mM bovine serum albumin (BSA), 0.125 mM acetyl-CoA, and 3.75 mM ATP,
and the reaction was monitored at 340 nm.
The carnitine palmitoyltransferase (CPT) activity assay [21], was based on measuring the initial
rates of total free CoA (CoASH) formed by the 5,5′-dithio-bis-2-nitrobenzoic acid (DTNB) reaction
from palmitoyl CoA by individual mitochondria with l(-) carnitine by an ELISA. Mitochondria in
the medium, were incubated with 116 mM Tris-HCl buffer, 0.09% Triton X-100, 1.1 mM EDTA-2Na,
0.035 mM palmitoyl CoA (Sigma, Darmstadt, Germany), 0.12 mM DTNB, and 1.1 mM 1(-) carnitine.
The reaction was monitored at 412 nm.
The assay of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase activity was based
on measuring the initial rates of total NADP+ formed from NADPH, by microsomes by an ELISA.
Microsomes in the medium, were incubated with 0.2 M KCl, 0.16 M potassium phosphate, 0.004 M
EDTA, 0.01 M DL-dithiothreitol, 0.1 mM HMG-CoA, and 0.2 mM NADPH, and the reaction was
monitored at 340 nm [22–24].
2.5. Histology
Livers and RDWATs were steeped in 10% formalin, dehydrated, and packed in wax. After 2 days,
the specimens were stained with a hematoxylin and eosin solution.
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2.6. Statistical Analysis
All data are expressed as the mean ± SEM. Data from multiple groups were compared by
two-way ANOVA, and each group was compared with the others by Fisher’s protected least significant
difference (LSD) test. Statistical significance was defined as p < 0.05.
3. Results
3.1. Weight Gain and Organ Weights
Calories in the daily food intake during the experimental period did not differ among the groups.
After 8 weeks of treatment, the average body weight in the HS group was higher than in the other three
groups, and it was significantly higher than that of the LM group (p < 0.05, see Table 1). The average
RDWAT (%) in the HS group was significantly higher than that of the LM group (p < 0.05). The average
liver weight (w/w) in the HS group was lower than in the other three groups, and it was significantly
lower than that of the LM group (p < 0.05). The average brown fat and kidney weights of rats did not
differ among the groups (Table 1).
Table 1. Body and organ weights of type 2 diabetes mellitus rats fed the different diets for 8 weeks.
LS LM HS HM
0 week-Weight (g) 353.8 ± 11.5 354.1 ± 8.0 357.4 ± 18.7 350.6 ± 12.81
8 week-Weight (g) 373.1 ± 18.4 ab 340.3 ± 14.3 b 435.4 ± 12.0 a 392.8 ± 19.2 ab
RDWAT (g) 5.1 ± 1.0 4.9 ± 0.9 9.3 ± 0.9 8.4 ± 1.2
RDWAT % 1.2 ± 0.2 ab 1.2 ± 0.2 b 2.1 ± 0.2 a 1.9 ± 0.2 ab
BAT (g) 0.3 ± 0.1 0.3 ± 0.0 0.33 ± 0.0 0.34 ± 0.0
BAT % 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0
Liver (g) 11.5 ± 0.6 12.5 ± 0.6 12.6 ± 0.4 12.1 ± 0.4
Liver % 3.2 ± 0.1 ab 3.4 ± 0.1 a 3.0 ± 0.1 b 3.1 ± 0.1 ab
Kidney (g) 3.0 ± 0.1 3.2 ± 0.1 3.7 ± 0.2 3.1 ± 0.1
Data are expressed as mean ± SEM (n = 8 in each group). LS, diet contained 16% soybean oil; LM, diet contained 8%
soybean oil and 8% medium-chain triglyceride oil; HS, diet contained 58% soybean oil; HM, diet contained 29% soybean
oil and 29% medium-chain triglyceride oil. RDWAT, reproductive white adipose tissue; BAT, brown adipose tissue.
Values with different superscripts significantly differ at p < 0.05.
3.2. Blood Glucose, Insulin Concentrations, Intraperitoneal Glucose Tolerance Test (IPGTT) and Lipid Levels
After 8 weeks of treatment, blood glucose and serum insulin concentrations of T2DM rats did
not differ among the four groups (Table 2). The LM group had the least area under the curve (AUC)
of IPGTT, and the HS group had the greatest AUC of IPGTT (Figure 1). The LM group had a lower
TG concentration than the HS group (p = 0.07) (Table 2). The blood TC concentration did not differ
among the groups. The serum LDL-C concentration of the HS group was significantly higher than in
the other three groups (p < 0.05), and that in the HS group was higher than that of the HM group alone
(p < 0.05). The HS group had a lower HDL-C concentration than the HM group. Also, the MCT oil
groups had significantly higher HDL-C values than the soybean oil groups, with both the low- and
high-fat diets. The serum HDL-C/LDL-C ratio of the HM group was significantly higher than that in
the HS group (p < 0.05), and the NEFA concentration of the HS group was significantly higher than
that of the HM group (p < 0.05) (Figure 2).
3.3. Liver Lipid Levels
After 8 weeks of treatment, the low-fat diet groups had significantly lower hepatic TG levels,
than the high-fat diet groups (p < 0.05, Figure 3). The HS group had the highest levels of the hepatic
TG, TC, and NEFA. In groups with a low-fat diet, the hepatic TG, TC, and NEFA levels of the MCT oil
and soybean oil groups did not significantly differ. However, the hepatic TC levels of the HM group,
were significantly lower than those of the HS group (p < 0.05, Figure 3).
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Table 2. Blood glucose, insulin, triglyceride, and total cholesterol concentrations of type 2 diabetes
mellitus rats fed the different diets for 8 weeks.
LS LM HS HM
Blood glucose (mg/dL) 302.5 ± 15.4 287.9 ± 22.7 368.2 ± 32.8 297.9 ± 22.1
Insulin (ug/L) 0.4 ± 0.1 0.4 ± 0.1 0.5 ± 0.1 0.4 ± 0.1
Triglyceride (mg/dL) 55.9 ± 2.0 52.2 ± 1.8 69.2 ± 5.0 57.4 ± 3.6
Total cholesterol (mg/dL) 63.8 ± 3.3 63.3 ± 3.6 70.6 ± 1.6 64.2 ± 2.7
Data are expressed as the mean ± SEM (n = 8 in each group). LS, diet contained 16% soybean oil; LM, diet contained
8% soybean oil and 8% medium-chain triglyceride oil; HS, diet contained 58% soybean oil; HM, diet contained
29% soybean oil and 29% medium-chain triglyceride oil.
Figure 1. Area under the curve (AUC) of intraperitoneal glucose tolerance test (IPGTT) of type
2 diabetes mellitus rats fed the different diets for 8 weeks. Data are expressed as mean ± SEM (n = 8).
LS: diet contains 16% soybean oil, LM: diet contains 8% soybean oil and 8% medium-chain triglyceride
oil, HS: diet contains 58% soybean oil, HM: diet contains 29% soybean oil and 29% medium-chain
triglyceride oil. All values are multiplied by 10−4.
Figure 2. Serum low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol
(HDL-C), the HDL-C/LDL-C ratio, and non-esterified fatty acid (NEFA) concentrations of type 2
diabetes mellitus rats fed the different diets for 8 weeks. Data are expressed as the mean ± SEM
(n = 8). LS, diet contained 16% soybean oil; LM, diet contained 8% soybean oil and 8% medium-chain
triglyceride oil; HS, diet contained 58% soybean oil; HM, diet contained 29% soybean oil and 29%
medium-chain triglyceride oil. Values with different superscripts significantly differ at p < 0.05.
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Figure 3. Hepatic triglyceride, total cholesterol, and non-esterified fatty acid concentrations of type
2 diabetes mellitus rats fed the different diets for 8 weeks. Data are expressed as the mean ± SEM
(n = 8 in each group). LS, diet contained 16% soybean oil; LM, diet contained 8% soybean oil and 8%
medium-chain triglyceride oil; HS, diet contained 58% soybean oil; HM, diet contained 29% soybean
oil and 29% medium-chain triglyceride oil. Values with different superscripts significantly differ at
p < 0.05.
3.4. Liver Enzyme Activity Assay
Hepatic FAS is the enzyme involved in de novo lipogenesis pathway, leading to the accumulation
of fatty acids in tissues. After 8 weeks of treatment, no difference in hepatic FAS activity was found
among the four groups (Figure 4). The formation of malonyl-CoA from acetyl-CoA was an irreversible
process, catalyzed by ACC. T2DM rats, fed both low-fat diet groups had significantly lower hepatic
ACC activities than those fed the HS group (p < 0.05). There were no differences in hepatic ACC activity
between the HM group and the LM group. ACO is the key enzyme in the peroxisomal β-oxidation
pathway. When the activity of ACO increases, β-oxidation increases. In T2DM rats fed low-fat diets,
the MCT oil group had higher activity of hepatic ACO increases than the soybean oil group (p < 0.05).
Liver carnitine palmitoyltransferase (CPT), is the key step in mitochondrial β-oxidation for long-chain
fatty acid, binding to carnitine from cytosol to the matrix. T2DM rats fed a low-fat diet had significantly
lower hepatic CPT activities than the high-fat diet groups (p < 0.05). HMG-CoA reductase, is the key
enzyme for endogenous cholesterol synthesis in the liver. In groups with a low-fat diet, the MCT group
had slightly less activity than the soybean oil group; the same result was found for the high-fat diet
(Figure 4).
3.5. Histology
Examination of RDWAT slices showed that the HS group had the largest adipocytes, and the LM
group had the smallest (Figure 5). The LM group had smaller adipocytes than the LS group; the same
result was found in high-fat diet groups. The HM group had smaller adipocytes than the HS group.
The liver tissue slice results showed that the two high-fat diet groups had more lipid droplets than the
two low-fat diet groups, corresponding to the hepatic TG concentrations (Figure 5).
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Figure 4. Liver acetyl-CoA carboxylase, fatty acid synthase, acyl-CoA oxidase, carnitine palmityltransferase,
and HMG-CoA reductase activities of type 2 diabetes mellitus rats fed the different diets for 8 weeks.
Data are expressed as the mean ± SEM (n = 8 in each group). LS, diet contained 16% soybean oil;
LM, diet contained 8% soybean oil and 8% medium-chain triglyceride oil; HS, diet contained 58%
soybean oil; HM, diet contained 29% soybean oil and 29% medium-chain triglyceride oil. Values with
different superscripts significantly differ at p < 0.05.
Figure 5. Reproductive white adipose tissues (upper row) and liver tissues (lower row) of type
2 diabetes mellitus rats fed the different diets for 8 weeks, shown with hematoxylin and eosin staining
(10×). LS, diet contained 16% soybean oil; LM, diet contained 8% soybean oil and 8% medium-chain
triglyceride oil; HS, diet contained 58% soybean oil; HM, diet contained 29% soybean oil and 29%
medium-chain triglyceride oil.
4. Discussion
After 8 weeks of treatment, the body weight of diabetic rats consuming a high-fat diet with soybean oil
was significantly higher than that of rats consuming a low-fat diet with MCT oil (p < 0.05). MCT undergoes
faster and more-complete hydrolysis to MCFA than LCT to LCFA [25,26], and MCFAs are absorbed
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and oxidized more quickly than LCFAs, reducing body weight by decreasing fat accumulation [4–6].
However, the daily calories from food intake during the experimental period did not differ among the
groups. Additionally, the body weight of the LS group was approximately 18% less than that of the
HS group. Thus, the LM group compared with the HS group, not only had MCT oil, but also had a
lower percentage of oil in the diet. The LM group had a significant decrease in RDWAT compared to
the HS group. MCT reduces the percentage of body fat by increasing the activity of hepatic lipolytic
enzymes (ACO) [6]. Thus, feeding a low-fat with MCTs-rich diet, caused a much greater reduction of
body weight and adipose tissues in T2DM rats.
In the low-fat diet, the MCT oil group had a slightly smaller AUC (glucose) than the soybean oil
groups; the same was found for the high-fat diet. Insulin resistance in mice is reduced by a low-fat
diet [27]. Also, the area under the curve can be an index of the body’s insulin resistance [28]. MCT oil
consumption might have benefits to blood glucose levels and insulin resistance [27], although our
results did not have statistical significance. In our study, the serum TG of the LM group was less than
that of the HS group, and the serum NEFA concentration in the HM group was significantly lower
than that of the HS group. MCT oil reduced hepatic TG synthesis by decreasing hepatic lipogenic
enzyme (ACC) activity, increasing hepatic lipolytic enzyme (ACO) activity, and lowering serum TG [6].
Reducing the percentage of oil in the diet may have the same effect [29]. Thus, MCT reduced body fat
more effectively with a low-fat diet. The serum LDL-C concentration of the HS group was significantly
higher than that of the HM group. The number of hepatic LDL receptors is reduced significantly
by high insulin concentrations [30,31]. High hepatic TC also diminishes hepatic LDL receptors [32].
Thus, MCT oil might increase the recovery of serum LDL-C, accompanied with the reduction in serum
NEFA concentrations, by increasing hepatic LDL receptors, not hepatic HMG-CoA reductase activity.
The most common form of atherosclerosis in diabetes, is induced by abnormal LDL-C metabolism [33];
rats in the HS group were most likely at risk of atherosclerosis. In addition, subjects with higher plasma
small-dense LDL levels have up to a 3-fold increased risk of myocardial infarction [34]. Future research,
may need to investigate the effect of MCT oil on advanced lipoprotein particles. The serum HDL-C
concentrations of the MCT oil groups were significantly higher than those of the soybean oil groups,
in both the low- and high-fat diets. Defective ABCA1 mediating the efflux of cellular free cholesterol,
defective LCAT activity, or increased selective delivery of HDL cholesteryl ester to hepatocytes may be
involved in the low HDL levels present with severe insulin resistance [35]. The serum HDL-C/LDL-C
ratio of the HM group was significantly higher than that of the HS group. The HDL-C/LDL-C ratio
can be a predictor of the risk of coronary heart disease [36]. Thus, the HS group might have the highest
risk of coronary heart disease. Additionally, MCTs enhanced serum HDL-C concentrations, and may
have achieved more efficient protection of cardiovascular health in T2DM rats fed a high-fat diet.
After 8 weeks of treatment, the low-fat diet groups had significantly lower hepatic TG and NEFA
levels than the high-fat diet groups. A high-fat diet induced TG accumulation in adipose tissues.
In T2DM, resistance to the action of insulin in adipose tissues increased NEFAs from TG hydrolysis and
released them to the blood, and seriously high NEFAs in the blood were carried into the liver where
the de novo synthesis of TGs occurred [37]. Hepatic TC levels in the HM group were significantly
lower than those of the HS group; but hepatic HMG-CoA reductase activity in the HM group did
not differ compared to that of the HS group. Takase et al. reported that hepatic HMG-CoA reductase
activity was significantly lower in MCT-fed rats [38]. The reason why a high-fat with MCT oil diet
reduced hepatic TC levels, accompanied with higher serum HDL-C levels, might be associated with
hepatic LDL receptors [32] and other proteins, such as the hepatic scavenger receptor (SR-B1) and
hepatic cholesterol 7-hydroxylase (CYP7A1), involved in liver cholesterol metabolism [39,40].
White adipose tissue is an energy storage and is related with insulin resistance of T2DM and
cardiovascular complications of obesity. With a low-fat diet, replacement of soybean oil with MCT
oil may improve fat oxidation by increasing hepatic ACO activities to reduce reproductive white
adipocyte size. In some animal studies, the mean adipocyte size was smaller in MCT- than in LCT-fed
rats [10]; those of the LM group were smallest. In obese and diabetic B6 mice that were switched from
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a high- to a low-fat diet, obesity was completely reversed [41]. Thus, the small adipocyte size of our
LM group was related to consumption of MCT, accompanied with a reduction in the percentage of oil.
Rats fed a higher-fat diet had higher ACC and FAS activities, and a faster hepatic lipogenetic pathway
to accumulate TGs in the liver. The liver tissue slice results corresponded to hepatic TG levels.
5. Conclusions
Consequently, we concluded that MCTs can achieve more efficient protection of cardiovascular
health in T2DM rats fed a high-fat diet, by improving serum lipid profiles and reducing hepatic total
cholesterol. Moreover, T2DM rats fed a low-fat and MCTs-rich diet, had much greater losses of body
weight and adipose tissues, compared with those fed a high-fat with soybean oil diet.
Author Contributions: M.-H.S. and Y.-W.C. were responsible for study design. M.-H.S. was responsible for data
collection and analysis. All authors were responsible for writing the manuscript. None of the authors had a
conflict of interest, either financial or personal, with this study.
Funding: This research received no external funding.
Acknowledgments: This study was supported by a grant from the National Science Council of Taiwan
(NSC95-2320-B-038-039). The authors gratefully acknowledge Hsing-Hsien Cheng for assistance with the
Stabilwax-DA capillary column and G-3000 chromatograph detection system. The results/data/figures in
this manuscript have not been published elsewhere, nor are they under consideration (from all our contributing
authors) by another publisher.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Bommer, C.; Sagalova, V.; Heesemann, E.; Manne-Goehler, J.; Atun, R.; Bärnighausen, T.; Davies, J.; Vollmer, S.
Global Economic Burden of Diabetes in Adults: Projections from 2015 to 2030. Diabetes Care 2018, 41, 963–970.
[CrossRef] [PubMed]
2. Wu, Y.; Ding, D.; Tanaka, Y.; Zhang, W. Risk Factors Contributing to Type 2 Diabetes and Recent Advances
in the Treatment and Prevention. Int. J. Med. Sci. 2014, 11, 1185–1200. [CrossRef] [PubMed]
3. Chang, H.C.; Yang, H.C.; Chang, H.Y.; Yeh, C.J.; Chen, H.H.; Huang, K.C.; Pan, W.H. Morbid obesity in
Taiwan: Prevalence, trends, associated social demographics, and lifestyle factors. PLoS ONE 2017, 12, e0169577.
[CrossRef] [PubMed]
4. Bach, A.C.; Babayan, V.K. Medium-chain triglycerides: An update. Am. J. Clin. Nutr. 1982, 36, 950–962. [CrossRef]
[PubMed]
5. Johnson, R.C.; Young, S.K.; Cotter, R.; Lin, L.; Rowe, W.B. Medium-chain-triglyceride lipid emulsion:
Metabolism and tissue distribution. Am. J. Clin. Nutr. 1990, 52, 502–508. [CrossRef] [PubMed]
6. Schönfeld, P.; Wojtczak, L. Short- and medium-chain fatty acids in energy metabolism: The cellular perspective.
J. Lipid Res. 2016, 57, 943–954. [CrossRef] [PubMed]
7. Crozier, G.; Bois-Joyeux, B.; Chanez, M.; Girard, J.; Peret, J. Metabolic effects induced by long-term feeding
of medium-chain triglycerides in the rat. Metabolism 1987, 36, 807–814. [CrossRef]
8. Lavau, M.M.; Hashim, S.A. Effect of medium chain triglyceride on lipogenesis and body fat in the rat. J. Nutr.
1978, 108, 613–620. [CrossRef] [PubMed]
9. Birk, R.Z.; Brannon, P.M. Regulation of pancreatic lipase by dietary medium chain triglycerides in the
weanling rat. Pediatr. Res. 2004, 55, 921–926. [CrossRef] [PubMed]
10. Geliebter, A.; Torbay, N.; Bracco, E.F.; Hashim, S.A.; Van Itallie, T.B. Overfeeding with medium-chain
triglyceride diet results in diminished deposition of fat. Am. J. Clin. Nutr. 1983, 37, 1–4. [CrossRef] [PubMed]
11. Hill, J.O.; Peters, J.C.; Yang, D.; Sharp, T.; Kaler, M.; Abumrad, N.N.; Greene, H.L. Thermogenesis in humans
during overfeeding with medium-chain triglycerides. Metabolism 1989, 38, 641–648. [CrossRef]
12. Geelen, M.J.; Schoots, W.J.; Bijleveld, C.; Beynen, A.C. Dietary medium-chain fatty acids raise and (n-3)
polyunsaturated fatty acids lower hepatic triacylglycerol synthesis in rats. J. Nutr. 1995, 125, 2449–2456.
[PubMed]
13. Lepage, G.; Roy, C.C. Direct transesterification of all classes of lipids in a one-step reaction. J. Lipid Res. 1986, 27,
114–120. [PubMed]
25
Nutrients 2018, 10, 963
14. Srinivasan, K.; Viswanad, B.; Asrat, L.; Kaul, C.L.; Ramarao, P. Combination of high-fat diet-fed and low-dose
streptozotocin-treated rat: A model for type 2 diabetes and pharmacological screening. Pharmacol. Res. 2005, 52,
313–320. [CrossRef] [PubMed]
15. Reeves, P.G.; Nielsen, F.H.; Fahey, G.C., Jr. AIN-93 purified diets for laboratory rodents: Final report of the
American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet.
J. Nutr. 1993, 123, 1939–1951. [CrossRef] [PubMed]
16. Folch, J.; Lees, M.; Sloane Stanley, G.H. A simple method for the isolation and purification of total lipides
from animal tissues. J. Biol. Chem. 1957, 226, 497–509. [PubMed]
17. Erickson, R.H.; Zakim, D.; Vessey, D.A. Preparation and properties of a phospholipid-free form of microsomal
UDP-glucuronyltransferase. Biochemistry 1978, 17, 3706–3711. [CrossRef] [PubMed]
18. Nepokroeff, C.M.; Lakshmanan, M.R.; Porter, J.W. Fatty-acid synthase from rat liver. Methods Enzymol. 1975, 35,
37–44. [PubMed]
19. Small, G.M.; Burdett, K.; Connock, M.J. A sensitive spectrophotometric assay for peroxisomal acyl-CoA
oxidase. Biochem. J. 1985, 227, 205–210. [CrossRef] [PubMed]
20. Numa, S.; Ringelmann, E.; Lynen, F. On inhibition of acetyl-CoA-carboxylase by fatty acid-coenzyme A
compounds. Biochem. Z. 1965, 343, 243–257. [PubMed]
21. Bieber, L.L.; Abraham, T.; Helmrath, T. A rapid spectrophotometric assay for carnitine palmitoyltransferase.
Anal. Biochem. 1972, 50, 509–518. [CrossRef]
22. Edwards, P.A.; Gould, R.G. Turnover rate of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase as
determined by use of cycloheximide. J. Biol. Chem. 1972, 247, 1520–1524. [PubMed]
23. Edwards, P.A.; Lemongello, D.; Fogelman, A.M. Improved methods for the solubilization and assay of
hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase. J. Lipid Res. 1979, 20, 40–46. [PubMed]
24. Heller, R.A.; Gould, R.G. Solubilization and partial purification of hepatic 3-hydroxy-3-methylglutaryl
coenzyme A reductase. Biochem. Biophys. Res. Commun. 1973, 50, 859–865. [CrossRef]
25. Fernando-Warnakulasuriya, G.J.; Staggers, J.E.; Frost, S.C.; Wells, M.A. Studies on fat digestion, absorption,
and transport in the suckling rat. I. Fatty acid composition and concentrations of major lipid components.
J. Lipid Res. 1981, 22, 668–674. [PubMed]
26. Mascioli, E.A.; Lopes, S.; Randall, S.; Porter, K.A.; Kater, G.; Hirschberg, Y.; Babayan, V.K.; Bistrian, B.R.;
Blackburn, G.L. Serum fatty acid profiles after intravenous medium chain triglyceride administration. Lipids
1989, 24, 793–798. [CrossRef] [PubMed]
27. Muurling, M.; Jong, M.C.; Mensink, R.P.; Hornstra, G.; Dahlmans, V.E.; Pijl, H.; Voshol, P.J.; Havekes, L.M.
A low-fat diet has a higher potential than energy restriction to improve high-fat diet-induced insulin
resistance in mice. Metabolism 2002, 51, 695–701. [CrossRef] [PubMed]
28. Monzillo, L.U.; Hamdy, O. Evaluation of insulin sensitivity in clinical practice and in research settings. Nutr. Rev.
2003, 61, 397–412. [CrossRef] [PubMed]
29. Gerhard, G.T.; Ahmann, A.; Meeuws, K.; McMurry, M.P.; Duell, P.B.; Connor, W.E. Effects of a low-fat diet
compared with those of a high-monounsaturated fat diet on body weight, plasma lipids and lipoproteins,
and glycemic control in type 2 diabetes. Am. J. Clin. Nutr. 2004, 80, 668–673. [CrossRef] [PubMed]
30. Kissebah, A.H. Low density lipoprotein metabolism in non-insulin-dependent diabetes mellitus. Diabetes Metab.
Rev. 1987, 3, 619–651. [CrossRef] [PubMed]
31. Streicher, R.; Kotzka, J.; Müller-Wieland, D.; Siemeister, G.; Munck, M.; Avci, H.; Krone, W. SREBP-1 mediates
activation of the low density lipoprotein receptor promoter by insulin and insulin-like growth factor-I. J. Biol. Chem.
1996, 271, 7128–7133. [CrossRef] [PubMed]
32. Fernandez, M.L.; West, K.L. Mechanisms by which dietary fatty acids modulate plasma lipids. J. Nutr. 2005, 135,
2075–2078. [CrossRef] [PubMed]
33. Betteridge, D.J. Diabetes, lipoprotein metabolism and atherosclerosis. Br. Med. Bull. 1989, 45, 285–311. [CrossRef]
[PubMed]
34. Austin, M.A.; Breslow, J.L.; Hennekens, C.H.; Buring, J.E.; Willett, W.C.; Krauss, R.M. Low-density lipoprotein
subclass patterns and risk of myocardial infarction. JAMA 1988, 260, 1917–1921. [CrossRef] [PubMed]
35. Ginsberg, H.N.; Zhang, Y.L.; Hernandez-Ono, A. Regulation of plasma triglycerides in insulin resistance and
diabetes. Arch. Med. Res. 2005, 36, 232–240. [CrossRef] [PubMed]
36. Baliarsingh, S.; Beg, Z.H.; Ahmad, J. The therapeutic impacts of tocotrienols in type 2 diabetic patients with
hyperlipidemia. Atherosclerosis 2005, 182, 367–374. [CrossRef] [PubMed]
26
Nutrients 2018, 10, 963
37. Raz, I.; Eldor, R.; Cernea, S.; Shafrir, E. Diabetes: Insulin resistance and derangements in lipid metabolism.
Cure through intervention in fat transport and storage. Diabetes Metab. Res. Rev. 2005, 21, 3–14. [CrossRef]
[PubMed]
38. Takase, S.; Morimoto, A.; Nakanishi, M.; Muto, Y. Long-term effect of medium-chain triglyceride on hepatic
enzymes catalyzing lipogenesis and cholesterogenesis in rats. J. Nutr. Sci. Vitaminol. 1977, 23, 43–51. [CrossRef]
[PubMed]
39. Trapani, L.; Segatto, M.; Pallottini, V. Regulation and deregulation of cholesterol homeostasis: The liver as a
metabolic “power station”. World J. Hepatol. 2012, 4, 184–190. [CrossRef] [PubMed]
40. Xu, Q.; Xue, C.; Zhang, Y.; Liu, Y.; Wang, J.; Yu, X.; Zhang, X.; Zhang, R.; Yang, X.; Guo, C. Medium-chain
fatty acids enhanced the excretion of fecal cholesterol and cholic acid in C57BL/6J mice fed a cholesterol-rich
diet. Biosci. Biotechnol. Biochem. 2013, 77, 1390–1396. [CrossRef] [PubMed]
41. Parekh, P.I.; Petro, A.E.; Tiller, J.M.; Feinglos, M.N.; Surwit, R.S. Reversal of diet-induced obesity and diabetes
in C57BL/6J mice. Metabolism 1998, 47, 1089–1096. [CrossRef]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Fish Oil Supplementation Reduces Inflammation but
Does Not Restore Renal Function and Klotho
Expression in an Adenine-Induced CKD Model
Juan S. Henao Agudelo 1, Leandro C. Baia 1,2, Milene S. Ormanji 1, Amandda R. P. Santos 1,
Juliana R. Machado 3, Niels O. Saraiva Câmara 1,4, Gerjan J. Navis 2, Martin H. de Borst 2
and Ita P. Heilberg 1,*
1 Division of Nephrology, Federal University of São Paulo (UNIFESP), Rua Botucatu 740,
04023-900 São Paulo, Brazil; juanelmono17@hotmail.com (J.S.H.A.); leandronut@yahoo.com.br (L.C.B.);
milene.ormanji@gmail.com (M.S.O.); amandda.rpds@gmail.com (A.R.P.S.); niels@icb.usp.br (N.O.S.C.)
2 Division of Nephrology, University of Groningen, University Medical Centre Groningen (UMCG),
P.O. Box 30.001, 9700 RB Groningen, The Netherlands; g.j.navis@umcg.nl (G.J.N.);
m.h.de.borst@umcg.nl (M.H.d.B.)
3 Tropical Medicine & Public Health, Federal University of Goiás (UFG), Rua 235 s/n-University Sector,
74605-050 Goiânia, Brazil; juliana.patologiageral@gmail.com
4 Department of Immunology, Institute of Biomedical Sciences, University of São Paulo (USP),
Av. Prof. Lineu Prestes 1730, ICB IV, Sala 238, 05508-000 São Paulo, Brazil
* Correspondence: ita.heilberg@gmail.com
Received: 15 August 2018; Accepted: 4 September 2018; Published: 11 September 2018
	

Abstract: Background: Chronic kidney disease and inflammation promote loss of Klotho expression.
Given the well-established anti-inflammatory effects of omega-3 fatty acids, we aimed to investigate
the effect of fish oil supplementation in a model of CKD. Methods: Male C57BL/6 mice received
supplementation with an adenine-enriched diet (AD, n = 5) or standard diet (CTL, n = 5) for
10 days. Two other experimental groups were kept under the adenine diet for 10 days. Following
adenine withdrawal on the 11th day, the animals returned to a standard diet supplemented
with fish oil (Post AD-Fish oil, n = 9) or not (Post AD-CTL, n = 9) for an additional period of
7 days. Results: Adenine mice exhibited significantly higher mean serum urea, creatinine, and renal
expression of the pro-inflammatory markers Interleukin-6 (IL-6), C-X-C motif chemokine 10 (CXCL10),
and Interleukin-1β (IL-1β), in addition to prominent renal fibrosis and reduced renal Klotho gene
expression compared to the control. Post AD-Fish oil animals demonstrated a significant reduction of
IL-6, C-X-C motif chemokine 9 (CXCL9), and IL-1β compared to Post AD-CTL animals. However,
serum creatinine, renal fibrosis, and Klotho were not significantly different in the fish oil-treated group.
Furthermore, renal histomorphological changes such as tubular dilatation and interstitial infiltration
persisted despite treatment. Conclusions: Fish oil supplementation reduced renal pro-inflammatory
markers but was not able to restore renal function nor Klotho expression in an adenine-induced
CKD model.
Keywords: klotho; CKD; fish oil; fibrosis; inflammation
1. Introduction
Inflammation plays a central role in the pathogenesis and progression of chronic kidney disease
(CKD). The activation of innate and adaptive arms of immune response leads to cell infiltration
(mainly macrophages) and the production of proinflammatory molecules that ultimately lead to
collagen deposition and loss of renal function [1].
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The α-Klotho protein was originally identified as an anti-aging gene in 1997 and was later
recognized as a transmembrane co-receptor of fibroblast growth factor (FGF23) [2]. Under healthy
conditions, Klotho is a protein highly expressed in the renal distal convolute tubule [3], which under
homeostatic conditions may also be present in soluble form in the blood, urine and cerebrospinal
fluid. Soluble Klotho has several endocrine functions like anti-senescence, anti-oxidative,
anti-renal angiotensin–aldosterone system (RAAS), and anti-inflammatory modulation [4].
Klotho deficiency is associated with reduced renal function, hyperphosphatemia, increased FGF23
levels, RAAS activation, and chronic complications such as ectopic calcification, cardiac hypertrophy,
secondary hyperparathyroidism, and progression of CKD [4,5]. Klotho-deficient rodents exhibit
manifestations of CKD and conversely, rodent CKD models show markedly reduced Klotho mRNA
expression [4].The reasons why Klotho is reduced in patients with CKD are not completely understood,
but it seems that inflammation could be one of the underlying mechanisms. The exogenous
administration of TWEAK (Tumor Necrosis Factor-like weak inducer of apoptosis) decreased renal
expression of Klotho and the blockade of TWEAK by neutralizing antibodies restored renal expression
of Klotho [6]. These data suggest the existence of a bidirectional relationship between Klotho and
inflammation. Therefore, treatment strategies targeting renal inflammation could potentially restore
Klotho expression, reducing renal damage and preventing the associated comorbidities.
Omega-3 fatty acids such as docosahexaenoic (DHA) and eicosapentaenoic (EPA) exert
anti-inflammatory effects and may have reno-protective properties in kidney diseases [7,8].
Experimental data showed reduced tubulointerstitial cell infiltration, pro-inflammatory mediators
such as Cyclooxygenase-2 (COX-2) and Monocyte chemoattractant protein-1 (MCP-1), and attenuation
of fibrosis [9]. In addition, we previously observed that higher intake of EPA–DHA was independently
associated with lower levels of FGF23 in renal transplant recipients [10], suggesting that omega-3 fatty
acids could favorably affect the FGF23–Klotho axis. In the present study, we investigated whether fish
oil, rich in omega-3 fatty acids, increases renal Klotho expression and reduces renal inflammation and
fibrosis in a mouse model of inflammatory CKD.
2. Materials and Methods
2.1. Animal Model
C57BL/6 wild-type mice, aged 8 to 12 weeks, were obtained from a local facility. All the
procedures were developed according to international guidelines for care of laboratory animals and
approved by the Animal Ethics Committee of the Federal University of São Paulo (CEUA, 1558280214).
In order to ensure that renal inflammation and fibrosis were induced in this adenine CKD model,
initial experiments were conducted over 10 days in two groups, which received either a standard diet
(7.0% soy oil, CTL group, n = 5), or the same diet enriched with 0.25% adenine (AD group, n = 5).
Once the renal inflammation and fibrosis were confirmed in the model, two additional experimental
groups were initiated to evaluate the effects of fish oil supplementation. Both groups received adenine
supplementation to the standard diet for 10 days. From the 11th day on, adenine administration
was discontinued and the animals were either switched back to their standard diet (7.0% soy oil,
Post AD-CTL group, n = 9), or started supplementation with fish oil (6.3%, Post AD-Fish oil group,
n = 9), for 7 additional days (see experimental design in Figure 1a). The diets were purchased from
Rhoster, Araçoiaba da Serra, Brazil and were in accordance with the American Institute of Nutrition
recommendations (AIN 93G). At the end of the study, the animals were anesthetized with xylazine
(10 mg/kg) and ketamine (50 mg/kg) by intra-peritoneal injection for blood sample collection by
cardiac puncture and euthanized thereafter. The kidneys were harvested and immediately dissected,
washed with saline, embedded in paraffin, sectioned longitudinally, and processed routinely for
histologic examination. The remaining part was snap frozen in liquid nitrogen and stored at −80 ◦C.
Serum creatinine was measured by the Jaffe modified method, and serum urea was measured using a
Labtest Kit (Minas Gerais, Brazil) according to the manufacturer’s instructions.
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Figure 1. Experimental design and assessment of renal function: (a) experimental design, (b) serum
creatinine, and (c) urea from the standard diet (CTL) and adenine (AD) mice. (d,e) Serum creatinine
urea of Post AD-CTL and Post AD-Fish oil animals. (* p < 0.05, ** p < 0.01).
2.2. Real-Time PCR
IL-6 (Mm00446190_m1), IL-1β (Mm00434228_m1), TGF-β (Mm01178820_m1), HPRT (Mm00446968_m1),
CXCL10, CXCL9, and Klotho gene expressions were assessed by real-time RT-Polymerase Chain
Reaction (PCR). Renal tissues were crushed and homogenized, and the RNeasy Mini Purification
Kit (Qiagen, Valencia, CA, USA) was used to extract RNA from all samples. RNA quantification
was carried out using a NanoDrop Spectrophotometer (NanoDrop ND-1000 Spectrophotometer;
Thermo Scientific, Wilmington, DE, USA). Nucleic acid concentration was determined using ultraviolet
spectrophotometry at 260 nm and purity was determined using the absorbance ratios of 260/280
and 260/230. RNA was reverse transcribed using the QuantiTec SYBR Green Kit (Qiagen) and the
manufacturer’s instructions were followed. Reverse transcription and Real-Time PCR were performed
using commercially available reagents and a 7500 Fast Real-Time Thermocycler (Applied Biosystems,
Carlsbad, CA, USA). For relative quantification of message expression (ΔCT Method), target gene
expression was normalized to Hypoxanthine Phosphoribosyltransferase (HPRT) gene expression.
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The following primers were assessed for quantitative Syber Green RT-PCR:
KLOTHO fw: GGTGTCCATTGCCCTAAGCTC; KLOTHO rev: TCGGTCATTCTTCGAGGATTGA.
CXCL9 fw: 5-TGCACGATGCTCCTGCA-3; CXCL9 rev:5-AGGTCTTTGAGGGATTTGTAGTGG-3.
CXCL10 fw:5-GACGGTCCGCTGCAACTG-3; CXCL10 rev: 5-GCTTCCCTATGGCCCTCATT-3.
2.3. Histological Evaluation
Formaldehyde-fixed paraffin kidney sections (3 m) were dewaxed and stained with Picrosirius
solution. Sections were immersed in saturated picric acid solution for 15 min and then in Picrosirius
for 20 more minutes. Counter-staining was carried out with Harris hematoxylin. Picrosirius-stained
sections were analyzed by an Olympus BX50 microscope (Olympus, Feasterville, PA, USA) with an
Olympus camera attached. Manual shots were taken of the cortex, magnified 40X, and observed under
polarized light. Photos of at least five different fields in each slide were taken, and structures such
as the glomeruli, subcapsular cortex, large vessels, and medulla were excluded. The pictures were
digitalized in a HP Scanjet 2400 (Hewllet Packard, Barueri, São Paulo, Brazil) and then the interstitial
volume of collagen in the cortex compared to the overall cortex area was quantified by morphometry.
For the morphometric analysis, the Image Processing and Analysis in Java (Image J—image processing
program, National Institutes of Health, Maryland, MD, USA) was used. The result of the analysis
is represented as a percentage of cortical interstitial collagen volume relative to the total cortical
interstitial volume. Subsequently, the arithmetic mean of the analyzed fields was calculated for each
slide. Collagen type I was associated with yellow/red birefringence and type III with green color,
according to the description of Montes GS and Junqueira LC [11]. The assessment of the interstitial
fibrosis volume obtained by morphometric analysis of the digital image stained with picrosirius was
based on previous studies [12].
2.4. Western Blotting
Here, 50 ug of total protein was obtained from kidney lysate of CTL, AD, Post AD-CTL, and Post
AD-Fish oil mice. The protein extract was denatured by heating at 5 min at 95 ◦C and separated by
10% polyacrylamide gel electrophoresis (SDS-PAGE). Subsequently, protein extract was transferred
into nitrocellulose membrane and next, the immunostaining was performed with the following
primary antibodies: E-cadherin (Dako: M3612, Santa Clara, CA, USA), alpha smooth muscle actin
(α-SMA, DAKO: M0851, Santa Clara, CA, USA), Klotho: (CosmoBIO: K0603, Carlsbad, CA, USA),
and α-tubulin (InVitrogen: 32-2500, Sunnyvale, CA, USA). Then, nitrocellulose membrane was
incubated with conjugated secondary antibodies (anti-rabbit or anti-mouse peroxidase/1: 125.0000,
Sigma-Aldrich, St. Louis, MO, USA) and revealed by chemiluminescence methods using an ECL
kit (Millipore, Burlington, MA, USA). Finally, the image was acquired on Amersham Imager 600
(GE Healthcare, Marlborough, MA, USA) and analyzed with Image J.
2.5. Statistical Analyses
Differences between AD versus CTL and Post AD-CTL versus Post AD-Fish oil groups were
assessed using Student’s t-test. All statistical analyses were performed using GraphPad Prism version
5.0 (GraphPad Software, La Jolla, CA, USA). The results are presented as mean and SD for parametric
variables. Differences were considered significant if p < 0.05.
3. Results
3.1. Adenine Supplementation Induces Inflammation, Loss of Renal Function, and Klotho Reduction
Animals fed with adenine for 10 days exhibited higher mean levels of serum creatinine and
urea when compared with the control group (Figure 1b,c). AD mice exhibited significantly higher
renal expression of IL-6, IL-1β, and CXCL10 versus CTL (Figure 2a,b,d). Finally, we noted that Klotho
mRNA expression was at least six-fold lower in the renal tissues of AD mice when compared with CTL
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(Figure 3a) (0.163 ± 0.01 vs. 1.001 ± 0.02), which was also confirmed by Western blot (Figure 4a,d).
In summary, these data indicate that experimental adenine-induced CKD was associated with impaired
renal function, increased pro-inflammatory mediators, and decreased Klotho expression.
Figure 2. Pro-inflammatory markers: (a) IL-6, (b) IL-1b, (c) CXCL9 and (d) CXCL10 in the CTL/AD
and Post AD-CTL and Post AD-Fish oil groups (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001).
Figure 3. mRNA Klotho by PCR: (a) CTL/AD and (b) Post AD-CTL and Post AD-Fish oil mice
(** p < 0.01, **** p < 0.0001).
3.2. Fish Oil Supplementation Reduces Pro-Inflammatory Markers but Does Not Improve Renal Function
Fish oil treatment promoted reduction of renal IL-6, IL-1β, and CXCL9 expression (Figure 2a–c).
The reduction of CXCL10 by fish oil did not reach statistical significance (Figure 2d). Interestingly,
the expression of IL-1β and CXCL9 was even higher in the Post AD-CTL group when compared
descriptively with group AD (Figure 2b,c). Such an increase of inflammatory mediators in Post AD-CTL
indicated that following the withdrawal of adenine on the 10th day, the process of inflammation
continued to be active for the next 7 days during which the animals returned to the standard diet.
Present findings suggested that treatment with fish oil exerted some renal anti-inflammatory effects on
CKD animals subjected to adenine supplementation. However, the Post AD-Fish oil and Post AD-CTL
animals did not differ statistically with respect to renal function (Figure 1d,e).
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3.3. Fish Oil Supplementation Does Not Revert Progressive Renal Fibrosis
The deposition of crystals in tubular lumens from the kidneys of AD mice, coupled with tubular
dilatation, interstitial infiltrate and hyaline cylindersresulting in tubular damage was confirmed by
histomorphological analysis (Figure 5a). Furthermore, renal deposition of types I and III collagens,
revealed by Picrosirius staining, were evidenced in AD mice (Figure 5b). In addition, other pro-fibrotic
markers such as transforming growth factor beta (TGFβ) expression (Figure 5d) and alpha smooth
muscle actin (α-SMA) evaluated by Western blot, were significantly higher in AD mice compared with
CTL (Figure 4a,b). These data confirm that mice fed with adenine for 10 days had tubulointerstitial
inflammation with progressive fibrosis.
Figure 4. Klotho and alpha smooth muscle actin (α-SMA) expression by Western blot: (a) α-SMA
and Klotho expression in renal tissue, normalized by α-tubulin in the CTL, AD, Post AD-CTL,
and Post AD-Fish oil groups. Relative quantification of α-SMA (b,c) and Klotho (d,e) in the CTL,
AD, Post AD-CTL and Post AD-Fish oil groups (** p < 0.01).
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Figure 5. Fibrosis evaluation through picrosirius and transforming growth factor beta (TGFβ):
(a) Images from Hematoxylin and eosin (HE) stain and picrosirius the kidney samples of CTL/AD and
Post AD-CTL and Post AD-Fish oil groups. Graphical quantification of fibrosis observed by picrosirius
in (b) CTL/AD and (c) Post AD-CTL and Post AD-Fish oil groups. TGF-β expression in (d) CTL/AD
and (e) Post AD-CTL and Post AD-Fish oil groups (* p < 0.05, ** p < 0.01).
Both Post AD-CTL and Post AD-Fish oil mice showed the same degree of renal tissue injury as
observed in AD mice. (Figure 5a). Similarly, interstitial deposition of types I and III collagen was not
statistically different between Post AD-Fish oil and Post AD-CTL mice (Figure 5c). Although TGFβ
expression was reduced in Post AD-Fish oil versus Post AD-CTL mice (Figure 5e), we showed that
protein expression of α-SMA was not different between both groups (Figure 4a,c). Taken together,
these results suggest that fibrosis was not ameliorated by fish oil in this CKD model.
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3.4. Fish Oil Does Not Restore Renal Klotho
The expression of Klotho mRNA (Figure 3b) and transmembrane Klotho expression, shown by
Western blot (Figure 4a,e) could not be restored by fish oil treatment; Klotho expression in Post AD-Fish
oil was even slightly lower than in Post AD-CTL mice. Nevertheless, this difference did not seem to
yield an important biological effect, given that some consequences such as impact on renal function
and magnitude of fibrosis observed in both groups were quite similar.
4. Discussion
Several factors contribute to downregulate Klotho expression in CKD, including uremic toxins,
vitamin D deficiency, phosphate overload, activation of RAAS, oxidative stress, and inflammation [4,5].
In the same way, experimental studies have shown that exogenous Klotho supplementation or its
transgenic overexpression attenuates renal injury [4,13]. In various mice models of inflammatory
disease, renal Klotho expression is suppressed [6,14–16] and Klotho possesses anti-inflammatory
properties as well [17,18]. Given the potential anti-inflammatory effects of omega-3 fatty acids,
largely shown in vitro and in vivo [19,20], we hypothesized that fish oil could restore the
downregulation of Klotho in an adenine-induced CKD mice model. We found that fish oil
supplementation reduced intra-renal inflammation but was not enough to ameliorate renal function
and interstitial fibrosis nor retrieved kidney Klotho expression. The rationale for choosing the
experimental model of adenine-induced tubulointerstitial nephritis [21] relied on the characteristic
features of progressive renal dysfunction and interstitial fibrosis of this model [22] coupled with an
intense local tissue inflammation with high expression of pro-inflammatory cytokines [12] which
ultimately leads to progression of the disease. The model resembles the adenine phosphoribosyl
transferase (APRT) deficiency, a rare human monogenic disease in which adenine cannot be salvaged
to adenosine monophosphate, but is catabolized instead to 2,8-DHA in which crystals deposition
leads to irreversible renal failure [23,24]. In the present study, aiming to determine the therapeutic
rather than the preventive effects of fish oil on the amelioration of the renal inflammatory damage,
adenine feeding was withdrawn at the 10th day, when according to our experimental design,
the animals were either returned to a standard diet or switched to the fish oil-supplemented one.
In the first set of experiments, we found that compared to controls, adenine-fed animals exhibited
significantly higher renal expressions of inflammatory markers such as IL-6 and IL-1β, and of CXCL10
(a chemokine responsible for leucocyte recruitment), as well as increased renal tissue expressions
of α-SMA (indicating myofibroblast deposition), and of TGF-β (a surrogate marker of fibrosis).
Histomorphological analyses confirmed the presence of crystals in tubular lumen, tubular dilatation,
interstitial infiltration, and leukocyte casts. Fibrosis was clearly evident by picrosirius staining as well.
All these findings agreed well with other studies employing the adenine TIN mouse model [12,22,25].
As might be expected, renal function was also reduced in adenine-fed mice groups, as evidenced by
the rises in serum urea and creatinine, in agreement with previous reports [12,21,22,25]. Although
the elevation of serum creatinine level in this model has been described in a time-dependent manner,
this parameter is already significantly higher after 7 days following the initiation of adenine feeding [22].
Moreover, previous data from our group have shown that the inflammatory process and enhanced
cellular infiltration accompanied by collagen deposition leading to a progressive renal dysfunction is
readily installed at 10 days after adenine supplementation [12]. In view of the presence of CKD [4,26,27],
inflammation [15,16], or both, current experiments disclosed a marked reduction in renal Klotho
expression in these adenine-fed animals, corroborating previously published data who showed
extremely low levels of serum and renal Klotho after 4 and 6 weeks of adenine feeding [25,28].
Of note, our findings revealed an even earlier Klotho loss, at 10 days. A precocious Klotho deficiency
has been described at the earliest stage of CKD (stage 1) when Glomerular Filtration Rate (GFR) is still
normal [29]. Animal experiments have demonstrated that EPA and DHA provide benefits in a range of
models of inflammatory conditions [30]. Nevertheless, the results of human clinical trials on prevention
of inflammation-driven diseases using fish oil have been heterogeneous, with no overall clear evidence
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of efficacy [31]. With respect to kidney function, a small beneficial effect of an additional amount of
400 mg EPA–DHA per day on kidney function in patients with a history of myocardial infarction and
a low habitual EPA–DHA intake has been observed [8]. However, no beneficial effect on inflammation
markers such as high-sensitivity C-reactive protein (hsCRP) was further obtained [32]. Dose-dependent
actions of marine omega−3 Polyunsaturated Fatty Acids (PUFAs) on inflammatory responses have
not been well described, but it appears that a dose of at least 2 g per day is necessary to achieve an
anti-inflammatory effect, an unlikely quantity to obtain from the diet [31]. Although other randomized
controlled trials employing higher doses of omega-3 fatty acids also did not show a significant effect
on circulating parameters of inflammation [33,34], an effect on intra-renal inflammation could not be
ruled out by clinical studies.
In the present study, fish oil promoted a reduction in renal expression of IL-6, IL-1β, and CXCL9,
reflecting, at least in part, diminished intra-renal inflammation. This is in accordance with experimental
data in rodents dealing with other types of renal injuries such as tacrolimus-induced nephrotoxicity
and polycystic kidney disease [35,36]. Despite of the decreased inflammation markers, we observed
no restoration of renal expression of Klotho in the fish oil group. As reduced Klotho expression level
in the kidney may sensitize the kidneys to injury and aggravation of renal interstitial fibrosis [37,38],
hence accelerating renal disease progression, a vicious cycle may ensue.
Several other reasons might also explain why renal Klotho expression could not be restored.
Given the persistence of loss of renal function in our model, irrespective of the fish oil administration,
Klotho deficiency is expected, since the kidneys produce/release α-Klotho into the circulation
and help clearing it [27]. Moreover, in the CKD setting, over production of reactive oxygen
species [39], elevation of uremic toxins [40], high serum phosphate/excess FGF23 [41], and low serum
1,25-dihydroxy vitamin D3 (1,25 Vit D3) are expected to further suppress Klotho production [37,42,43].
Unfortunately, parameters of mineral metabolism such as phosphate, FGF23, and 1,25 Vit D3 have not
been measured in the present study.
Other factors which could account for by renal Klotho deficiency in some circumstances depend
on its epigenetic modulation. Methylation of the Klotho gene promoter, which has been shown to reduce
its activity up to 40%, may inhibit Klotho gene expression in CKD [39,44,45] and TGF-β is known to
induce global changes in DNA methylation [46]. Accordingly, demethylation of Klotho gene promoter
remarkably reversed renal Klotho deficiency and reduced renal fibrosis [25]. The hyperacetylation
of histone in the Klotho promoter also may contribute to Klotho underexpression [6]. In summary,
decreased Klotho expression may result from an epigenetic response to inflammation inside or outside
the kidney [47]. The possibility of a time delay in the response to local inflammation in our model
cannot be ruled out. One could argue that a persistent uremic environment has not been fully
accomplished in 10 days, but an irreversible renal failure after 2 weeks has been achieved in rats [48].
Given that the progression of renal failure is faster in mice, and that the current histomorphometric
results obtained 7 days after the withdrawal of adenine feeding (17th day from baseline) showed a still
important interstitial fibrosis, indeed suggest that the latter might have been responsible for the lack of
Klotho restoration.
The present study had several limitations as well as strengths. The first concerns with the length
of adenine administration/fish oil treatment and the eventual concomitancy of both supplementations.
Had fish oil treatment been simultaneously administered with the adenine-supplemented diet,
no inflammation or a shorter period of inflammation could have occurred, hence preventing the
progression of fibrosis and loss of renal function. In this scenario, Klotho reduction could have even
been averted. However, as discussed above, we aimed to determine the therapeutic rather than the
preventive effects of fish oil on inflammation, given that in the clinical practice, the exact moment of
initiation of a renal insult cannot be predicted. Second, higher doses of fish oil to achieve a more potent
anti-inflammatory effect could have been employed. Nevertheless, few dose finding experimental
and clinical studies have been performed to help determine optimal dose-response effects. A third
limitation of the present study was that adhesion molecule expression and leucocyte chemotaxis
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(CXCL8 and MCP1) have not been currently determined in our model to more properly assess both
the magnitude and recovery of inflammation. The lack of measurement of parameters of mineral
metabolism such as phosphate, FGF23, and 1,25 Vit D3, which are involved in Klotho regulation,
compromised a further discussion of the absence of Klotho recovery. Finally, we are aware that
the current model represents a specific tubulointerstitial insult with no glomerular injury, thus not
reflecting all types of CKD.More studies employing different timing and dose of fish oil treatment
in this and other models of CKD are still warranted in order to better understand the link between
Klotho reduction and inflammation, fibrosis, and renal dysfunction.
5. Conclusions
The present study suggested that fish oil supplementation reduces renal expression of
pro-inflammatory markers, but was not able to restore renal function or Klotho expression in an
inflammatory model of CKD.
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Abstract: The role of dietary fat has been long studied as a modifiable variable in the prevention
and treatment of noncommunicable cardiometabolic disease. Once heavily promoted to the public,
the low-fat diet has been demonstrated to be non-effective in preventing cardiometabolic disease,
and an increasing body of literature has focused on the effects of a relatively higher-fat diet. More
recent evidence suggests that a diet high in healthy fat, rich in unsaturated fatty acids, such as the
Mediterranean dietary pattern, may, in fact, prevent the development of metabolic diseases such as
type 2 diabetes mellitus, but also reduce cardiovascular events. This review will specifically focus
on clinical trials which collected data on dietary fatty acid intake, and the association of these fatty
acids over time with measured cardiometabolic health outcomes, specifically focusing on morbidity
and mortality outcomes. We will also describe mechanistic studies investigating the role of dietary
fatty acids on cardiovascular risk factors to describe the potential mechanisms of action through
which unsaturated fatty acids may exert their beneficial effects. The state of current knowledge on
the associations between dietary fatty acids and cardiometabolic morbidity and mortality outcomes
will be summarized and directions for future work will be discussed.
Keywords: cardiometabolic disease; unsaturated fat; Mediterranean diet; low-fat diet
1. Introduction
Cardiometabolic diseases are estimated to cause over 700,000 deaths per year in the United
States (US) and nearly 50% of these deaths are directly related to diet [1,2], although this could be
questioned due to so much data being based on potentially flawed food frequency questionnaires
(FFQs) [3,4]. Numerous foods, dietary patterns, and individual nutrient consumption have been
studied for associations with cardiometabolic disease and its risk factors, but few have received
scrutiny as intense and lengthy as dietary fat. As early as 1953, Ancel Keys published a proposed
link between dietary fat and cardiovascular diseases (CVD), and five years later, his Seven Countries
study began collecting data in an effort to establish a relationship between diet and CVD [5,6]. During
the same period, controlled-feeding studies demonstrated a link between increasing saturated fatty
acids (SFA) in the diet and increased levels of total cholesterol and, more importantly, of low-density
lipoprotein cholesterol (LDL-C), which were known to be associated with incidence of coronary heart
disease (CHD) [7]. These controlled-feeding studies, in addition to observational evidence, were relied
on as sufficient evidence that a higher total fat and SFA intake leads to an increased incidence of CHD
by increasing plasma total cholesterol and LDL-C—the “diet-heart hypothesis” [7–9]. In response to
this accruing evidence, the very first Dietary Guidelines for Americans in 1980 recommended lowering
total fat and SFA [10], which was updated in 1990 to recommend Americans select a low-fat diet,
specifically one that consisted of ≤30% total fat and ≤10% SFA of total daily energy [11].
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In the decades following these recommendations, total dietary fat decreased in the American
diet [12], refined grain intake increased [13], prevalence of type 2 diabetes mellitus (T2DM) continued
to rise, and CVD remained the most common cause of death in US adults [14,15]. It is evident that
perhaps the most important finding from the Seven Countries Study, that unsaturated fatty acids (UFA)
were correlated with a lower risk of CVD in the context of a Mediterranean-style dietary pattern, was
not properly communicated and implemented [16]. Evidence in favor of higher UFA consumption
within a healthy dietary pattern has continued to accumulate and in 2015, the Dietary Guidelines for
Americans was published for the first time in 35 years without a recommended limit on total dietary
fat consumption while continuing to promote UFA consumption [17].
This review will discuss the evidence behind the recommendation of the low-fat diet for the
past few decades as well as the evidence of UFA intake for cardiometabolic health by first reviewing
morbidity and mortality outcomes. Finally, we will discuss the potential underlying mechanisms
through which fatty acids may affect overall cardiometabolic health.
2. Methodology
To identify the works used in this critical review, the comprehensive electronic literature search
using PubMed and Google Scholar included the use of the following key words and their combination:
“Low-fat diet”, “high-fat diet”, “Mediterranean diet”, “fatty acids”, “mortality”, “cardiovascular
disease”, “weight gain”, “weight loss”, “type II diabetes”, “insulin resistance”, “blood pressure”,
“heart failure”, “dyslipidemia”, and “cancer”. All works meeting the subject matter were considered
including observational cohort studies, randomized controlled trials, reviews, meta-analyses, and
editorials, in animals and adult humans. Preference was placed on the most recent papers with the
exception of those providing historical context to subject matter.
3. Introduction to Dietary Fat Nomenclature
Dietary fat can be broadly broken down into 3 broad subtypes—UFA, SFA and trans fat. UFA can
be further divided into monounsaturated fat (MUFA) and polyunsaturated fats (PUFA). Numerous
unique fatty acid molecules belong to each subtype of fat, sometimes with divergent effects due to
their unique properties as well as the foods they exist within. Additionally, complex mechanisms
exist within the body to process consumed nutrients and knowledge continues to accrue regarding
the metabolism of dietary fat. A recent example is the recognition of the skeleton and particularly
bone marrow as major contributors to fatty acid metabolism [18]. SFA exist in small amounts in many
diverse sources of dietary fat, but animal products such as dairy (milk, butter, cheese) and meat are
higher in SFA than most plant oils. Notable exceptions are tropical plant oils such as palm and coconut
oil, which are also rich sources of SFA. Major sources of SFA include lauric acid (C12:0), myristic acid
(C14:0), and palmitic acid (PA) (C16:0) which all increase LDL-C, and stearic acid (C18:0), which does
not [19]. There has been some suggestion that PA (C16:0) found in both animal products and palm
oil has particularly deleterious effects on cardiometabolic health, such as increased inflammation,
oxidative stress, and impaired nitric oxide and insulin signaling, but due to food sources being high in
multiple SFAs and endogenous production of PA by the body it is somewhat difficult to distinguish
divergent effects [20,21]. Different sources of SFA may have slightly different risk profiles—recent
data has suggested that dairy fat in particular may be neutral or even beneficial on cardiovascular
(CV) outcomes [22,23]. This, however, seems to be related to the relative risk compared to refined
carbohydrate: animal meat sources of SFA and dairy fat still increases atherosclerotic lipoproteins and
replacement with UFA results in a decreased risk of CHD [24]. MUFA are also found in meat and
dairy, but rich plant sources of MUFA include extra-virgin olive oil, canola oil, and some other plant
oils such as rapeseed and high-oleic sunflower and safflower. The major MUFA present in Western
diets and referenced in this review is oleic acid (C18:1n-9), however, some populations have a high
intake of rapeseed oil, and therefore a high intake of erucic acid (c22:1n-9) [19]. PUFA are found in
nuts and seeds, cold-water fish, and plant oils such as soybean and flaxseed. PUFA are divided in two
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categories, n-6 and n-3, based on the position of the first double bond from the omega end of the fatty
acid. The primary source of PUFA in the diet is linoleic acid (LA) (C18:2n-6), an n-6 fatty acid [19].
Plant sourced n-3 alpha linolenic acid (ALA) (C18:3n-3) is present to a lesser degree, and even less
prevalent are the marine n-3 fatty acids eicosapentaenoic acid (EPA) (C22:5n-3) and docosahexaenoic
acid (DHA) (C22:6n-3) [19]. Though n-3 and n-6 PUFAs will be discussed separately in this review,
both have been shown to be beneficial to human health when consumed in food sources and n-6 PUFAs
are no longer considered to be inflammatory [25]. Trans fats occur to a very small degree naturally
but mostly exist in the form of engineered fats in highly-processed convenience foods or fast food.
Engineered trans fats have been established as harmful to human health and widespread efforts to
remove sources of trans fat from the global food supply are ongoing [19,26].
3.1. Low-Fat Diet and CVD
In spite of the decades of guidelines recommending a low-fat diet, few trials have explored
the long-term implementation of a low-fat diet and the resulting morbidity and mortality outcomes.
The largest trial examining the cardiometabolic effects of the low-fat diet was the Women’s Health
Initiative Dietary Modification Trial (WHI) which tested the effects of a low-fat diet targeted at
reducing the percentage of daily calories from dietary fat to 20%, while increasing servings of
grains, fruits, and vegetables [27]. Over 48,000 postmenopausal women were randomized to either a
low-fat intervention (40% of participants) or a control arm with minimal dietary interference (60% of
participants) [28]. The women in the intervention arm received 18 group counseling sessions focused on
dietary modification in the first year and then quarterly for the reminder of the trial [28]. A prescription
for grams of daily dietary fat was given to each participant but no weight loss or physical activity
goal was specified or encouraged [29]. Subjects in the control group received no dietary guidance but
regular clinic visits [28]. After an average of 8.1 years follow up, the intervention group successfully
decreased dietary fat intake by an absolute 8.2% from a baseline of 32%. No difference in the rate of
CHD, stroke, or CVD was found between the intervention group and the control group, as recorded in
Table 1. Although the women decreased total fat by 8.2%, SFA intake only decreased by an absolute
2.9% to a mean of 9.5% calories from SFA in the intervention group, which was significantly above
the indicated target of 7% defined at the begin of the study. Although this aligns with the World
Health Organization and American Dietary Guidelines 2015–2020 recommendations to reduce SFA
to below 10% of total calorie intake in the general population, this recommendation did not result in
improved clinical outcomes in the WHI study. Of note, the women enrolled in the WHI trial were
post-menopausal and overweight with a mean body-mass index (BMI) of 29 kg/m2, and were perhaps
at a greater CVD risk compared to the general population [17,27,30]. The American Heart Association
recommends that individuals with a high LDL-C reduce SFA to 5–6% of daily calories, which may
have applied to many of the individuals who developed CVD events during the trial [31].
A recent analysis explored deeper into the neutral CVD outcomes of the WHI trial, examining
the difference in CVD disease risk modification for those in the low-fat intervention group [32].
This analysis divided the women into three strata: subjects with baseline CVD, normotensive subjects
without baseline CVD, and hypertensive subjects without baseline CVD [32]. Interestingly, the results
diverged: in subjects with a prior history of CVD randomized to the low-fat intervention, risk was
significantly increased for composite CHD as well as all causes of death [32]. In contrast, normotensive
women without a history of CVD had a significantly reduced risk of CHD, which was overshadowed
by an increase in stroke risk, particularly ischemic stroke risk [32]. No difference in disease risk was
seen in hypertensive women without a history of CVD [32]. It is important to note that CHD was a
secondary outcome for the WHI trial, while stroke risk was not a designated primary or secondary trial
outcome. The authors of the analysis attribute the adverse CHD outcomes in the subjects with prior
CVD to alterations in statin use and the increased stroke risk seen in normotensive women without
baseline CVD to possible multiple-testing bias [32]. The findings of this analysis are inconclusive
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but do bring up a disturbing possibility that the low-fat diet is not just neutral on cardiometabolic
outcomes, but could potentially be harmful.
3.2. Low-Fat Diet and Metabolic Diseases
The WHI investigators also tracked the incidence of T2DM throughout the length of the trial [29].
They hypothesized that a low-fat dietary pattern, even in the absence of weight loss or exercise, would
reduce T2DM incidence [29]. Type I diabetes mellitus was an exclusion factor for the trial and subjects
with T2DM at baseline were excluded from this analysis [29]. Incidence of T2DM was self-reported and
based on medication reconciliation at regular 6-month visits throughout the trial as only around 5% of
the over 45,000 women included in this analysis had regular lab work drawn as part of the trial for a
confirmative diagnosis [29]. Participants did not differ in risk factors for T2DM at baseline [29]. After
8.1 years, as shown in Table 1, there was no difference in incidence of self-reported T2DM between
subjects in the low-fat intervention and control groups [29,33]. Greater reduction of dietary fat from
baseline was initially associated with reduced T2DM but this was no longer significant after controlling
for weight loss [29].
Low-fat diets were once considered to be superior weight loss tools as fat, at 9 calories per
gram, is more energy-dense than carbohydrate and protein, so reducing fat intake appeared to be
an effective way to cut calories from a person’ diet [34]. In contrast, evidence suggests that low-fat
diets are equivalent, at best, to other diets for weight loss, not superior [35–39]. A recent meta-analysis
that included randomized controlled trials (RCTs) with over one year of follow up concluded that
low-fat dietary trials did not result in greater weight loss when compared to higher fat interventions of
similar intensity as measured by the time, individual attention, and program materials given by the
investigative team to participants [37]. When weight loss was the goal, higher fat, lower-carbohydrate
diets actually resulted in greater weight loss over time [37]. A lack of difference between the two diets
in terms of weight loss was recently demonstrated in the high-profile Diet Intervention Examining the
Factors Interacting with Treatment Success (DIETFITS) trial, which examined the effects of genotyping
and insulin response on weight loss in 609 overweight and obese individuals randomized to a low-fat or
low-carbohydrate diet [38]. The DIETFITS intervention employed intensive counseling and education
over a 12 months period to both groups, but at the conclusion of the trial, no difference in weight
loss was seen between individuals randomized to a low-fat or low-carbohydrate diet, regardless of
genotype or insulin-response at baseline [38].
In summary, low-fat dietary patterns do not seem to aid in the prevention of CVD or T2DM,
and are not superior to other diets in terms of weight loss. Continued promotion of the low-fat
diet is ineffective at preventing cardiometabolic disease at best, and exploratory findings cannot
exclude harms.
3.3. High-Fat Diet and CVD
In the last decades, strong evidence has emerged to suggest a diet higher in UFA in the context of
a healthy dietary pattern holds strong promise in the prevention and treatment of cardiometabolic
disease. This is exemplified in a traditional Mediterranean diet (MedDiet) which is best known as the
traditional dietary pattern consumed in Greece, southern Italy and the island of Crete, first brought
to the attention of the nutrition scientific community by Ancel Key’s Seven Countries Study [16,40].
Briefly, the MedDiet is a diet rich in fruits, vegetables, whole grains, legumes and UFA, principally
from extra-virgin olive oil (EVOO) and nuts. Other features of the MedDiet include the consumption
of fish and poultry in moderate amounts, red wine with meals, and low consumption of red meat and
refined carbohydrates compared to other Western societies. The Prevención con Dieta Mediterránea
(PREDIMED) trial, first published in 2013 [41] and retracted and subsequently republished with
corrections in 2018 with similar results [42,43], tested a Mediterranean diet (MedDiet) supplemented
with nuts or EVOO against a low-fat control diet in nearly 7500 individuals at high CVD risk to assess
prevention on a primary composite endpoint of nonfatal myocardial infarction (MI), stroke, and death
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from CVD [41–43]. This multicenter randomized controlled trial performed in Spain assigned patients
1:1:1 to a MedDiet plus at least 4 tablespoons of EVOO, a MedDiet with 30 g of mixed nuts per day,
or a low-fat control diet [42,44]. Notably, no caloric restriction was recommended, and at conclusion
of the trial after an average of 4.8 years follow-up the MedDiet groups were consuming 42% total
daily energy from fat while individuals in the relatively low-fat control group were consuming around
37% [45]. Patients in the MedDiet groups received group and individual counseling by a dietitian
at baseline and then quarterly for the remaining duration of the study [42]. The subjects assigned
to the low-fat diet group were initially only given a leaflet with advice on adopting a low-fat diet,
but midway through the trial were transitioned to quarterly dietary counseling as well [42].
Adherence to a MedDiet using a 14-point dietary questionnaire was assessed at baseline in all
subjects and quarterly thereafter in the MedDiet groups [42]. Control subjects filled out a 9-point
dietary questionnaire at dietary counseling sessions assessing their adherence to a low-fat diet [42].
The planned duration of the trial was 6 years but an interim analysis at 4.8 years demonstrated sufficient
evidence for benefit to terminate the trial early [46]. In fact, both MedDiet groups demonstrated a 30%
relative risk reduction for the primary endpoint compared to their control counterparts [42], as shown
in Table 1. This may have been largely driven by a reduction in stroke risk—the combined MedDiet
groups demonstrated an impressive 42% relative risk reduction, as seen in Table 1, while death from
CVD and nonfatal MI were non-significant independently [42].
The benefit of the relatively high fat MedDiet was not limited to CVD. Although fear of weight gain
exists with a higher-fat diet, after 5 years of follow up all three groups showed a weight reduction from
baseline and the MedDiet group supplemented with EVOO demonstrated greater weight reduction
compared to control participants [47]. Furthermore, both MedDiet groups exhibited a lower increase in
waist circumference during the trial than the control group [47,48]. Another analysis of the PREDIMED
examined development and reversal of metabolic syndrome (MetS), defined under the integrated
International Diabetes Federation/American Heart Association/National Heart, Lung and Blood
Institute standards, and found that while there was not a difference between groups in risk of
developing MetS, reversal from baseline MetS was more likely in the MedDiet groups compared
to control [49]. Additionally, participants in the EVOO group were more likely to have developed
a decrease in fasting plasma glucose from baseline [49]. Remarkably, after a median follow-up of
4 years, incidence of new-onset T2DM was reduced by 53% in the two MedDiet groups compared to
the control [50,51] (Table 1).
Table 1. Cardiometabolic outcomes comparison of the Prevención con Dieta Mediterránea (PREDIMED)
and Women’s Health Initiative Dietary Modification Trial (WHI) trials.





Composite Cardiovascular Outcome 2 0.94 (0.86–1.02) 0.70 (0.55–0.89)
Non-fatal myocardial infarction 0.91 (0.80–1.04) 0.80 (0.53–1.21)
Nonfatal Stroke 1.02 (0.90–1.17) 0.58 (0.42–0.82)
Type 2 Diabetes Mellitus Incidence 0.96 (0.90–1.03) 0.47 (0.26–0.87)
Breast Cancer incidence 0.91 (0.83–1.01) 0.49 (0.25–0.94)
1 Data are presented as hazard ratio and 95% confidence interval. 2 For WHI: myocardial infarction, coronary
heart disease, death or revascularization. For PREDIMED: non-fatal myocardial infarction, cardiovascular death or
non-fatal stroke. Hazard ratios and confidence intervals for the WHI versus the PREDIMED on primary prevention
of cardiovascular, metabolic and cancer-related endpoints [27,29,42,50–53].
Prevention of heart failure (HF) was also explored in the PREDIMED, but while levels of HF
prognostic biomarkers (i.e., NT-proBNP) were reduced in the MedDiet groups in one analysis [54],
incidence of new-onset HF was not lower in the MedDiet groups than the control group, perhaps
due to a small number of events making the study likely underpowered to investigate the effects on
new-incident HF [55]. A recent prospective cohort study, Mediterranean Diet in Acute Heart Failure
(MEDIT-AHF), explored secondary prevention potential of the MedDiet for patients who had already
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experienced acute HF (AHF) [56]. Individuals were enrolled in this study in the emergency department
(ED) setting and were administered the 14-point dietary questionnaire used in PREDIMED to assess
adherence to the MedDiet [56]. The primary outcome of the MEDIT-AHF trial was all-cause mortality
at the end of the trial, secondary outcomes consisted of ED visits for HF, hospitalization due to HF,
all-cause mortality, and a composite of the three secondary outcomes if one was present [56]. After
an average follow up of 2.1 years, ED visits, all-cause mortality, and the combined variable were not
different between adherent and non-adherent individuals, however hospitalization was significantly
lower in individuals adhering to the MedDiet [56]. It should be noted that both individuals with HF
with a preserved ejection fraction (HFpEF) and HF with a reduced ejection fraction (HFrEF) were
enrolled in this study. HFpEF is a condition that currently lacks effective clinical therapies and therefore
the reduction in hospitalization seen in this study has important implications for future work [57].
Recently, higher consumption of UFA was correlated with greater cardiorespiratory fitness (CRF) as
well as better cardiac diastolic function and body composition in a cohort of obese HFpEF patients [58].
The investigators have initiated a novel pilot study in obese HFpEF patients (NCT03310099) exploring
the capabilities of UFA supplementation to improve CRF, metabolic flexibility and glucose tolerance.
3.4. High-Fat Diet and Metabolic Diseases
Recently, the results of the Prospective Urban Rural Epidemiological (PURE) study, a prospective
cohort of over 135,000 individuals from 18 different countries, called into question whether the type of
fatty acid consumed matters in the human diet [59]. Briefly, PURE collected dietary intake through
FFQs and followed participants for an average of 7.4 years. Primary outcomes were designated as
major CVD events and total mortality. At analysis, high carbohydrate intake was associated with an
increased risk of total mortality but was not associated with CVD events or mortality [59]. Total fat
and each category of fats (SFA, MUFA and PUFA) were associated with lower risk of total morality
but not MI or overall CVD mortality [59]. The investigators stated they were unable to analyze trans
fatty acids [59]. SFA alone were associated with lower risk of stroke [59]. The findings of PURE are
in direct opposition to current guidelines, which recommend that SFA should be limited in the diet
to help prevent CVD [17,60,61]. It is possible in the PURE cohort that FFQs estimated UFA mostly
from food sources not deriving from vegetable oils and missed or underestimated vegetable oils [62].
Vegetable oils are major sources of UFA that mostly lack SFA, while animal sources of UFA are also
rich sources of SFA [62,63]. It is possible that analyses of the trial, which take different dietary sources
into account, could show divergent results between the consumption of different fatty acids.
A recent analysis of the Nurse’s Health Study (NHS) and Health Professional’s Follow Up Study
(HPFS) in a cohort of similar size to PURE (>126,000), which also utilized FFQs in a prospective cohort
design, illustrated careful comparison of the effects of different fatty acids consumption on clinical
outcomes [64]. Similar to what was found in PURE, total dietary fat consumption was inversely
associated with total mortality when substituted for total dietary carbohydrates [64]. The authors
then performed substitution analysis of different macronutrients [64]. When SFA and trans fatty
acids were substituted for total carbohydrate, a higher risk of mortality ensued, but when PUFA and
MUFA were substituted for carbohydrate, as seen in Figure 1, a significant reduction in mortality
was observed. Likewise, when PUFA and MUFA were substituted for 5% of energy from SFA, a 27%
and 13% reduction in mortality was observed [64]. When trans fatty acids were substituted for 2% of
energy from SFA, a 16% mortality increase followed [64].
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Figure 1. Substitution of different fatty acids for carbohydrate in the Nurse’s Health Study (NHS)
and Health Professional’s Follow Up Study (HPFS). Hazard ratios for total mortality by replacing
carbohydrates with specific dietary fats. Used with permission from O’Keefe et al. [65].
The results of the PURE study also called into question the ideal percentage of calories from
carbohydrates vs. protein and fat, as high carbohydrate intake was associated with increased risk
of total mortality [59]. The composition of a very low-carbohydrate diet or “ketogenic diet” varies
in the literature, making up from <30–130 g of carbohydrate per day [66]. In a true ketogenic state,
reserves of glycogen are depleted over the course of a few days on extremely low carbohydrate
intake, and the liver begins producing ketone bodies as an alternate fuel source for the central nervous
system [66]. In human subjects, positive cardiometabolic effects have been seen, including improved
lipid panels and glucose metabolism, but concerns have been raised over the lack of long-term
data, high intakes of saturated fat and/or protein, and maintaining adherence to a strict dietary
pattern [66]. Additionally, a recent analysis suggested that both low (<40% daily calories from
carbohydrate) and high (>70%) carbohydrate diets were associated with a greater risk for all-cause
mortality [67]. The lowest mortality occurred with a diet composed of 50–55% of calories from
carbohydrate [67]. Importantly, low-carbohydrate diets varied in risk profile—when carbohydrate was
replaced by a diet high in plant-based protein and fat, a lower mortality risk was observed, but when
calories from carbohydrate were replaced by animal fat and protein, an increased risk of all-cause
mortality was observed [67]. Notably, participants in the PREDIMED consumed around 42% of their
energy from carbohydrate at baseline, and MedDiet groups slightly decreased intake, while control
participants slightly increased. Future work should focus on the effects of a plant-based ketogenic diet
(KD) vs. animal-based KD as well as modulating carbohydrates (low vs. moderate) in a high-UFA
Mediterranean dietary pattern.
4. Potential Mechanisms of Action of Fatty Acids on Cardiometabolic Disease Risk Factors
The cardiometabolic risk reduction observed with a diet higher in UFA is likely multifaceted.
Evidence suggests that a diet higher in UFA may affect multiple related risk factors for cardiometabolic
disease, including blood pressure (BP), weight maintenance, blood-glucose levels, blood lipids,
and inflammation [68]. Though the discussion below focuses on independent mechanisms of
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improvement for each risk factor, these improvements may also be achieved by the nature of their
relation to other risk factors (i.e., weight loss and blood pressure improvement).
Hypertension is responsible for more deaths from CVD in the US than any other modifiable
risk factor. Consuming a diet rich in UFA may help lowering BP modestly, by less than 5 mmHg
each in systolic and diastolic pressure [69,70], while SFA have an unclear relationship with BP [25].
The mechanism for this reduction is not fully established and may differ between different sources
of UFA. Particularly for EVOO, the BP reduction induced may be mediated by OA (C18:1n-9) [71],
the main fatty acid of EVOO. In pre-clinical studies, administration of EVOO actually altered membrane
lipid structure by increasing the amount of OA (C18:1n-9) in the cell membrane, which altered G-protein
mediated signaling and reduced BP in rats [72].
Nuts may also contribute to the BP-lowering effects of UFA, however, the effects seem to
differ, perhaps due to the varying nutrient profile of different nuts. In a meta-analysis including
21 randomized-controlled trials with BP as the primary or secondary outcome, pistachios, but not
other nuts, were significantly associated with a significant reduction in systolic BP (SBP) and diastolic
BP(DBP) [73]. The authors postulated this could be due to their higher amount of MUFA (particularly
OA (C18:1n-9)), antioxidants, and the amino acid arginine—a precursor to nitric oxide (NO), a potent
vasodilator [74]. A meta-analysis of n-3 fatty acids, EPA (C22:5n-3) and DHA (C22:6n-3) and from
food sources and supplementation found that SBP and DBP was lowered in both hypertensive
and non-hypertensive subjects [75]. Multiple mechanisms have been suggested for this effect,
predominantly relating to endothelial improvements. A recent retrospective analysis of a double-blind,
placebo-controlled crossover study supplementing EPA (C22:5n-3) and DHA (C22:6n-3) in adult
subjects attempted to isolate the hypotensive mechanisms of these fatty acids. Though there were no
changes in endothelial function or BP in the overall group, SBP was lowered in individuals found
to have systolic hypertension [76]. As for the mechanism of action, results demonstrated no effect
of adhesion molecule expression in the endothelium or improvement in microvascular function [76].
The investigators also examined the effect of the eNOSrs1799983 gene, associated with lower circulating
NO and CVD incidence, and found no treatment x genotype effect leading to speculation that the
hypotensive response is independent of the effects of NO [76]. Overall, the effects of different sources
of UFA on BP appear to be modest. However, a diet rich in UFA from multiple sources may produce a
greater additive effect and subsequent protection against CVD.
Diverging effects on lipid panels are perhaps the one of the earliest and most often cited properties
of dietary fats on cardiometabolic health. The National Lipid Association recommends that UFA
should be substituted for SFA in lieu of carbohydrates for greater lowering of atherogenic cholesterol
levels [77]. The expert consensus was that oils rich in n-6 PUFA lower atherogenic cholesterol levels
more effectively than MUFA based on controlled feeding trials [77]. However, fatty acids exist within
different food sources creating complex effects on lipoproteins. MUFA, especially as part of EVOO,
has protective effects against oxidation of LDL-C and high-density lipoprotein cholesterol (HDL-C)
as well as promoting an increase in HDL-C [78]. Nuts have varying nutrient profiles and therefore a
likely variable effect on lipoproteins [79]. A pooled analysis of 25 intervention trials demonstrated that
dietary interventions consisting of nuts alone reduced total cholesterol, LDL-C, and the ratio of LDL-C
to HDL-C, but had no effect on HDL-C [80]. The investigators found that this was dose-responsive
with higher nut consumption leading to a greater reduction in TC and LDL-C [80]. In addition to UFA,
nuts are a source of dietary fiber and plant sterols, which may help reduce cholesterol absorption at
the gut level. Lastly, the n-3 fatty acids EPA (C22:5n-3) and DHA (C22:6n-3) have a well-recognized
lowering effect on triglycerides (TGs) [81,82]. This reduction in TGs is possibly mediated by multiple
mechanisms, including a reduction in circulating fatty acids by increased beta oxidation/decreased
lipogenesis, decreased TG synthesizing enzymes, and increased phospholipid synthesis [82]. Again,
sources of UFA provide varying effects and mechanisms by which they improve lipid panels and
therefore reduce cardiometabolic risk. It is likely the best result is achieved by consuming a diet rich in
multiple different sources of UFA.
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Weight gain in adulthood is a major risk factor for cardiometabolic disease and some evidence has
demonstrated that low-fat diets are not superior to higher-fat diets in terms of weight maintenance or
loss [35,37,38,47]. Results from the PREDIMED discussed above suggest that a diet relatively high in
UFA may be protective against weight gain [47]. A recent analysis of the European Prospective
Investigation into Cancer and Nutrition (EPIC) cohort of over 375,000 European participants
corroborated an association between nut consumption and protection against weight gain [83].
The investigators demonstrated that for every 15 g of additional nut consumption per day, participants
gained slightly less weight, average of −0.04 kg over 5 years compared to their counterparts, which
corresponded to a small but significant 2.5% reduction in body weight increase [83]. Additionally,
individuals in the highest quartile of nut consumption who were of a normal weight or overweight
at baseline had a 5% lower chance of moving up a body-mass index (BMI) category [83]. Strong
evidence is available to indicate that nuts, which contain 50% calories from fat, at the very least do
not contribute to increased adiposity [84] and may aid in weight maintenance [47,83]. Nuts likely
exert their protective effects against weight gain through several different mechanisms including
the effects of the dietary fiber, protein, and fat on satiety, and incomplete absorption of fat at the
intestinal level from physical structure [84]. EVOO also demonstrated a protective effect against
weight gain and central adiposity during the PREDIMED trial [47]. This was previously demonstrated
in the 7368-subject SUN prospective cohort in Spain [85]. In this cohort, participants with the lowest
EVOO consumption at baseline who did not increase consumption during the 28.5-month follow-up
period gained the most weight [85]. The lowest weight gain was demonstrated in individuals with
moderate baseline consumption who increased EVOO during follow up [85]. The mechanisms behind
the protective effects of EVOO on weight maintenance are not well established but could be due in
part to lowered action of stearoyl-CoA desaturase 1 (SCD1), an obesogenic enzyme that catalyzes
the production of MUFA from SFA [86]. Moreover, MUFA can slightly increase resting metabolic
rate [87] and physical activity [88], which are, in turn, associated with weight loss in absence of major
changes in food intake. Pre-clinical studies also support the beneficial effects on body weight of
high-UFA diet, independent of caloric intake [58]. Overall, the evidence shows that nutrient-rich foods
high in UFA do not increase the risk of weight gain and may be even protective against increased
adiposity. Since 1980, prevalence of T2DM worldwide has doubled in men and increased by 60% in
women [89]. Around 8–9% of the world’s adult population now suffers from diabetes, and 8–95% from
T2DM, which is heavily associated with lifestyle factors [89]. The scale of this epidemic underlines
the importance of the PREDIMED sub-analysis that demonstrated new-onset T2DM was reduced
over 50% in the higher-fat MedDiet groups compared to the low-fat control [50,51]. The authors
suggested this may be due to the effects of lowered chronic systemic low-grade inflammation—
an early sub-analysis showed significantly lowered markers of inflammation including Interleukin-6
(IL-6), soluble intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule
(VCAM-1) in the MedDiet groups [90]. Additionally, C-Reactive Protein (CRP) was reduced in the
EVOO MedDiet group [90]. The anti-inflammatory effects of EVOO and nuts are multi-factorial and
may include enhancement of the body’s endogenous antioxidant defenses, protection against weight
gain for individuals in the MedDiet groups and the rich source of polyphenols EVOO provides [91].
Additionally, intake of EVOO with a meal has been shown to affect glycemia by improving insulin
sensitivity and increasing glucagon like peptide-1 [92].
However, despite the impressive findings of the PREDIMED, evidence associating total dietary
fat and subtypes of dietary fat has been inconsistent, which may be due to the differing food sources of
fatty acids [93]. For example, n-3 FA supplementation is not recommended by the American Diabetes
Association due to lack of demonstrated benefit, but the organization continues to recommend the
intake of marine fish rich in n-3 for more general health benefits [94]. A meta-analysis and systematic
review of 102 trials and over 4200 subjects enrolled in controlled feeding trials demonstrated overall
beneficial effects of UFA on glucose-insulin homeostasis [95]. In a replacement analysis of 5% of calories,
PUFA and MUFA were associated with improved HOMA-IR and HbA1c when replacing carbohydrate
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or SFA [95]. PUFA improved insulin secretion capacity whether the PUFA replaced carbohydrate
or SFA or MUFA [95]. Only the replacement of SFA with PUFA reduced fasting glucose levels [95].
When SFA or PUFA was substituted for carbohydrate, fasting insulin was reduced but substitution of
SFA for carbohydrate resulted in a significantly increased c-peptide in several trials [95]. Longer-term
randomized-controlled trials supplementing UFA in individuals at risk for T2DM are needed.
5. Discussion and Conclusions
Preventing cardiometabolic disease with targeted lifestyle therapy such as evidence-based nutrition
interventions must be made a global health priority [96]. There is a lack of evidence demonstrating
that a low-fat diet is protective against the development of cardiometabolic disease [27,29,32,33].
Evidence continues to accrue that a diet higher in fat, particularly of UFA, especially in the context of a
Mediterranean style dietary pattern may be protective against multiple risk factors for cardiometabolic
disease [47,49,90,97]. Most importantly, evidence indicates that improvement in these intermediate
markers does translate to prevention of CVD and T2DM in individuals consuming a higher UFA
diet [42,50].
It should be noted that while a low-fat diet is not effective in the prevention of cardiometabolic
disease, the WHI did demonstrate a reduction in death after breast cancer in the low-fat intervention
group versus the control during the trial and throughout the 16.1-year follow up period [52].
No significant reduction in breast cancer incidence was observed [52], as seen in Table 1. Breast
cancer incidence was also analyzed in the PREDIMED [53]. During the 4.8 years of follow up, as shown
in Table 1, incidence of breast cancer was significantly reduced in both MedDiet groups—the released
analysis did not include mortality outcomes [53]. Further research is needed to directly compare
a healthy low-fat dietary pattern with a higher-fat MedDiet pattern to determine which pattern is
superior in preventing breast cancer as well as mortality during and after treatment.
The PREDIMED was conducted in Spain, a country where a Mediterranean dietary pattern rich
in UFA is commonly consumed—EVOO is the main dietary fat source in the Spanish population
studied [98]. Interest in replicating the PREDIMED in a non-Mediterranean country is substantial.
An expert working group has thoroughly explored the necessary resources, accommodations, and
anticipated problems investigators may face in attempting to replicate the PREDIMED in the US [98].
Compared to the PREDIMED participants at baseline, the Mediterranean diet adherence score
(MEDAS) of US participants estimated from the National Health and Nutrition Examination Survey
is substantially lower [98], as seen in Table 2. Importantly, whether the supplementation of nuts
and EVOO works in the context of a non-Mediterranean dietary pattern such as in United States is
unknown [99]. The working group suggested that a goal of the trial would be to increase the MEDAS
score of the US modestly and not to the level of Spanish participants which they felt would be very
difficult to achieve and perhaps maintain [98], as seen in Table 2.









Energy, kcal/day 2172 2229 2141
Carbohydrate, % Energy 40 40 48 Decrease(type matters)
Protein, % Energy 16 16 16
Total fat, % Energy 41 42 34 Increase(type matters)
Saturated fat, % Energy 9 9 11 Decrease
Monounsaturated Fatty Acids, % E 22 21 12 Increase
Polyunsaturated Fatty Acids, % Energy 6 8 8 None
α-Linolenic acid, g/day 1.3 1.9 Not Available Not Available
Marine n-3 fatty-acids, g/day 0.9 0.8 0.1 Increase
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Fiber, g/day 25 27 17 Increase
Cholesterol, g/day 339 338 293 None
Food intake
Virgin olive oil, g/day 50 32 Not Available Increase
Refined olive oil, g/day 0.9 10.3 Not Available
Nuts, g/day 10 40 11 Increase
Fruit, g/day 401 406 149 Increase
Vegetables, g/day 340 336 246 Increase
Legumes, g/day 22 22 6 Increase
Whole grains, g/day 27 28 28 None
Refined grains, g/day 181 178 165 None
Pastry, sweets, g/day 17 16 Not Available Decrease
Meat, g/day 119 119 118 None
Fish/seafood, g/day 101 103 17 Increase
Dairy, g/day 366 370 399 None
Characteristics of average US diet gathered from NHANES 2011–2012 data as compared to PREDIMED MedDiet
participant’s diets. Used with permission from Jacobs Jr. et al. [98].
In summary, a relatively high-UFA diet, especially in the context of the MedDiet, decreases risk
factors as well as morbidity and mortality related to CVD. In contrast, there is no evidence that a
low-fat diet leads to lower morbidity or mortality related to cardiometabolic disease. Randomized
controlled trials are warranted to test the effects of UFA-supplemented MedDiet in diverse global
populations on risk factors and outcomes of T2DM and CVD.
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Abstract: The dietary fatty acid 10,12 conjugated linoleic acid (10,12 CLA) promotes weight loss by
increasing fat oxidation, but its effects on atherosclerosis are less clear. We recently showed that
weight loss induced by 10,12 CLA in an atherosclerosis-susceptible mouse model with characteristics
similar to human metabolic syndrome is accompanied by accumulation of alternatively activated
macrophages within subcutaneous adipose tissue. The objective of this study was to evaluate
whether 10,12 CLA-mediated weight loss was associated with an atheroprotective phenotype. Male
low-density lipoprotein receptor deficient (Ldlr−/−) mice were made obese with 12 weeks of a
high-fat, high-sucrose diet feeding (HFHS: 36% fat, 36% sucrose, 0.15% added cholesterol), then either
continued on the HFHS diet with or without caloric restriction (CR), or switched to a diet with 1%
of the lard replaced by either 9,11 CLA or 10,12 CLA for 8 weeks. Atherosclerosis and lipid levels
were quantified at sacrifice. Weight loss in mice following 10,12 CLA supplementation or CR as a
weight-matched control group had improved cholesterol and triglyceride levels, yet only the 10,12
CLA-treated mice had improved en face and aortic sinus atherosclerosis. 10,12 CLA-supplemented
mice had increased lesion macrophage content, with enrichment of surrounding perivascular adipose
tissue (PVAT) alternative macrophages, which may contribute to the anti-atherosclerotic effect of
10,12 CLA.
Keywords: alternatively activated macrophages; perivascular adipose tissue; type 2 cytokines
1. Introduction
Conjugated linoleic acids (CLAs), of which the major isomers are cis-9, trans-11 conjugated linoleic
acid (9,11 CLA) and trans-10, cis-12 CLA (10,12 CLA), are microbial metabolites found naturally
in ruminant animal food products and are major components of widely used CLA weight loss
supplements [1–3]. Commercial CLA supplements differ significantly in the ratio of 9,11 CLA to
10,12 CLA (approximately 1:1) when compared to levels found in food (approximately 5:1). As such,
CLA supplement users ingest significantly more 10,12 CLA than would be obtained from the diet.
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Supplemental CLA promotes significant weight loss in animals and modest weight loss in humans, an
effect now attributed to the 10,12 CLA isomer [4]. We have previously shown that 10,12 CLA reduces
lipid accumulation by increasing fatty acid oxidation in a cell line derived from (mouse) 3T3 cells
(3T3-L1) adipocytes [5]. Moreover, obese mice supplemented with 10,12 CLA lose body weight and fat
mass due to enhanced fatty acid oxidation with increased energy expenditure and white adipose tissue
browning [4]. These changes in energy expenditure are not the result of weight loss per se, as a control
group undergoing caloric restriction to mirror weight loss by the 10,12 CLA-supplemented group did
not exhibit these changes [4]. While the weight loss properties of 10,12 CLA are well established, if
and how 10,12 CLA impacts atherosclerosis is less well-defined.
Studies of CLA supplementation in small animal models susceptible to the development of
atherosclerosis have yielded mixed results. Initial studies in rabbits suggested that mixed CLA
supplementation, an approximately equal mixture of the two most common isomers, 9,11 CLA and
10,12 CLA, was protective against atherosclerosis [6,7]. Subsequent studies have shown a similar
effect in atherosclerosis-prone mice that lack the apolipoprotein-E gene (ApoE−/−) when fed a diet
containing mixed CLA [8,9], or a CLA diet containing 80% 9,11 CLA and 20% 10,12 CLA [10–12].
While these studies have shown atheroprotective effects of mixed CLA supplementation, there is
also abundant evidence that CLA-containing diets do not provide protection from atherosclerosis,
and may even contribute to its development [13–16]. Additional studies could clarify the impact of
supplemental CLA on atherosclerosis.
Most previous CLA supplementation studies with the end point of atherosclerosis assessment
utilized ApoE−/− mice. However, while these mice are an efficient model with which to study
atherosclerosis, they poorly replicate human atherosclerotic lipoprotein profiles and co-morbidities
such as obesity and insulin resistance. While ApoE−/− mice develop hypercholesterolemia due to
elevated low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL), they also exhibit
decreased high-density lipoprotein (HDL) [17]. Conversely, low-density lipoprotein receptor deficient
(Ldlr−/−) mice accumulate LDL and HDL cholesterol with more modest VLDL elevation, which more
closely resembles dyslipidemic humans [18]. Humans inclined to take CLA supplements would likely
be obese with characteristics of metabolic syndrome, including insulin resistance, hepatic steatosis,
and systemic inflammation. As such, a better mouse model with which to study the effects of CLA
supplementation on atherosclerosis would include these phenotypes, as well as the propensity to
develop atherosclerosis. We therefore utilized Ldlr−/− mice consuming a diet high in saturated fat and
refined carbohydrates, which has previously been shown to promote a phenotype closely resembling
human metabolic syndrome [19], to study the effects of 10,12 CLA on atherosclerosis. In addition, and
in contrast to previous studies, mice in this study were supplemented with individual isomers of CLA
rather than mixed CLA in order to clearly identify effects due to 9,11 or 10,12 CLA alone.
2. Materials and Methods
2.1. Mouse Study Design
Ten-week-old adult male Ldlr−/− mice were randomized into treatment groups, and fed either
normal chow or a high-fat, high-sucrose ((HFHS): 36% fat from lard, 36.2% sucrose diet with 0.15%
added cholesterol) for 12 weeks (chow: n = 5; HFHS: n = 10–15). Mice were then switched to one of
five test diets for an additional 8 weeks: (1) chow → chow diet; (2) HFHS → HFHS diet; (3) HFHS →
HFHS + 1% 9,11 CLA; (4) HFHS → HFHS + 1% 10,12 CLA; (5) HFHS → HFHS + caloric restriction
(CR). The study design is shown in Figure 1. CLA diets replaced 1% lard with 1% of either CLA
isomer (>90%purity, Nu-Check Prep, Waterville, MN, USA). All test diets were prepared by BioServ
(Flemington, NJ, USA) and have been previously described [4]. CR was begun at 85% total food
intake per mouse and adjusted daily to mirror weight loss by 10,12 CLA, ending at an average of
74.4% CR after 8 weeks. HFHS, 9,11 CLA, and 10,12 CLA diets were fed ad libitum. Mice were
individually housed for the duration of test diet feeding. Body weights were recorded weekly, and
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body composition, glucose and insulin tolerance, energy intake, and energy expenditure for these exact
mice have been previously reported [4], with relevant phenotypes shown in Table S1. As such, this
study adheres strongly to the “Reduction” component of the “Replacement, Reduction and Refinement
(3Rs)” of animal research, as the same animals were utilized for multiple studies. At sacrifice, blood
was collected and phosphate buffered saline (PBS)-perfused harvested tissues were snap-frozen in
liquid nitrogen and stored at −70 ◦C or were fixed with 10% neutral-buffered formalin and embedded
in paraffin wax. All experimental procedures were undertaken with approval from the Institution
Animal Care and Use Committee of the University of Washington (#3104-01 03/15/13–02/28/19) and
followed the guidelines of the National Institutes of Health guide for the care and use of laboratory
animals (NIH Publications No. 8023, revised 1978).
 
Figure 1. Study schematic. 10-week male low-density lipoprotein receptor deficiency (Ldlr−/−) mice
were fed either a chow or obesogenic high-fat, high-sucrose (HFHS) diet for 12 weeks, then either
maintained on those diets or switched to a HFHS diet containing 1% 9,11 conjugated linoleic acid (9,11
CLA) (w/w), 1% 10,12 conjugated linoleic acid (10,12 CLA) (w/w), or calorically restricted (CR) on the
HFHS diet to consume 85% of baseline food intake for an additional 8 weeks. wks: weeks.
2.2. Plasma Analyses
Triglycerides and cholesterol were measured from fasting plasma, and pooled plasma fast-phase
liquid chromatography (FPLC) fractions using colorimetric assays as previously described [20]. Lipids
were extracted from plasma using the Bligh and Dyer method [21], the fatty acid components were
derivatized into methyl esters, and fatty acid compositions were quantified using gas chromatography
as previously described [4]. Serum amyloid A (SAA) was quantified from plasma using enzyme-linked
immunosorbent assay (ELISA) [22].
2.3. Atherosclerosis
Aortas were perfused with saline, the perivascular adipose tissue (PVAT) surrounding the thoracic
aorta was completely removed and collected, and the thoracic aorta was excised down to the level of
the diaphragm. PVAT samples were flash frozen and stored at −80 ◦C, and aortas were fixed in 4%
formalin. Atherosclerosis from the aortic arch was quantified using the en face method using Sudan
IV staining as described previously [23,24], and from the aortic sinus using Movat’s pentachrome
staining as described previously [25]. Quantification for total lesion size and necrotic core areas was
performed blinded on digital images of stained tissue sections using Image Pro Plus analysis software
Version 6 (Media Cybernetics, Inc., Rockville, MD, USA). Necrotic cores were identified and outlined
for quantification using Image J software, as in shown in Figure S1.
2.4. Immunohistochemistry
Formalin-fixed, paraffin-embedded hearts were sectioned through the aortic sinus and stained
with Movat’s pentachrome for lesion quantification, Picro-Sirius Red for collagen quantification, and
a rat monoclonal Galectin-3 (MAC2) antibody (1:3000 dilution, Cedarlane Laboratories, Burlington,
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NC, USA) for relative quantification of atherosclerotic plaque macrophages. To further characterize
plaque macrophage phenotypes, sequential sections were also stained with rabbit polyclonal
antibodies against CD206 (Mannose receptor) to identify resident macrophages (1:100 dilution, AbCam,
Cambridge, MA, USA). Area quantification for MAC2 and Cluster of Differentiation 206 (CD206)
staining was performed on digital images of immunostained tissue sections using image analysis
software Image Pro Plus software Version 6 (Media Cybernetics, Inc., Rockville, MD, USA).
2.5. Quantitative Real-Time PCR
Aortas were perfused through the left ventricle with RNA-later (Thermo Fisher Scientific,
Waltham, MA, USA), excised from the heart to the diaphragm, snap frozen in liquid nitrogen and
stored at −80 ◦C until processed. PVAT was completely removed from the aortas prior to freezing.
Total RNA was extracted and purified using a commercially available kit (Qiagen RNeasy Mini
Kit (Qiagen, Hilden, Nordrhein-Westfalen, Germany)). After spectroscopic quantification, 2 μg of
RNA was reverse-transcribed, and the cDNA thus obtained was analyzed by real-time quantitative
polymerase chain reaction (RT-PCR) by standard protocols using an ABI 7900HT instrument (Thermo
Fisher Scientific, Waltham, MA, USA). Primer and probe set for individual genes (TaqMan system)
were purchased from Thermo Fisher Scientific. Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH)
was used as a housekeeping gene, levels of which did not change with the various treatments. Relative
amounts of the target gene were calculated using the ΔΔCt formula and expressed as a fold change
from HFHS-fed control mice. Accession numbers for Taqman primers used are shown in Table S2.
2.6. Bone Marrow-Derived Macrophage Culture
Bone marrow was isolated from donor C57Bl/6 male mice (n = 3) and differentiated into bone
marrow-derived macrophages (BMDMs) in Roswell Park Memorial Institute (RPMI)-1640 medium
(GE Life Sciences, Pittsburgh, PA, USA) that contained 30% L-cell conditioned medium over the course
of 7 days. Non-polarized BMDMs were treated with media alone (control), lipopolysaccharides (LPS)
(10 ng/mL for 4 h), interleukin-4 (IL-4) (10 ng/mL for 24 h), 9,11 CLA or 10,12 CLA (100 μM for
24 h, conjugated to bovine serum albumin (BSA, Sigma-Aldrich, St. Louis, MO, USA) as described
previously [5]). In a separate experiment, BMDMs were treated for 24 h with 10% v/v serum that
had been isolated from mice fed the HFHS diet with or without 1% 9,11 CLA or 1% 10,12 CLA. Total
RNA was extracted from >1 × 106 macrophages and reverse transcribed for RT-PCR analysis as
described above. To determine if CLA isomers influenced cholesterol loading, BMDMs were loaded
with acetylated low-density lipoprotein (Ac-LDL, 50 μg/mL) in the presence or absence of 9,11 CLA
or 10,12 CLA (100 μM) for 24 h. Intracellular cholesterol was quantified using an Amplex Red assay
(Thermo Fisher Scientific), presented normalized to total protein content (bicinchoninic acid (BCA)
assay, Thermo Fisher Scientific, Waltham, MA, USA).
2.7. Statistics
Data were analyzed using GraphPad Prism 6 software (GraphPad Software Inc., California, CA,
USA) and are represented as means ± standard errors. One-way analysis of variance (ANOVA) was
used to compare differences between mice receiving the different diets as indicated, and Bonferroni
post-hoc testing was used to detect differences among mean values of the groups. A p value < 0.05 was
considered statistically significant.
3. Results
3.1. Weight Loss by 10,12 CLA and CR Improves Plasma Triglycerides, Cholesterol, Fatty Acids, and
Lipoprotein Profiles
We previously reported that mice supplemented with 10,12 CLA lost significant body weight
and body fat, while mice calorically restricted to lose equivalent body weight lost mass equally from
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lean and fat compartments [4]. Control obese mice consuming the HFHS diet with or without 9,11
CLA remained obese [4]. Metabolic parameters such as glucose tolerance and energy expenditure
have been reported previously [4]. Consistent with weight loss, 10,12 CLA supplementation improved
plasma triglyceride (TG), cholesterol, and fatty acid (FA) levels when compared with obese HFHS-fed
control mice with and without 9,11 CLA, as seen in Figure 2A–C. Circulating lipoprotein profiles
measured using FPLC were similarly improved by 10,12 CLA, as seen in Figure 2D, with reduced
cholesterol content of VLDL and LDL-containing fractions. While mice that had undergone CR lost
equivalent body weight as 10,12 CLA-supplemented mice, they exhibited further improvements
in plasma triglycerides (TG), cholesterol, fatty acids (FA), and lipoprotein profiles, as shown in
Figure 2A–D. Moreover, plasma serum amyloid A (SAA), an acute phase reactant that becomes
chronically elevated during obesity [26], was also improved by CR, as shown in Figure 2E, but not
10,12 CLA. Supplementation with 9,11 CLA had no effect on plasma lipids or SAA. Collectively, weight
loss by both 10,12 CLA and CR resulted in improvements in plasma lipid levels, with significantly
lower lipid levels and SAA seen following CR-mediated weight loss.
Figure 2. Fasting plasma lipid levels were decreased by 10,12 conjugated linoleic acid (CLA) and
caloric restriction (CR). (A) Triglycerides (TG), (B) cholesterol, (C) fatty acids (FA), (D) fast phase liquid
chromatography (FPLC)-fractionated cholesterol, and (E) serum amyloid A (SAA) were quantified
from plasma following a 4-year. Fast in mice that had been fed chow or high-fat, high-sucrose (HFHS)
diet for 12 weeks followed by 8 weeks of the indicated diets. Plasma samples were pooled prior to
FPLC fractionation. Data are presented as mean ± standard error of mean (SEM), n = 5–15 mice/group.
* p < 0.05 from HFHS control; # p < 0.05 from 10,12 CLA. LDL, low-density lipoprotein; VLDL,
very-low-density lipoprotein; HDL, high-density lipoprotein.
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3.2. Weight Loss Following 10,12 CLA Supplementation Improves Atherosclerosis
To determine if weight loss-mediated reductions in plasma lipids improved atherosclerosis,
the extent of thoracic aortic atherosclerosis was evaluated using the en face technique. Obese mice
consuming the HFHS diet with or without 9,11 CLA, shown in Figure 3A,B, displayed extensive
atherosclerosis compared to chow-fed control mice, evident by increased Sudan IV staining. In
contrast, mice supplemented with 10,12 CLA had significantly reduced levels of atherosclerosis, with
no significant reductions following CR, despite having greater reductions in circulating lipid levels
and systemic inflammation. To determine if the anti-atherogenic effect of 10,12 CLA was not an effect
exclusive to the thoracic aorta, atherosclerotic lesions were quantified from the aortic sinus. Similarly,
obese mice fed the HFHS diet with or without 9,11 CLA had extensive lesion development in the aortic
sinus, as seen in Figure 3C,D. Also consistent with the en face analysis, 10,12 CLA supplementation
significantly reduced aortic sinus lesion size, shown in Figure 3C,D, with no significant reductions
following CR. Collagen levels were equivalent among treatment groups, shown in Figure 3E. Further,
necrotic core areas represented a smaller proportion of atherosclerotic lesions in 10,12 CLA-treated
mice as shown in Figure 3F,G. Taken together, 10,12 CLA supplementation significantly reduced
atherosclerotic lesion area from both the aorta and the aortic sinus with reduced necrotic core size,
with no significant differences evoked by CR-mediated weight loss or by 9,11 CLA. Thus, improved
aortic atherosclerosis appears to be an effect specific to 10,12 CLA supplementation, and not weight
loss or reduced circulating lipid levels per se.
3.3. Aortic Sinus Lesions Contain More Macrophages Following 10,12 CLA Supplementation
To further characterize the aortic sinus lesions in response to different diets, sections from the
aortic sinus were stained for Mac2, a general macrophage-specific marker. As expected, obese mice fed
the HFHS diet with or without 9,11 CLA or CR, shown in Figure 4A–C, exhibited higher Mac2-positive
areas than lean chow-fed mice. However, mice supplemented with 10,12 CLA had significantly elevated
Mac2 staining when expressed as total stained area or the percentage of total lesion area, as seen in
Figure 4B,C. Gene expression from the aortic arches of a separate cohort of mice confirmed elevation
of macrophage-specific genes Emr1 and Cd68 from mice given 10,12 CLA, as seen in Figure 4D. The
lack of a corresponding increase in monocyte recruitment chemokines Ccl2 and Saa3 implies that the
enrichment in lesion macrophages may not be due to increased monocyte recruitment, as shown in
Figure 4F. These results suggest that while 10,12 CLA supplementation results in fewer atherosclerotic
lesions, those lesions contain more macrophages.
Figure 3. Cont.
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Figure 3. Atherosclerosis lesion size was decreased by 10,12 CLA, but not CR. Mice were fed either
chow or HFHS diet for 12 weeks, then continued on the indicated diets for an additional 8 weeks. (A,B)
Aortas were prepared en face (A), stained with Sudan IV, and lesions imaged and quantified using
Image Pro Plus software (B). (C–G) Sections through the aortic sinus of the heart were stained with
Movat’s pentachrome, and lesion area (C), collagen (D), and necrotic core area (F–G) was quantified
using Image Pro Plus software. Data are presented as mean ± SEM, n = 5–10 mice/group. * p < 0.05
from HFHS control.
Figure 4. 10,12 CLA increases macrophage content of atherosclerotic lesions. Mice were fed either
chow or HFHS diet for 12 weeks, then continued on the indicated diets for an additional 8 weeks. (A)
Sections through the aortic sinus of the heart were stained with a Mac2 antibody, and (B,C) quantified
using Image Pro Plus software. n = 5–10 mice/group. Different letters indicate a significant difference
(p < 0.05). (D–G) Gene expression was quantified from the aortic arch (D,F) or the surrounding
perivascular adipose tissue (PVAT, E,G) from a different cohort of different mice. n = 8 mice/group.
Data are presented as mean ± SEM. * p < 0.05 from HFHS control.
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Macrophages are generally classified based on their function, stratified as “classically”,
“alternatively”, or “metabolically” activated [27]. Classically-activated macrophages will be defined
herein as those that express Nos2 and secrete pro-inflammatory cytokines such as tumor necrosis
factor (TNF), while alternatively-activated, or resident, macrophages express Egr2 and secrete type-2
cytokines such as IL-4 [27]. A previous study in the exact same mice presented herein showed
that adipose tissue from 10,12 CLA-treated mice exhibited a significant elevation in gene expression
for markers indicative of alternative activation, or resident M2 macrophages, including Arg1 and
Egr2 [4]. To determine if the elevation of macrophages in sinus lesions was due to enrichment in M2
macrophages, sinus sections were stained for the mannose receptor, CD206. As shown in Figure S2A,
there were no differences in CD206 staining between groups. Gene expression from aortic arches
confirmed the lack of enrichment in resident macrophage markers Egr2 and Mrc1 (encodes CD206),
with a significant reduction in the M1 marker Nos2, as seen in Figure 4D, promoting a reduction in
the M1/M2 ratio shown in Figure S2B. This suggests that M2 macrophages may predominate in 10,12
CLA-supplemented mouse aortas. In contrast, perivascular adipose tissue (PVAT) surrounding the
aortic arches was enriched in the general macrophage markers Mac2 and Emr1 as well as resident
macrophage markers Egr2 and Mrc1 following 10,12 CLA supplementation as seen in Figure 4E.
Moreover, PVAT from 10,12 CLA-supplemented mice was enriched with type-2 cytokine expression,
including Il4 and Il10, further supporting an M2 phenotype. Expression of chemokines Ccl2 and Ccl7
was increased in PVAT in response to 10,12 CLA, shown in Figure 4G, suggesting the recruitment of
new macrophages. Finally, Fndc5, the gene encoding the browning marker irisin, and Gpr43, a major
short-chain fatty acid (SCFA) receptor, were also enriched in PVAT from 10,12 CLA-treated mice, as
seen in Figure 4G, supporting the known effects of 10,12 CLA to promote the browning of adipose
tissue and increases in fecal and systemic SCFA [4,28]. In summary, while 10,12 CLA increased the
macrophage content of aortic and sinus lesions and the surrounding PVAT, macrophage polarization
towards a resident M2 phenotype was only observed in PVAT.
3.4. 10,12 CLA Induces a Resident Alternatively-Activated Macrophage Phenotype
To further examine what effect 10,12 CLA has on macrophage polarization in vitro, bone
marrow-derived macrophages (BMDMs) were cultured with or without agents known to polarize
macrophages towards classically- or alternatively-activated profiles. As shown in Figure 5A–F, BMDMs
that have been classically-activated by treatment with lipopolysaccharide (LPS) express high levels of
type-1 cytokines Il1β and Tnf and the classic marker of classically activated macrophages Nos2, while
BMDMs that have been alternatively-activated by IL-4 treatment express Il4, Arg1, and Egr2, markers
that have been previously associated with resident macrophage populations [29]. BMDMs treated with
10,12 CLA express a similar complement of markers as those treated with IL-4, as seen in Figure 5A–F,
suggesting that 10,12 CLA promotes an alternative macrophage phenotype. Further, BMDMs treated
with 10% serum collected from mice that had been fed a HFHS diet that contained 10,12 CLA, as
in Figure 1, exhibited a similar gene expression profile as shown in Figure 5G–L, suggesting that
a component of the serum in 10,12 CLA-supplemented mice promotes the alternative activation of
macrophages. Co-treatment with 9,11 CLA or 10,12 CLA had no impact on acetylated LDL-mediated
cholesterol loading of BMDMs as seen in Figure S3. Collectively, these results suggest that 10,12
CLA: (1) reduces plasma lipid levels and atherosclerotic lesion area, (2) increases atherosclerotic
lesion macrophage content, and (3) polarizes the surrounding adipose tissue macrophages towards an
alternative phenotype.
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Figure 5. 10,12 CLA promotes the alternative polarization of macrophages in vitro. (A–F) bone
marrow-derived macrophages (BMDMs) were treated with media alone (control), lipopolysaccharides
(LPS) (10 ng/mL for 4 h), interleukin-4 (IL-4) (10 ng/mL for 24 h), or 10,12 CLA (100 μM for 24 h). (G–L)
BMDMs were treated for 24 h with 10% serum isolated from mice fed a HFHS diet with or without 1%
9,11 or 10,12 CLA. Total RNA was extracted from >1 × 106 macrophages and reverse transcribed for
real-time quantitative polymerase chain reaction (RT-PCR) analysis. n = 3; data are presented as mean
± SEM. * p < 0.05 from media or HFHS control.
4. Discussion
While it has been suggested that mixed CLA supplementation may have anti-atherogenic
properties in certain mouse models [8–12,30], we now show for the first time that obese HFHS diet-fed
Ldlr−/− mice, which represent a more humanized model of metabolic syndrome, are protected from
atherosclerosis following CLA supplementation, and that the 10,12 isomer of CLA is responsible for
this protection. Further, the anti-atherosclerotic effects of 10,12 CLA may be independent from its
weight loss and lipid-lowering effects, as a weight-matched control group undergoing CR-mediated
weight loss does not exhibit equivalent atheroprotection. Moreover, a potential mechanism by which
10,12 CLA is atheroprotective may involve its effects on local macrophage populations.
It is well known that dramatic lipid-lowering therapies, such as statins or PCSK9 inhibitors,
improve atherosclerosis in humans and mice [31,32], and that atherosclerosis has a strong inflammatory
component [33]. It is therefore striking that 10,12 CLA supplementation resulted in reduced
atherosclerotic lesion size while CR did not, despite profoundly improved systemic triglyceride,
cholesterol, and SAA levels by CR. It is possible that CR-mediated improvements in lipids and SAA
were insufficient to modulate atherosclerosis in the time frame of this study. It is also possible that the
improvements in systemic lipids and inflammation by CR were trumped by a lack of improvement at
the local tissue level.
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The reduction of atherosclerosis by 10,12 CLA supplementation was also striking, given the
increased macrophage content of those lesions. It has been previously reported that atherosclerosis
regression in response to thiazolidinedione treatment occurs despite increased lesion macrophage
content [34], which were identified as largely resident M2 macrophages. Moreover, it is becoming
increasingly appreciated that M2 macrophages support lesion regression by resolving inflammation
and promoting tissue remodeling [34–36]. Mice deficient in transcription factors that are required for
M2 polarization have accelerated atherosclerosis [37], while administering type-2 cytokines such as
IL-4 to mice protects against atherosclerosis [38]. Thus, it is tempting to speculate that the reduction
in atherosclerosis in response to 10,12 CLA is due to enhanced M2 macrophage content. Indeed,
we previously showed that these exact same mice supplemented with 10,12 CLA had increased
markers of alternatively activated macrophages within adipose tissue as seen in Table S1 [4]. The
polarization towards an M2 phenotype could explain the increased macrophage content, as IL-4 (which
is secreted from M2 macrophages) is a strong stimulus for macrophage proliferation [39]. While we
did not observe appreciable changes in alternative macrophage markers directly quantified from
atherosclerotic lesions in these mice, it is possible that a more sensitive method such as analysis
of laser capture microdissected macrophages would reveal a more robust effect. Nevertheless, the
observed decrease in the M1/M2 ratio within the aortas of 10,12 CLA-treated mice suggest that M2
macrophages play a more dominant role, supporting previous observations that the M1/M2 ratio
is positively correlated with the severity of coronary artery disease [40]. Notably, and in contrast
to the current study, a growing body of work suggests that IL-4 may exert pro-atherogenic effects
by accelerating endothelial cell apoptosis and/or enhancing vascular inflammation and oxidative
stress [41–47]. While we did not observe enhanced inflammation (i.e., increased Tnf, Saa3, or Ccl2) in
aortic or PVAT tissue from mice supplemented with 10,12 CLA, nor in macrophages treated with IL-4,
whether the observed increase in IL-4 is causally associated with improved atherosclerosis in these
mice remains to be explored.
The lesion microenvironment, which includes adjacent PVAT, is thought to be important for
atherosclerotic progression and/or regression [48]. Mice deficient in PVAT exhibit endothelial
dysfunction, and lose cold-mediated protection from atherosclerosis [49]. Our observation that resident
macrophages and anti-inflammatory signals are enriched in the PVAT immediately adjacent to the aorta
suggests that a signal from the PVAT may confer atheroprotection. It is possible that the “alternative”
M2 milieu in the lesion microenvironment (in this case PVAT) promotes regression of atherosclerosis
and/or plaque stabilization, as is evidenced by the reduced necrotic core size. Previous observations in
humans support this notion, as epicardial adipose tissue M1:M2 macrophage ratios positively correlate
with the severity of coronary artery disease [40]. PVAT is a plastic adipose tissue depot, and can possess
a phenotype resembling brown adipose tissue [50]. As we have previously shown that 10,12 CLA
supplementation promotes the browning and M2 macrophage enrichment of white adipose tissue [4],
and we now show that PVAT in these mice expresses elevated levels of irisin and the M2 markers
Egr2 and Mrc1, it is plausible that M2 macrophage-containing PVAT secretes factors that promote
atherosclerosis regression. Future PVAT transplantation studies could address whether this is the case.
In addition to changes in adipose tissue, 10,12 CLA consumption promotes significant alterations
to the gut microbiota, characterized by increased abundance of species that produce SCFAs such as
acetate and butyrate [28]. Metabolic diseases such as atherosclerosis are associated with decreased
SCFA-producing bacteria such as the butyrate-producing genera Butyrivibrio and Roseburia [51]. In
our previous study using the exact same mice presented herein, Butyrivibrio and Roseburia species
were significantly enriched in the gut microbiota of mice given 10,12 CLA [28]. Atherosclerosis-prone
ApoE−/− mice fed a butyrate-supplemented chow diet are protected from atherosclerosis [52,53],
and mounting evidence shows that butyrate blunts macrophage inflammation [54–56], suggesting
that butyrate has anti-atherogenic properties. Further, evidence suggests that butyrate promotes
macrophage M2 polarization [57]. Thus, it is tempting to speculate that at least part of the
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atheroprotection incurred by 10,12 CLA may be related to its effects on the gut microbiota and
gut-derived SCFA.
In conclusion, mice supplemented with 10,12 CLA experience reduced atherosclerosis and an
anti-inflammatory, M2-like state in the aortic lesion microenvironment. Mice that are calorically
restricted with markedly lowered cholesterol, triglyceride, and systemic inflammation do not
experience such atheroprotection, suggesting that alterations to the aortic microenvironment may
be more effective at impacting atherosclerosis. Future studies will evaluate a causal role for PVAT
components and the gut microbiota in promoting atherosclerosis regression.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/10/10/
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CLA conjugated linoleic acid
HFHS high fat high sucrose
PVAT perivascular adipose tissue
LDLR low-density lipoprotein receptor
CR caloric restriction
SAA serum amyloid A
BMDM bone marrow-derived macrophages
FPLC fast phase liquid chromatography
TG triglycerides
FA fatty acids
SCFA short-chain fatty acids
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Abstract: The European Food Safety Authority (EFSA) published a risk assessment of erucic acid
(22:1n-9) in 2016, establishing a Tolerable Daily Intake (TDI) for humans of 7 mg kg−1 body weight
per day. This report largely excluded the contribution of erucic acid from fish and seafood, due to this
fatty acid often not being reported separately in seafood. The Institute of Marine Research (IMR) in
Norway analyzes erucic acid and has accumulated extensive data from analyses of fish feeds, farmed
and wild fish, and seafood products. Our data show that rapeseed oil (low erucic acid varieties)
and fish oil are the main sources of erucic acid in feed for farmed fish. Erucic acid content increases
with total fat content, both in farmed and wild fish, and it is particularly high in fish liver, fish oil,
and oily fish, such as mackerel. We show that the current TDI could be exceeded with a 200 g meal of
mackerel, as at the maximum concentration analyzed, such a meal would contribute 143% to the TDI
of a 60 kg person. These data cover a current knowledge gap in the scientific literature regarding the
content of erucic acid in fish and seafood.
Keywords: erucic acid; fish; seafood
1. Introduction
The long-chain fatty acid erucic acid (22:1n-9) is a naturally occurring fatty acid, found in high
concentrations in seeds of the family Brassicaceae, such as rapeseed and mustard seed. Even though
natural forms of rapeseed contain high levels of erucic acid (usually more than 40% of the total fatty
acids), commercially bred rapeseed cultivars today (also known as canola) typically have levels below
0.5% of total fatty acids [1]. High erucic acid cultivars are still grown for industrial, non-food purposes,
while mustard oil that is sold for human consumption still may have a high content of erucic acid
(up to ~50%) [2]. Low concentrations of erucic acid are naturally present in other food sources, such
as fish.
The heart is the target organ for adverse effects of exposure to high concentrations of erucic acid,
which may lead to lipidosis (accumulation of triacylglycerol as lipid droplets) in the heart muscle,
reduced contractility, and eventually tissue damage [3]. This condition has never been documented
in humans, but in both experimental and production animals, such as rats, pigs, and chicken [4].
The cause appears to be poor mitochondrial beta-oxidation of this fatty acid, especially in the heart,
resulting in an accumulation of erucic acid in neutral lipid droplets. There is primarily an increase in
triacylglycerol, while the levels of phospholipids and cholesterol remain relatively constant [5].
The European Food Safety Authority (EFSA) published a risk assessment of erucic acid in feed
and food in 2016 [4], establishing a Tolerable Daily Intake (TDI) for humans of 7 mg/kg body weight
per day based on the occurrence of cardiac lipidosis in experimental animals. The EFSA report largely
excluded the contribution of erucic acid from seafood, on the following grounds: “Besides the occurrence
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in oil seeds, erucic acid also occurs naturally in fish and seafood. These food groups mainly contain cetoleic
acid (22:1n-11), which is usually accompanied by minor proportions of erucic acid [6]. It is also of importance
that the database of the Max Rubner Institut provides a single value for 22:1 fatty acids, with no distinction
between erucic acid (22:1n-9) and cetoleic acid (22:1n-11) or between the cis and trans isomers. Similarly, the US
Department of Agriculture database does not differentiate between erucic acid and cetoleic acid, and it reports
cis 22:1 as the sum of both 22:1n-9 and 22:1n-11. Therefore, information from these databases has not been
included”. Clearly, there is a knowledge gap regarding the occurrence of erucic acid in fish and seafood.
Erucic acid (22:1 n-9) and cetoleic acid (22:1 n-11) are quantified separately at the Institute of
Marine Research (IMR) in Norway, with an accredited method that obtains good results in proficiency
testing (ring trials). Validity tests and parameter controls are performed on a daily routine basis and
our quality control systems are audited annually by Norwegian Accreditation, which is the national
signatory of the European co-operation for Accreditation Multilateral Agreement (EA MLA). Through
national surveillance programs of fish feed, farmed fish, wild caught fish, and commercial seafood
products, our institute has extensive data on the fatty acid composition of these products, including
the content of erucic acid. While some of these data are available in our seafood database [7], data on
erucic acid have never been compiled for different seafood products and have not been published
in a scientific journal. Furthermore, we have unpublished data on the metabolism of erucic acid in
farmed fish from feeding trials with Atlantic salmon (where the main focus of previous publications
has been on other fatty acids). This paper aims to fill current knowledge gaps in the scientific literature
on erucic acid in seafood, by giving an overview of data on the occurrence of erucic acid in fish and
seafood, and how this fatty acid is metabolized in farmed fish. The data are discussed in the context of
fish and human health.
2. Materials and Methods
2.1. Feed, Fish and Seafood Samples
Data for this paper was compiled from analyses that were conducted in surveillance programs on
fish feed, farmed fish, wild fish, and seafood products performed on behalf of the Norwegian Food
Safety Authority. Samples of fish feed and fish feed ingredients were sampled by the Norwegian
Food Safety Authority from Norwegian feed producers or at fish farms, representative of fish feed
production in Norway. Before analysis, feed samples were prepared using standardized methods
for the official control of feed. Samples of farmed fish were collected by official inspectors from the
Norwegian Food Safety Authority from all fish-producing regions in Norway. The sampling was
randomized with regard to season and geographical location. Wild fish and seafood samples were also
collected through national surveillance programs in Norway.
2.2. Method of Fatty Acid Analysis
Fatty acids were analyzed by an accredited method. Briefly, lipids from the samples were extracted
in chloroform/methanol (2:1, v/v), according to the method of Folch et al. [8]. The extracted lipids
were filtered, saponified, and fatty acid methyl esters were prepared by boron trifluoride (12% BF3
in methanol), as described previously [9]. Methyl esters were separated on a Thermo Finnegan
Trace 2000 GC equipped with a fused silica capillary column (CP-sil 88; Chrompak Ltd., Middelburg,
The Netherlands). The temperature programming was 60 ◦C for 1 min, 160 ◦C for 28 min, 190 ◦C for
17 min, and finally, 220 ◦C for 10 min, with all temperature ramps being 25 ◦C per min. Individual
methyl esters were identified by retention time in comparison to standard mixtures of methyl esters
(Nu-Chek, Elysian, Waterville, MN, USA). All of the samples were integrated using the software
Chromeleon®, connected to the gas liquid chromatograph. Amount of fatty acid per gram sample was
calculated using 19:0 methyl-ester as an internal standard. The separation of 22:1n-9 and 22:1n-11 is
shown in Figure 1.
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Figure 1. Chromatogram showing the separation of cetoleic acid (22:1n-11) and erucic acid (22:1n-9) in
the fatty acid analysis.
2.3. Feeding Trial with Atlantic Salmon
Data are from a published feeding trial with Atlantic salmon [10], where data specifically on
erucic acid were not included. Fatty acid analysis was conducted, as described above, in some cases
with prior separation of the neutral and polar lipid fraction, as described by Sissener et al. [11]. Yttrium
oxide for digestibility calculations was analysed in freeze dried faeces and feed samples by ICP-MS
(inductively coupled plasma mass spectrometry) [12]. Digestibility was calculated as follows:
Apparent digestibility coefficient = 100 − (% yttrium in feed ÷ % yttrium in feces) ×
(% nutrient in feces ÷ % nutrient in feed) × 100) (1)
Retention of erucic acid in whole fish during the experiment was calculated as follows:
Nutrient retention = (final biomass × final nutrient concentration − initial biomass ×
initial nutrient concentration) × 100 ÷ (Total feed intake × nutrient concentration in feed). (2)
Linear regression analyses were conducted in GraphPad Prism 6.0 (Graphpad Software Inc.,
La Jolla, CA, USA).
3. Results
3.1. Content of Erucic Acid in Fish Feed Ingredients and Fish Feed
Erucic acid as a percentage of total fatty acids analyzed in fish feed ingredients in the period
2004–2008 and in fish feed from 2006, 2008, and 2012–2016 is given in Table 1. Erucic acid is present in
several feed ingredients, with the highest maximum value being found in rapeseed oil (canola) at 3.2%
of fatty acids, and secondly in fish oil with 2.5%. The mean values are, however, similar in fish oil,
rapeseed oil, and fish silage (where the lipid fraction naturally would be similar to fish oil).
Table 1. Erucic acid (22:1n-9) as percentage of total fatty acids in fish feed and feed ingredients.
The table shows the number of samples (N) for each year and matrix, the mean value of erucic acid,
as well as the minimum and maximum values.
Year Matrix N Mean Min. Max.
2004 1 1.0 1.0 1.0
2005 6 0.9 0.7 1.1
2006 Fish silage 8 1.1 1.0 1.2
2007 5 0.9 0.5 1.3
2008 2 1.0 1.0 1.0
2007 1 0.1 0.1 0.1
2008 Fish meal 4 0.6 0.1 1.3
2004 2 0.1 0.1 0.2
2005 Vegetable oil 3 0.8 0.2 1.5
2006 (uspecified) 4 0.2 0.0 0.5
2007 2 0.8 0.7 0.8
2008 1 0.7 0.7 0.7
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Table 1. Cont.
Year Matrix N Mean Min. Max.
2004 3 0.6 0.2 0.8
2005 Rapeseed oil 9 0.8 0.2 2.4
2006 (canola) 7 1.3 0.0 3.2
2007 7 0.7 0.3 0.9
2008 7 0.7 0.2 2.7
2004 6 1.4 0.1 2.4
2005 Fish oil 10 0.6 0.1 1.8
2006 9 0.7 0.1 2.1
2007 10 0.7 0.2 1.5
2008 6 0.7 0.1 1.1
2006 30 0.8 0.0 1.7
2008 10 0.8 0.3 1.0
2012 Fish feed 13 0.6 0.2 1.1
2013 69 0.5 0.2 1.0
2014 73 0.5 0.2 0.9
2015 20 0.4 0.2 0.9
2016 10 20 0.3 0.2 0.5
10, [13]. Data from the other years have not been published in reports.
Additionally, the concentration of erucic acid in mg/100 g in fish feeds from 2012–2016 is given in
Table 2, while quantitative data are not available for the feed ingredients or the feed samples that were
collected before 2012.
Table 2. Concentration of erucic acid (22:1n-9), given as mg fatty acid/100 g sample, in fish feed.
The table shows the number of samples (N) for each year, the mean value of erucic acid, as well as the
minimum and maximum values.
Year N Mean Min. Max.
Fish Feed
2012 13 152 29 317
2013 69 138 22 250
2014 73 146 56 333
2015 20 113 53 181
2016 5 20 096 52 151
5, [13].
3.2. Transfer from Feed to Fish
The digestibility of erucic acid was calculated from a previously published feeding trial with
Atlantic salmon [10], with an average value of 98.1%. The digestibility was not affected by the content
of erucic acid in the eight experimental feeds, which varied from 40–170 mg/100 g feed. The water
temperature was 12 ◦C and the digestibility of erucic acid was similar to other unsaturated fatty acids
of similar chain length. Fatty acid retention in salmon (the amount of a fatty acid accumulated in
the fish, in percentage of the amount of the fatty acid consumed from the feed) was also calculated.
The retention varied among the dietary groups, and it displayed a clear decline with increasing dietary
erucic acid concentration (see Figure 2).
Values above 100% in several of the dietary groups suggest that this fatty acid, in addition to being
efficiently stored in the fish, was also produced to some extent from other fatty acids, most likely from
18:1n-9, which was retained in the fish to a much lower extent. This suggests selective beta-oxidation
and/or bioconversion to other fatty acids. Despite an increased storage/production of erucic acid
when the dietary content was low, the absolute amount of erucic acid in the salmon fillet increased
with increasing dietary content of this fatty acid (see Figure 3).
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Figure 2. Retention (the amount of erucic acid accumulated in the fish during the feeding period in
percentage of the amount eaten) of erucic acid in whole fish in relation to dietary content of erucic acid,
in a feeding trial with Atlantic salmon [10] given eight experimental feeds ranging from 40–170 mg
erucic acid/100 g feed. The adjusted R-value and the p-value for a linear regression model are given.
Figure 3. Content of erucic acid (22:1n-9) in salmon fillet in relation to dietary content of erucic acid,
in a feeding trial with Atlantic salmon [10] given eight experimental feeds ranging from 40–170 mg
erucic acid/100 g feed. The adjusted R-value and the p-value for a linear regression model are given.
In the polar lipids (cell membranes) of the heart, the content of erucic acid was mainly below
the limit of detection (<0.1% of total fatty acid). This was also the case in the polar lipids of the liver.
The content of erucic acid in liver neutral lipids (NL) was also low, but it increased somewhat with
increasing dietary erucic acid (data not shown). Erucic acid was also low in neutral lipids in the
heart, but somewhat higher than liver NL, and increased with increasing dietary erucic acid (Figure 4).
There was no correlation between the total amount of neutral lipid in the heart and dietary erucic acid
content (p = 0.26).
The feed with the highest erucic acid concentration in this trial contained 170 mg/100 g and it
was a feed with a high inclusion of low erucic acid rapeseed (canola) oil (18% of the recipe/74% of
added oil), while the use of other vegetable oils gave lower concentrations in the other feeds.
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Figure 4. Content of erucic acid (22:1n-9) in neutral lipids (NL) of the heart in Atlantic salmon,
in relation to the dietary content of erucic acid. The data are from a feeding trial [10] where salmon
were given eight experimental feeds ranging from 40–170 mg erucic acid/100 g feed. The adjusted
R-value and the p-value for a linear regression model are given.
3.3. Erucic Acid in Seafood
Concentrations of erucic acid in fish fillet, some whole fish and fish livers are given in Figure 5.
Figure 5. Content of erucic acid (22:1n-9), given as mg fatty acid/100 g sample in fish (in fillets if
not otherwise specified, as well as some data for whole fish and fish livers towards the right of the
figure). The bars show the mean values of erucic acid, as well as the minimum and maximum values.
The number of samples analyzed for each category (N) are as follows; salmon, farmed n = 590, salmon,
wild n = 99, trout n = 16, cod n = 60, saithe n = 40, tusk n = 63, ling n = 70, blue ling n = 10, wold
fish n = 3, pollack n = 50, hake n = 46, American plaice n = 5, plaice n = 20, halibut n = 68, Greenland
halibut n = 18, dogfish n = 15, North sea herring n = 19, NSS herring n = 30, mackerel n = 20, horse
mackerel n = 21, capelin (whole fish) n = 10, sprat (whole fish) n = 8, blue whiting (whole fish) n = 10,
cod liver n = 51, saithe liver n = 30. Many of the values were below the level of quantification (LOQ)
for the analytical method, which is 1mg/100g. When some values were below the LOQ, 0 was used
in calculation of the mean (lowerbound LOQ). Source of data: from the Institute of Marine Research’
seafood database [7].
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The content of erucic acid was highly variable, among both species and individual samples
within the same species. In farmed salmon, the mean concentration of erucic acid was 89.4 mg/100 g,
with a range from 11.5 to 179.0 mg/100 g. Low levels were found in the fillets of lean fish species
(e.g., cod, saithe, tusk, ling, wolf fish, and pollock, mean values from <LOQ–3.7 mg/100 g), as compared
to the much higher levels in fillets of oily fish (e.g., mackerel, halibut, herring, and salmon, mean values
from 33.8–260.4 mg/100 g). The highest levels were detected in liver of cod and saithe (mean values
>400 mg/100 g). In processed seafood products (Figure 6), the highest concentrations of erucic acid
were found in fish oil supplements for human consumption (mean value 371.3 mg/100 g and maximum
value 678 mg/100 g), followed by mustard herring (mean value 334.4 mg/100 g) and different mackerel
products (~250 mg/100 g in peppered mackerel, spiced mackerel, and cold- smoked mackerel).
Figure 6. Content of erucic acid (mg fatty acid/100 g sample) in processed seafood products sampled
in Norway. The bars show the mean value of erucic acid, as well as the minimum and maximum
values. The number of samples for each category were as follows; lobster, white meat n = 15, king crab
n = 151, crab, brown meat n = 10, crab, claw n = 10, shrimp n = 11, crayfish n = 52, blue mussel n = 12,
gratinated fish n = 5, fish cakes n = 5, fish patties n = 5, fish sticks n = 5, fish pudding n = 5, breaded
saithe n = 2, saithe w/onion n = 5, breaded cod n = 3, herring sandwich toppings n = 44, mackerel in
tomato sauce n = 11, other mackerel sandwich toppings n = 13, smoked salmon n = 18, warm-smoked
salmon n = 3, gravlax n = 6, smoked trout n = 4, fish oil (dietary supplement) n = 17, canned sprat n = 8.
Many of the values were below the level of quantification (LOQ) for the analytical method,
which is 1 mg/100 g. When some values were below the LOQ, 0 was used in calculation of the mean
(lowerbound LOQ). Source of the data: the Institute of Marine Research’ seafood database [7].
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3.4. Human Consumption
The human intake of erucic acid from seafood depends on the amount of seafood consumed and
the concentration of erucic acid in that seafood. Table 3 gives examples of erucic acid intake associated
with consumption of a 200 g portion of different fish and the contribution to the TDI for a person with
a body weight of 60 kg. A 200 g portion of farmed salmon with the mean analyzed concentration of
erucic acid would contribute with 43% of the TDI in a 60 kg person, while 200 g of mackerel would
cover the entire TDI (102%). However, at the maximum analyzed concentrations in these species,
a 200 g portion of farmed salmon or mackerel would contribute 85% and 143% of the TDI, respectively.
Table 3. Intake of erucic acid (22:1n-9) when consuming 200 g fish and the proportion of the Tolerable
Daily Intake (TDI) of 7 mg per kg bodyweight per day, for a 60 kg person, using the mean and the








Farmed salmon 179 43 358 85
Wild salmon 141 34 290 69
North sea herring 271 65 411 98
Mackerel 429 102 601 143
4. Discussion
The ubiquitous presence of erucic acid in the lipids of fish and shellfish indicates that this fatty
acid is naturally present in the marine food chain. Our data clearly show a relationship between the
lipid content and the erucic acid content in various fish species, with a higher content in fish fillets
with a high lipid level. These data support the limited data set on seafood from the EFSA report,
showing the highest seafood levels of erucic acid in the oily fish species halibut, salmon, herring, sprat,
and mackerel, with maximum values between 220–430 mg/100 g [4]. Average levels of erucic acid
reported by the EFSA for salmon and trout’ samples (~100 mg/kg), were also comparable to those that
were found in the present study. Higher concentration of erucic acid in farmed as compared to wild
salmon probably reflect the higher lipid content in farmed salmon, which was reported to be almost
twice as high in the farmed salmon [14]. Our data show that both fish oil and rapeseed oil are sources
of erucic acid in commercial feeds for farmed salmon, contributing similar amounts. For fish oils,
the geographical origin of the oil might affect erucic acid content, since long chain monounsaturated
fatty acids are particularly high in oily fish species from the Northern hemisphere, such as capelin.
However, the origin of the fish oils was not specified for the oils in the current dataset. In a previous
salmon feeding trial that used capelin oil as the lipid source, the experimental feed contained 440 mg
erucic acid/100 g feed [15], exceeding the levels of erucic acid in all of the commercial feeds that were
analysed in the surveillance programme. This was gradually reduced to 120 mg/100 g with increasing
replacement of the capelin oil by low erucic acid rapeseed oil (25–100% replacement). This shows that
certain fish oils can be a greater source of erucic acid in fish feeds than rapeseed oil. However, high
inclusion of fish oil is not a common feeding strategy used in commercial salmon feeds. Currently,
commercial salmon feeds in Norway contain on average about two-thirds rapeseed oil (low erucic
acid varieties) and one-third fish oil [16].
The main adverse effect of erucic acid found in various animal species is accumulation of lipid
droplets (neutral lipids) in myocardial cells. This is a reversible effect, but high doses of erucic acid
may cause degenerative lesions in the muscle fibers, followed by necrosis of the myocardial tissue [3].
A feeding study with high erucic acid rapeseed oil (HEAR) was conducted in Atlantic salmon [17],
where both HEAR, low erucic acid rapeseed oil (LEAR), and soybean oil were used to replace capelin
oil, resulting in dietary erucic acid concentrations varying from 0.3 to 28.1% of total fatty acids. There
was no effect on weight gain, unlike observations in warm-blooded animals, possibly indicating
a higher tolerance for this fatty acids in fish [17]. The lack of significant differences in heart lipid
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content after two and four weeks of feeding was probably due to low n and high variation (as there
were large numerical differences), while heart lesions were not investigated. Heart lesions have been
reported in Atlantic salmon fed sunflower oil [18], compared to few such lesions in fish fed a fish oil
diet. While dietary erucic acid level was not reported in that paper, it is likely to have been higher in
the fish oil diet. Consequently, the dietary content of erucic acid was not a likely cause of these lesions.
The presence of lesions in the coronary artery have been investigated in both a short term study in
salmon fed with diets containing fish oil, rapeseed oil, or 50:50 fish oil and rapeseed oil [19], and in
a long-term study where fish oil was compared with a blend of vegetable oils [20]. There were no
apparent effects on lesions in the coronary artery of fish oil versus vegetable oil fed fish in either study.
In the feeding trial described in the current paper, there was no correlation between the total amount
of neutral lipid in the heart and dietary erucic acid content, and hence no indication that erucic acid
causes an accumulation of neutral lipids in the heart at these low dietary levels. In another study,
increased level of TAG was found in the heart of salmon fed vegetable oil when compared to salmon
fed fish oil, while the content of erucic acid in both heart tissue and muscle tissue was the same in both
dietary groups (erucic acid levels were not reported for the diets) [21]. To sum up, there is limited
information on how erucic acid might affect lipid accumulation in the heart, development of lesions or
other health parameters in farmed fish, but the available information does not indicate such effects at
the concentrations of erucic acid present in commercial salmon feeds.
Salmon and other fish are capable of both chain elongation and beta-oxidation of fatty acids,
and are hence able to produce erucic acid from shorter chain fatty acids, such as oleic acid (18:1n-9)
and gondoic acid (20:1n-9), as well as from longer chain fatty acids, such as nevronic acid (24:1n-9).
Fish are also able to desaturate fatty acids, including the insertion of double bonds in the n-9 position
of the carbon chain, and are thus theoretically able to produce erucic acid from saturated fatty acids.
Although the retention of erucic acid (possibly including some in vivo production) appeared to increase
with decreasing dietary levels in the present feeding trial, total erucic acid levels in the fish decreased
with decreasing dietary levels. The retention of this fatty acid is also likely to be dependent on feed
concentrations, as most other fatty acids are retained in salmon to a high extent when low levels are
provided in the feed (like for erucic acid in the present trial), while the retention is much lower when
feed concentrations are high [22]. In support of this, fish that were fed a HEAR diet (with erucic acid
constituting 28.1% of dietary fatty acids) for 18 weeks, had only 6.5% erucic acid of the total fatty acids
in heart triacylglycerols and 11.5% in muscle triacylglycerols [17]. If one would want to reduce the
amount of erucic acid in farmed fish as compared to current levels, this could easily be achieved by
utilizing other lipid sources than fish oils and rapeseed oil, for instance, other vegetable oils.
Our data indicate that seafood consumption might contribute considerably to the TDI, especially
for population groups with a high intake of oily fish. One may even exceed the TDI by eating a single
200 g portion of mackerel. Based on the maximum erucic acid concentration found in cod liver, a 50 g
serving would exceed the TDI for a 60 kg person. However, it must be taken into account that the TDI
is a chronic health-based guidance value and includes an uncertainty factor of 100. It is more correct
to compare the TDI with chronic exposure rather than intake from a single meal. In the EFSA report,
the contribution of “fish meat” to total erucic acid exposure was important in some adult populations in
different dietary surveys, with contributions up to 41% of the total exposure [4]. Higher contributions
than this could be expected in certain population groups in Norway (and high consumption population
groups in other European countries), due to the consumption of oily fish, fish liver, and the intake
of fish oil supplements, such as cod liver oil. In Norway, the mean consumption of fish in two-year
old’s is 16 g/day, and the 95th percentile consumption is 36 g/day; for adults, the mean consumption
of fish is 52 g/day and the 95th percentile consumption is 201 g fish /day [23]. Mean consumption
of fish oils and cod liver oil in two-year-old’s was 2 g/day, while the 95th percentile was 6 g/day;
in adults, the mean consumption of fish oils and cod liver oil was 3 g/day and the 95th percentile was
10 g/day [23]. However, these data are not detailed enough to regarding distribution of fish species etc
to assess erucic acid exposure, which should be included in future risk-benefit assessments of seafood.
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Despite the potentially high contribution of oily fish to erucic acid intake, there are few indications
that seafood intake, and, in particular, oily fish, has a negative impact on cardio-vascular health
in humans. On the contrary, the risk of cardiovascular disease was reported to be reduced by the
intake of oily fish, see, e.g. [24]. The Norwegian Scientific Committee for Food Safety (VKM) has
conducted risk-benefit evaluations of fish consumption in the Norwegian diet and recommends that
most people should increase their consumption due to the health benefits [23]. However, erucic acid
exposure has not been specifically addressed in these risk-benefit evaluations. Increased levels of
22:1 fatty acids in plasma phospholipids have been associated with a higher incidence of congestive
heart failure in two independent cohorts [25]. However, fish consumption seemed to lower the risk of
congestive heart failure in both of these cohorts [26,27]. In another cohort, higher levels of erucic acid
in erythrocytes was associated with lower incidence of coronary heart disease, leading the authors
to conclude on a cardioprotective effect [28]. Another study on patients with coronary artery disease
found no association between erucic acid in erythrocytes and all-cause mortality or CVD-mortality [29].
Indian studies have shown positive effects of mustard seed oil, which is high in erucic acid, on ischemic
heart disease, and myocardial infarction [30,31]. These positive effects are more likely to be associated
with the high content of α-linolenic acid (18:3n-3) in mustard seed oil in a population with a generally
low seafood intake, but at least they occurred despite the high content of erucic acid.
There are currently a number of knowledge gaps regarding erucic acid, and especially erucic acid
from seafood. Data on health effects of erucic acid in humans is scarce, and the TDI set by EFSA is
based on effects that were observed in animal studies [4]. Exposure should be assessed in population
groups with a high consumption of oily fish and/or fish oil, and erucic acid should be specifically
included in future risk-benefit assessments regarding seafood intake.
5. Conclusions
The concentrations of erucic acid in fish and other seafood varies considerably among species
and individual samples, with the highest concentrations being found in fish liver, fish oil, and in the
fillet of oily fish. Consumption of a 200 g portion of oily fish contributes significantly to the TDI set by
EFSA in 2016, and may even exceed it.
There are currently many knowledge gaps regarding erucic acid, and further studies regarding its
metabolism and its health effects in fish and humans are warranted. This paper contributes with new
knowledge on the presence of erucic acid fish feeds, fish, and seafood products.
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Abstract: Cardiovascular disease (CVD) is a major cause of mortality. The effects of
several unsaturated fatty acids on cardiometabolic health, such as eicosapentaenoic acid (EPA)
docosahexaenoic acid (DHA), α linolenic acid (ALA), linoleic acid (LA), and oleic acid (OA) have
received much attention in past years. In addition, results from recent studies revealed that several
other uncommon fatty acids (fatty acids present at a low content or else not contained in usual
foods), such as furan fatty acids, n-3 docosapentaenoic acid (DPA), and conjugated fatty acids, also
have favorable effects on cardiometabolic health. In the present report, we searched the literature in
PubMed, Embase, and the Cochrane Library to review the research progress on anti-CVD effect of
these uncommon fatty acids. DPA has a favorable effect on cardiometabolic health in a different way
to other long-chain n-3 polyunsaturated fatty acids (LC n-3 PUFAs), such as EPA and DHA. Furan
fatty acids and conjugated linolenic acid (CLNA) may be potential bioactive fatty acids beneficial
for cardiometabolic health, but evidence from intervention studies in humans is still limited, and
well-designed clinical trials are required. The favorable effects of conjugated linoleic acid (CLA) on
cardiometabolic health observed in animal or in vitro cannot be replicated in humans. However, most
intervention studies in humans concerning CLA have only evaluated its effect on cardiometabolic
risk factors but not its direct effect on risk of CVD, and randomized controlled trials (RCTs) will
be required to clarify this point. However, several difficulties and limitations exist for conducting
RCTs to evaluate the effect of these fatty acids on cardiometabolic health, especially the high costs
for purifying the fatty acids from natural sources. This review provides a basis for better nutritional
prevention and therapy of CVD.
Keywords: furan fatty acids; docosapentaenoic acid; conjugated fatty acids; cardiovascular disease;
metabolic disease; blood lipids; inflammation; antioxidant
1. Introduction
Cardiovascular disease (CVD) is a major cause of mortality [1]. In addition to genetic factors,
dyslipidemia [2], poor glycemic control [3], oxidative stress [4], inflammation [5], obesity [6],
hyperhomocysteinemia [7], smoking [8], lack of exercise [8], and dietary factors [8] are all related to
the development of CVD.
Fatty acids are important structural components of biological membranes and an energy source
for living organism. In addition, they also play an important role in regulating many physiological
processes, such as inflammation, glycemic control, lipid metabolism and oxidative stress. All these
physiological processes are closely related to the development of CVD and metabolic disorders. The
beneficial effect of several unsaturated fatty acids, such as eicosapentaenoic acid (EPA) docosahexaenoic
acid (DHA), α linolenic acid (ALA), linoleic acid (LA), and oleic acid (OA), on cardiometabolic health
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has been given much attention [9–19]. However, the effect of several other uncommon fatty acids
(fatty acids present at a low content or else not contained in usual foods) on cardiometabolic health,
such as furan fatty acids, n-3 docosapentaenoic acid (DPA), and conjugated fatty acids, is also worthy
of attention. In the present review, we searched PubMed, Embase, and the Cochrane Library for the
terms (docosapentaenoic acid OR n-3 polyunsaturated fatty acids OR DPA OR furan fatty acids OR
CMPF OR conjugated linolenic acid OR conjugated linoleic acid OR conjugated fatty acid OR CLNA
OR CLA) in combination with (cardiometabolic health OR cardiovascular disease OR CVD OR blood
lipids OR diabetes mellitus OR glucose metabolism OR oxidative stress OR inflammation) up to July
2018, to review the research progress on the effect of these uncommon fatty acids on cardiometabolic
health. Studies in humans, animals or in vitro evaluating the relationship between uncommon fatty
acids (furan fatty acids, conjugated fatty acids or DPA) and cardiometabolic health were included in
the present review. The review should provide a basis for better nutritional prevention and therapy of
CVD and metabolic disorders.
2. Furan Fatty Acids and Cardiometabolic Health
2.1. Origin of Furan Fatty Acids
Naturally occurring furan fatty acids are a family of fatty acids consisting of a furan ring with
a fatty acid chain on the α1-position, a short straight alkyl group on the α2-position, a methyl
group on the β1-position, and either a methyl group or a hydrogen atom on the β2-position [20].
Structures of the most abundant furan fatty acids are shown in Figure 1. Furan fatty acids have
been found in different biological species, in low concentrations, including marine and freshwater
fish [21], plants [22], algae [23,24], crustaceans [25,26], mammals [27], human tissues [28], fungi [29],
ascidian [30], bacteria [31], bivalves [32], and echinoidea [33]. Furan fatty acids are mainly enriched
in cholesterol ester and fraction of triacylglycerol (TAG) in liver of mammals, but occur mainly in
phosphatidylcholine (PC) and phosphatidylethanolamine (PE) in plasma [34].
Figure 1. Structure of most abundant furan fatty acids (F1–F8) [35] and their bioactive metabolite
3-carboxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF).
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2.2. Evidence from Human Studies
In addition to EPA and DHA, furan fatty acids may be another bioactive constituent of
marine food and its oil product beneficial for cardiometabolic health despite its low concentration
(around 1% in some species of fish [21,28]). Fish oil consumption significantly increased
3-carboxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF), a metabolite of common furan fatty
acids, by 3-fold and 5 to 6-fold in serum and urine of humans, respectively [36]. Our recent
randomized controlled trial (RCT) in subjects with type 2 diabetes mellitus (T2DM) indicated that fish
oil consumption significantly increased the serum CMPF level, and most importantly, the change of
CMPF during intervention was negatively correlated with the change of plasma TAG levels [37]. In
another randomized crossover study, a multifunctional diet (MFD) formulated according to the Nordic
Nutrition Recommendations improved serum total cholesterol (TC), low density lipoprotein cholesterol
(LDLC), triacylglycerol (TAG), ratios of LDL to high density lipoprotein (HDL) and apolipoprotein
B (ApoB) to ApoA1, glycated hemoglobin (HbA1c), C-reactive protein (CRP) and systolic blood
pressure [38]. Metabolomics analysis indicated that this MFD significantly increased plasma level of
four furan fatty acids, including CMPF, 3,4-dimethyl-5-pentyl-2-furanpropanoic acid (a furan fatty
acids have been identified in crayfish), and furan fatty acids with molecular weights of 226.084 and
252.172 (accurate structure was not confirmed). Furthermore, a strong inverse correlation of CMPF
and 3,4-dimethyl-5-pentyl-2-furanpropanoic acid with TC, LDLC, and the LDLC to HDLC ratio was
observed [38]. Furan fatty acids may also have an anti-inflammatory effect: The New Zealand green
lipped mussel contains a certain amount of furan fatty acids [32], and our previous RCT indicated
a lipid extract from mussels effectively improved clinical conditions of patients with rheumatoid
arthritis, significantly decreased levels of tumor necrosis factor α (TNF-α), interleukin 1β (IL-1β) and
prostaglandin E2 (PGE2), and significantly increased levels of IL-10 [39].
However, until now, no clinical trials have been conducted to evaluate the effect of furan fatty
acids with relatively high purity on cardiometabolic health because they are usually difficult to separate
in quantity and high purity from other fatty acids. One previous study indicated that starvation could
dramatically increase the weight percentage of furan fatty acids in total lipids of cod liver by more than
34% [21]. A method for isolation of furan fatty acids from fish lipids has been reported, and the process
included: lipid extraction by chloroform and methanol (2:1), methylation of fatty acids, hydrogenation
of common straight-chain unsaturated fatty acid methyl esters, and removal of saturated fatty acid
methyl esters by crystallization as urea complexes [35]. In addition to isolation of furan fatty acids
from lipids of food, artificial synthesis is another option to obtain furan fatty acids with relatively high
degree of purity [40].
2.3. Evidence from Animal and In Vitro Studies
One recently published animal study indicated that purified CMPF supplementation improved
insulin sensitivity, increased beta-oxidation, reduced lipogenic gene expression, and ameliorated
steatosis [41]. This suggested that CMPF has a favorable metabolic effect. However, a contradictory
result concerning the effect of CMPF on glucose metabolism was observed by another animal study,
including glucose intolerance, impaired glucose-stimulated insulin secretion, and decreased glucose
utilization [42]. Sand et al. extracted furan fatty acids from northern pike (Esox lucius) testes, and
supplementation of furan fatty acids to rats led to the appearance of CMPF in urine, indicating
that CMPF was a metabolite of common furan fatty acids [43]. Wakimoto et al. extracted furan
fatty acids (predominantly F4 and F6) from mussels and compared their anti-inflammatory effect
with EPA, commercially available F6, and the anti-inflammatory drug Naproxen in a rat model of
adjuvant-induced arthritis, and found that furan fatty acids extracted from mussels had comparable
anti-inflammatory effect with Naproxen and commercially available F6; the anti-inflammatory effect of
furan fatty acids was more potent than that of EPA [32]. The anti-inflammatory effect of a lipid extract
from mussel was also observed in our previous animal study which found that a lipid extract from
mussel had an equivalent protective effect to fish oil on intestinal integrity after lipopolysaccharide
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(LPS) challenge in mice, by increasing the expression of anti-inflammatory cytokine IL-10, decreasing
the expression of pro-inflammatory cytokines TNF-α and IL-1β and downregulating toll-like receptor
4 (TLR-4) signal pathway [39]. These results indicated that furan fatty acids, long neglected, might be
one bioactive component responsible for the anti-inflammatory effect of lipid products of marine food.
Okada et al. synthesized four kinds of furan fatty acids, F2, F3, F6, and 9,12-epoxyoctadeca-9,11-dienoic
acid (NMF), and found that tetra-alkyl substituted furan fatty acids (F3 and F6) had the best antioxidant
activity in vitro by decomposing hydroperoxides and scavenging peroxyl radicals; the antioxidant
activity of tri-alkyl substituted compound (F2) was about 50% as effective as the tetra-alkyl substituted
one, while di-alkyl substituted one (NMF) revealed no significant activity [44]. Another in vitro study
by Okada et al. compared the hydroxyl radical scavenging activity of artificially synthesized furan
fatty acids (F2, F3, and NMF) with other common hydroxyl radical scavengers, and found that the
hydroxyl radical scavenging activity of furan fatty acids was better than mannitol and ethanol, and was
comparable with that of histidine and dimethyl sulfoxide (DMSO) [45]. Lipid oxidation is an important
aspect in the pathogenesis for CVD [46]. Therefore, furan fatty acids, because of their antioxidant
activity, may also play a role in protecting against aspects of CVD.
2.4. Brief Summary
Evidence from previous studies implied a favorable effect of furan fatty acids on cardiometabolic
health. Clinical trials are required to confirm the direct effect of furan fatty acids on cardiometabolic
health by using purified furan fatty acids as treatment.
3. DPA and Cardiometabolic Health
3.1. Origin of DPA
DPA is a long chain n-3 polyunsaturated fatty acid (LC n-3 PUFA) widely existing in marine
foods and fish oils, together with EPA and DHA. The structures of DPA, EPA, and DHA are shown in
Figure 2. The content of DPA in most fish is typically much less than that of EPA and DHA, and in
salmon flesh, fish oil, and seal oil the levels are about 0.3%, 2–5%, and 4–5%, respectively [47]. One
previous study dramatically increased DPA content in a marine fish, nibe croaker, from 1.8% to 4.1%
by addition of an elongase gene to the fish [48].
Figure 2. Structure of n-3 docosapentaenoic acid (DPA), eicosapentaenoic acid (EPA), and
docosahexaenoic acid (DHA).
3.2. Evidence from Human Studies
Most previous studies evaluating the effect of LC n-3 PUFA on cardiometabolic health did not
discriminate between the effect of EPA, DHA, and DPA. Results from recent studies indicated that
DPA could also influence cardiometabolic health. Our previous meta-analysis based on 10 prospective
cohort studies in 20,460 individuals indicated that the risk of stroke was negatively associated with
circulating level of DPA (relative risk (RR) 0.74, 95% confidence interval (CI) 0.60 to 0.92) and DHA
(RR 0.78, 95% CI 0.65 to 0.94), but not EPA (RR 0.95, 95% CI 0.82 to 1.12) [49]. Dose–response analysis
indicated that 1% increment of DPA and DHA proportions in circulating blood was associated with
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25% (RR 0.75, 95% CI 0.64 to 0.87) and 11% (RR 0.89, 95% CI 0.83 to 0.95) reduced risk of stroke,
respectively [49]. One meta-analysis based on prospective cohort studies indicated that coronary risk
was negatively associated with circulating levels of DPA (RR 0.64, 95% CI 0.47 to 0.87, 7155 subjects in
four studies) [50]. Evidence from observational studies indicated that the circulating DPA level was
also negatively associated with the risk of cardiovascular mortality (hazard ratio (HR) 0.68, 95% CI
0.52 to 0.89) [51], sudden cardiac death (odds ratio (OR) 0.70, 95% CI 0.51 to 0.97) [52], heart failure
(OR 0.81, 95% CI 0.68–0.95) and peripheral arterial disease (OR 0.61, 95% CI 0.45 to 0.82) [53] as well as
carotid intimal–medial thickness (β = −0.0002 ± 0.0007 (standard error), p = 0.037) [54].
Our previous double blind crossover study found that pure DPA supplementation could
significantly reduce postprandial plasma chylomicronemia compared with pure EPA or olive oil
supplementation in healthy subjects [55]. Another crossover study found that compared with EPA
alone, EPA + DPA supplementation could significantly lower TAG, TC, non-high-density lipoprotein
cholesterol, very low-density lipoprotein cholesterol (VLDLC), ApoC3, and proprotein convertase
subtilisin kexin type 9 (PCSK9) in subjects with severe hypertriglyceridemia [56]. This trial also
reported that EPA + DPA supplementation rather than EPA alone could significantly reduce nile
red staining of lipids in monocytes, and that both EPA + DPA and EPA alone significantly reduce
monocytes surface markers CD11c, CD36, and CCR5, indicating that DPA might protect against
atherosclerosis by inhibiting foamy monocyte formation and modulating monocyte phenotype [57]. In
addition, DPA can modulate lipid mediator profile in a different way compared with EPA: in a crossover
study, DPA supplementation increased 19,20-dihydroxy-DPA (19,20-DiHDoPE), 7,17-DiHDoPE, and
15-keto-prostaglandin E2, while EPA increased monohydroxy-eicosapentaenoic acids (HEPEs), and
there was no overlap in PUFA metabolites formed after DPA and EPA supplementation [58]. One
RCT found that EPA + DPA supplementation dose-dependently increased erythrocyte membrane DPA
content, and DPA level was inversely associated with serum CRP level. A cohort study in 2547 children
with elevated risk of type 1 diabetes indicated that erythrocyte membrane DPA content but not EPA or
DHA was negatively associated with the risk of islet autoimmunity [59]. Our cross-sectional study in
healthy subjects indicated that after adjusting for potential confounding factors, platelet phospholipid
DPA content but not EPA was inversely correlated with mean platelet volume, an independent risk
factor for acute myocardial infarction [60].
3.3. Evidence from Animal and In Vitro Studies
In a rat model of rheumatoid arthritis, DPA showed a comparable reducing effect with EPA
on the progression and severity of arthritic disease as well as pro-inflammatory cytokines, such as
IL-17A, IL-1β, IL-6, and TNFα [61]. In addition, DPA and EPA both significantly down-regulated
the activation of mitogen-activated protein kinases (p38 MAPK) and nuclear factor-kappa B (NF-κB)
pathways and decreased the expression of cyclooxygenase-2 (COX-2), matrix metalloproteinase-2
(MMP-2) and MMP-9 [61]. This can help explain the mechanism for their anti-inflammatory effect.
Moreover, pro-resolving mediators derived from DPA can also contribute to its anti-inflammatory
effect, but the types of pro-resolving mediators derived from DPA were different from those derived
from other LC n-3 PUFA, such as EPA and DHA [62]. In mice fed a high-fat diet, purified DPA,
EPA, or DHA supplementation improved serum TC, glucose, and liver cholesterol content; only
DPA improved insulin resistance rather than EPA or DHA. DPA and DHA but not EPA prevented
decreased serum adiponectin and increased serum alanine aminotransferase (ALT) [63]. Either high-fat
diet or high-fructose diet significantly decreased plasma DPA and DHA level in rats, and both LC
n-3 PUFAs were positively associated with insulin sensitivity [64]. Our previous study in rat liver
cells indicated that DPA could down-regulate a series of genes involved in fat synthesis, including
sterol-regulatory element-binding protein-1c (SREBP-1c), 3-hydroxy-3-methyl-glutaryl-coenzyme A
reductase (HMG-CoA reductase), acetyl coenzyme A carboxylase (ACC-1), and fatty acid synthase
(FASn) [65]. This result can help explain the mechanism for the protecting effect of DPA against
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hypertriglyceridemia. Reduced platelet aggregation by DPA was also observed in our previous in vitro
study [66].
3.4. Brief Summary
DPA has a favorable effect on cardiometabolic health in a different way to the other LC n-3 PUFAs,
such as EPA and DHA. However, few intervention studies in humans have been conducted to evaluate
the direct effect of DPA on risk of CVD. Well-designed RCTs should be conducted by using purified
DPA as treatment to clarify this point.
4. Conjugated Fatty Acids and Cardiometabolic Health
4.1. Origin of Conjugated Fatty Acids
Conjugated fatty acids is the general term for positional and geometric isomers of polyunsaturated
fatty acids with conjugated double bonds [67]. The most common conjugated fatty acids are conjugated
linoleic acids (CLAs), such as cis-9,trans-11 CLA and trans-10,cis-12 CLA, and conjugated linolenic
acids (CLNAs), such as α-eleostearic acid, punicic acid, and jacaric acid. cis-9,trans-11 CLA is the
main naturally occurring isomer of CLA, and it was first found as an intermediate for the conversion
from PUFA to saturated stearic acid by rumen bacteria [68]. This explained its presence in food from
ruminant-animal origin, such as beef, sheep and goat meat and dairy products [67]. In addition, CLA
has also been found in low proportions in some plant oils and seafood [69]. CLNA naturally occurs in
plant seeds, such as tung seed, bitter gourd seed, snake gourd seed, pomegranate seed, trichosanthes
seed, pot marigold seed, jacaranda seed, and catalpa seed [70–72]. Several studies in humans and
animals indicated that CLNA could be metabolized into CLA in vivo [73,74]. The structures of the
most common conjugated fatty acids are shown in Figure 3.
Figure 3. Structure of most abundant conjugated linoleic acids (CLAs) and conjugated linolenic acids
(CLNA).
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4.2. CLA and Cardiometabolic Health
4.2.1. Evidence from Human Studies
Few significant effects of CLA on CVD and its risk factors have been observed in human
studies. Only one case-control study reported a significant negative association between cis-9,trans-11
CLA in adipose tissue and risk of myocardial infarction [75]. One RCT indicated that 6-month
supplementation of cis-9,trans-11 CLA had no significant influence on blood lipids, glucose, CRP,
blood pressure, insulin resistance, body composition and 10-year absolute risk of fatal CVD calculated
by the European Systematic Coronary Risk Evaluation (SCORE) formula in overweight and obese
subjects [76]. Consistent results concerning CVD risk factors were also observed in another two RCTs
in healthy subjects and patients with atherosclerosis [77,78]. In addition, results from RCTs even
indicated that cis-9,trans-11 CLA consumption could increase lipid peroxidation [77,79]. One RCT
found that supplementation of another isomer of CLA, trans-10,cis-12 CLA, significantly increased CRP
as well as lipid peroxidation [80]. Only one RCT reported a significant lowering effect of CLA (mixture
of cis-9,trans-11 CLA and trans-10,cis-12 CLA, 50:50) on CRP in patients with atherosclerosis [81].
4.2.2. Evidence from Animal and in Vitro Studies
Lee et al. first reported that CLA (the isomer of CLA used was not reported) could significantly
decrease TC, LDLC, TAG, the ratios of LDLC to HDLC and TC to HDLC and led to less atherosclerosis
in rabbits [82]. The protective effect of CLA (cis-9,trans-11 CLA, trans-10,cis-12 CLA or their mixture)
against atherosclerosis was also observed in other animal studies [83–85]. A more recent study
in mice indicated that CLA could inhibit platelet deposition, decrease macrophage accumulation
and expression of the macrophage scavenger receptor CD36 in the aorta, and increase apoptosis
in atherosclerotic lesions, and thus exert a pre-resolving effect on atherosclerosis [86]. Increased
expression of peroxisome proliferators-activated receptor α (PPARα) and PPARγ by CLA may be one
possible mechanism for its protective effects against atherosclerosis [86]. CLA could also suppress
monocyte adhesion in vitro by targetting β2 integrin expression [87]. This may be another mechanism
for the anti-atherosclerotic effect of CLA. CLA (mixture of cis-9,trans-11 CLA and trans-10,cis-12
CLA) decreased pro-inflammatory cytokines (including IL-1β, IL-6, and TNFα) expression in
mammary epithelial cells treated with LPS by inhibiting reactive oxygen species (ROS) production
and up-regulating PPARγ expression [88]. A PPARγ-dependent anti-inflammatory effect of CLA was
also observed in mice with inflammatory bowel disease [89]. Moreover, reducing pro-inflammatory
eicosanoids release by inhibiting COX expression is also involved in the regulatory effect of CLA on
inflammatory responses [90,91]. In addition, CLA could inhibit high glucose-induced hypertrophy and
contractile dysfunction in adult rat cardiomyocytes by modulating PPARγ activation [92]. However,
an unfavorable effect on cardiometabolic health was also observed: high dose of CLA supplementation
increased insulin resistance in rats fed either a low fat or a high fat diet [93].
4.2.3. Brief Summary
Although favorable effects of CLA on cardiometabolic health have been observed in animal
studies and an observational study in humans, there is little evidence from RCTs, which supports
this opinion, and several RCTs even reported unfavorable results concerning lipid peroxidation and
inflammation. However, few intervention studies in humans have been conducted to evaluate the
direct effect of CLA on risk of CVD. Well-designed RCTs should be conducted to clarify this point.
4.3. CLNA and Cardiometabolic Health
4.3.1. Evidence from Human Studies
Favorable effects of CLNA on lipid metabolism were observed in one RCT: pomegranate seed
oil supplementation (rich in punicic acid (cis-9,trans-11,cis-13 CLNA)) significantly lowered serum
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TAG, the ratios of TAG to HDLC and TC to HDLC, and increased serum HDLC in hyperlipidemic
subjects [94]. No studies in humans have evaluated the association between CLNA and CVD or other
risk factors.
4.3.2. Evidence from Animal and in Vitro Studies
α-eleostearic acid (cis-9,trans-11,trans-13 CLNA) supplementation significantly lowered blood
TAG level in diabetic rats [95]. Pomegranate seed oil supplementation, which is rich in punicic acid
(cis-9,trans-11,cis-13 CLNA), significantly lowered TC in broilers [96]. Punicic acid (cis-9,trans-11,cis-13
CLNA) also significantly decreased ApoB100 secretion by human HepG2 cell in vitro [97]. ApoB100 is
the essential component of very-low density lipoproteins and positively correlated with the incidence
of coronary heart disease and atherosclerosis [97]. Bitter gourd oil supplementation, which is rich
in α-eleostearic acid (cis-9,trans-11,trans-13 CLNA), decreased blood level of free cholesterol and
increased HDLC in rats [98]. Several animal and in vitro studies reported the antioxidative effect
of CLNA. Results from an animal study indicated that α-eleostearic acid (cis-9,trans-11,trans-13
CLNA) supplementation could significantly lower LDL-lipid peroxidation and erythrocyte membrane
lipid peroxidation in diabetic rats [95]. One in vitro study also demonstrated that both punicic
acid (cis-9,trans-11,cis-13 CLNA) and α-eleostearic acid (cis-9,trans-11,trans-13 CLNA) could more
effectively scavenge hydroxyl radical and inhibit lipid peroxidation at lower concentrations than at
higher concentrations [99]. Another animal study compared the antioxidant effect of punicic acid
(cis-9,trans-11,cis-13 CLNA) and α-eleostearic acid (cis-9,trans-11,trans-13 CLNA) in rats, and found
that both could effectively decrease oxidative stress and lipid peroxidation induced by sodium arsenite;
the antioxidant effect of α-eleostearic acid was more potent than that of punicic acid [100]. However,
contradictory results concerning the antioxidative effect of CLNA was observed in another animal
study: supplementation of bitter gourd oil (rich in α-eleostearic acid (cis-9,trans-11,trans-13 CLNA))
significantly increased plasma hydroperoxides level [98]. One animal study evaluated the antioxidative
effect of punicic acid at different dose, and found punicic acid could act as both pro-oxidant (dose as
1.2% in total fatty acids) and antioxidant (dose as 0.6% in total fatty acids) [101]. Therefore, differences
in dose may help explain the inconsistent results concerning antioxidative effects of CLNA observed
in previous studies. In addition, CLNA also has an anti-inflammatory effect. Intake of pomegranate
seed oil (rich in punicic acid (cis-9,trans-11,cis-13 CLNA)) effectively inhibited neutrophil-activation
and protected against trinitrobenzene sulfonic acid (TNBS)-induced colon inflammation in rats; the
mechanism involved inhibiting TNF-α induced priming of NADPH oxidase and myeloperoxidase
release [102]. One study reported that α-eleostearic acid (cis-9,trans-11,trans-13 CLNA) ameliorated
inflammatory bowel disease in mice by activating PPARγ [103]. Down-regulating pro-inflammatory
cytokines expression, COX expression and NF-κB signal pathway are potential mechanisms for the
anti-inflammatory effects of CLNA [104,105].
4.3.3. Brief Summary
CLNA may have a favorable effect on cardiometabolic health, but evidence from human studies
is still very limited, and well-designed RCTs should be conducted to evaluate the effect of CLNA
supplementation on CVD and its risk factors.
5. Conclusions and Perspectives
DPA has a favorable effect on cardiometabolic health in a different way to the other LC n-3 PUFAs,
such as EPA and DHA. Furan fatty acids and CLNA may be potential bioactive components beneficial
for cardiometabolic health, but evidence from intervention studies in humans is still limited, and
well-designed clinical trials will be required. The favorable effects of CLA on cardiometabolic health
observed in animals or in vitro have not been replicated in most studies of humans. However, most
intervention studies in humans concerning CLA have only evaluated its effect on cardiometabolic risk
factors but not its direct effect on risk of CVD, and RCTs with large sample size are still required to
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clarify this point. Several difficulties and limitations exist for conducting RCTs to evaluate the effect of
these fatty acids on cardiometabolic health, especially the high cost of purifying these fatty acids from
natural sources because they occur at low levels in natural oils or foods.
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Abstract: Obesity is often accompanied by metabolic and haemodynamic disorders such as
hypertension, even during childhood. Arachidonic acid (AA) is metabolized by cytochrome
P450 (CYP450) enzymes to epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid
(20-HETE), vasoactive and natriuretic metabolites that contribute to blood pressure (BP) regulation.
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) omega-3 polyunsaturated fatty acids
may compete with AA for CYP450-dependent bioactive lipid mediator formation. We aimed at
investigating the role of AA, EPA and DHA and their CYP450-dependent metabolites in BP control
and vascular function in 66 overweight/obese children. Fatty acid profile moderately correlated with
the corresponding CYP450-derived metabolites but their levels did not differ between children with
normal BP (NBP) and high BP (HBP), except for higher EPA-derived epoxyeicosatetraenoic acids
(EEQs) and their diols in HBP group, in which also the estimated CYP450-epoxygenase activity was
higher. In the HBP group, EPA inversely correlated with BP, EEQs inversely correlated both with
systolic BP and carotid Intima-Media Thickness (cIMT). The DHA-derived epoxydocosapentaenoic
acids (EDPs) were inversely correlated with diastolic BP. Omega-3 derived epoxymetabolites appeared
beneficially associated with BP and vascular structure/function only in obese children with HBP.
Further investigations are needed to clarify the role of omega-3/omega-6 epoxymetabolites in
children’s hemodynamics.
Keywords: CYP450 eicosanoids; omega-3 PUFA; omega-6 PUFA; blood pressure; hemodynamics;
children; EETs; EEQs
1. Introduction
The prevalence of overweight and obesity in children and adolescents has been increasing in the
last few decades worldwide. Childhood obesity can have serious short- and long-term consequences,
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including metabolic and hemodynamic complications, such as hypertension, insulin resistance and
dyslipidaemia [1].
Beside the impact of body mass index (BMI) per se on blood pressure (BP), several mechanisms
are implicated in hemodynamic control. Dietary habits, in particular, lipid intake can influence not
only body weight but also haemodynamics [2,3]. Indeed, in the last years many studies assessed the
role of different polyunsaturated fatty acids (PUFA), such as arachidonic acid (AA), an omega-6 PUFA
and eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which belong to omega-3 PUFA
family, indicating a beneficial cardiovascular effect of omega-3 PUFA [4,5], whereas it is not clear
whether omega-6 PUFA are cardioprotective or not [6,7]. Several trials and meta-analyses indicated
a possible beneficial effect of omega-3 PUFA supplementation on BP control, although the effect is
modest, and the results of the studies are not always consistent [5,8,9]. Furthermore, omega-3 PUFA
may improve vascular function, that is, arterial stiffness and endothelial function, as supported by
some studies and meta-analysis [10–12], suggesting a possible, at least partial, BP lowering effect of
omega-3 PUFA. We have recently shown, in the same study population, that omega-6 PUFA and in
particular AA are inversely associated with several features of the metabolic syndrome in a sample of
obese children, suggesting their possible protective role [13].
AA, EPA and DHA can be metabolized via cytochrome P-450 (CYP450) into lipid mediators, which
can have profound effects on blood pressure control [2,14], AA can be metabolized by different CYP450
enzymes leading to the formation of several compounds: 5,6-, 8,9-, 11,12-, 14,15-epoxyeicosatrienoic acids
(EETs) via epoxygenase and for example, 20-hydroxyeicosatetraenoic acid (20-HETE) via hydroxylases.
In general, EETs have been shown to play a protective role in cardiovascular diseases through their
anti-inflammatory, vasodilating and sodium excreting effects [15,16]. They are further metabolized
by soluble epoxide hydrolase (sEH) to dihydroxyeicosatrienoic acids (DHETs), which are less potent
or even inactive compounds. Instead, 20-HETE exerts a natriuretic action at kidney level, but, in the
systemic vasculature, it induces vasoconstriction [17,18]. Linoleic acid (LA) is also metabolized by
CYP450 epoxygenase to 9,10- and 12,13-epoxyoctadecenoic acids (EpOMEs), which are converted
by sEH to 9,10- and 12,13-dihydroxyoctadecenoic acids (DiHOMEs). They have potential toxic
cardiovascular effects, probably mediated by mitochondrial dysfunction and may affect the cardiac
inotropic response but the evidences are rare and diverging [19,20]. Epoxyeicosatetraenoic acids (EEQs),
yielded from EPA, have vasodilating and anti-inflammatory properties and are further metabolized
by sEH to diydroxxyeicosatetraenoic acids (DiHETEs) [21–23]. Epoxydocosapentaenoic acids (EDPs),
derived from DHA via CYP-epoxygenase, are potent vasodilators [23]; they are hydrolysed by sEH
to dihydroxydocosapentaenoic acids (DiHDPAs). Preliminary studies in animal models have shown
that the epoxymetabolites derived from EPA and DHA have a vasodilating action that largely exceeds
that of the AA-derived epoxides [24,25]. EPA and DHA can also be metabolized by CYP-hydroxylase
producing for example, 20-hydroxyeicosapentaenoic acid (20-HEPE) and 22-hydroxydocosahexaenoic
acid (22-HDHA) respectively, whose biological activities are still largely unknown.
Thus, the aim of the present study was to evaluate the possible association between the omega-3
and omega-6 PUFA metabolites via CYP450-epoxygenase/sEH in the modulation of haemodynamic
parameters and especially BP, in a sample of overweight/obese children.
2. Materials and Methods
2.1. Patients and Study Design
Obese children were recruited consequently from October 2012 to September 2014, coming from
the “Paediatric Obesity Outpatients Unit” of the University Hospital of Verona and of the “Local Health
Unit n. 20” of Verona. Inclusion criteria were: children and adolescents aged 5–18 years; overweight
or obesity (BMI ≥ 85th and 95th percentile for sex and age, respectively). We excluded children with
hepatic or renal chronic diseases, malignancies, diabetes mellitus, lipid-lowering or antihypertensive
therapy, secondary causes of obesity.
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The study was conducted according to a cross-sectional observational design.
The study was approved by the Ethical Committee of the University Hospital of Verona
(CE n. 2218) and written informed consent was obtained from each participant’s parents.
2.2. Anthropometric, Blood Pressure and Vascular Assessments
Each child was evaluated in a single occasion, between 8:00 and 9:00 a.m. A questionnaire
was administered to patients and to their parents, dealing with medical history, family history,
physiological and pathological information and use of drugs. Then, the participants underwent a
physical examination. They were advised not to engage in strenuous exercise and to avoid consuming
caffeine containing beverages within 12 h preceding the vascular studies.
During the visit, blood pressure was measured with a semiautomatic oscillometric device
(TM-2551, A&D instruments Ltd., Abingdon Oxford, UK) 3 times, 3 min apart with the patient
lying supine for at least 10 min before the first measurement in a room with controlled temperature
(22–24 ◦C). The mean value of the 3 clinostatic measurements were calculated and considered for
z-score and percentile calculation. Afterward, BP levels were confirmed by a measurement in the
sitting position by the oscillometric device and by auscultatory method. Ambulatory blood pressure
measurement (ABPM) was recorded with an oscillometric device (Spacelabs 90217; Spacelabs Inc.,
Issaquah, WA, USA), which measured BP every 15 min during the day and ever 30 min during the
night. Children and parents recorded physical activities, resting and sleeping time and symptoms on a
dedicated diary. After recording, the daytime and night-time periods (set to default at 7:00 A.M. and
10:00 P.M., respectively) were adapted to “real” awake and sleep times according to what was declared
in the activity diary.
All values derived from BP measurements were transformed in z-score and percentile, according
to normative values [26–28]. The 95th of office and ambulatory BP measurements was used as cut-off
for hypertension, according to current European guidelines [27].
Body weight, height and waist and hip circumferences were measured with the patient wearing
light clothes. Body weight was measured by a calibrated balance and height by a calibrated stadiometer.
Body mass index (BMI) calculated as weight in kg divided by the square of height in m; waist/hip
ratio was calculated as waist circumference in cm divided by hip circumference in cm and waist/height
ratio (WHtR) was calculated as waist circumference in cm divided by height in cm.
Waist circumference was transformed in z-score and percentile according to normative
values [29]. Overweight or obesity were defined for BMI ≥ 90th and 95th percentile for sex and
age, respectively [30]. WHO reference for BMI was used for categorizing children into the overweight
and obese groups [31].
Carotid Intima-media Thickness (cIMT) was assessed by ultrasound of carotid arteries
(LogiQ P5 Pro) and the cIMT was estimated tracking the artery wall in the last centimetre of the
common carotid artery and calculated by a dedicated software (Multimedia Video Engine II (MVE2)
DSP Lab., Pisa CNR, Italy). The relative z-score and percentile were calculated according to reference
values [32].
Endothelial function was assessed by ultrasound of the brachial artery using the Flow Mediated
Dilatation (FMD) technique according to international guidelines and with the aid of a dedicated
hardware (Multimedia Video Engine II (MVE2) DSP Lab., Pisa CNR, Italy) [33]. Common carotid
artery distensibility (DC) was calculated as: DC = ΔA/(A × ΔP) where A is the diastolic lumen area,
ΔA is the stroke change in lumen area and ΔP is pulse pressure (PP). Changes in diameters were
detected using ultrasound B-mode image sequences of the right and left common carotid arteries
acquired at different steps and analysed by the above-mentioned automatic system [34]. The relative
z-score and percentile were calculated according to reference values [32].
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2.3. CYP-Derived Eicosanoids Measurement
Plasma samples were subjected to alkaline hydrolysis and subsequent solid phase extraction was
performed as described previously [35].
In brief, 500 μL Methanol, 300 μL 10 molar sodium hydroxide and deuterated internal standards
were added to 500 μL Plasma. The samples were hydrolysed for 30 min at 60 ◦C. The solution
containing free fatty acids and metabolites were neutralized with acetic acid and adjusted to pH = 6.2.
A solid phase extraction procedure using Agilent Bond-Elut-Certify II was performed as formerly
described by Rivera [36].
The LC-ESI-MS/MS method for determination of metabolites was performed by the Lipidomix
GmbH, Berlin Germany, as described previously [35]. The plasma levels of individual metabolites are
given in ng/mL.
Moreover, biomarkers reflecting the endogenous CYP450 epoxygenase and sEH activities were
estimated by calculating the sum of epoxymetabolites plus their corresponding diols or the ratio
between diols and epoxymetabolites.
2.4. Red Blood Cell Membrane Fatty Acids Measurement
EDTA-blood tubes were centrifuged, plasma and buffy coat taken off and erythrocytes frozen at
−80 ◦C until analysis. Erythrocyte fatty acid composition was analysed using the HS-Omega-3
Index® methodology as previously described [37,38]. Fatty acid methyl esters were generated
from erythrocytes by acid transesterification and analysed by gas chromatography using a GC2010
Gas Chromatograph (Shimadzu, Duisburg, Germany) equipped with a SP2560, 100-m column
(Supelco, Bellefonte, PA, USA) using hydrogen as carrier gas. Fatty acids were identified by comparison
with a standard mixture of fatty acids characteristic of erythrocytes. A total of 26 fatty acids were
identified and quantified.
Results are given as percentage of total identified fatty acids after response factor correction.
The coefficient of variation for EPA plus DHA and for most other fatty acids was 4%. Analyses were
quality-controlled according to DIN ISO 15189. All fatty acid determinations were performed by
Omegametrix GmbH, Munich, Germany.
2.5. Statistics
Data are presented as the median and range unless otherwise stated. The statistical analysis was
performed using the software Statistical Package for Social Sciences software (SPSS/PC for Windows
version 21.0; IBM, Armonk, New York, NY, USA). Bivariate nonparametric correlations were estimated
by Spearman coefficient (rS).
Differences in the measured parameters between normotensive and hypertensive children were
analysed by nonparametric (Wilcoxon-Mann-Witney U) tests. A two-tailed test with a p < 0.05 was
considered statistically significant. In order to take into account the multiple comparisons, along with
original p-values, the false discovery rate (FDR) adjusted p-values were also calculated and reported
in the tables, where appropriate.
3. Results
3.1. Patient Characteristics
From the whole study consisting of 72 children we included 66 children (females n: 28; 42%) with
full phenotypic data about eicosanoids, red blood cell membrane FA, ABPM and vascular tests in the
present study.
The collection lasted from October 2012 to October 2014 and included children are 5 to 17 years
old. Four children were overweight (BMI > 90th) and 62 children were obese (BMI > 95th percentile
for sex and age). All children had a central distribution of adiposity (percentile of waist circumference
>90th percentile).
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On the basis of ABPM, we divided the population in two subgroups: high blood pressure (HBP)
(n: 17; 26%) and normal blood pressure (NBP) (n: 49; 74%). In an exploratory analysis we investigated
the correlations of fatty acids and their metabolites with BP and vascular function in each subgroup,
in order to check different associations related to the hypertensive status.
General characteristics of the obese children split by gender and NBP and HBP, diagnosed on
the basis of ABPM (daytime, night-time or 24-hours systolic BP(SBP) or diastolic BP (DBP) ≥ 95th
percentile), are detailed in Table 1. The characteristics of the children divided according to pubertal
status are listed in Table S1.
Table 1. General characteristics of the population divided according to gender and blood pressure status.
Male (n = 38) Female (n = 28) NBP (n = 49) HBP (n = 17)
Variable Median (Range) Median (Range) p-Value * Median (Range) Median (Range) p-Value *
Age, years 11.5 (10.0–14.0) 11.0 (9.0–13.0) 0.187 12.0 (10.0–13.5) 11.0 (8.5–12.5) 0.181
BMI, Kg/m2 28.3 (25.4–31.0) 29.3 (26.1–33.2) 0.392 28.4 (25.7–31.0) 30.4 (26.7–35.3) 0.125
BMI percentile 98.3 (97.2–99.0) 98.7 (97.8–99.3) 0.238 98.0 (97.3–99.0) 99.1 (98.3–99.5) 0.011
Office-SBP, mmHg 119.0 (112.9–125) 116.3 (109.8–129) 0.471 117.0(110.2–110.2)
123.3
(114.5–133.2) 0.031
Office-SBP percentile 83.1 (64.9–94.8) 79.9 (67.7–96.4) 0.697 77.7 (64.7–93.7) 95.6 (76.7–99.3) 0.012
Office-DBP, mmHg 68.3 (63.3–76.1) 66.7 (64.1–72.7) 0.673 66.7 (63.7–72) 75.0 (63.7–77.3) 0.179
Office-DBP percentile 65.1 (43.9–80.7) 66.1 (50.8–77.9) 0.577 64.3 (46.9–76.2) 83.0 (51.4–87.2) 0.033
24 h-SBP, mmHg 118.0 (114–121) 112.0 (107–116) 0.001 ◦ 114.0 (109–118) 121.0(118.5–128.0) <0.001
◦
24 h-SBP, percentile 73.7 (50.6–82.6) 54.4 (35.3–79.8) 0.169 51.7 (37.8–74.6) 90.4 (80.0–98.8) <0.001 ◦
24 h-DBP, mmHg 68.0 (64.0–70.3) 64.0 (61.3–67.0) 0.001 ◦ 65.0 (62.0–68.5) 70.0 (65.5–74.5) 0.002 ◦
24 h-DBP, percentile 57.4 (28.5–74.5) 34.5 (18.7–50.6) 0.007 35.1 (20.0–57.4) 69.9 (42.5–94.5) 0.001 ◦
cIMT, mm 0.46 (0.42–0.51) 0.41 (0.39–0.47) 0.032 0.44 (0.40–0.48) 0.46 (0.42–0.51) 0.179
cIMT, percentile 98.4 (80.3–99.7) 82.3 (60.4–96.7) 0.021 88.2 (59.6–99.1) 96.5 (82.2–99.7) 0.207
cDC, 10−3/Kpa 39.7 (33.5–46.4) 43.8 (34.9–48.3) 0.199 42.0 (34.7–48.5) 37.3 (33.0–42.5) 0.127
cDC, percentile 6.4 (2.4–23.2) 12.8 (2.2–27.0) 0.249 12.3 (2.9–27.0) 4.2 (2.2–13.2) 0.110
Glucose, mg/dL 88.0 (84.0–93.0) 85.0 (79.0–88.0) 0.026 86.0 (83–90) 87.0 (82–93.8) 0.855
Insulin, uU/mL 18.5 (12.4–27.5) 17.8 (13.0–28.2) 0.887 17.7 (11.8–27.6) 24.1 (17.1–30.0) 0.110
Cholesterol, mg/dL 160 (139.9–186.8) 165.0 (134–192) 0.536 165.0 (139–192) 151.5 (132–173.3) 0.297
Triglycerides, mg/dL 79 (55–103.5) 79 (54–100) 0.744 76.5 (54–99.8) 87 (59.5–118) 0.231
FMD, % 7.7 (5.3–10.2) 6.2 (3.4–9.6) 0.403 7.4 (4.2–10.2) 7.6 (3.2–9.8) 0.682
LA, % 11.8 (11.1–12.9) 11.8 (11.1–12.8) 0.841 11.7 (11.0–12.6) 12.4 (11.4–13.1) 0.104
AA, % 16.0 (14.9–17.1) 16.4 (15.8–17.3) 0.082 16.4 (15.6–17.5) 15.5 (14.6–16.6) 0.038
EPA, % 0.4 (0.3–0.5) 0.4 (0.3–0.5) 0.340 0.37 (0.30–0.47) 0.4 (0.3–0.6) 0.127
DHA, % 4.3 (3.8–4.7) 4.4 (3.8–5.0) 0.425 4.4 (3.8–4.8) 4.2 (3.5–4.8) 0.367
Omega-3 Index, % 4.6 (4.1–5.2) 4.6 (4.3–5.5) 0.417 4.6 (4.2–5.3) 4.5 (3.9–5.3) 0.639
EpOMEs, ng/mL 11.2 (8.2–15.9) 10.8 (8.7–15.7) 0.907 11.5 (8.4–15.9) 10.8 (8.3–12.4) 0.613
DiHOMEs, ng/mL 7.2 (5.3–9.7) 6.3 (5.3–8.8) 0.340 6.5 (5.3–9.2) 7.5 (5.6–9.6) 0.363
EpOMEs/DiHOMEs 1.6 (0.9–2.1) 1.6 (1.3–2.4) 0.347 1.7 (1.3–2.3) 1.2 (0.8–1.9) 0.093
EpOMEs+DiHOME 18.6 (14.0–25.7) 18.4 (15.3–22.2) 0.795 19.4 (14.8–23.7) 17.0 (13.4–24.2) 0.634
EETs, ng/mL 7.4 (6.6–8.9) 7.7 (6.8–8.9) 0.460 7.5 (6.6–8.5) 8.4 (7.2–9.2) 0.131
DHETs, ng/mL 4.1 (3.3–4.7) 4.0 (3.5–4.7) 0.726 4.0 (3.4–4.5) 4.0 (3.5–5.1) 0.367
EETs/DHETs 1.9 (1.6–2.4) 2.0 (1.6–1.2) 0.902 1.9 (1.6–2.3) 2.0 (1.6–2.2) 0.814
EETs+DHETs 11.7 (10.1–13.3) 12.1 (10.7–13.2) 0.448 11.8 (10.2–13.0) 12.7 (10.8–14.3) 0.110
EEQs, ng/mL 0.3 (0.2–0.4) 0.4 (0.3–0.5) 0.302 0.3 (0.2–0.5) 0.4 (0.3–0.7) 0.047
DiHETEs, ng/mL 0.9 (0.7–1.3) 0.9 (0.7–1.3) 0.568 0.9 (0.7–1.1) 1.2 (0.9–1.6) 0.021
EEQs/DiHETEs 0.33 (0.31–0.38) 0.42 (0.33–0.54) 0.004 ◦ 0.37 (0.31–0.46) 0.34 (0.31–0.51) 0.872
EEQs+DiHETEs 1.3 (1.0–1.8) 1.3 (0.9–1.8) 0.871 1.2 (1.0–1.5) 1.8 (1.2–2.2) 0.025
EDPs, ng/mL 2.9 (2.4–3.3) 3.2 (2.7–4.2) 0.050 2.9 (2.4–3.3) 3.3 (2.5–3.9) 0.221
DiHDPAs, ng/mL 0.9 (0.8–1.0) 0.9 (0.8–1.1) 0.399 0.9 (0.8–1.1) 0.9 (0.8–1.1) 0.665
EDPs/DiHDPAs 3.3 (2.9–3.6) 3.6 (2.8–4.3) 0.186 3.4 (2.8–3.8) 3.2 (3.0–4.2) 0.878
EDPs+DiHDPAs 3.8 (3.1–4.3) 4.3 (3.5–5.3) 0.044 3.8 (3.3–4.4) 4.3 (3.3–4.9) 0.238
20-HETE 0.74 (0.61–0.86) 0.64 (0.57–0.87) 0.459 0.7 (0.58–0.84) 0.83 (0.53–0.91) 0.553
22-HDHA 0.65 (0.44–0.92) 0.66 (0.41–0.83) 0.721 0.67 (0.42–0.89) 0.64 (0.43–0.91) 0.837
BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure, cIMT: carotid intima-media
thickness, cDC: carotid distensibility coefficient, FMD: flow-mediated dilation, LA: Linoleic acid, AA: Arachidonic
acid, EPA: Eicosapentaenoic acid, DHA: Docosahexaenoic acid, Omega-3 Index: (EPA + DHA)/total FA × 100,
EpOME: epoxyoctadecenoic acid, DiHOME: dihydroxyoctadecenoic acid, EET: epoxyeicosatrienoic acid, DHET:
dihydroxyeicosatrienoic acid, EEQ: epoxyeicosatetraenoic acid, DiHETE: dihydroxyeicosatetraenoic acid, EDP:
epoxydocosapentaenoic acid, DiHDPA: dihydroxydocosapentaenoic acid, 20-HETE: 20-hydroxyeicosatetraenoic
acid, 22-HDHA: 22-hydroxydocosahexaenoic acid, HBP: high blood pressure subgroup, NBP: normal blood pressure
subgroup, n: number. 20-hydroxyeicosapentaenoic acid (20-HEPE) plasma concentration was under the limit of
detection. *: Mann-Whitney U-Test; ◦: p < 0.05 after False Discovery Rate correction.
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Girls showed higher BP at ABPM compared to boys. Omega-3 Index, a marker of dietary intake
of long-chain omega-3 PUFA, was 4.61% (2.87–6.61%).
3.2. Omega-6 PUFA
3.2.1. LA and CYP450-Derived Eicosanoids
Associations of LA with Clinical Features and with its Metabolites
LA was similarly distributed according to gender and hypertensive status (Table 1 and Figure 1).
LA directly correlated with DiHOMEs in the whole population and in particular in HBP children
(Table 2 and Figure 2). LA also directly correlates with the estimated CYP450 epoxygenase activity in
HBP (Figure S1).
Figure 1. Comparison of fatty acids and their metabolites via CYP450-epoxygenase in HBP and
NBP obese children. The histograms represent the comparison between HBP and NBP obese
children for: (a) concentration of fatty acids in red blood cell membranes, that is, LA, AA, EPA and
DHA; (b) plasma concentration of the CYP450 epoxygenase generated metabolites, that is, EpOMEs,
EETs, EEQs and EDPs; (c) the estimated CYP450 epoxygenase activity, calculated as the sum of
epoxymetabolites plus their corresponding diols; (d) the estimated sEH activity, calculated as the
ratio between plasma concentrations (ng/mL) of diols and epoxymetabolites. Data are presented
as mean and SEM. LA: Linoleic acid; AA: Arachidonic acid; EPA: Eicosapentaenoic acid; DHA:
Docosahexaenoic acid; EpOME: epoxyoctadecenoic acid; DiHOME: dihydroxyoctadecenoic acid;
EET: epoxyeicosatrienoic acid; DHET: dihydroxyeicosatrienoic acid; EEQ: epoxyeicosatetraenoic
acid; DiHETE: dihydroxyeicosatetraenoic acid; EDP: epoxydocosapentaenoic acid; DiHDPA:
dihydroxydocosapentaenoic acid; HBP: high blood pressure subgroup; NBP: normal blood pressure
subgroup; sEH: soluble epoxide hydrolase; p: p-value. Vertical lines represent the standard errors.
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Table 2. Correlations between fatty acids (precursors) and the derived eicosanoids via CYP450-
epoxygenase/sEH.
Whole Population NBP HBP
LA
9,10-EpOME 0.102 0.064 0.434
12,13-EpOME 0.094 0.063 0.465
9,10-DiHOME 0.438 ˆ 0.311 * 0.674 ˆ
12,13-DiHOME 0.336 ˆ 0.265 0.659 ˆ
EpOME/DiHOME −0.292 * −0.172 −0.424
EpOME+DiHOME 0.292 * 0.234 0.718 ˆ
AA
5,6-EET 0.029 0.152 −0.049
8,9-EET 0.061 0.162 −0.064
11,12-EET 0.049 0.096 0.177
14,15-EET 0.040 0.114 0.074
5,6-DHET 0.032 0.196 −0.251
8,9-DHET 0.105 0.201 −0.051
11,12-DHET 0.014 0.166 −0.418
14,15-DHET 0.210 0.218 0.220
EET/DHET −0.007 −0.053 0.292
EET+DHET 0.051 0.186 −0.081
EPA
8,9-EEQ 0.434 ˆ 0.267 ◦ 0.784 ˆ,◦
11,12-EEQ 0.575 ˆ 0.482 ˆ,◦ 0.794 ˆ,◦
14,15-EEQ 0.641 ˆ 0.590 ˆ,◦ 0.808 ˆ,◦
17,18-EEQ 0.552 ˆ 0.509 ˆ,◦ 0.643 ˆ,◦
5,6-DiHETE 0.512 ˆ 0.441 ˆ,◦ 0.652 ˆ,◦
8,9-DiHETE 0.398 ˆ 0.337 *,◦ 0.446
11,12-DiHETE 0.217 0.244 −0.023
14,15-DiHETE 0.464 ˆ 0.393 ˆ,◦ 0.532 *,◦
17,18-DiHETE 0.484 ˆ 0.431 ˆ 0.440
EEQ/DiHETE 0.228 0.138 0.521 *,◦
EEQ+DiHETE 0.605 ˆ 0.578 ˆ,◦ 0.652 ˆ
DHA
7,8-EDP 0.482 ˆ,◦ 0.553 ˆ,◦ 0.666 ˆ◦
10,11-EDP 0.375 ˆ,◦ 0.360 *,◦ 0.569 *
13,14-EDP 0.467 ˆ,◦ 0.515 ˆ,◦ 0.563 *
16,17-EDP 0.502 ˆ,◦ 0.591 ˆ,◦ 0.546 *
19,20-EDP 0.456 ˆ,◦ 0.581 ˆ,◦ 0.473
7,8-DiHDPA 0.453 ˆ,◦ 0.521 ˆ,◦ 0.324
10,11-DiHDPA 0.220 0.310 *,◦ 0.205
13,14-DiHDPA 0.256 *,◦ 0.325 *,◦ 0.290
16,17-DiHDPA 0.386 ˆ,◦ 0.531 ˆ,◦ 0.086
19,20-DiHDPA 0.383 ˆ,◦ 0.565 ˆ,◦ 0.010
EDP/DiHDPA 0.150 0.072 0.433
EDP+DiHDPA 0.526 *,◦ 0.617 ˆ,◦ 0.575 *
The table shows the coefficients of correlations (rS) between the fatty acid precursors, namely LA, AA, EPA and DHA
and their metabolites via CYP450-epoxygenase/sEH in the whole sample and in the subgroups of HBP and NBP
children. The underlined correlations remained significant after adjustment for sex, age, pubertal status and BMI.
The sum of epoxymetabolites and corresponding diols estimates the CYP450-epoxygenase activity, whereas their
ratio estimates the sEH activity. *: p < 0.05; ˆ: p < 0.01; ◦: p < 0.05 after False Discovery Rate correction. NBP: normal
blood pressure; HBP high blood pressure; LA: Linoleic acid; AA: Arachidonic acid; EPA: Eicosapentaenoic
acid; DHA: Docosahexaenoic acid; EpHOME: epoxyoctadecenoic acid; DiHOME: dihydroxyoctadecenoic acid;
EET: epoxyeicosatrienoic acid; DHET: dihydroxyeicosatrienoic acid; EEQ: epoxyeicosatetraenoic acid; DiHETE:
dihydroxyeicosatetraenoic acid; EDP: epoxydocosapentaenoic acid; DiHDPA: dihydroxydocosapentaenoic acid.
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Figure 2. Correlations between fatty acids and their metabolite via CYP450-epoxygenase. The graphs
represent the correlations of the fatty acids with their corresponding epoxymetabolites. The two
subgroups of obese children with high (HBP) and normal blood pressure (NBP) are differently
graphically depicted. The panels represent: (a) the correlation of LA with EpOMEs, which was stronger
in HBP children; (b) the association of AA with EETs; (c) the correlation of EPA with EEQs, which was
stronger in HBP children; (d) the association of DHA with EDPs. LA: Linoleic acid; AA: Arachidonic
acid; EPA: Eicosapentaenoic acid; DHA: Docosahexaenoic acid; EpOME: epoxyoctadecenoic acid;
EET: epoxyeicosatrienoic acid; EEQ: epoxyeicosatetraenoic acid; EDP:epoxydocosapentaenoic acid;
HBP: high blood pressure subgroup; NBP: normal blood pressure subgroup, p: p-value; rS: Spearman
correlation coefficient; n.s.: not significant.
CYP450-Derived Eicosanoids of LA and Their Associations with Clinical Features
LA did not show any significant correlation with BP (Table 3), whereas DiHOMEs, especially
9,10-DiHOME, directly correlated with DBP in the whole sample and in the NBP subgroup (Table 4).
(The associations of the eicosanoids with BP percentiles are reported in Table S2). Vascular tests did
not show any significant correlation with LA and its metabolites (Table 5).
Table 3. Correlations between red blood cell membrane fatty acids and BP in the whole study
population and in the subgroups of HBP and NBP obese children.
LA AA EPA DHA
Whole population
Office-SBP, mmHg −0.091 −0.070 0.035 0.090
Office-SBP percentile 0.002 0.002 −0.049 −0.094
Office-DBP, mmHg 0.168 −0.130 −0.167 −0.106
Office-DBP percentile 0.217 −0.095 −0.175 −0.210
24 h-SBP, mmHg 0.096 −0.329 ˆ 0.154 0.016
24 h-SBP percentile 0.229 −0.134 0.014 −0.214
24 h-DBP, mmHg 0.171 −0.222 −0.069 −0.140
24 h-DBP percentile 0.200 −0.176 −0.092 −0.175
Day-time SBP, mmHg 0.070 −0.277 * 0.172 0.043
Day-time SBP, percentile 0.192 −0.129 0.086 −0.132
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Table 3. Cont.
LA AA EPA DHA
Whole population
Day-time DBP, mmHg 0.136 −0.132 −0.075 −0.142
Day-time DBP, percentile 0.136 −0.092 −0.084 −0.142
Night-time SBP, mmHg 0.066 −0.327 ˆ 0.154 −0.001
Night-time SBP, percentile 0.213 −0.178 0.051 −0.121
Night-time DBP, mmHg 0.145 −0.359 ˆ 0.014 −0.046
Night-time DBP, percentile 0.159 −0.353 ˆ 0.043 −0.040
HBP
Office-SBP, mmHg 0.013 0.088 −0.639 ˆ −0.050
Office-SBP percentile 0.017 0.172 −0.609 ˆ −0.113
Office-DBP, mmHg 0.206 −0.136 −0.564 * −0.377
Office-DBP percentile 0.218 0.083 −0.668ˆ −0.157
24 h-SBP, mmHg −0.425 0.220 −0.111 0.236
24 h-SBP percentile −0.279 0.387 −0.043 0.250
24 h-DBP, mmHg −0.278 −0.205 −0.251 0.010
24 h-DBP percentile −0.228 −0.184 −0.269 −0.012
Day-time SBP, mmHg −0.433 0.055 0.013 0.257
Day-time SBP, percentile −0.277 0.306 0.037 0.257
Day-time DBP, mmHg −0.263 −0.167 −0.164 0.001
Day-time DBP, percentile −0.252 −0.142 −0.188 0.015
Night-time SBP, mmHg −0.413 0.319 −0.225 0.172
Night-time SBP, percentile −0.193 0.466 −0.029 0.076
Night-time DBP, mmHg −0.258 −0.182 −0.427 −0.021
Night-time DBP, percentile −0.228 −0.191 −0.426 −0.049
NBP
Office-SBP, mmHg −0.180 −0.034 0.169 0.188
Office-SBP percentile −0.087 0.042 0.063 −0.050
Office-DBP, mmHg 0.089 −0.144 −0.049 0.025
Office-DBP percentile 0.128 −0.111 −0.079 −0.125
24 h-SBP, mmHg 0.059 −0.325 * 0.060 0.057
24 h-SBP percentile 0.217 −0.037 −0.163 −0.311 *
24 h-DBP, mmHg 0.233 −0.221 −0.131 −0.151
24 h-DBP percentile 0.268 −0.172 −0.159 −0.196
Day-time SBP, mmHg 0.062 −0.268 0.092 0.067
Day-time SBP, percentile 0.184 −0.069 −0.058 −0.160
Day-time DBP, mmHg 0.208 −0.124 −0.136 −0.176
Day-time DBP, percentile 0.209 −0.060 −0.147 −0.176
Night-time SBP, mmHg 0.052 −0.335 * 0.090 0.025
Night-time SBP, percentile 0.249 −0.154 −0.042 −0.212
Night-time DBP, mmHg 0.229 −0.340 * −0.044 −0.025
Night-time DBP, percentile 0.251 −0.333 * −0.027 −0.035
The table shows the spearman coefficients of correlations (rs) between fatty acids (precursors), namely LA,
AA, EPA, DHA and office and ambulatory BP in the whole sample and in the subgroups of HBP and NBP
children. The underlined correlations remained significant after adjustment for sex, age, pubertal status and BMI.
*: p < 0.05; ˆ: p < 0.01 after False Discovery Rate correction. NBP: normal blood pressure; HBP high blood pressure;
AA: arachidonic acid; DHA: docosahexaenoic acid; DBP: diastolic blood pressure; EPA: eicosapentaenoic acid;
LA: linolenic acid; SBP: systolic blood pressure.
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Table 5. Correlations of LA, AA, EPA, DHA and the derived CYP450-epoxygenase/sEH metabolites with
vascular tests in the whole sample and in the two individual subgroups of HBP and NBP obese children.
cIMT cIMT, (Percentile) DC DC, (Percentile) FMD, %
Whole population
LA 0.112 0.143 0.119 0.094 −0.150
AA −0.142 −0.097 0.108 0.063 −0.005
EPA −0.212 −0.305 * −0.067 −0.015 0.176
DHA −0.071 −0.170 −0.106 −0.053 0.139
EpOMEs 0.069 0.064 0.120 0.140 −0.141
DiHOMEs −0.083 −0.077 0.095 0.085 −0.155
EETs 0.093 0.084 0.072 0.073 −0.185






DiHETEs 0.008 −0.026 0.012 0.024 0.176
EDPs −0.082 −0.119 0.136 0.147 −0.158
DiHDPAs −0.171 −0.206 0.091 0.121 −0.101
HBP
LA −0.121 −0.025 0.175 0.207 −0.400
AA −0.172 −0.174 0.011 −0.039 −0.121
EPA −0.304 −0.378 0.432 0.407 0.268
DHA 0.027 −0.002 −0.121 −0.136 −0.146
EpOMEs −0.063 0.034 0.050 0.093 −0.050
DiHOMEs 0.067 0.071 −0.132 −0.132 0.004
EETs −0.231 −0.061 0.314 0.214 0.118













11;12-EEQ 0.582 * 0.288
DiHETEs −0.3545;6-DiHETE −0.559 *
−0.323
5;6-DiHETE −0.577 * 0.290 0.209
0.375
5;6-DiHETE −0.576 *
EDPs −0.098 0.002 0.312 0.237 −0.220
DiHDPAs −0.114 −0.104 0.148 0.086 −0.091
NBP
LA 0.142 0.181 0.132 0.108 −0.082
AA −0.067 −0.016 0.088 0.043 0.029
EPA −0.243 −0.359 * −0.174 −0.099 0.137
DHA −0.097 −0.217 −0.137 −0.061 0.248
EpOMEs 0.095 0.078 0.107 0.140 −0.189
DiHOMEs −0.163 −0.145 0.196 0.186 −0.209
EETs 0.159 0.101 0.032 0.068 −0.272
DHETs 0.010 0.025 −0.103 −0.091 −0.165
EEQs −0.162 −0.23514,15-EEQ −0.308 * 0.013 0.046 −0.116
DiHETEs 0.050 −0.014 −0.024 0.019 0.155
EDPs −0.185 −0.24719,20-EDP −0.296 * 0.081 0.121 −0.067
DiHDPAs 0.223 0.259 0.195 0.180 −0.095
The table shows the spearman coefficients of correlations (rS) between LA, AA, EPA, DHA and their metabolites
via CYP450-epoxygenase/sEH with the vascular tests and their percentiles for sex and age in the whole
sample and in the subgroups of HBP and NBP children. The underlined correlations remained significant after
adjustment for sex, age, pubertal status and BMI. * p< 0.05; ˆ p < 0.01. NBP: normal blood pressure; HBP high
blood pressure; AA: arachidonic acid; DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; LA: linolenic
acid; EpOME: epoxyoctadecenoic acid; DiHOME: dihydroxyoctadecenoic acid; EET: epoxyeicosatrienoic acid;
DHET: dihydroxyeicosatrienoic acid; EEQ: epoxyeicosatetraenoic acid; DiHETE: dihydroxyeicosatetraenoic acid;
EDP: epoxydocosapentaenoic acid; DiHDPA: dihydroxydocosapentaenoic acid; cIMT: carotid intima-media
thickness; cDC: carotid distensibility; FMD: flow-mediated dilation.
3.2.2. AA and CYP450-Derived Eicosanoids
Associations of AA with Clinical Features and with Its Metabolites
AA was higher in NBP as compared to HBP children (Table 1 and Figure 1). In the whole sample,
AA was inversely correlated to ABPM and this inverse association was confirmed in the NBP subgroup
(Table 3). No significant correlations were found between AA and vascular features (Table 5).
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Considering the metabolic pathway of AA via CYP450 and sEH, AA was not significantly
correlated with its metabolites via CYP450/sEH neither in the whole population nor in the subgroups
of HBP and NBP children (Table 2 and Figure 2). AA did not show any significant difference also with
the estimated CYP450 epoxygenase activity (Figure S1).
CYP450-Derived Eicosanoids of AA and Their Associations with Clinical Features
EETs and DHETs, the epoxymetabolites and the corresponding diols derived from AA
respectively, did not show any significant association with BP and vascular function markers
(Tables 4 and 5. The associations of the eicosanoids with BP percentiles are detailed in Table S2).
Twenty-hydroxyeicosatetraenoiic acid (20-HETE), the hydroxymetabolite of AA, did not differ between
HBP and NBP subgroups (Table 1) and did not show any significant correlation with BP and
vascular features.
3.3. Omega-3 PUFA
3.3.1. EPA and CYP450-Derived Eicosanoids
Associations of EPA with Clinical Features and with Its Metabolites
The amount of EPA in red blood cell membrane was similar in both groups of HBP and NBP
obese children (Table 1 and Figure 1). EPA inversely correlated with office BP and with cIMT in the
HBP subgroup and the inverse correlation with cIMT was significant also in the whole population
(Tables 3 and 5).
EPA was directly correlated with its epoxymetabolites and the corresponding diols, especially the
14,15-isomer, in the whole sample and in both subgroups (Table 2). In the subgroup of HBP children
the strength and the slope of the correlations between the precursor and the products were higher
and EEQs and DiHETEs were more elevated than in NBP (Figure 2). Moreover, the estimated CYP450
activity (sum of EEQs and DiHETEs) was higher in the HBP than in NBP children (Figure 1 panel (c))
and EPA correlated stronger with the estimated CYP450 activity in the HBP than in NBP subgroup,
whereas the estimated sEH activity did not differ between the two groups (Table 2 and Figure S1).
CYP450-Derived Eicosanoids of EPA and Their Associations with Clinical Features
EEQs and DiHETEs inversely correlated with office and ambulatory BP, in particular 11,12-EEQ
and 17,18-DiHETE (Table 4 and Figure 3. The associations of the eicosanoids with BP percentiles
are reported in Table S2). In the whole sample, only 8,9-EEQ showed an inverse correlation
with office DBP (Table 4.). The epoxymetabolites of EPA inversely correlated also with cIMT,
in particular 14,15- and 17,18- EEQ (Figure 3) and these associations were more evident in the
HBP group, in which also 5,6-DiHETE sowed an inverse correlation with cIMT. In this subgroup
11,12-EEQ was also directly correlated with carotid distensibility (Table 5). Plasma concentration of
twenty-hydroxyeicosapentaenoic acid (20-HEPE), the hydroxymetabolite of EPA, was under the limit
of detection.
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Figure 3. Correlations of EEQ with BP and cIMT in the high blood pressure (HBP) and normal blood
pressure (NBP) obese children subgroups. The first column represents the correlation of 17,18-EEQ
with: (a) office SBP; (b) night-time SBP; (c) cIMT. The second column represents the correlation of
the estimated CYP450 epoxygenase activity, as calculated as the sum of epoxymetabolites plus the
corresponding diols, with: (d) office SBP; (e) night-time SBP; (f) cIMT. * there is a significantly difference
between the slopes of the two subgroups, p < 0.05. The correlations in all panels are stronger in HBP
than in NBP children. The two subgroups of obese children with high and normal blood pressure are
differently graphically depicted. cIMT: carotid intima-media thickness; EEQ: epoxyeicosatetraenoic
acid; DiHETE: dihydroxyeicosatetraenoic acid; HBP: high blood pressure subgroup; NBP: normal
blood pressure subgroup; SBP: systolic blood pressure, p: p-value; rS: Spearman correlation coefficient.
3.3.2. DHA and CYP450-Derived Eicosanoids
Associations of DHA with Clinical Features and with Its Metabolites
DHA had a similar distribution among genders and hypertensive status (Table 1) and was
associated neither with BP nor with the main vascular features (Tables 3 and 5).
DHA was directly correlated with its epoxymetabolites, the EDPs, in the whole population and in
both subgroups and was directly correlated with DiHDPAs in particular in NBP children (Table 2 and
Figure 2). DHA directly correlated with the estimated CYP450 epoxygenase activity in both subgroups
(Figure S1).
CYP450-Derived Eicosanoids of EPA and Their Associations with Clinical Features
EDPs and DiHDPAs were not associated with BP and vascular features, except an inverse
correlation of most isomers of EDPs with office SBP in HBP children (Table 4. The associations
of the eicosanoids with BP percentiles are detailed in Table S2). Plasma concentrations of
22-hydroxydocosahexaenoic acid (22-HDHA) did not differ between HBP and NBP subgroups (Table 1)
and did not show any significant correlation with BP and vascular characteristics, except an inverse
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correlation with cIMT (rS = −0.292, p < 0.01) and the relative z-score (rS = −0.297, p < 0.01) in the
NBP subgroup.
Most of the above-mentioned significant correlations remained significant after adjustment for sex,
age and pubertal status, as indicated in the relative tables. After False Discovery Rate (FDR) correction
only most of the correlations between the precursors and the respective products remained significant.
4. Discussion
Our main hypothesis was that several PUFA, mainly assumed by the diet, could affect
hemodynamics and in particular blood pressure, through the formation of specific PUFA-derived lipid
mediators generated via the CYP450-epoxygenase/sEH pathway. Scarce is the evidence linking the
amount of fatty acids introduced by diet and their metabolites via CYP450/sEH with hemodynamics
in humans and, to our knowledge, this is the first study that investigated this link in children. Indeed,
red blood cell membrane fatty acids are a reliable marker of dietary intake, especially for essential fatty
acids, reflecting the preceding intake of the fatty acid [38].
A complex link between PUFA and BP is supported by the literature, where the putative beneficial
effect of omega-3 PUFA on BP and subsequent cardiovascular events is often blurred, being evident in
some trials but not in others or in meta-analyses [5,39], with some studies also available in children [40–42].
The underlying mechanisms are multifactorial and may include an improvement in endothelial function
and in arterial stiffness [10–12], although the relative effects of omega-3 PUFA and their CYP450 generated
metabolites remain not completely understood.
Despite plenty of studies in animal models [43], especially rats, the evidence that EETs could
affect BP in humans is scanty. In particular, our group found lower plasma EETs in patients affected by
renovascular hypertension as compared to essential hypertension and controls [44] and an augmented
production of EETs in plasma and placentas obtained by preeclamptic women [45,46]. Surprisingly,
we did not find any association of EETs neither with BP nor vascular function in this sample of
obese children.
Little is known about the specific actions of the EPA/DHA-derived metabolites via CYP450/sEH
on hemodynamic modulation both in animal models and humans but a few studies support a protective
effect on blood pressure, at least for some single isomers [23,25] suggesting that their actions could be
even more potent with respect to EETs.
In this study, we found interesting correlations between EPA and DHA and the corresponding
metabolites via CYP450-epoxygenase, supporting the hypothesis that a dietary assumption of specific
omega-3 PUFA (or at least a higher storage in cellular membranes) drives a higher production of
their metabolites. Interestingly, these metabolic steps appear different in HBP and in NBP children.
Indeed, the association between precursor and products, especially for EPA metabolism, is stronger
and steeper in HBP than in NBP and, moreover, also the estimated CYP450-epoxygenase activity
(sum of epoxides and diols) itself is higher in HBP children whereas no difference in the estimated
sEH activity (epoxide/diol ratio) was evident between the two subgroups. These data suggest that in
HBP obese children the CYP450-epoxygenase, in particular for EPA, might have a different efficacy or
regulation as compared to NBP. We could hypothesize that in obese children with HBP is a modulation
in CYP450-epoxygenase activity, rather than in sEH activity, leading to an enhanced formation of the
epoxymetabolites, which are supposed to have more favourable cardiovascular effects.
Furthermore, the exploratory analyses in the subgroup of HBP children, seems to reveal a potential
role of some metabolites (especially EEQs and EDPs) on BP. Especially EEQs and in particular 14,15-
and 17,18- EEQ, showed inverse associations with several BP measurements and with the markers
of vascular structure and function (namely, cIMT and distensibility) in HBP obese children. Even if
this is only an exploratory analysis and should be examined with caution, it is compatible with the
hypothesis that the effect of endothelium derived hyperpolarizing factors (such as EETs/EEQs/EDPs)
is detectable only in circumstances when the effect of nitric oxide (NO) is altered [47,48]. Indeed,
some of the beneficial cardiovascular effects of long-chain omega-3 PUFA and especially EPA, at least
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those mediated by CYP450/sEH metabolites, could act as compensatory mechanism and thus being
more evident in more disadvantageous conditions, that is, obesity together with high blood pressure.
Only a few studies addressed this issue: a study in transgenic mice with endothelial expression of the
human CYP2J2 and CYP2C8 demonstrated that increased endothelial CYP450 epoxygenase expression
reduced BP increase especially when nitric oxide synthase and cyclooxygenase were inhibited [49].
Data from studies in humans also support the hypothesis that the CYP450 pathways compensate
the impairment of vasodilation due to classical pathways, like NO, for example in hypertensive
patients [47] and in subjects with hyperpathyroidism, which is generally associated with high blood
pressure and an increased CV risk [50].
In line with our observations, also some other studies suggest that EPA and DHA exert a stronger
effect in hypertensive as compared to normotensive subjects, as suggested also by meta-analyses [5,39,51].
Interestingly, the inverse association of 14,15- and 17,18-EEQ with cIMT, is even stronger in the HBP
subgroup compared to the whole group as well.
The observational study design and the exploratory analyses suggest looking at all these
associations with caution. Anyhow, we hypothesize that EPA could exert a somehow protective
action on blood pressure through their metabolites via CYP450-epoxygenase/sEH, probably mediated
by a beneficial influence on vascular structure and function and this effect could be stronger in HBP
obese children than in NBP. The stronger correlations of EPA with its metabolites in HBP rather than
in NBP children support the hypothesis that their effect becomes more important when BP is higher.
Interestingly, DiHOME, the diols derived from LA via CYP450 and sEH metabolism, showed
a direct correlation with diastolic BP in NBP but not in HBP, suggesting that they negatively affect
vascular stiffness and BP but only in normotensive obese children. Very little is known about the actions
of EpOMEs and DiHOMEs; first data indicated a toxic effect of EpOME and probably of DiHOME
that could be dose-dependent; they also could affect cardiac contractility but the results are not always
consistent [12,13]. On the other hand, a recent study has proposed a possible protective effect of
12,13-DiHOME on metabolic profile, due to its action on brown adipose tissue uptake of fatty acids [52].
Furthermore, an epoxy-keto derivative of LA has been identified as a possible stimulating factor for
aldosterone secretion but its precursor and its metabolic pathway is not known [53]. Furthermore,
we found that LA was inversely correlated to BP in HBP subjects, suggesting a possible beneficial
effect of LA on BP. These data are not easy to interpret, considering the results of the metabolite of
LA, especially the possible positive role of 12,13-DiHOME. Anyhow, it should be considered that from
each fatty acid derives a range of lipid mediators, which can have different actions. Moreover, also in a
previous animal model a discrepancy has been found regarding the effect of dietary intake of fatty
acids, that is, LA and ALA, on the composition of PUFA and their related metabolites [54].
As mentioned above, the present study has limitations: the lack of data about the total food intake
of fatty acids and the amount of fatty acids in the diet, the sample size is relatively low, which can
primarily expose a problem of statistical power; after statistical adjustment for multiple testing only
several correlations remained significant. Thus, considering also the observational design of the study,
the results should be regarded as exploratory and need confirmation in new studies. Furthermore,
we decided to define hypertension on the basis of a single ABPM registration, considering it being
more accurate to establish hypertension based on a single exam. Finally, these results need to be
confirmed in other studies analysing also samples of children of different ages and body size, including
non-obese children and different ethnic groups.
Anyhow, we obtained also several office BP measurements, both in the supine position and in the
recommended sitting position, which strengthened the results derived from ABPM.
Globally, our data suggest that single lipid mediators may exert specific actions in hemodynamic
control in obese children, that may be different in hypertensive rather than in normotensive children.
What remains to be understood are the regulatory mechanisms that can modulate the metabolic
pathways of the fatty acids, leading to the production of specific lipid mediators. Moreover, also the
relations, or the competition, between different metabolic pathways might affect the productions of
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active metabolites, thus influencing the final effect [2]. Furthermore, the omega-3 index of the obese
children included in this study was quite low (mean: 4.6%), far below the proposed target of 8% or
more, which is suggested as CV protective level by the evaluation of epidemiological and clinical
studies [55,56]. Thus, another question that should be addressed by future studies is whether obese
children with HBP may benefit from dietary EPA/DHA supplementation.
In conclusion, this study sets out the steps to further investigate, in children as well in
adults, the metabolism of dietary fatty acids, especially via CYP450 and their possible influence
on hemodynamics and BP control.
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and the estimated CYP450-epoxygenase activity.
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Abstract: The fatty acid compositions of plasma lipids and cell membranes of certain tissues are
modified by dietary fatty acid composition. Furthermore, many other factors (age, sex, ethnicity,
health status, genes, and gene × diet interactions) affect the fatty acid composition of cell membranes
or plasma lipid compartments. Therefore, it is of great importance to understand the complexity
of mechanisms that may modify fatty acid compositions of plasma or tissues. We carried out an
extensive literature survey of gene × diet interaction in the regulation of fatty acid compositions.
Most of the related studies have been observational studies, but there are also a few intervention
trials that tend to confirm that true interactions exist. Most of the studies deal with the desaturase
enzyme cluster (FADS1, FADS2) in chromosome 11 and elongase enzymes. We expect that new
genetic variants are being found that are linked with the genetic regulation of plasma or tissue fatty
acid composition. This information is of great help to understanding the contribution of dietary fatty
acids and their endogenic metabolism to the development of some chronic diseases.
Keywords: fatty acid; diet; genotype; human; FADS
1. Introduction
Traditionally, the fatty acid compositions of plasma and its components (triglycerides (TG),
phospholipids (PL), cholesteryl esters (CE)) have been used as biomarkers of dietary intake of certain
fatty acids. Furthermore, the fatty acid compositions of adipose tissue and erythrocyte and platelet
membranes reflect the dietary intakes of different fatty acids [1–4]. In particular, proportions of omega-3
long-chain unsaturated fatty acids in CE and in erythrocyte and platelet membranes reflect quite well
the intakes of these fatty acids, e.g., from fatty fish. On the contrary, the major dietary saturated fatty
acid, palmitic acid, is more problematic as a biomarker of saturated fatty acid intake due to its rapid
desaturation and elongation to longer-chain fatty acids in the body and due to its endogenous de novo
lipogenesis [5]. Still, based on long-term trial evidence, the palmitic acid content of CE also reflects
dietary intake [4]. Odd-chain fatty acids (15:0 and 17:0) have been used as biomarkers for dairy fat
intake, but they are also produced from gut-derived propionate [6] and exist in fish [7–9]. Moreover,
the measured contents of given fatty acids in different biomarkers indicate only relative patterns of
the fatty acids in the diet, and, e.g., incorporation of omega-3 polyunsaturated fatty acids (PUFAs)
into various biomarkers may vary considerably [10,11]. Various fatty acid biomarkers reflect dietary
intakes from a few days even to years, as does adipose tissue fatty acid composition [11]. Furthermore,
well-known competition occurs between n-6 and n-3 PUFA; the higher the intakes and proportions
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of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are, the lower the relative linoleic
acid content of biomarkers [12,13]. Endogenous fatty acid metabolism is also quite complex, and some
studies suggest, e.g., retroconversion of DHA to EPA and that DHA also interferes with linoleic acid
metabolism [10]. Another example is that trans-fatty acid 18:1t incorporates markedly higher into
TG and PL than CE and may result in a decreased conversion of linoleic acid to its more unsaturated
metabolites [14]. Oleic acid (18:1n-9) is the dominant fatty acid in TGs, whereas linoleic acid (18:2n-6)
is very abundant in CE fraction [15].
Postprandial fatty acid metabolism and fatty acid composition of biomarkers may be modified by
other dietary components and factors related to glucose and insulin metabolism and cardio-metabolic
health in general [16,17]. Finally, the fatty acid composition of various biomarkers is under genetic
regulation [18,19]. Figure 1 summarizes the major factors affecting the fatty acid composition of serum
lipids and cell membranes.
Figure 1. Factors affecting endogenous fatty acid metabolism. T2D, type 2 diabetes.
We became interested in the genetic regulation of fatty acid metabolism over 20 years ago
when we examined whether polymorphism of the fatty acid binding protein 2 gene (FABP2) that is
expressed in intestinal enterocytes modified postprandial lipemic response in humans [20]. In our
oral fat-loading test, we examined postprandial triglyceride, chylomicron, and very-low-density
lipoprotein TG in individuals homozygous for the Ala encoding allele (wild type) and individuals
homozygous for the Thr54 allele variant. The Thr54 genetic variant was suggested to result in an
increased absorption and processing of fatty acids in the intestine and showed an association with
higher lipid oxidation and insulin resistance in Pima Indians [21] and with insulin resistance and
increased intra-abdominal fat mass in Japanese men [22]. We found a markedly higher postprandial
lipemic response in Finnish individuals homozygous for the Thr54 allele. Consequently, we also found
an increased postprandial response of C14–C18 fatty acids in chylomicron and very-low-density
lipoprotein (VLDL) TG in study persons homozygous for Thr54 variant [20]. However, we did
not find any relative differences in the amounts of individual fatty acids introduced to these lipid
fractions between these two genotype groups [23]. This particular genetic variant may also affect the
postprandial TG content of high-density lipoprotein (HDL) in visceral obese individuals heterozygous
for the Thr54 allele [24], and, interestingly, it may associate with reduced delta-6 desaturase (D6D)
activity and lowered arachidonic acid (AA, 18:2n-6) content in obese children homozygous for Thr54
allele D [25]. In a clinical trial in patients with type 2 diabetes (T2D), individuals homozygous for
the Thr54 allele showed an increased postprandial response of mono- and polyunsaturated fatty
acids as an indication of increased fatty acid absorption [26]. In some other studies, postprandial
lipemic response has not been related to this genetic polymorphism [16]. Nevertheless, these results
on FABP2 genetic variation, along with rapidly increasing knowledge about genes involved in fatty
acid desaturation and elongation, indicate that fatty acid absorption and metabolism are under tight
genetic regulation, and there may occur gene–diet interaction in fatty acid metabolism [19].
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2. Methods
We carried out a literature survey of genes and diet in the context of the regulation of fatty acid
compositions in PubMed. We used the following search term: (genotype OR gene OR fads OR elovl)
AND fatty acid AND (diet OR dietary intake OR nutrition) AND (plasma OR erythrocyte membrane)
AND human NOT animal. The search was performed on 3 July 2018 and it gave 553 hits altogether.
Relevant articles were selected based on their abstracts (n = 32).
3. Genetic Variants of Fatty Acid Metabolism and Disease Risk
Figure 2 illustrates how a given genetic variant of fatty acid metabolism could modify endogenous
fatty acid metabolism, their downstream metabolites, and, finally, risk of diseases. Principally, genetic
variation may increase or decrease the activity of certain steps in endogenous fatty acid metabolism,
affecting either desaturation or elongation processes. This effect is also modified by other factors,
as shown in Figure 1. Altogether, modified fatty acid metabolism can be demonstrated by examining
the fatty acid content of plasma and its components, cell membranes, or adipose tissue. In most
studies [15,27,28], enzyme activities involved in fatty acid metabolism have been estimated by different
ratios of certain fatty acids reflecting either desaturation or elongation of fatty acids to their longer chain
metabolites (Figure 3 and Table 1). Furthermore, most of the known genetic variants (single-nucleotide
polymorphisms, SNPs) associated with altered fatty acid metabolism are in fact genetic markers and
their exact function is unknown. Even less is known about the interaction of genes and diet with
regard to genetic regulation of endogenous fatty acid metabolism. In particular, genetic variants of
the fatty acid desaturase (FADS) gene cluster in chromosome 11 (FADS1, FADS2) and elongases (e.g.,
ELOVL2 and ELOVL5) are involved in the regulation of fatty acid metabolism.
Figure 2. Impacts of genetic variants regulating fatty acid metabolism in the body.
Table 1. Fatty acid ratios used for the estimation of desaturase and elongase activities.
Estimated Desaturase/Elongase Fatty Acid Ratio
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Figure 3. Simplified figure of the synthesis of fatty acids in the human body including key enzymes
regulating fatty acid metabolism and genes coding them. AA, arachidonic acid; ALA, alpha-linolenic acid;
DGLA, Di-homo-gamma linolenic acid; DHA docosahexaenoic acid; ELOVL, fatty acid elongase; EPA,
eicosapentaenoic acid; FADS, fatty acid desaturase; LA, linoleic acid; SCD, stearoyl-CoA desaturase 1.
Many studies suggest that delta-5-desaturase (D5D) activity (FADS1) is associated with a lower
risk of T2D [29], while stearoyl-CoA desaturase 1 (SCD1) [27] and delta-6-desaturase (D6D, FADS2)
variants are linked with insulin resistance and worsening of glucose tolerance or an increased risk of
T2D [15,29–32]. In the longitudinal Finnish Diabetes Prevention Study, we confirmed the preventive
effect of D5D activity on future T2D risk, and we showed that a higher insulin sensitivity may
explain this finding [33]. Furthermore, based on the Metabolic Syndrome in Men (METSIM) study
population where erythrocyte membrane fatty acids were analyzed, high estimated elongase activity
was associated with a beneficial effect on glucose tolerance [30]. In another study carried out with the
METSIM study population where the fatty acid compositions of serum lipids from TG, CE, and PL were
analyzed, D6D activity predicted a worsening of glycemia, whereas elongase activity had an opposite
effect on glycemia [15]. Furthermore, it is not surprising that genetic markers of the FADS cluster
are also associated with lipid metabolism, in particular with HDL and triglyceride metabolism [34],
but the data on cardiovascular disease (CVD) risk are lacking. In a meta-analysis studying associations
between omega-3 fatty acid biomarkers and coronary heart disease (CHD), there was no significant
interaction identified by FADS variant for incident CHD events [35]. Interestingly, in a genome-wide
association study (GWAS) of Greenland Inuits, ELOVL2 showed an association with sleep duration,
age, and DNA methylation, and ELOVL5 coding mutations may lead to spinocerebellar ataxia; as an
example of epigenetic effect, epigenetic markers were associated with depression and suicide risk [19].
Disease per se may also modify enzyme activities involved in endogenous fatty acid metabolism.
For instance, non-alcoholic steatohepatitis was found to affect desaturase enzyme activities in the liver
in a cross-sectional study [36].
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4. Genetic Regulation of Endogenous Fatty Acid Metabolism
Figure 3 summarizes the key enzymes regulating fatty acid metabolism in the body. Recently,
many new genetic variants have been identified that may modify endogenous fatty acid metabolism
and, consequently, the profile of fatty acid composition in different plasma components or tissues.
In particular, the knowledge of genes participating in elongation processes has increased rapidly.
We expect that new genetic variants linked with biomarkers reflecting the fatty acid composition of
plasma components or cell membranes will be identified in the future. Some of these novel genetic
variants are listed and briefly discussed in Table 2A–C and the next chapter.
There has been huge progress in research into fatty acid metabolism over the last 20 years.
Both single-nucleotide polymorphism studies and GWAS have focused on enzymes regulating
endogenous fatty acid metabolism (Figure 3). Specifically, these enzymes regulate both desaturation
and elongation processes in fatty acid metabolism. Their genetic variations are associated with altered
accumulation of long-chain PUFAs in the cell membranes of tissues and plasma lipid components [19].
Epigenetic variation of these genes may also play a role in this context [37,38]. In the present review
based on a literature survey and our own studies, we focus on studies investigating the genetic
regulation of plasma and membrane fatty acids in relation to the putative interaction between dietary
fat and fatty acid incorporation into different biomarkers used to evaluate the quality of dietary fat in
observational and intervention studies.
Table 2 summarizes the current knowledge about the genetic variants that have been associated
with endogenous fatty acid metabolism. Most of the studies deal with individual SNPs of the FADS
cluster (Table 2B) or elongases, and only some of them are based on GWAS (Table 2A). Among
them, only a couple studies are true intervention trials (Table 2C), most without a specific hypothesis,
and others are observational trials.
A GWAS based on the Invecchiare in Chianti (InCHIANTI) study population and Genetics of
Lipid Lowering Drugs and Diet Network (GOLDN) study population used for replication observed
that the FADS genetic cluster located in chromosome 11 was associated with AA, eisosadienoic acid
(EDA), and EPA, and the EVOLV2 genetic variant in chromosome 6 with EPA concentrations, but in
the replication study, the association with EPA was not confirmed [18] (Table 2A). A few years earlier,
two cross-sectional studies from Germany reported that haplotypes of the FADS1 and FADS2 region
was associated with AA and many other longer-chain fatty acids of both the n-6 and n-3 series [39]
(Table 2B); specifically, minor alleles of FADS1/FADS2 showed mostly an association with decreased
levels of plasma phospholipids. In a later study [40], associations between FADS1/FADS2 haplotypes
and fatty acids in phospholipids were replicated, and this study also showed similar associations
with phospholipids of erythrocyte membranes, but only regarding omega-6 PUFAs (Table 2B). In 2011,
Lemaitre and co-authors [41] published an important GWAS from five cohorts comprising altogether
8866 individuals of European ancestry, and smaller African, Chinese, and Hispanic populations were
also examined. In line with previous studies, minor alleles of FADS1 and FADS2 were associated with
higher ALA but lower EPA and docosapentaenoic acid (DPA), while minor alleles of ELOVL2 were
associated with higher EPA and DPA but lower DHA content. The results on FADS1 were replicated in
other ancestries examined. Furthermore, this study reported a novel association of DPA with several
SNPs in GCKR.
With regard to interaction, ethnicity may also have an impact on gene–diet interactions. In a study
on Inuits applying GWAS, several SNPs were examined in relation to erythrocyte membrane fatty
acids [42]. Novel genes and polymorphisms that modified fatty acid composition were identified
(Table 2A). This study also suggests that genetic and physiological adaptation to the intake of a diet
rich in omega-3 PUFAs could happen with time.
5. Interaction between Genes and Dietary Fatty Acids
Most of the studies on interactions between genes and dietary fat in terms of the regulation of fatty
acid composition of plasma or erythrocyte membranes are based on observational studies in various
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study populations. These studies have limitations relating to the accuracy of dietary data collection
and possible weaknesses associated with controlling confounding factors (e.g., age, sex, ethnicity,
lifestyle factors, liver status, and cardiometabolic health). Furthermore, genetic effect on fatty acid
composition may vary depending on the fatty acid biomarker used. Therefore, intervention studies
may give more comprehensive data on the variation of biomarker fatty acid composition according to
the genetic background. Intervention studies also have limitations. They are laborious to carry out
and without a pre-genotyped study population, the screening, especially regarding rare gene variants,
is demanding. In our studies, we have been able to invite participants from the large METSIM cohort
with wide genotype and phenotype data [43]. A big limitation related to experimental studies with a
prior hypothesis is that in intervention studies, only one preselected genetic marker can be examined at
a time. Furthermore, a highly experimental diet may not reflect the effects achieved with habitual diet,
and adherence to an experimental diet may remain insufficient in free-living conditions in longer-term
interventions. In large-scale observational studies, a multitude of genetic variations can be examined
at the same time, and it is possible to combine the data collected from different study populations or
the results may be confirmed in other study populations.
Zietemann and co-authors examined the fatty acid composition of erythrocyte membranes and
estimated desaturase activities in relation to the rs174546 FADS genotype variant in their cross-sectional
study [44] (Table 2B). The estimated activities of FADS1 and FADS2 were strongly decreased in
individuals with the minor allele, and in principle, fatty acid compositions reported were in line with
earlier observations. Furthermore, this study described an interaction with diet, i.e., the dietary fatty
acid n-6 to n-3 ratio was suggested to modify the association between the FADS1 and FADS2 genotype
and estimated D5D activity calculated from measured fatty acids (see Table 1). In one study [45]
(Table 2B), 309 pregnant women in the Netherlands were examined at the 36th gestational week and
then one month postpartum. Both plasma phospholipids and milk fat composition postpartum were
examined in relation to high fish or fish oil intakes. The results were divergent in phospholipids
and milk: a higher omega-3 PUFA intake from fish or fish oil compensated for the lower DHA in
plasma phospholipids irrespective of genotype, but the proportion of DHA in excreted milk remained
unchanged in women who were homozygous for minor alleles of FADS1/FADS2. This study suggests
that there may even be tissue-specific interactions regarding genes regulating fatty acid metabolism.
Porenta and co-authors [46] (Table 2C) randomized 108 individuals with increased risk for colon cancer
into the Mediterranean type diet or the Healthy Eating diet for 6 months. Serum and colonic mucosa
fatty acid compositions were examined in relation to selected FADS1/FADS2 alleles. In individuals
with major alleles of the FADS cluster, interaction was suggested between the diets and colonic AA
content that remained unchanged after the Mediterranean diet. In a small intervention study on
putative interaction between fish oil supplementation and the FADS cluster, no significant interaction
was found, but fish oil supplementation resulted in greater increases in erythrocyte EPA levels in
minor allele carriers of FADS1/FADS2 variants [47] (Table 2C).
In a large updated meta-analysis of the Cohorts for Heart and Aging Research in Genomic
Epidemiology (CHARGE) consortium [48] (Table 2B), interaction between dietary PUFAs and 5
different genes affecting fatty acid composition was examined. However, no significant interactions
were found after corrections. Interestingly, the results varied according to the compartments used.
Specifically, regarding the FADS1 interaction term for ALA, even opposite effects were found in
proportions of fatty acids between plasma and erythrocyte membranes.
In a small randomized cross-over trial [49], individuals homozygous for the minor allele of
FADS1/FADS2 had a lower plasma AA and AA/LA ratio when compared with the major allele carriers
after each diet, while ELOVL2 had no effect on PUFAs. Furthermore, flaxseed oil, which is rich in ALA,
resulted in increased plasma composition of EPA beyond that of major allele homozygotes consuming
a typical “western” diet (Table 2C). While very sophisticated methodologies were applied, the study
design was quite complicated in this particular study.
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In one of our own cross-sectional studies [64], we reported a nominally significant gene–diet
interaction between EPA in erythrocytes, CE and TG, and dietary intake of EPA in 962 men who were
participating in the METSIM study (Table 2B). Interestingly, exclusion of fish oil supplement users
strengthened the observed interaction with diet. We also confirmed that the minor allele of rs174550 of
FADS1 (C allele) was strongly associated with a lower hepatic mRNA expression, as observed recently
by Wang et al. in their cross-sectional study [71]. Thus, we concluded that the observed interaction
could be explained by divergent activity of the liver D5D enzyme in the genetic variants of FADS
examined in our study.
Ideally, gene–diet interaction would be studied using an intervention design with participants
with pre-selected genotypes. In our recent trial (Lankinen et al., Am J Clin Nutr 2018, in press), our aim
was to test the hypothesis that the FADS1 rs174550 genotype modifies the effect of dietary LA intake
on the fatty acid composition of plasma lipids. Altogether, 59 men who were homozygotes for FADS1
rs174550 SNP (TT or CC) completed the 4-week dietary intervention with a diet enriched in LA. During
the 4-week intervention period, participants consumed their habitual diet with a supplement of 30 mL,
40 mL, or 50 mL (27–45 g) sunflower oil daily depending on their BMI. The doses of sunflower oil
provided 17–28 g (6 E%) LA daily on top of the average intake of approximately 10–12 g (4.5 E%).
The response in the proportion of AA in plasma phospholipids and cholesteryl esters differed between
the genotype groups (Table 2C). The proportion of AA decreased in participants with the CC genotype,
but remained unchanged (in PL) or decreased only slightly (in CE) in participants with the TT genotype.
We also found that the FADS1 genotype modified the lipid mediator profile (including eicosanoids and
oxylipins) and inflammatory response, measured as serum high-sensitivity C-reactive protein, to an
LA-rich diet.
6. Concluding Remarks
In this review, we aimed to summarize the current evidence regarding genes and dietary fatty
acids in the regulation of the fatty acid composition of plasma lipids and erythrocyte membranes.
The knowledge related to this topic has increased markedly during recent years, but there is no earlier
review article compiling it together. The fatty acid composition of blood lipids and tissues is modified
by dietary intake, but endogenous metabolism of fatty acids, which is strongly genetically regulated,
also has an important role. In particular, genetic variants of the FADS gene cluster in chromosome
11 and elongases (ELOVLs) are involved in the regulation of fatty acid metabolism. In recent years,
some new genetic variants have been shown to be associated with the fatty acid composition of plasma
lipids or erythrocytes, and we expect that new variants will be identified in the near future. Many of
the known genetic variants are quite common. Therefore, it is important to understand better how the
enzymes regulating fatty acid metabolism, and the genes coding them, modify the effect of dietary
intake of fatty acids on metabolism, low-grade inflammation, and metabolic diseases such as T2D.
This understanding may help us to move towards personalized nutrition. It is also noteworthy that
ethnicity may have an impact on gene–diet interactions. Most of the studies on interactions between
genes and dietary fat in the regulation of fatty acid composition of plasma lipids are observational.
Study designs and data collection should be carefully considered in the interpretation of the results.
There are only a few intervention trials regarding this topic, and most of them were performed
without pre-selected genotypes. Definite answers regarding true gene × diet interactions may need
well-planned intervention studies with specific hypotheses and pre-selected genotypes.
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Abstract: Fatty acid desaturases (FADS) catalyze the formation of unsaturated fatty acids and
have been related to insulin sensitivity (IS). FADS activities differ between tissues and are
influenced by genetic factors that may impact the link to IS. Genome-wide association studies
of δ-5-desaturase (D5D), δ-6-desaturase (D6D) and stearoyl-CoA desaturase-1 (SCD) activities
(estimated by product-to-precursor ratios of fatty acids analyzed by gas chromatography) in serum
cholesterol esters (n = 1453) and adipose tissue (n = 783, all men) were performed in two Swedish
population-based cohorts. Genome-wide significant associated loci were evaluated for associations
with IS measured with a hyperinsulinemic euglycemic clamp (n = 554). Variants at the FADS1
were strongly associated with D5D in both cholesterol esters (p = 1.9 × 10−70) and adipose tissue
(p = 1.1 × 10−27). Variants in three further loci were associated with D6D in cholesterol esters (FADS2,
p = 3.0 × 10−67; PDXDCI, p = 4.8 × 10−8; and near MC4R, p = 3.7 × 10−8) but no associations with
D6D in adipose tissue attained genome-wide significance. One locus was associated with SCD
in adipose tissue (PKDL1, p = 2.2 × 10−19). Genetic variants near MC4R were associated with IS
(p = 3.8 × 10−3). The FADS cluster was the main genetic determinant of estimated FADS activity.
However, fatty acid (FA) ratios in adipose tissue and cholesterol esters represent FADS activities in
separate tissues and are thus influenced by different genetic factors with potential varying effects
on IS.
Keywords: fatty acid; desaturase; Genome-wide association study (GWAS); Insulin sensitivity;
adipose tissue; cholesterol ester
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1. Introduction
Fatty acid desaturases (FADS) catalyze the formation of mono- and polyunsaturated fatty acid
and thus influence the fatty acid (FA) composition of the blood stream and in adipose tissue (AT).
The major human FADS include δ-5-desaturase (D5D), δ-6-desaturase (D6D) and δ-9-desaturase or
stearoyl-CoA desaturase-1 (SCD). While SCD synthesizes monounsaturated FA from saturated FA,
D5D and D6D catalyze the formation of polyunsaturated FA. Since in vivo measurement of enzyme
activity can be challenging, ratios of substrate and product concentrations are commonly used to
estimate activities of SCD, D6D and D5D [1].
Both circulating fatty acid composition and estimated FADS activities have previously been
associated with insulin sensitivity (IS) and incidence of type 2 diabetes (T2D), although the mechanisms
underlying these relationships have not been fully determined [2]. It has been suggested that the
effects of FADS on IS are mediated by alterations in FA compositions. This could lead to effects on cell
membranes (influencing insulin receptor binding and affinity, translocation of glucose transporters
and intercellular signaling) and altered levels of polyunsaturated fatty acids (PUFA) which function as
ligands for a variety of transcription factors [3]. In addition, polymorphisms in the genes encoding
for FADS have been was associated with fasting glucose levels and estimated β-cell function in
a large-scale meta-analysis of genome-wide association studies (GWAS) [4].
Genome-wide associations of FADS activity estimated in the circulation have been reported
previously and demonstrated that not only variants in desaturase encoding genes are associated
with estimated FADS activity [5,6]. However, no prior GWAS have reported associations between
genotype and activities of SCD, D5D, or D6D estimated in AT. Furthermore, previous studies
investigating relationships between FADS polymorphisms and IS have relied on indirect measurements
(e.g., fasting glucose and insulin) instead of gold standard methodology, such as the hyperinsulinemic
euglycemic clamp.
The aim of the present study was to perform GWAS of FA metabolizing enzymes in AT and serum
cholesterol esters (CE) in participants of the Uppsala Longitudinal Study of Adult Men (ULSAM) and
the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS). Subsequently, analyses
were performed to investigate relationships between desaturase-associated genetic variants and
cardiometabolic risk factors, including IS assessed by hyperinsulinemic euglycemic clamp.
2. Materials and Methods
2.1. Study Samples
Details about The Uppsala Longitudinal Study of Adult Men (ULSAM) are available in previous
publications [7] and online at http://www.pubcare.uu.se/ulsam/. In brief, at the first collection
time-point, all 50-year-old men living in Uppsala County, Sweden, 1970–74, were invited. The present
study includes individuals at the re-examination undertaken from August 1991 to May 1995 at the
approximate age of 71 years, where 1221 out of 1681 invited individuals participated (73% of those still
alive and living in Uppsala). For the present study, we excluded individuals with missing microarray
genotyping data (n = 5), failing sample quality control (QC) (n = 37), or missing all estimates of FADS
activity (n = 615, cholesterol esters; n = 396, adipose tissue).
A detailed study description of The Prospective Investigation of the Vasculature in Uppsala
Seniors (PIVUS) has been published previously [8] and additional information can be found at http:
//www.medsci.uu.se/pivus/pivus.htm. In brief, all 70-year-old individuals living in Uppsala County,
Sweden, between April 2001 and June 2004 were eligible for the study, out of which 2025 randomly
selected subjects were invited. In total, 1016 subjects (50% women) participated and were examined
within one month of their 70th birthday to standardize for age. For the present study, we excluded
individuals with missing microarray genotyping data (n = 34), failing sample QC (n = 33), or missing
all outcome measurements (n = 60).
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Both the ULSAM and PIVUS studies were approved by the ethics committee of Uppsala University
and all participants provided written informed consent.
2.2. Assessments of Fatty Acid Composition and Enzyme Activities
Procedures for measurements of fatty acid composition in ULSAM and PIVUS have previously
been described in detail [9,10]. Briefly, FA were measured in CE from blood samples drawn after
an overnight fast, during which both medication and smoking were disallowed. A hexane-isopropanol
solution was used to extract serum, from which cholesterol esters were separated by thin-layer
chromatography followed by inter-esterification with acidic methanol. Free cholesterol was removed
by aluminum oxide to avoid contamination of the column. The relative proportion of methylated
FA was determined by gas chromatography (25-m NB-351 silica capillary column) with a coefficient
of variation <5.0%. In addition, FA in subcutaneous AT were analyzed in ULSAM as previously
described [10]. An estimate of enzyme activity was calculated as the product-to-substrate ratio;
20:4n−6/20:3n−6 for D5D, 18:3n−6/18:2n−6 for D6D and 16:1/16:0 for SCD.
2.3. Assessments of Cardiometabolic Risk Factors
Body mass index (BMI) was calculated as the ratio of body weight (in kg) to height (in m) squared.
Concentrations of cholesterol and triglycerides were measured in serum and in isolated lipoprotein
fractions by enzymatic techniques utilizing Instrumentation Laboratories (IL) Test Cholesterol
Trinders’s Method and IL Test enzymatic-colorimetric method for use in a monarch apparatus
(Instrumentation Laboratories, Lexington, MA, USA). High-density lipoprotein (HDL) particles were
separated by precipitation with magnesium chloride/phosphotungstate. IS was directly measured
in the ULSAM cohort using the hyperinsulinemic euglycemic clamp, as previously described [11].
In addition, indices of insulin resistance (HOMA-IR) were assessed in both ULSAM and PIVUS as
calculated using fasting concentrations of plasma glucose and insulin.
2.4. Preparation of Genotype Data
Genotyping was performed using the Illumina OmniExpress and Illumina Metabochip in
PIVUS and Illumina Omni2.5M and Illumina Metabochip in ULSAM. General sample exclusion
criteria included: (1) genotype call rate <95%; (2) heterozygosity >3 SD from mean; (3) gender
discordance; (4) duplicated samples; (5) identity-by-descent match; and (6) ethnic outliers. General
single nucleotide polymorphism (SNP) exclusion criteria of genotyped data before imputation included:
(1) monomorphic SNPs; (2) Hardy-Weinberg equilibrium (HWE) p-value <1 × 10−6; (3) genotype
call rate < 99% (SNPs with minor allele frequency (MAF) < 5%) or < 95% (SNPs with MAF ≥ 5%);
(4) MAF < 1%. In ULSAM, for Omni2.5, further SNP exclusions were made if a SNP had large position
disagreements, did not map in the genome, mapped more than once in the genome or had bad
probe assays.
In PIVUS, 949 out of 982 samples passed QC for the OmniExpress; and Metabochip with the
exclusions listed in Table S1. The genotyped data in PIVUS used in the present study consisted
of 738,879 SNPs after QC. In ULSAM, 1179 out of 1216 samples passed QC for the Omni2.5 and
Metabochip, with the exclusions listed in Table S1. The genotyped data in ULSAM consisted of
1,621,833 SNPs after QC. Imputation was performed for the quality-controlled genotype data of each
cohort with IMPUTE v.2.2.2 using haplotypes from the 1000 Genomes, March 2012 release (multi-ethnic
panel on NCBI build 37 (b37)). Population substructures in the genotype data were captured using
multidimensional scaling (MDS) of a genetic relationship matrix (genome file) constructed on the basis
of linkage disequilibrium (LD)-pruned SNPs in PLINK 1.07 [12].
2.5. Statistical Analysis
Estimated enzyme activity levels were normalized using Blom’s inverse normal transformation.
Regression analyses of genetic variants and estimated desaturase activities were adjusted for the first
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two principal components of the MDS analysis. All regression analyses of the autosomes in ULSAM
and PIVUS were performed separately in each study and then combined in sample size-weighted
Z-score meta-analysis assuming fixed effects in the software METAL. [13] The same settings were used
in the analysis of the X-chromosome as for the autosomes, with the exception that the analyses in
PIVUS were stratified on gender before combining the results in the meta-analysis.
To identify single common variants associated with the estimated enzyme activity in CE,
a genome-wide association analysis was performed using the score-based test in SNPTEST 2.4.1.
(manufacturer, city, country) [14] Common variants (MAF ≥ 5%) available in both studies and with an
information quality metric ≥ 0.4 were included in the analyses. A p-value < 5 × 10−8 was considered
to be genome-wide significant in these analyses. Further, to identify independent variants in each
locus associated with enzyme activity levels, a forward selection conditional analysis was performed,
where independent signals were considered down to a p-value of ~1 × 10−5. In addition, genome-wide
association analyses of the estimated enzyme activity in AT were performed in ULSAM only.
A lookup was performed for the significant SNPs in the single variant analyses using literature and
publicly available databases including RegulomeDB version 1.1 (http://www.regulomedb.org/) [15],
GTEx (http://www.gtexportal.org/home/) [16], Metabolomics GWAS server (http://mips.helmholtz-
muenchen.de/proj/GWAS/gwas/) [5,6] and PhenoScanner (http://www.phenoscanner.medschl.cam.
ac.uk/phenoscanner) [17].
Associations of identified variants with cardiometabolic risk factors including triglycerides,
HDL-C, BMI and HOMA-IR were assessed by linear regression in ULSAM and PIVUS separately
and subsequently meta-analyzed using sample size-weighted fixed effects models. Similarly,
associations between the same variants and M-value determined by hyperinsulinemic euglycemic
clamp were assessed in ULSAM using linear regression models. For these associations between
desaturase-associated loci and cardiometabolic risk factors, false discovery rate was used to correct for
multiple testing [18].
3. Results
The clinical characteristics of individuals with available genotype and cholesterol ester fatty acid
data in ULSAM (n = 564) and PIVUS (n = 889) are shown in Table 1. In addition, a number of men
(n = 783) in ULSAM also had data available on genotype and desaturase activity assessed in adipose
tissue. The correlation between the estimated enzyme activity in CE and AT was low to moderate for
D5D (r = 0.36, p < 0.0001), D6D (r = 0.10, p = 0.098) and SCD (r = 0.40, p < 0.0001).
Table 1. Clinical characteristics of individuals in ULSAM and PIVUS with genotype data and estimated
desaturase activity in cholesterol esters. 1
ULSAM (n = 564) PIVUS (n = 889)
Age 71.3 (0.4) 70.2 (0.2)
Women (%) 0 49
BMI (kg/m2) 26.3 (3.4) 27.0 (4.4)
Antihypertensive treatment (%) 37 31
Total cholesterol (mmol/L) 5.8 (1.0) 5.4 (1.0)
HDL cholesterol (mmol/L) 1.3 (0.3) 1.5 (0.4)
Triglycerides (mmol/L) 1.5 (0.8) 1.3 (0.6)
Lipid lowering treatment (%) 9.4 15.9
Fasting plasma glucose (mmol/L) 5.8 (1.5) 6.0 (1.8)
Glucose disposal, M (mg/kg/min) 5.2 (2.1) N/A
Diabetes treatment (%) 6.5 6.5
Never smokers (%) 40 48
Previous smokers (%) 40 41
Current smokers (%) 20 11
Values are mean (SD) or percentage. 1 PIVUS, Prospective Investigation of Uppsala Seniors; ULSAM, Uppsala
Longitudinal Study of Adult Men; HDL, high-density lipoprotein; BMI, body mass index; M, in vivo
insulin-mediated glucose disposal.
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3.1. GWAS of Desaturase Activity
Quantile-quantile plots of p-values from the single variant association test of the enzyme
activities showed no systematic deviation from the null (data not shown). Variation in one locus
(fatty acid desaturase 1, FADS1) was associated with D5D and variants in or near three loci were
associated with D6D (fatty acid desaturase 2, FADS2; pyridoxal-dependent decarboxylase domain
containing 1, PDXDC1/N-terminal asparagine amidase, NTAN1; and near melanocortin 4 receptor,
MC4R) (Figures S1 and S2). The significant lead variant for CE-D5D was also significant when analyzed
in AT (Figure 1), unlike D6D, where no signal could be seen in AT (Table 2). No locus was significantly
associated with CE-SCD (Figure S3) but one variant close to SCD, in polycystic kidney disease 2-like
1 (PKD2L1), was significantly associated with AT-SCD, which was analyzed in ULSAM (Table 2).
The same direction of effect was seen for CE-SCD, though the association was weaker (P = 1.6 × 10−4).
By conditional association tests of the FADS1-FADS2-FADS3 region, in a forward selection
approach, two SNPs (rs174549, rs968567) were independently associated with CE-D5D and two
SNPs (rs138194593, rs2072113) were independently associated with CE-D6D (Table S2). The four SNPs



















































Figure 1. Estimated δ-5-desaturase (D5D) activity in cholesterol esters (a) and adipose tissue
(b) by genotype at rs174549. Values are means and error bars represent 95% confidence
intervals of means. D5D activity was estimated as the ratio of arachidonic acid (20:4n−6) and
dihomo-gamma-linolenic acid (20:3n−6).
3.2. SNP Lookup
Database searches revealed that the variants independently associated with D5D activity are
located in transcription factor binding regions (cited in RegulomeDB [15]) and have been associated
with expression of FADS1 and FADS2 in diverse tissues (cited in GTEx [16]). In previous GWAS, the two
SNPs independently associated with D5D (or variants in full LD) have been linked to circulating
polyunsaturated fatty acids [6,19–22]. In studies utilizing candidate SNP approaches, the same SNPs
have been associated with FA and ratios thereof in circulation and tissue [23–27].
The lead variant associated with estimated D6D activity, rs138194593, is located in an intronic
region of the FADS2 gene and has been associated with FADS2 expression in blood from Estonian
coronary artery disease patients [28]. The second independent D6D-associated SNP in the FADS2
gene, rs2072113, or proxies in full LD have been associated to FADS expression (as cited in GTEx [16])
and been linked to circulating PUFA in previous GWAS [5,6,19,21]. Another variant linked with D6D
activity, rs6498540, is located in PDXDC1 and has been associated with circulating PUFA and FA
ratios [6,21].
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In addition, rs6498540 is in perfect LD with rs4500751, a SNP in a transcription binding region
(as cited in RegulomeDB [15]) close to PDXDC1 and NTAN1 that has been associated with circulating
PUFA and ratios thereof in previous GWAS [5,6,29]. This SNP is also located 300 kb from PLAG10,
a gene involved in phospholipid metabolism, possibly with a fatty-acid specific mechanism [29].
The top SNP of the third locus associated with D6D activity, rs9957425, is not in strong LD with
other SNPs (r2 < 0.32) and is not likely in a transcript factor binding region but may affect epigenetic
modifications (as cited in RegulomeDB [15]). It has not yet been associated with circulating FA or FA
ratios and has not been strongly associated (p ≥ 0.02) with any traits in the GWAS included in the
Metabolomic GWAS scanner [5,6] or PhenoScanner [17]. The variant is located 576 kb downstream of
MC4R, in close proximity to a region strongly associated with diabetes and related traits.
The variant associated with AT-SCD, rs603424 in the PKLD1 gene, is located 31 kb from the SCD
gene [29] and has previously been associated with adipose SCD expression and circulating saturated
fatty acids, monounsaturated fatty acids and ratios thereof [5,29,30].
3.3. Associations of Identified Loci with Metabolic Traits
After correcting for multiple testing, the lead SNP at one of the loci significantly associated with
estimated D6D activity, rs9957425, was associated with BMI (p = 7.4 × 10−4) and plasma triglycerides
(p = 2.1 × 10−3) in a meta-analysis of ULSAM and PIVUS data (Table 3). The same locus was also
associated to M-value in ULSAM (p = 3.8 × 10−3). Associations of the other loci with BMI, HOMA-IR,
M-value plasma HDL, triglycerides, or M-value were not evident after correcting for multiple testing
(Table 3). All significant loci from the single variant analysis, except rs603424 (PKD2L1, close to SCD),
were associated with HDL cholesterol or triglycerides (p < 0.05) in a large meta-analysis of lipid values
(Table S3) [31]. In additional lookups of published data, no significant associations were seen for
HOMA-IR [4] and only rs6498540 showed some evidence of association for BMI [32].
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4. Discussion
In the present study, five loci were associated at a genome-wide significant level with estimated
activities of D5D, D6D, or SCD in the two population-based Swedish cohort studies ULSAM and
PIVUS. One of these loci, downstream of MC4R, was additionally associated to BMI and triglycerides
in the combined study populations; and to M-value in ULSAM, after correcting for multiple testing.
Most variants identified in the present study or proxies in perfect LD have been associated with
circulating FAs, ratios thereof or FADS gene expression in previous GWAS [5,6,19–22,28–30]. However,
one novel variant near the MC4R gene was identified. Polymorphisms downstream of the MC4R
gene are among the strongest genetic determinants of BMI and they have been associated with food
preference, IS and HDL [33]. Estimated D6D activity has likewise previously been positively associated
to obesity [34,35] and it can be speculated that the observed associations of rs9957425 with desaturase
activity, BMI and IS are due to MC4R-mediated effects on food and fatty acid intake, which could
influence FA proportions and thereby the FA ratio used for estimating D6D activity.
As expected, the strongest associations with estimated D5D and D6D activities in ULSAM and
PIVUS were observed with variants mapped to the FADS cluster, which supports the use of FA ratios
as estimates of desaturase activity. Polymorphism in FADS encoding genes may be directly linked to IS
and T2D [36]; however, identification of such associations could be hampered by high LD in the FADS
region and pleiotropy of the FADS genes. Most genetic variants associated with FADS activity were
linked to blood lipid levels in meta-analysis of published GWAS [31], supporting the relationships
between FADS activity and development of metabolic syndrome [37]. Thus, it is a challenge to
disentangle the potential direct role of FADS gene variants on IS, from that of closely related metabolic
disorders such as triglycerides and HDL.
The correlations between the estimated enzyme activities in CE and AT observed in the present
study confirm results from a previous study in which activities of D5D and SCD in AT and serum were
correlated in Swedish men and women [35]. In that study, D6D activity estimated in AT was correlated
with that estimated in phospholipids but not non-esterified serum FA. Another study reported that
estimated enzyme activities of D5D, D6D and SCD in serum (calculated from total FA in serum) were
highly correlated with corresponding activities in liver tissue but not in AT [38]. Similarly, enzyme
activities of fatty acid desaturases estimated in different plasma lipid fractions are not ubiquitously
correlated, though enzyme activities estimated in cholesteryl esters used in the present study are
considered to reflect hepatic fatty acid desaturation [35,39].
Associations between gene expression and enzyme activity of SCD have been observed in
liver [40], AT [41] and brain [42]. It should be noted that SCD gene expression may differ in different
adipose tissue depots and we have reported that SCD gene expression was correlated with estimated
SCD activity in subcutaneous but not in visceral adipose tissue [43].
Similar associations for D5D have been observed in brain [42] and for D6D in liver [40]. Although
product-to-substrate ratios are indirect measurements of enzyme activity and their accuracy has
been questioned [44,45], FA ratios correlate with direct enzyme activity measurements (by isotope
tracer) [46]. The FA composition of CE is regulated in the liver and plasma, while the composition in
AT is influenced by adipose metabolism [47]. For example, FA are released from AT by lipase-catalyzed
lipolysis and diverse mobilization of individual FA from AT that could affect the ability of FA ratios to
estimate enzyme activity in AT [48]. Hence, as FA ratios in CE and AT represent desaturase activities in
various tissues (i.e., liver, plasma and adipocytes) they may be affected by diverse genetic determinants.
A major strength of the present study is the availability of data on FADS activity estimated in both
AT and serum and to our knowledge this is the first GWAS of adipose FADS activity. Furthermore,
IS was assessed both by the gold standard methodology hyperinsulinemic euglycemic clamp and
calculated using HOMA-IR. The combination of the two cohorts, ULSAM and PIVUS resulted in
dataset consisting of men and women with measured FA composition.
The relatively small sample size of the two cohorts utilized is a limitation of the present study.
Also, data on adipose FADS activity and M-value were only available in one of the cohorts, ULSAM.
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As the two cohorts consist of individuals from the same geographical location, there is a possibility that
the two study population are too homogeneous and thus the possibility to identify associations between
genes and fatty acid metabolism are hampered by low genetic variation. Further, the generalizability
to other ethnicities is unknown.
Our findings have implications for future research. First, our findings support the use of FA ratios
as indirect estimates of desaturase activity, given that the variants most strongly associated with FA
ratios were located in or near desaturase encoding genes. However, certain lipid fractions may be less
suitable to assess desaturase activity by FA ratios as suggested by the inconsistency in loci associated
with D6D and SCD in different fractions. In addition, our findings warrant further evaluation of
rs9957425, associated with both desaturase activity and cardiometabolic traits.
5. Conclusions
In conclusion, the activities of FADS estimated in CE and AT were associated with variants in or
near five independent loci (FADS1, FADS2, MC4R, PDKL1 and PDXDC1). One of the loci (FADS1) was
associated with FADS activity in both CE and AT. One variant associated with estimated D6D activity
(rs9957425 near MC4R) was additionally was associated to BMI, TG and intravenously assessed IS.
Activities of D5D and SCD estimated in CE and AT were correlated, while no correlation was observed
for D6D activity estimated in the different tissues.
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Abstract: Chronic obstructive pulmonary disease (COPD) is a growing healthcare concern and will
represent the third leading cause of death worldwide within the next decade. COPD is the result
of a complex interaction between environmental factors, especially cigarette smoking, air pollution,
and genetic preconditions, which result in persistent inflammation of the airways. There is growing
evidence that the chronic inflammatory state, measurable by increased levels of circulating cytokines,
chemokines, and acute phase proteins, may not be confined to the lungs. Cardiovascular disease
(CVD) and especially coronary artery disease (CAD) are common comorbidities of COPD, and
low-grade systemic inflammation plays a decisive role in its pathogenesis. Omega-3 polyunsaturated
fatty acids (n-3 PUFAs) exert multiple functions in humans and are crucially involved in limiting
and resolving inflammatory processes. n-3 PUFAs have been intensively studied for their ability to
improve morbidity and mortality in patients with CVD and CAD. This review aims to summarize
the current knowledge on the effects of n-3 PUFA on inflammation and its impact on CAD in COPD
from a clinical perspective.
Keywords: omega 3; PUFA; n-3 PUFA; COPD; inflammation; coronary artery disease; ischemic heart
disease; CAD; CHD
1. Introduction
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and
mortality worldwide [1]. Data from the Global Burden of Disease Study estimate that, to date,
approximately 328 million people suffer from COPD globally, and suggest that this number may
be even higher because of a substantial number of undiagnosed cases and increasing exposure to
environmental factors, which promote COPD development and progression. It is estimated that, by
the year 2030, COPD will represent the third leading cause of death worldwide [1–5].
COPD is the result of a complex interaction between lifestyle factors, especially cigarette smoking
and air pollution, and genetic preconditions, resulting in persistent inflammation of the airways even
after smoking cessation, causing sustained peripheral airflow limitation [1,6]. The latter is defined
as the ratio between forced expiratory volume in one second (FEV1) versus forced vital capacity
(FVC) being less than 0.7, determined via spirometry after bronchodilator therapy [1]. The exact
mechanisms behind these processes are not yet understood, but the challenge to oxidative stress and
the resulting imbalance of proteases and anti-proteases seem to be causative [6]. Moreover, there
is growing evidence that the chronic inflammatory state reflected by increased levels of circulating
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cytokines, chemokines, and acute phase proteins may not be confined to the lungs [7]. Cardiovascular
disease (CVD) and coronary artery disease (CAD) are the typical and most common comorbidities of
COPD, and significantly impact on patients’ prognosis and quality of life (Figure 1) [8–11].
Figure 1. Interplay between smoking, pulmonary and systemic inflammation, coronary artery disease
and omega-3 polyunsaturated fatty acids (n-3 PUFAs). COPD = chronic obstructive pulmonary disease,
CAD = coronary artery disease.
Omega-3 polyunsaturated fatty acids (n-3 PUFAs) exert multiple functions in humans and are
crucially involved in limiting and resolving inflammatory processes [12,13]. Eicosapentaenoic (EPA)
and docosahexaenoic (DHA) acid are the main long-chain PUFA of the n-3 PUFA family, and seafood
is the richest dietary source of these essential fatty acids, whereas their metabolic precursor, α-linolenic
acid (ALA), is contained in substantial amounts only in vegetables [14].
2. Systemic Inflammation in COPD
The principal pathological features of COPD are obstructive bronchiolitis and emphysema, as
well as increased mucus secretion. These conditions are the result of a rather complex and chronic
inflammatory process, which is initiated mostly by chronic inhalation of irritants, predominantly
cigarette smoking, air pollutants, and biomass fuel [6]. In this context, it ought to be mentioned that
each puff of a cigarette contains more than 2000 xenobiotic compounds and 1014 free radicals, which
injure lung epithelial cells with dose-dependent cytotoxicity [15,16]. These irritants subsequently
activate pattern recognition receptors, such as Toll-like receptors (TLR), either directly, or indirectly
by causing injury to epithelial cells, which release damage-associated molecular patterns. Interleukin
(IL)-1ß has been demonstrated to be crucially involved in this first step, and IL-1 receptor knockout
mice exposed to cigarette smoke showed reduced pulmonary inflammation and were significantly
protected from development of emphysema compared with littermate controls [17]. On activation,
innate immune cells release pro-inflammatory cytokines and chemokines, such as tumor necrosis factor
α (TNFα) and IL-8, which leads to further recruitment of neutrophils and inflammatory monocytes to
the lung [18]. Activated neutrophils and macrophages, in turn, foster lung destruction through the
release of reactive oxygen species and proteolytic enzymes such as neutrophil elastase and matrix
metalloproteinases [19,20].
Activation of the adaptive immune system is a second step in the pathogenesis of COPD, and
cigarette smoke is crucially involved in activation of dendritic cells in the lower respiratory tract,
leading to T cell activation [21]. CD8 cytotoxic T cells are the predominant T cells in the airways of
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COPD patients [15], however, CD4+ T helper-1 cells and CD4+ T helper-17 cells are also found in high
quantities [6,22,23]. Furthermore, B cells organized into lymphoid follicles are frequently detected in
the airways of patients with COPD, as shown in central bronchial biopsy specimens [24].
Several inflammatory cytokines, including TNFα; IL-6; IL-8; IL-18; and acute phase proteins
such as C-reactive protein (CRP), serum amyloid A, and fibrinogen, as well as white blood cells
(WBC), are detected at increased concentrations in the circulation of patients affected by COPD [25,26].
Similarly, these cytokines are also increased in the sputum and bronchoalveolar lavage fluid of COPD
patients [8], suggesting a close relationship between airway and systemic inflammation. The latter
has been described as an overspill of inflammatory mediators from the peripheral lung to systemic
circulation contributing to the development of comorbidities of COPD [7]. Agusti et al. analyzed six
inflammatory biomarkers (WBC, CRP, IL-6, IL-8, fibrinogen, and TNFα) in one of the largest available
COPD cohorts, the ECLIPSE cohort [26]. The study included COPD patients, smokers without airflow
limitation, and non-smokers. Thirty percent of COPD patients had no signs of systemic inflammation,
whereas 16% had persistent systemic inflammation. The study group with persistent inflammation had
significantly increased all-cause mortality, as compared with individuals without chronic inflammation
(13% vs. 2%). The authors concluded that systemic inflammation is not a constant feature in all COPD
patients, because approximately one-third of those analyzed did not have any abnormal biomarker
neither at baseline nor at one year after follow-up. In a logistic regression analysis, body mass index
(BMI), age, current smoking, and airflow limitation were identified as risk factors for persistent
inflammation in COPD patients. Similarly, Garcia-Aymerich et al. were able to identify a COPD
phenotype characterized by high proportion of obesity, cardiovascular disease, diabetes, and systemic
inflammation in approximately one-third of patients recruited at the first hospital admission because
of acute exacerbated COPD (AECOPD) [27]. Yet, the mechanisms linking COPD to the development
or progression of COPD associated comorbidities are not fully understood, as these studies only show
associations and do not prove causality.
3. Coronary Artery Disease in COPD
CAD prevalence rates in COPD patients range from 7% to 34% [28–30]. COPD and CAD have
a close relationship, as they share common risk factors such as advanced age, cigarette smoking,
and environmental pollution. There are evident epidemiologic data connecting COPD with CAD.
In a cross-sectional study of patients with suspected CAD, patients with COPD had a significantly
higher frequency of obstructive coronary lesions as compared with CAD patients without airflow
limitation [31]. Additionally, the severity of airflow limitation correlated with coronary lesion size
and quantity. No difference was found between COPD and non-COPD CAD patients regarding risk
factors, and a univariate analysis revealed COPD as an independent predictor of CAD. Multiple other
studies have shown similar results and identified COPD as a powerful and independent risk factor
for CVD and CAD. Spirometry tests, especially FEV1, and airflow obstruction defined as FEV1/FVC
less than 0.70, for instance, have strong predictive potential for CAD. For every 10% decrease in FEV1,
cardiovascular mortality was found to increase by about 28%, and even among individuals with
severe airways obstruction, the leading causes of death are predominantly sequels of cardiovascular
disease [31–34]. On the other side, studies investigating airflow limitation in patients with CAD are
scarce, but the prevalence of obstructive ventilation in CAD patients might be underestimated in the
literature [28].
The pathophysiological mechanism linking COPD to its comorbidities is not yet certain, but
chronic exposure to low-grade systemic inflammation might play a central role. Inflammation is a
key factor in the development and progression of atherosclerotic lesions, and numerous cytokines,
mediators, and immune cells have been identified to promote vascular inflammation, cholesterol
deposition in the arterial wall, and the formation of atherosclerotic plaques [35,36].
Most large epidemiologic studies identified C-reactive protein (CRP) as a key player and predictor
of CAD [35,37], as well as “upstream” inflammatory cytokines like IL-6, IL-18, and TNFα strongly
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correlated with disease activity and severity in CAD [38,39]. Similar systemic alterations of systemic
inflammatory markers are found in those COPD patients that revealed an increased prevalence of
cardiovascular disease [26].
However, even though persistent inflammation may constitute the pathophysiological link
between COPD and CAD, alternative mechanistic approaches ought to be mentioned.
Pulmonary emphysema, a phenotype of COPD, is a pathologic condition characterized by
abnormal and permanent enlargement of the airspaces distal to the terminal bronchioles that leads
to destruction of airspace walls and usually to progressive airflow limitation [1]. Studies about the
pathogenesis of emphysema revealed an association with endothelial apoptosis [40–42] and endothelial
dysfunction [43]. The subsequently altered pulmonary perfusion can lead to impaired left ventricular
filling, reduced stroke volume, and lower cardiac output [44]. The endothelial damage, however,
is not limited to the lungs and large cross-sectional studies linked the presence of emphysema to
subclinical atherosclerosis and peripheral arterial stiffness [45] as a consequence of endothelial and
vascular smooth muscle dysfunction [46]. Arterial stiffness is a strong predictor of cardiovascular
disease [47,48], and emphysema severity based on quantitative computed tomography scans in turn
was revealed as the most powerful predictor of arterial stiffness [49]. Moreover, systemic vascular
dysfunction seems to already be present in the earlier stages of COPD, and particularly in patients
with emphysema, although presenting with a largely preserved FEV1 [50].
Still, many other potential mechanisms, for instance, physical inactivity secondary to more
advanced COPD stages, chronic hypoxia, genetic predisposition, as well as direct endothelial damage
caused by cigarette smoking, may help to further explain the frequent association between COPD and
CAD [51].
4. Anti-Inflammatory Proprieties of n-3 PUFA and the Benefits in Cardiovascular Disease
n-3 PUFA exert multiple functions in humans and are crucially involved in limiting and
resolving inflammatory processes. A recent American Heart Association science advisory recommends
consuming nonfried seafood, especially species higher in long chain n-3 PUFA, one to two times per
week for cardiovascular benefits [52]. However, data about the specific n-3 PUFA supplementation
for influencing the risk of CVD are still ambiguous, underlined by recent findings from randomized
controlled trials and meta-analyses, which led to a class III recommendation by the American Heart
Association for dietary supplementation with n-3 PUFAs in populations at high risk of CVD [53]. This is
further supported by a Cochrane Systematic Review providing information that EPA and DHA slightly
reduce serum triglycerides and raise high density lipoprotein cholesterol (HDL-C), however, little or
no effect on all-cause deaths and cardiovascular events and probably little or no difference in terms
of cardiovascular death, coronary deaths or events, stroke, or heart irregularities was described. [54].
The hypothesized protective mechanisms are not solely related to reduced overall inflammation, but
also include effects on lipid metabolism and thrombogenesis, as well as anti-arrhythmic proprieties,
reducing the rate of sudden cardiac death in secondary prevention [53,55,56].
Increased bioavailability of n-3 PUFAs, by means of EPA and DHA, change the balance between n-3
and n-6 PUFA with arachidonic acid (AA) as the major precursor of the latter, favoring the synthesis of
anti-inflammatory eicosanoids [57]. The incorporation of EPA and DHA into human inflammatory cells
occurs in a dose-response fashion, and because less substrate is available for synthesis of AA-derived
eicosanoids, n-3 PUFA supplementation to human diet has been shown to result in decreased production
of prostaglandin E2 (PGE2), thromboxane A2, Leukotriene B4 (LTB4), 5-hydroxyeicosatetraenoic acid, and
leukotriene E4 by inflammatory cells [57]. Plenty of evidence supporting this hypothesis is available from
rheumatoid arthritis disease, a disease primarily characterized by inflammation [58]. There are many
studies about patients with rheumatoid arthritis, where fish oil supplements decreased LTB4 production
by neutrophils and monocytes, 5-hydroxyeicosatetraenoic acid production by neutrophils, and PGE2
production by mononuclear cells [58]. A recently published prospective trial concluded that the intake of
fish oil resulted in a shift of n-6/n-3 PUFA ratio and in a higher incorporation of n-3 PUFA precursors
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for the anti-inflammatory lipid mediators in plasma phospholipids. This further induced a significant
improvement in the clinical status by improving joint inflammation, as well as reducing inflammatory
parameters (CRP, erythrocyte sedimentation rate) [59]. However, the altered ratio between n-6/n-3 PUFA
occurred solely through an increase of n-3 PUFA, while n-6 PUFA remained unchanged. In the literature,
similar concerns with the n-6/n-3 PUFA ratio were identified and discussed. Depending on how the
proportion of n-6 PUFA changes, the proportion of n-3 PUFA could decrease, remain unchanged, or
increase and still lead to a lower n-6/n-3 PUFA ratio, although the active biochemical effects of a decrease,
no change, or an increase in the proportion of n-3 PUFA are distinctly different. Moreover, the single
aspect of an n-3/n-6 PUFA ratio neglects the source of n-3 PUFA, and it is well established that the
biological effects of α-linolenic acid (ALA), EPA, and DHA are diverse [60]. In terms of cardiovascular
diseases, one would hypothesize that higher levels of n-6 PUFA and lower levels of n-3 PUFA could
increase cardiovascular risk. This has not been demonstrated, as both n-6 and n-3 fatty acids are associated
with reduced cardiovascular risk in several studies [61]. Similarly, two prospective trials concluded
that the ratio of n-6/n-3 polyunsaturated fatty acids is of no value in modifying cardiovascular disease
risk [62–64].
The anti-inflammatory mechanism of n-3 PUFA also expands on leukocyte recruitment by affecting
the expression of adhesion molecules on endothelial cells [65]. This step is crucial, as monocytes in
particular migrate into the vessel wall, differentiate into macrophages, and may become foam cells,
contributing to the initiation and progression of inflammatory atherosclerotic lesions [66,67]. Moreover,
resolution of inflammation is an actively programmed biochemical progress, regulated by specialized
pro-resolving mediators (SPM) derived from n-3 and n-6 PUFA (Figure 2) [68]. While n-3 PUFAs are
synthesized to resolvins, protectins, and maresins, n-6 PUFAs are synthesized to lipoxins [69]. SPMs
are predominantly involved in the regulation of neutrophil activity, as well as cyto- and chemokine
release, and induce the resolution of an inflammatory tissue state towards tissue homeostasis [70].
Figure 2. Inflammatory response and inflammatory resolution: the role of molecular mediators derived
from n-3 PUFA and n-6 PUFA. EPA = eicosapentaenoic acid, DHA = docosahexaenoic acid, AA =
arachidonic acid, PGI = prostaglandins, TNFα = tumor necrosis factor α.
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Figure 2 illustrates the complexity of SPM involvement in inflammation resolution. Resolvin E1,
derived from EPA, is involved in the limitation of neutrophil migration, the enhancement of neutrophil
and eosinophil clearance, and the reduction of IL-23 and 12 release. Also, resolvin E1 inhibits platelet
and vascular smooth muscle activation [71].
Similarly, resolvin D1, derived from DHA, limits neutrophil transmigration, and promotes the
clearance of apoptotic cells and allergens. Moreover, resolvin D1 stimulates the production of IgM and
IgG. Resolvin D2, on top of limiting neutrophil activity and enhancing macrophage activity, reduces
the possibility of leukocyte–endothelial interaction by stimulating NO production [71].
Protectin D1 effectively inhibits T cell migration and apoptosis, and reduces the production
and release of TNFα and Interferon gamma, besides limiting neutrophil activity and promoting
macrophage activation [70].
Maresin 1, on the other hand, predominately affects pulmonary tissue by reducing the overall
amount of neutrophils in the lung, limiting edema, tissue hypoxia, and pro-inflammatory cytokines [70].
Also, IL-5 and IL-13 secretion is reduced, thereby affecting innate lymphoid cells. Another beneficial
effect of this SPM is the stimulation of regulatory T cells, stimulating innate lymphoid cells type 2
mediated effects [70]. Finally, n-3 PUFAs also directly impact arterial stiffness by decreasing the pulse
wave velocity and improving arterial compliance [72], as was shown in a meta-analysis by Pase et al.
Similarly, the effects were further confirmed by more recent randomized controlled trials in patients
with metabolic syndrome and patients at elevated cardiovascular risk [73,74].
5. n-3 PUFA in COPD Patients, Smokers, and Subjects at Risk
The beneficial effects of an inflammation-modulating diet using n-3 PUFA in patients with acute
lung injury or acute respiratory distress syndrome have been reported previously [75,76]. Therefore, it
was hypothesized that n-3 PUFA might also have beneficial effects in patients with COPD and the effect
might extend to linked comorbidities potentially related to systemic inflammation, including CAD.
Investigations on n-3 PUFA and the impact on airflow limitation and smoking were published in
the past (a schematic overview of the discussed studies is given in Table 1). One of the first available
studies was conducted by Sharp et al. in 1994 [77]. A large cross-sectional cohort study (Honolulu
Heart Program) revealed a protective function of elevated fish consumption (major source of n-3
PUFA) in smokers by decelerating the FEV1 decline. However, the effect was limited to subjects with a
maximum inhalation of 30 cigarettes per day, indicating a dose-dependent limitation. Interestingly,
an analysis of the same cohort also showed a decrease in the risk of CAD morbidity and mortality in
smokers with increased fish intake (defined as >2 times/week), suggesting a relationship between
airflow limitation, CAD, and n-3 PUFA [78]. No information is available on whether patients matching
the current definition of COPD were included in this analysis.
152




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Nutrients 2018, 10, 1864
Shahar et al. analyzed the dietary impact of n-3 PUFA (assessment of EPA and DHA intake via
questionnaire) on 8960 current or former smokers from the “Atherosclerosis Risk in Communities—ARIC”
study cohort and studied its relation with COPD [79]. COPD was assessed by a questionnaire on
respiratory symptoms and by spirometry. The definition of COPD, however, was slightly different when
compared with the current GOLD definition [1]. The authors describe a strong inverse relation between
COPD severity and intake of n-3 PUFA. Moreover, higher intake of n-3 PUFA and fish consumption also
predicted better lung function in smokers and former smokers. Many other investigations, including the
same cohort, were subsequently published; n-3 PUFAs were associated with a modification of hemostatic
factors—key components of CAD and acute myocardial infarction—resulting in a hypocoagulable
profile [80]. Data from the same cohort also revealed lower levels of plasma PUFA (especially n-6
PUFA) among participants who developed CAD [81]. Yamagishi et al. found an increased risk of heart
failure in subjects with higher plasma levels of saturated fatty acids, and n-3 PUFAs were associated with
a decreased risk of heart failure in women in the ARIC cohort [82].
A positive association between n-3 PUFA (assessment of n-3 PUFA via questionnaire) consumption
and ventilatory function (FEV1% and FVC%) was found in 1232 adults aged between 22 and
28 years [83]. The analyzed cohort had no signs of obstructive ventilatory dysfunction, and statistical
significance was lost after adjusting for multiple comparisons, suggesting only a weak effect of n-3
PUFA. The idea of analyzing a cohort of young adults was related to the fact that reduced maximal
attained lung function (as measured by spirometry) may identify individuals who are at increased risk
for the subsequent development of COPD [1,84].
Leng et al. conducted a nutritional epidemiological study in two separate cohorts (Hispanic and
non-Hispanic white smokers; assessment of EPA, DHA, and docosapentaenoic acid (DPA) intake via
questionnaire) to identify nutrients associated with FEV1 and its decline [85]. Of the analyzed n-3
PUFAs, EPA, DHA, and DPA intake were positively associated with better FEV1 volumes, and DPA
was associated with a reduced age-related FEV1 decline. No increased FEV1 decline of currently
smoking participants was observed in one of the two cohorts (Lovelace Smoker’s cohort) if high
amounts of DPA were consumed. The study only included approximately 25% COPD patients, and
both cohorts showed a mean FEV1/FVC ratio of >0.7, limiting the disease to mild-to-moderate stages.
No data about CVD prevalence in the two analyzed cohorts are provided.
Conflicting evidence came from another population-based cohort study showing that an increased
proportion of dietary fat consumption was associated with increased IL-6 levels, which were significant
predictors of FEV1 and FVC [86]. Plasma IL-6 is a clinically relevant marker of inflammation and has
been linked to cardiovascular outcomes in some epidemiological studies [87]. n-3 PUFA (assessment via
questionnaire) intake was not found to be associated with %FEV1 in the linear regression model, and no
information is given about the relation between n-3 PUFA and IL-6. Overall, the patients included in the
study had no absolute limitation of FEV1 (approximately 80% predicted) and obstructive ventilation, a
typical feature of COPD, was not found (FEV1/FVC > 0.7.) Moreover, the assessed smoking status
revealed non-smokers in 73% of female patients and 39% of male patients and, therefore, the odds of
COPD patients being included in the study are low.
In 2016, Scaglia et al. analyzed dietary habits related to PUFA consumption (red blood cell
membrane determination of alpha linoleic acid (ALA), EPA, DPA, and DHA) in smokers and lifetime
non-smokers [88]. They found significant differences in the dietary consumption of n-3 PUFA between
the two groups and showed lower levels of DHA and EPA in smokers. They hypothesized that PUFA
might interfere with smoking habits, suggesting dietary supplementation as a potential therapeutic
option for smoking cessation. Still, this observation was not confirmed in follow up studies thus far
and urges further elucidation.
The anti-inflammatory proprieties of n-3 PUFA in COPD patients have been studied [89] in
sixty-four patients receiving either an n-3 PUFA (ALA) or an n-6 PUFA (linoleic acid) supplementation
diet for two years. Apart from clinical improvements (decrease of dyspnea according to Borg
scale and decrease of arterial oxygen saturation after a 6 min walking test), leukotriene B4 levels
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in serum and sputum, as well as TNFα and IL-8 levels in sputum, decreased significantly in patients
consuming an n-3 PUFA rich diet, while there was no significant change in individuals receiving
dietary supplementation of n-6 PUFA.
A cross-sectional study including 250 COPD patients analyzed inflammatory parameters related
to dietary intake of n-3 (EPA, DHA, ALA) and n-6 PUFA [90]. Higher intake of alpha linoleic acid
(ALA) was associated with lower TNFα concentrations in serum, while no differences were seen with
other assessed inflammatory parameters (IL-6, IL-8, and CRP). A higher ALA intake was related to
higher IL-6 and CRP serum concentrations.
The effects of PUFA supplementation (blend of PUFA, 9 g, mainly n-3 PUFA, namely ALA, EPA,
and DHA) on the outcome of pulmonary rehabilitation were studied in 80 COPD patients randomized
to an intervention or a placebo group [91]. The peak exercise capacity increased in both groups.
However, a significantly higher increase was observed in the intervention group after eight weeks of
training. Also, the duration of the constant work rate increased far more in patients receiving PUFA.
However, the measured systemic inflammatory parameters, namely CRP, IL-6, and TNFα, did not
change after rehabilitation or after PUFA intervention, contrasting the results of others [89,90], who
observed modulation of systemic inflammation after n-3 PUFA supplementation. Thus, systemic
inflammation is not a common feature of all COPD patients. Therefore, a more detailed analysis of
the subgroup of “inflamed COPD” patients would be desirable. Still, it is unanswered as to how the
biochemical phenotype of an “inflamed COPD” patient is defined.
The beneficial effects of n-3 PUFA in COPD associated cachexia were studied in a randomized
controlled trial including 45 patients [92]. Patients in the intervention group received 2.0 g DHA + EPA
as well as 10 g whey protein concentrate and 10 μg 25-hydroxy-vitamin D3 twice daily for 12 weeks
versus a milk-based comparator. Both groups gained weight, but the intervention group gained more
fat mass. Moreover, a significant reduction in systolic blood pressure and increases in high-density
lipoprotein cholesterol were observed in the intervention group compared with controls, parameters
that can be regarded as risk factors for CAD [93]. No significant changes in the measured inflammatory
parameters (CRP, IL-6, IL-8, and TNF) were observed.
In summary, several limitations of the described studies must be discussed. First, the most
important limitation is that most of the studies are cross-sectional observational cohort studies. Second,
n-3 PUFA sources are indirectly measured using food frequency questionnaires. Dietary habits reported
from questionnaires are surrogate parameters of the real dietary consumption of n-3 PUFA; this may
lead to inaccurate n-3 PUFA consumption estimations, although studies suggest a plausible correlation
between the two factors [94,95]. Third, the causality and the direction of a causal relation cannot
be explained when considering a cross-sectional study design. Finally, COPD patients and smokers
may have changed their lifestyles and dietary habits, reducing fish consumption. Therefore, further
prospective studies are warranted to investigate the impact of n-3 PUFA consumption on systemic
inflammatory parameters in such patients.
6. n-3 PUFA, CAD, and COPD
Evidence on the beneficial effects of n-3 PUFA on CAD and CVD in COPD patients is scarce.
Many large randomized controlled trials have been conducted to study the benefits of n-3 PUFA in
CAD and CVD [53,54], however, although most of the included patients were smokers, the prevalence
and severity of COPD were rarely reported.
We reviewed all included studies from the Cochrane systematic database review, “Polyunsaturated
fatty acids for the primary and secondary prevention of cardiovascular disease”, and the American Heart
Association Science Advisory, “Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and
the Prevention of Clinical Cardiovascular Disease”, in regard to included COPD patients [53,54]. Of the
included 65 studies, only 4 reported on COPD patients in their cohort.
Nodari et al. analyzed the benefits of n-3 PUFA (850 to 882 mg of EPA and DHA) in the prevention
of atrial fibrillation (AF) recurrence rates after electrical cardioversion in a prospective randomized
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controlled trial, including 199 patients [96]. After one year of follow-up, the probability of maintained
sinus rhythm was significantly higher in the n-3 PUFAs-treated patients as compared with the placebo
group. A small subgroup of approximately 10% COPD patients (n = 12 placebo vs. n = 13 intervention)
was included in the study, however, no separate details on the subgroup were discussed.
Rauch et al. analyzed the effect of n-3 PUFA (460 mg EPA, 380 mg DHA) if given on top of modern
guideline-adjusted therapy in survivors of acute myocardial infarction [97]. The study was designed
as a randomized, placebo-controlled trial with a duration of one year, and included 3851 patients, of
whom approximately 6% were highlighted as COPD patients (n = 122 placebo vs. n = 108 intervention
group). Overall, guideline-adjusted treatment of acute myocardial infarction already resulted in a low
rate of sudden cardiac death and other clinical events within one year of follow-up, and the application
of n-3 PUFA could not further improve the outcome. No details are provided regarding such effects in
the COPD subgroup.
The GISSI-HF investigators published a randomized, double-blind, placebo-controlled trial
analyzing the effect of n-3 PUFA (850–882 mg EPA and DHA) in patients with chronic heart failure [98].
In total, 6975 patients with chronic heart failure of New York Heart Association class II–IV were
randomly assigned to n-3 PUFA intervention or placebo. A subpopulation of 205 COPD patients was
included in the study (n = 793 placebo vs. n = 740 intervention). Primary endpoints were time to death
from any cause or death/admission to hospital for a cardiovascular reason. A slight, yet significant
reduction of death from any cause or death/admission to hospital for cardiovascular reasons was
found in the PUFA group. No specific details are provided for the COPD subpopulation.
Finally, Mozaffarin et al. analyzed the effect of n-3 PUFA (EPA 465 mg and DHA 375 mg) in the
prevention of AF in 1516 patients who underwent cardiac surgery [99]. Patients were randomized
to receive fish oil or placebo until hospital discharge or postoperative day 10. A small subgroup of
approximately 11% of COPD patients (placebo n = 90 vs. intervention n = 80) was included in the
study. The authors concluded that perioperative supplementation with n-3 PUFA did not reduce the
risk of postoperative AF and, similarly to the aforementioned studies, no details are provided about
the COPD subgroup.
In summary, these studies showed a weak benefit of n-3 PUFA supplementation in the setting
of atrial fibrillation recurrence rate after electrical cardioversion and a slight reduction of death and
hospital admission in patients with left heart failure, both diseases closely associated with CAD.
No benefits were seen in survivors of acute myocardial infarction or patients with atrial fibrillation
after cardiac surgery. The weak benefits seem to also apply to COPD patients, which were included
in 5–20% of the discussed studies. However, as already mentioned earlier, the high number of
undiagnosed COPD cases and low awareness of investigators towards this chronic disease in patients
with cardiac pathologies led to neglect of this important aspect even in large and prospective trials.
In our opinion, it seems plausible that other studies also included COPD patients at a rate of at least
5–10%. Thus, the results from the Cochrane systematic database review and the American Heart
Association Science Advisory might also apply to COPD patients.
7. Conclusions and Future Perspectives
COPD represents a growing healthcare concern worldwide. Pathophysiological aspects of COPD
imply a local inflammatory reaction, initiated by inhalation of noxious substances, which, in some
cases, led to the emergence of inflammatory mediators in the systemic circulation. Epidemiologic and
mechanistic studies indicate that COPD is frequently associated with CAD, congestive heart failure,
and cardiac arrhythmias, independent of shared risk factors. A possible pathway is highlighted as
chronic low-grade systemic inflammation, an aspect that likely also contributes to coronary artery
disease. n-3 PUFAs have been intensively studied for their ability to improve morbidity and mortality
in patients with CAD. However, little evidence exists toward the beneficial anti-inflammatory aspects
of n-3 PUFA in COPD patients, and even less evidence is available in regard to patients with COPD
and associated CAD.
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Overall, the available literature suggests a weak benefit of n-3 PUFA in COPD patients related to
clinical outcomes, and n-3 PUFA mediated borderline amelioration of local and systemic inflammation.
To date, the specific interplay between n-3 PUFA, COPD, and CAD has not been investigated in
prospective trials.
In-depth keyword guided research on ongoing trials on n-3 PUFA in COPD and CAD revealed
a relatively small number of registered trials on http://ClinicalTrials.gov. To date, only one trial
investigating the effect of fish oil on endothelial function by FMD (flow-mediated dilation) in COPD has
been registered (NCT00835289). Another trial has investigated the effect of both training and nutritional
supplementation on body composition, activity, and cardiometabolic risk in COPD (NCT01344135).
However, as nutritional supplementation has not occurred in all subjects and as an observational
period of eight months may not be enough to reach clinically important cardiovascular and COPD
endpoints, prospective, randomized controlled studies are warranted. Future studies ought to measure
atherosclerotic disease progression, as well as establish relevant COPD inflammation parameters in
order to determine the role of PUFA in inflammation-mediated diseases such as COPD and CAD.
Moreover, standardized PUFA administration as well as a sufficient observation period may be
crucial to understanding the role of PUFA in these diseases. Successful trials may help introduce a
standardized supplementation of PUFA in patients with CAD or COPD or both to reduce disease
progression or development.
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Abstract: A moderately high-fat Mediterranean diet does not promote weight gain. This study
aimed to investigate the association between dietary intake of specific types of fat and obesity and
body weight. A prospective cohort study was performed using data of 6942 participants in the
PREDIMED trial, with yearly repeated validated food-frequency questionnaires, and anthropometric
outcomes (median follow-up: 4.8 years). The effects of replacing dietary fat subtypes for one another,
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proteins or carbohydrates were estimated using generalized estimating equations substitution models.
Replacement of 5% energy from saturated fatty acids (SFA) with monounsaturated fatty acids (MUFA)
or polyunsaturated fatty acids (PUFA) resulted in weight changes of −0.38 kg (95% Confidece Iinterval
(CI): −0.69, −0.07), and −0.51 kg (95% CI: −0.81, −0.20), respectively. Replacing proteins with MUFA
or PUFA decreased the odds of becoming obese. Estimates for the daily substitution of one portion of
red meat with white meat, oily fish or white fish showed weight changes up to −0.87 kg. Increasing
the intake of unsaturated fatty acids at the expense of SFA, proteins, and carbohydrates showed
beneficial effects on body weight and obesity. It may therefore be desirable to encourage high-quality
fat diets like the Mediterranean diet instead of restricting total fat intake.
Keywords: fat; obesity; body weight; cohort study; substitution models
1. Introduction
Obesity is one of the most important risk factors of noncommunicable diseases. The epidemic
has been described extensively in scientific literature, providing cogent evidence for its role in the
development of cardiovascular diseases, diabetes, musculoskeletal disorders, and certain types of
cancer [1]. Dietary fat intake has long been believed to be an important predictor of obesity as it is the
most energy-dense macronutrient, providing about 9 kcal per gram versus 4 kcal/g from proteins or
carbohydrates. Consequently, to control obesity, dietary guidelines have focused on reducing total fat
intake for almost four decades [2]. Even after a large body of evidence showed the beneficial health
effects of unsaturated fatty acids [3,4], total fat restrictions remained [5], as well as the gradual increase
in the global prevalence of overweight and obesity [6].
Currently, some aspects of guidelines are being revised. A report of the third FAO (Food and
Agriculture Organization of the United Nations)/WHO (World Health Organization) Expert
Consultation on Fats and Fatty Acids in Human Nutrition (Geneva, 2008) showed the focus is clearly
shifting from fat quantity to quality [7]. Additionally, the latest US Dietary Guidelines Advisory
Committee (DGAC) report concluded that emphasis should be put on optimizing types of dietary
fat and not reducing total fat [5]. The quality of fat is generally specified by the relative intake
of monounsaturated (MUFA) and polyunsaturated fatty acids (PUFA) versus saturated (SFA) and
trans fatty acids. Furthermore, PUFA may be subdivided into plant-derived linoleic (C18:2n-6)
and α-linolenic acid (ALA, C18:3n-3) and marine-derived eicosapentaenoic (EPA, 20:5n-3) and
docosahexaenoic acid (DHA, C22:6n-3) [8].
The Mediterranean diet (MeDiet) is typically high in fat and there is evidence about its role in the
prevention of cardiovascular disease [9,10], in which the proportions of unsaturated and saturated
fatty acids have been shown to play an important role [11]. Moreover, multiple systematic reviews and
meta-analyses have shown a MeDiet does not promote weight gain [12–15]. In fact, it may even result
in greater and more long-lasting weight loss than low-fat diets and be protective against increases
in waist circumference [12–15]. This outcome has also been shown for nut intake, a predominant
food product in the MeDiet [16–18]. Other food, more specific components of the MeDiet, and their
association with obesity-related outcomes have not received as much attention to date.
Although assessing a complete dietary pattern provides insight into the cumulative effects of
consuming certain products, determining which nutrients or food items induce the greatest change
may lead to better understanding of the associations. The main objective of this study is therefore to
investigate the association between dietary fat intake of both specific types of fatty acids and of food
items within the MeDiet and body weight and obesity.
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2. Materials and Methods
2.1. Study Population
This prospective study was a secondary analysis using data of the large, randomized
controlled trial PREDIMED (prevención con dieta Mediterránea, prevention with Mediterranean
diet). Participants within the PREDIMED study were Spanish men and women at high risk for
cardiovascular disease, recruited from multiple centers across the country between October 2003 and
June 2009. After inclusion, participants were assigned to two groups receiving a MeDiet supplemented
with either extra virgin olive oil or mixed nuts, and—in the case of the control group—solely receiving
advice on following a low-fat diet. The PREDIMED protocol was approved by institutional review
boards and all participants provided written informed consent. Further details on the design and
protocol of the study have been described elsewhere [19,20].
The trial was stopped in December 2010 and included 7447 participants. After exclusion of
participants without food-frequency questionnaire (FFQ) data, without BMI follow-up data, with
implausible energy intakes (<800 or >4200 kcal/day in men <500 and >3500 kcal/day in women) [21]
or without other data necessary to perform the analyses, the population available for the present
analyses included 6942 participants with a median follow-up of 4.8 years (interquartile range: 2.9
to 5.8).
2.2. Dietary Exposure Assessment
At baseline and yearly thereafter, a semiquantitative 137-item food-frequency questionnaire (FFQ)
was collected and reviewed by trained, registered dieticians. The used FFQ was repeatedly validated
and found to be highly reproducible and have a reasonably good validity with regard to nutrient intake
reported [22,23]. Spanish food-composition tables were used to derive energy and nutrient intake [24].
Dietary intakes were considered as the cumulative average of all available data, from baseline to each
follow-up measurement, to optimally represent long-term intake and reduce measurement error [25].
2.3. Outcome Assessment
Anthropometric measurements were taken by trained personnel once a year. Weight was
measured on a calibrated scale, without shoes and with light clothing. Height was determined
using a wall-mounted stadiometer.
Participants with a BMI ≥25 and <30 kg/m2 were classified as overweight and ≥30 kg/m2 as
obese. Substantial weight gain or loss was defined as a change ≥10% when compared to baseline
body weight [26]. Body weight was analyzed as continuous outcomes and dichotomized using this
cut-off (a change ≥10%), additional to the dichotomous variables for incidence (increasing to a BMI
≥30 kg/m2) and reversion of obesity (decreasing to a BMI <30 kg/m2).
2.4. Assessment of Other Variables
At each yearly visit, sociodemographic variables and risk factors like educational level and
working, marital, and smoking status were assessed using in a general questionnaire. Physical activity
was assessed using the Spanish version of Minnesota Leisure-Time Physical Activity, validated in both
sexes [27,28]. Based on frequency and duration of 67 activities, a MET (Metabolic equivalents) score was
assigned to each participant. The analyses considered updated the measurements of these covariates
and in case of missing data, the last observations were carried forward to prevent participants being
excluded from the analyses.
2.5. Statistical Analyses
Participant characteristics were reported according to extreme quintiles of fatty acid intakes, as
mean (SD) for continuous variables and % for categorical variables.
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Generalized estimating equations (GEE) were fit to analyze the association between the cumulative
average of yearly measured consumption of dietary fatty acids and body weight. For these continuous
outcomes, the distribution was set to Gaussian and link function to identity. Effects of isocaloric
substitution of fat types for one another, carbohydrates, and proteins were estimated as the difference
between β coefficients of macronutrients exchanged per 5% of energy from these sources. Logistic
GEE regression models were used to determine odds ratios for incidence and reversion of obesity
and ≥10% changes in body weight. The effects of replacing specific high-fat food products for other,
higher-quality options were estimated using non-isocaloric substitution models, by considering the
replacement of single portions of meat, fish and seafood (100 g), oils, butter and margarine (10 g), and
nuts (30 g). For all GEE models, an exchangeable correlation structure was assumed.
The model included intakes of all energy delivering dietary variables except for one (the last one
being omitted as they add up to 100% for any person) and was adjusted for age, sex, intervention
group, baseline BMI or body weight, leisure-time physical activity (quintiles of MET-min/week),
smoking status (never, former, current smoker), educational level (none/primary, secondary,
academic/graduate), working status (employed, unemployed, housewife, retired), marital status
(single/widowed, married), and dietary fiber intake (continuous).
Sensitivity analyses were performed using mixed-effects models instead of GEE models and both
observed and updated measurements of exposure instead of cumulative averages. Missing values of
dietary variables and weight were imputed using multilevel multiple imputation in the GEE model
with body weight as the continuous outcome. Data were assumed to be MAR (missing at random) and
m = 20 datasets were created using multivariate normal (MVN) as the imputation algorithm [29].
All statistical analyses were performed using STATA/SE V.12.1 (StataCorp, College Station, TX,
USA) and p-values < 0.05 were considered statistically significant.
3. Results
3.1. Baseline Characteristics
The population available for the analyses consisted of 6942 participants with a mean age of 67
(SD: 6) years and of which a proportion of 47% was obese at baseline. Table 1 shows the baseline
characteristics of participants. Mean total fat intake was 30.5% of total energy intake (EN%) in the
lowest quintile versus 50.6 EN% in the highest.
3.2. Substitution of Fat Subtypes
3.2.1. Body Weight Differences
The results of GEE substitution models presented in Table 2 show the predicted effects of replacing
5% of energy from a specific fat subtype for 5 EN% of another fat subtype, proteins or carbohydrates.
The results suggested consuming PUFA is associated with a significant weight difference when
replacing SFA (mean change −0.51 kg; 95% confidence interval (CI): −0.81, −0.20), proteins (−0.27 kg;
95% CI: −0.49, −0.04) or carbohydrates (−0.20 kg; 95% CI: −0.37, −0.02). Additionally, isocaloric
substitution of 5 EN% of SFA with MUFA was inversely associated with body weight (−0.38, 95% CI:
−0.69, −0.07). Increasing SFA at the expense of carbohydrates was found to be directly associated
with body weight (0.31 kg; 95% CI: 0.06, 0.56).
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Table 1. Participant characteristics according to extreme quintiles of total fat (in EN%) at baseline 1.
Q1 Q5
Participants, n 1391 1387
Age (year) 67 (6) 67 (6)
Women (%) 53.9 62.5
Control group (%) 35.6 32.2
Physical activity (MET-min/week) 249 (259) 216 (226)
Smoking habit: Never smoker (%) 61.0 64.4
Smoking habit: Former smoker (%) 24.4 22.4
Smoking habit: Current smoker (%) 14.6 13.2
Marital status: Married (%) 75.0 76.5
Marital status: Single/widowed (%) 25.0 23.5
Educational level: Lower than high school (%) 80.5 75.3
Educational level: High school (%) 11.9 17.7
Educational level: University (%) 7.6 7.0
Employment status: Employed/housewife 41.6 51.8
Employment status: Unemployed (%) 3.5 3.5
Employment status: Retired (%) 54.9 44.7
Total energy intake (kcal/day) 2262 (573) 2163 (513)
Carbohydrates (EN%) 51.6 (5.8) 35.1 (4.5)
Protein (EN%) 17.4 (3.1) 16.7 (2.8)
Total fat (EN%) 27.7 (3.2) 46.5 (3.7)
MUFAs (EN%) 14.4 (2.4) 26.3 (3.4)
PUFAs (EN%) 5.0 (1.6) 7.9 (2.4)
SFAs (EN%) 8.1 (1.7) 12.1 (2.1)
trans fat (EN%) 0.18 (0.12) 0.28 (0.17)
Alcohol (g/day) 11.2 (18.7) 5.1 (9.2)
Dietary fiber (g/day) 28.9 (10.1) 21.7 (6.6)
1 Q, quintile; MET, metabolic equivalent task; EN%, energy as a proportion of total energy intake. Data are mean
(SD) unless otherwise stated.
Table 2. Estimated mean changes (95% confidence interval) 1 in body weight (kg) after isocaloric
substitutions of 5% energy from MUFA, PUFA, and SFA, proteins, and carbohydrates.
Substitution ↑MUFA ↑PUFA ↑SFA
↓PUFA 0.13 (−0.09, 0.34) - -
↓SFA −0.38 (−0.69, −0.07) * −0.51 (−0.81, −0.20) * -
↓proteins −0.14 (−0.30, 0.02) −0.27 (−0.49, −0.04) * 0.24 (−0.08, 0.56)
↓carbohydrates −0.07 (−0.17, 0.03) −0.20 (−0.37, −0.02) * 0.31 (0.06, 0.56) *
1 Adjusted for age, sex, baseline weight, recruitment center, intervention group, cumulative average of total
energy intake, BMI, leisure-time physical activity (metabolic equivalent task in min/day), smoking status
(never, former, current smoker), educational level (primary education, high school, university), working status
(employed, unemployed, housewife, retired), and marital status (single, married). * p < 0.05. ↑ means increases,
↓ means decreases.
3.2.2. Obesity Incidence and Reversion, Substantial Weight Gain and Loss
In a total number of 3700 initially non-obese participants, 657 incident cases of obesity were
observed during follow-up. Table 3 shows the results of the logistic GEE investigating the association
between nutrient substitution and 2 dichotomous outcomes: Obesity incidence and substantial weight
gain (≥10%).
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Table 3. Estimated odds ratios (95% confidence interval) 1 for incidence of obesity and substantial
weight gain (≥10%) after isocaloric substitution of 5% energy from MUFA, PUFA, and SFA, proteins,
and carbohydrates.
Substitution Obesity Incidence Weight Gain (≥10%)
↑MUFA, ↓PUFA 1.36 (1.02, 1.81) * 1.16 (0.82, 1.65)
↑MUFA, ↓SFA 1.04 (0.69, 1.56) 1.11 (0.71, 1.65)
↑MUFA, ↓Proteins 0.85 (0.69, 1.03) 0.82 (0.66, 1.02)
↑MUFA, ↓Carbohydrates 1.08 (0.95, 1.23) 1.02 (0.87, 1.18)
↑PUFA, ↓SFA 0.77 (0.51, 1.15) 0.96 (0.62, 1.47)
↑PUFA, ↓Proteins 0.62 (0.47, 0.83) * 0.70 (0.50, 0.99) *
↑PUFA, ↓Carbohydrates 0.80 (0.63, 1.01) 0.87 (0.67, 1.15)
↑SFA, ↓Proteins 0.81 (0.53, 1.24) 0.73 (0.46, 1.17)
↑SFA, ↓Carbohydrates 1.04 (0.75, 1.24) 0.91 (0.63, 1.31)
1 Adjusted for age, sex, baseline weight, recruitment center, intervention group, cumulative average of total
energy intake, BMI, leisure-time physical activity (metabolic equivalent task in min/day), smoking status (never,
former, current smoker), educational level (primary education, high school, university), working status (employed,
unemployed, housewife, retired), and marital status (single, married). * p < 0.05.
Replacing 5 EN% of proteins with 5 EN% of PUFA decreased the odds of obesity incidence (OR:
0.62, 95% CI: 0.47, 0.83) and ≥10% weight gain (OR: 0.70, 95% CI: 0.50, 0.99). The odds ratio (95% CI)
for obesity incidence was 1.36 (1.02, 1.81) when 5 EN% of PUFA was replaced by MUFA. Reversion
of obesity occurred 819 times within the 3242 participants who were obese at baseline. Note that in
Figure 1 an odds ratio (OR) >1 indicates increased odds of reversion of obesity or weight loss (≥10%),
so desirable changes.
Figure 1. Estimated odds ratios (95% confidence interval) for reversion of obesity (grey squares) and
substantial weight loss (≥10%, black diamonds) after isocaloric substitution of 5% energy from MUFA,
PUFA, and SFA, proteins (Prot), and carbohydrates (CHO). Adjusted for the same confounders as the
analyses in Table 3.
Replacing SFA with PUFA significantly increased the odds of the reversion of obesity (OR: 1.57,
95% CI: 1.09, 2.25) and substantial weight loss (OR: 1.58, 95% CI: 1.09, 2.28). Slightly less strong but
significant associations were found for the odds of substantial weight loss when PUFA intake was
increased at the expense of proteins (OR: 1.44, 95% CI: 1.12, 1.86) or carbohydrates (OR: 1.29, 95%
CI: 1.06, 1.57). Increasing MUFA at the expense of PUFA resulted in an OR of 0.78 (0.61, 1.00) for a
169
Nutrients 2018, 10, 2011
≥10% weight loss. As a summary, all significant results in Table 3 and Figure 1 advocate for a higher
PUFA intake.
3.3. Substitution of Food Items
The estimated effects of non-isocaloric food item substitutions on body weight are shown in
Table 4. Significant weight difference estimates were observed when daily replacing a 100 g portion of
red meat with white meat (−0.64 kg, 95% CI: −0.94, −0.35), oily fish (−0.75 kg, 95% CI: −1.13, −0.38)
or white fish (−0.87 kg, 95% CI −1.17, −0.56).
Table 4. Estimated mean changes in body weight (kg) (95% confidence interval) 1 after substitution of
one daily portion of high-fat food items in the MeDiet for a priori healthier options.
Substitution Mean Body Weight (kg) Difference (95% Confidence Interval)
↓Red meat, ↑White meat −0.64 (−0.94, −0.35) *
↓Red meat, ↑Oily fish −0.75 (−1.13, −0.38) *
↓Red meat, ↑White fish −0.87 (−1.17, −0.56) *
↓Butter, ↑Olive oil −0.25 (−0.56, 0.06)
↓Butter, ↑Other vegetable oils −0.11 (−0.44, 0.22)
↓Margarine, ↑Olive oil 0.04 (−0.18, 0.25)
↓Margarine, ↑Other vegetable oils 0.26 (0.02, 0.50) *
↓Mixed nuts, ↑Walnuts −0.15 (−0.61, 0.32)
1 Substitutions of a portion of 100, 10 and 30 g for meat/fish, butter/margarine/oils, and nuts, respectively. Adjusted
for age, sex, baseline weight, recruitment center, intervention group, cumulative average of total energy intake,
BMI, leisure-time physical activity (metabolic equivalent task in min/day), smoking status (never, former, current
smoker), educational level (primary education, high school, university), working status (employed, unemployed,
housewife, retired), and marital status (single, married). * p < 0.05. ↑ means increases, ↓ means decreases.
Replacing a 10 g portion of margarine with vegetable oils other than olive oil resulted in a
significant estimate, suggesting a weight gain of 0.26 kg (95% CI: 0.02, 0.50). No significant associations
were observed for the replacement of butter and margarine with olive oil or replacing 30 g of mixed
nuts with an equivalent portion of walnuts.
Estimates of nutrient substitutions for continuous outcomes were consistent when using
mixed-effects models with random intercepts for recruitment center and identity level. Mixed-effects
models are a little more conservative, however, thus showing wider confidence intervals (data not
shown).
4. Discussion
The results of this prospective study suggest that increasing the intake of unsaturated fatty acids
(especially PUFA) at the expense of SFA, proteins, and carbohydrates may have beneficial effects on
body weight and obesity. Reversing obesity seems to be especially successful when replacing SFA with
PUFA, and replacing proteins with PUFA lowers the risk of becoming obese in the first place. Increasing
MUFA at the expense of PUFA, on the other hand, shows a significantly increased risk of becoming
obese. These findings are in line with previous research [30], although there is still controversy [31].
Most prior research on the association between dietary fat and overweight/obesity merely considered
total fat intake or the MeDiet as a whole. Evidence from 53 randomized controlled trials summarized in
a systematic review and meta-analysis did not support low-fat diets over other dietary interventions for
long-term weight loss, when compared with dietary interventions of similar intensity [15]. A systematic
review of 5 RCTs found the MeDiet resulted in greater weight loss than low-fat diet at ≥12 months but
produced results similar to other comparator diets, like a low-carbohydrate diet [14]. These results are
in line with an earlier meta-analysis [13]. Although the results of the included studies were inconsistent
and the meta-analyses reported significant heterogeneity, the evidence ultimately points towards a
role of a high-quality, moderately high-fat diet like the MeDiet in the prevention of overweight and
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obesity. Results of the PREDIMED trial supported that the intervention did not have a differential
effect on body weight compared to the control group [32].
One prospective study in a Spanish sample of the EPIC (European Prospective Investigation into
Cancer and Nutrition) study further focused on dietary fat subtypes and concluded that the association
between consumption of specific types of dietary fat, olive oil, and obesity in Spain was not very
important [33]. However, the design of the study was cross-sectional. Ten years later, the results of the
EPIC–PANACEA study showed the MeDiet may prevent weight gain and the development of obesity.
Unfortunately, this study did not distinguish between types of fat [34].
Previous PREDIMED studies showed a protective effect of MeDiet interventions supplemented
by olive oil or nuts and of dairy consumption [35,36]. Moreover, extensive evidence was found that
nut consumption does not increase body weight and obesity incidence and may even be inversely
associated with these outcomes [17,37,38]. Most nuts are especially high in MUFA, whereas walnuts
are rich in PUFA. Adherence to the MeDiet in general has also been shown to be directly associated
with fulfilling nutrient recommendations [39,40].
Another important finding of our study, in the context of substitution models, is that reductions
in red meat consumption coupled with respective increases in white meat or fish would lead to less
weight gain. This is important because it represents a translation of fat substitution models into food
item replacement models and it generates a comprehensible and easily understandable message for
the population. This is in accordance with the concept of the MeDiet, which fosters the preference for
white meat consumption over red meat and includes regular fish consumption. It is also important to
focus on specific food groups or items, since different foods rich in a specific fat subtype may have
different effects on body weight [41].
The satiating effect of the MeDiet may explain some beneficial effects on body weight, especially
in a longer term. Furthermore, evidence shows mono- and polyunsaturated fatty acids are more readily
oxidized than saturated fatty acids and have a greater thermogenic effect, which can lead to reduced fat
accumulation [42]. The quantity and quality of dietary fat have also been shown to induce differential
lipid storage and processing gene expression, influencing adipokines release, but this process and
regulation is still only partially understood [43]. Adherence to MeDiet may also be inversely correlated
with proinflammatory biomarkers [44], and another potential important mechanism is the influence
on adipose tissue metabolism and secretory functions [45].
The major strengths of the present research include its prospective design, large sample size,
and repeated measurements of exposure, outcomes, and confounders over a long follow-up period.
Due to comprehensive data records, most relevant confounders could be controlled for. Nevertheless,
residual confounding is possible. Genetic determinants for instance may influence measures of
obesity and were not available in the dataset [46]. Systematic error may be present due to the large
proportion of obese individuals, known to have a tendency to underestimate their dietary intakes
(in particular total energy intake) and overestimate physical activity; however, this error will probably
be nondifferential [47]. Furthermore, well-known measurement errors as a result of methodological
issues in the memory-based assessment of dietary factors and physical activity may bias the results.
The study of waist circumference as a potential outcome measure was also considered and would
shine light on the matter, but the risk of substantial measurement error, especially in overweight
and obese participants [48], makes it worthy of special attention and more complex analyses are
warranted, so we decided not to include it in this manuscript for the sake of simplicity. Both the
FFQ and physical activity questionnaire have been validated, however [22,23,27,28]. Energy-adjusted
intraclass correlation coefficients for MUFAs, PUFAs, and SFAs in four 3-day dietary records and the
FFQ were 0.61, 0.60, and 0.75, respectively [22]. Analyses of trans fatty acids were considered. Intake
of this fat subtype was very low in this study, however (0.47 ± 0.13 EN%); thus, these investigations
may be more effective in a different population.
This study cannot fully demonstrate causality of the observed associations. Obesity and body
weight may be susceptible to reverse causation in the sense that once their body changes, participants
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adjust their eating habits [49]. The use of a generalized estimating equation was chosen for all of the
analyses. An alternative could have been multilevel mixed-effects models. Both GEE and mixed-effect
methods are appropriate for longitudinal data as they account for within-subject correlations occurring
as a result of repeated measurements, but GEE models are more flexible. For linear regression models
with continuous outcomes, the random effects assumption is equivalent to an exchangeable correlation
structure in GEE [50]. The sensitivity analyses confirmed this as estimates were very similar, though the
outcomes of the mixed-effects models were more conservative with wider confidence intervals. Models
assessing the effect of actual changes in diet on changes in weight may lead to more interpretable
results and better conclusions [41].
Although a lot of effort was put into collecting complete data, missing data are unavoidable in
longitudinal studies. Throughout the years, this problem has been well documented and a range
of solutions have been proposed [29]. In this case, multiple imputation was used only for the GEE
model with body weight as a continuous outcome, to verify that the results obtained by complete
case analyses with covariate adjustment were indeed unbiased. Multiple imputation is flexible when
it comes to assumptions regarding the randomness of the missing data, which makes it suitable for
sensitivity analyses in the case of MNAR scenarios. Complete case analysis was used for further
analyses as the results were similar and this method is less time-consuming, more transparent, and at
least as efficient as multiple imputation [29].
The population of this study consisted of older participants at high risk of cardiovascular disease
and (almost all) overweight or obese at baseline, which may affect the generalizability of the findings.
The number of subjects was, however, very large, and subjects came from different social levels
and geographical areas and biological mechanisms will be similar in other populations. Moreover,
mean total fat intake represented 40.5% of the total energy intake in this study population, which is
comparable to the intake observed in a pooled analysis of studies across Spain [51]. Mean intakes of
fat subtypes were slightly more desirable than intakes measured previously in Spain: MUFA 20.2 in
the present study versus 15.9 EN%, PUFA 6.5 versus 5.6 EN% and SFA 10.3 versus 12.0 EN%.
Lastly, body weight was a secondary outcome in the PREDIMED trial. Neither energy restriction
nor increased physical activity were advised for any treatment arm, as the intervention was not
designed with the intention of causing weight loss. It should also be noted that one diet does not fit
all, and weight control strategies should be based on personal goals. The MeDiet could, however,
be a useful method to achieve personal goals, due to its high palatability and satiating effects and,
therefore, better adherence [46]. Integrating energy restriction and increased physical activity could
further enhance weight loss and health benefits [38]. Currently, data are being collected for the
PREDIMED-Plus trial, including an intensive lifestyle intervention program with an energy-restricted
MeDiet, increased physical activity, and behavioral treatment.
5. Conclusions
In conclusion, this study provides evidence that increasing MUFA and PUFA intakes at the
expense of SFA, proteins, and carbohydrate intakes may contribute to losing weight and reverse
the state of obesity in an older and overweight/obese Spanish population. It could therefore be
recommendable to encourage a high-quality, moderately high-fat eating pattern like the MeDiet, which
means increasing the quality of dietary fat instead of restricting total fat intake in the prevention
of obesity.
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Abstract: Background: The prognostic value of erythrocyte levels of n-6 fatty acids (FAs) for total
mortality and cardiovascular disease (CVD) outcomes remains an open question. Methods: We
examined cardiovascular (CV) outcomes and death in 2500 individuals in the Framingham Heart
Study Offspring cohort without prevalent CVD (mean age 66 years, 57% women) as a function of
baseline levels of different length n-6 FAs (18 carbon, 20 carbon, and 22 carbon) in the erythrocyte
membranes. Clinical outcomes were monitored for up to 9.5 years (median follow up, 7.26 years).
Cox proportional hazards models were adjusted for a variety of demographic characteristics, clinical
status, and red blood cell (RBC) n-6 and long chain n-3 FA content. Results: There were 245 CV
events, 119 coronary heart disease (CHD) events, 105 ischemic strokes, 58 CVD deaths, and 350 deaths
from all causes. Few associations between either mortality or CVD outcomes were observed for
n-6 FAs, with those that were observed becoming non-significant after adjusting for n-3 FA levels.
Conclusions: Higher circulating levels of marine n-3 FA levels are associated with reduced risk for
incident CVD and ischemic stroke and for death from CHD and all-causes; however, in the same
sample little evidence exists for association with n-6 FAs. Further work is needed to identify a full
profile of FAs associated with cardiovascular risk and mortality.
Keywords: epidemiology; prospective cohort study; n-6 fatty acids; n-3 fatty acids; linoleic acid;
arachidonic acid
1. Introduction
The roles of n-3 and/or n-6 polyunsaturated fatty acids (PUFAs) in health and disease are
controversial. Whereas most studies have reported that higher circulating levels of the long-chain
n-3 PUFAs (i.e., eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) are protective against
cardiovascular disease (CVD) and premature death [1], the story is not as clear for the n-6 PUFAs.
Previous studies have reported that higher intakes of linoleic acid (LA) and higher circulating levels
of arachidonic acid (AA) are associated with cardiovascular (CV) benefit [1,2]. In addition, LA blood
levels are inversely associated with risk for type 2 diabetes mellitus [3]. Nevertheless, some warn
Nutrients 2018, 10, 2012; doi:10.3390/nu10122012 www.mdpi.com/journal/nutrients177
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that current intakes (and thus blood levels) of the n-6 PUFAs, especially these two major fatty acids
(FAs) in the n-6 family, are dangerous [4,5]. The proposed mechanism of harm is via increased
inflammation, driven by the conversion of AA into pro-inflammatory/pro-thrombotic eicosanoids
such as prostaglandin E2, thromboxane A2, and leukotriene B4 [6]. Accordingly, ratios like n-6:n-3 [7]
or AA:EPA [8] have been promoted as better summary metrics of PUFA status than either family alone.
This perspective has, however, been criticized on both theoretical [9–12] and evidential [13–15] bases.
In a previous report from the Framingham Offspring cohort, we examined relations between red
blood cell (RBC) n-3 FAs, specifically EPA and DHA (the sum of which is called the omega-3 index [16])
and risk for CVD and total mortality [17]. In this follow-up analyses, we focus on the n-6 FA family
and their relations with these outcomes.
2. Materials and Methods
2.1. Methods
The Framingham Heart Study is a longitudinal community-based cohort study that was initiated
in 1948. The selection criteria for the Framingham Offspring Cohort and the Framingham Omni Cohort
have previously been described [18,19]. Briefly, adult children of the original cohort were recruited
in 1971 into the Framingham Offspring Cohort. We evaluated Framingham Offspring participants
(n = 3021) who attended their eighth examination cycle (2005–2008). Participants were excluded in
hierarchical order if they were missing RBC fatty acid measurements or clinical covariates (n = 122),
or having prevalent cardiovascular disease (e.g., nonfatal coronary heart disease (CHD) or stroke;
n = 350), leaving n = 2500 for this analysis. The study protocol was approved by the Institutional Review
Board of the Boston University Medical Center. Informed consent was provided by all participants.
2.2. Covariates and Mortality Outcomes
We considered seventeen primary baseline demographic and cardiovascular risk covariates: sex,
age, body mass index (BMI), marital status, education level, employment status, health insurance
status, regular aspirin use, prevalent hypertensive status, use of cholesterol medication, prevalent
diabetes, alcohol consumption, smoking status, metabolic equivalent (METS), total to high-density
lipoprotein (HDL) cholesterol ratio, systolic blood pressure and C-reactive protein. Seven endpoints
were examined: four mortality-related outcomes ((1) any mortality, (2) CVD mortality (CHD death or
sudden cardiac death), (3) cancer mortality, or (4) death from non-CVD or cancer causes) and three
cardio-vascular related outcomes ((1) total stroke (any fatal or non-fatal ischemic stroke), (2) total CHD
(fatal or non-fatal myocardial infarction (MI), or CHD death or sudden cardiac death), and (3) total
CVD (any stroke, CHD or CHD mortality)). We focused our analyses on seven RBC FAs from the
n-6 family: 18:2n6 (linoleic acid, LA), 18:3n6 (gamma-linolenic acid, GLA), 20:2n6 (eicosadienoic acid,
EDA), 20:3n6 (dihomo-gamma linolenic acid, DGLA), 20:4n6 (arachidonic acid, AA), 22:4n6 (adrenic
acid, ADA) and 22:5n6 (docosapentaenoic acid, DPA n-6). In some analyses, we adjusted for the
omega-3 index (EPA + DHA).
2.3. RBC Fatty Acid Analysis
Blood was drawn after a 10–12 h fast into an EDTA tube, and RBCs were separated from plasma
by centrifugation. The RBC fraction was frozen at −80 ◦C immediately after collection. RBC fatty acid
composition was determined as described previously [20]. Briefly, RBCs were incubated at 100 ◦C with
boron trifluoride-methanol and hexane to generate fatty acid methyl esters that were then analyzed by
gas chromatography with flame ionization detection. The coefficients of variation for the seven n-6
FAs measured were <3% for 18:2n6, 20:3n6, 20:4n6, and 22:4n6; 7% for 22:5n6; 11% for 20:2n6 and 21%
for 18:3n6.
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2.4. Statistical Analysis
Description of sample characteristics was conducted using standard statistical metrics (e.g., means,
SDs, correlations). Hazard ratios were estimated using the survival package in R [21]. Primary analyses
predicted incident clinical outcomes (date of event (CVD or death) or date of censoring) by groups
of n-6 FAs (the 18-carbon, 20-carbon, and 22-carbon moities), with follow-up analyses adjusting for a
variety of demographic covariates, and finally for the omega-3 index. Secondary analyses explored the
relationship between event risk and n-6 FA levels by quintiles, individual omega-6 FA levels, and the
sum of all omega-6 FAs. All analyses used two-sided tests at the 0.05 significance level.
3. Results
3.1. Cohort Description
The Framingham Offspring study consists of 2500 individuals for whom FAs, clinical outcomes,
and demographic covariates were available, and who also did not have prevalent CVD at baseline.
At baseline, the average age was 66 and the sample contained slightly more females (57%) than males
(43%). The sample was fairly well educated (over two-thirds of the sample had at least some college
education), with approximately half of the sample employed and the majority of the remainder having
retired. Most (88%) of the sample had insurance at baseline and the distribution of cardiometabolic
traits followed expected distributions, with approximately 40% of the sample using aspirin regularly,
with similar numbers with prevalent hypertension, and high cholesterol. Rates of prevalent diabetes
was lower (13%). The majority of the sample periodically consumed alcohol, and the vast majority
(over 90%) were nonsmokers. Table 1 provides a complete overview of the demographic profile of the
sample. Supplemental Table S1 illustrates the correlation between and among the major n-3 and n-6
fatty acids in this sample. While correlations are generally higher within the n-3 or n-6 fatty acids than
between, this is not always the case (e.g., moderate negative correlations between both 20:2n6, 20:3n6,
and 20:4n6 levels). Supplemental Table S2 illustrates the number of events present in the sample with
350 of the participants having died from any cause during the course of the study, but only 58 of those
deaths were attributable to CVD. The maximum time to follow-up was approximately 9 years.
3.2. Omega-6 Fatty Acids and Mortality and Cardiovascular Disease Risk
Across all three classes of n-6 FAs (18-carbon, 20-carbon and 22-carbon) little evidence of
association with cardiovascular outcomes or mortality was observed. In unadjusted analyses,
the 18-carbon n-6′s showed an association with reduced risk of CVD and other (non-CVD, non-cancer)
mortality, however, these associations became non-significant after adjusting for demographic variables
(Table 2a). No associations were detected before or after evaluating 20-carbon n-6s (Table 2b).
While 22-carbon n-6′s showed some evidence of positive association with Total CVD, CHD, and
stroke risk after adjusting for demographic covariates, all of these associations became non-significant
after also adjusting for the omega-3 index (Table 2c). Notably, the omega-3 index remained significant
in many of the models for CVD event risk and CVD, non-cancer/non-CVD and all-cause mortality
(Table 2a–c; Figure 1).
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(n = 2150) Total
p-Value for Difference
(Chi-Squared or t-Test)
% (n) or Mean (SD) % (n) or Mean (SD) % (n) or Mean (SD)
Sex
Male 52.9% (185) 41.5% (893) 43.1% (1078)
<0.001Female 47.1% (165) 58.5% (1257) 56.9% (1422)
Age 72.9 (8.6) 64.4 (8.2) 65.56 (8.76) <0.001
Body Mass Index (BMI) 27.9 (5.9) 28.3 (5.4) 28.2 (5.4) <0.001
Marital Status
Single/Never Married 4.3% (15) 6.7% (144) 6.4% (159)
<0.001
Married 63.7% (223) 70.7% (1519) 69.7% (1742)
Separated/Divorced 12.0% (42) 12.7% (273) 12.6% (315)
Widowed 18.3% (64) 9.4% (203) 10.7% (267)
Education
Some High School (HS) or less 6.0% (21) 2.4% (51) 2.9% (72)
<0.001
HS graduate 33.7% (118) 24.8% (533) 26.0% (651)
Some college or vocational 22.9% (78) 21.9% (471) 22.0% (549)
College graduate 36.6% (128) 50.5% (1086) 48.6% (1214)
Employment
Employed 31.1% (109) 56.3% (1210) 52.8% (1319)
<0.001Disabled/unemployed 3.1% (11) 2.5% 53) 2.6% (64)
Retired 64.3% (225) 40.8% (877) 44.1% (1102)
Health insurance status
No insurance 2.3% (8) 1.9% (40) 1.9% (48)
0.053Insurance, but no prescription 11.4% (40) 8.4% (181) 8.8% (221)
Full insurance 84.0% (294) 88.7% (1906) 88.0% (2200)
Regular aspirin use 49.7% (174) 38.6% (830) 40.2% (1004) <0.001
Prevalent hypertension 57.1% (200) 42.2% (908) 44.3% (1108) <0.001
Cholesterol medication 41.4% (145) 36.9% (794) 37.6% (939) 0.06
Prevalent diabetes 22.3% (78) 11.6% (249) 13.1% (327) <0.001
Alcohol consumption
None 34.0% (119) 23.2% (499) 24.7% (618)
<0.001
<1 drink/day 36.0% (126) 50.7% (1089) 48.6% (1215)
1–2 drinks/day 22.6% (79) 20.2% (434) 20.5% (513)
>2 drinks/day 6.9% (24) 5.7% (123) 5.9% (147)
Smoking
Not current smoker 89.1% (312) 90.5% (1946) 90.3% (2258)
0.70Current 10.6% (37) 9.3% (200) 9.5% (237)




3.5 (1.1) 3.5 (1.0) 3.5 (1.1) <0.001
Systolic Blood Pressure 133.6 (19.8) 128.2 (16.9) 129.0 (17.4) <0.001
C-reactive protein 4.9 (12.7) 3.0 (6.1) 3.3 (7.4) <0.001
Omega-3 index 0.054 (0.017) 0.056 (0.017) 0.0554 (0.0168) <0.001
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3.3. Additional Fatty Acid Analyses
Supplemental Table S3a–g illustrate parallel analyses for each of the seven individual n-6 FAs.
In short, these analyses follow what was observed for the classes of FAs. Namely, few associations
were observed between the individual FAs and either cardiovascular events or mortality and what
few associations were observed in unadjusted models tended to become non-significant in models
that adjusted for demographic covariates. One exception was the positive association between ESA
(C20:2n6) and all-cause mortality, a relationship which remained even after adjusting for the omega-3
index (Table S3c). Other exceptions were the positive associations between DTA (C22:4n6) and stroke,
and the positive associations between DPA (C22:5n6) and all-cause mortality and non-CVD/non-cancer
mortality, though these associations all became non-significant after adjusting for the omega-3 index
(Table S3f–g). An analysis on the sum of all seven omega-6 FAs identified no significant associations
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(b) 
Figure 1. (a) Hazard ratios for total cardiovascular (CVD) risk by n-6 FAs and the omega-3 index.
Figure 1a illustrates the associations between n-6 or n-3 fatty acids and total CVD risk. Bar heights
are hazard ratios with 95% confidence intervals provided for each hazard ratio. Hazard ratios are
provided for each quintile are all relative to the risk within the lowest quintile. Statistically significant
HRs at the 0.05 level are denoted with asterisks. Hazard ratios depicted in this figure are from models
adjusting for all demographic variables in Table 1, but do not adjust for the omega-3 index and/or
other omega-6 FAs. There is no significant linear trend for the 18-carbon n-6 FAs (p = 0.68) or the
20-carbon n-6 FAs (p = 0.52), while the 22-carbon n-6 FAs (p = 0.031) and the omega-3 index (p = 0.008)
both have significant linear trends across the 5 quintile groups (see Table 2a–c for additional details).
Finally, we note that, as shown in Table 2c, both linear associations as well as all individual quintile
group associations become non-significant (p > 0.05) for both the omega-3 index and 22 carbon n-6 FAs
when both are simultaneously entered into the statistical model. (b) Hazard ratios for total mortality
(CVD) risk by n-6 FAs and the omega-3 index. Figure 1b illustrates the associations between n-6 or n-3
fatty acids and Total mortality. Bar heights are hazard ratios with 95% confidence intervals provided
for each hazard ratio. Hazard ratios are provided for each quintile are all relative to the risk within the
lowest quintile. Statistically significant HRs at the 0.05 level are denoted with asterisks. Hazard ratios
depicted in this figure are from models adjusting for all demographic variables in Table 1, but do not
adjust for the omega-3 index and/or other omega-6 FAs. There is no significant linear trend for the 18
carbon n-6 FAs (p = 0.69), the 20 carbon n-6 FAs (p = 0.16) and the 22 carbon n-6 FAs (p = 0.32), while,
the omega-3 index (p = 0.02) has a significant linear trend across the 5 quintile groups. Finally, we
note that, as shown in Table 2c, linear associations as well as all individual quintile group associations
become non-significant (p > 0.05) for all n-6 fatty acids when adjusting for the omega-3 index, while the
omega-3 index remains significant (p < 0.05) in all models.
4. Discussion
In this study of participants in the Framingham Offspring study, the n-6 PUFAs were generally
unrelated with vital status, especially in fully adjusted models accounting for subject characteristics
and the omega-3 index. The only exception was for EDA which was directly related with risk all-cause
mortality. The omega-3 index was inversely associated with most of the outcomes examined here
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even after adjustment for the n-6 FAs, whether in the full aggregate, the carbon-chain groups, or the
individual n-6 FAs.
Delgado et al. recently reported the relations between red blood cell (RBC) n-6 FA levels and
risk for death from all causes [22]. Using data from 3259 patients undergoing diagnostic coronary
artery catheterization and followed for 10 years, these investigators found that RBC levels of n-6 FAs
were inversely related with risk for death. However, a more granular examination revealed widely
varying associations with n-6 FAs depending on chain length. The 18-carbon species (LA and GLA)
were inversely associated with death, those with 20 carbons (AA and DGLA) were largely unrelated
with risk, and those with 22 carbons (ADA and DPAn-6) were directly related with risk. A case-control
study using RBC FA profiles from acute coronary syndrome patients found that a suite of 10 RBC
FAs was able to predict case status better than the classical risk factors included in the Framingham
Risk Score [23]. In that study, LA, AA, and GLA were predictors of lower risk for coronary disease,
whereas EDA was associated with higher risk. In yet another study, RBC both EPA and DPAn-6 added
independent predictive power to a standard algorithm used to predict risk for death in post myocardial
infarction patients [24]. All of these studies suggest that n-6 FAs are not all created equal, and that
to speak of them as a monolithic class of FAs with similar biochemical functions and physiological
roles is probably incorrect. In this study, we further illustrated a widely varying correlation structure
between n-3 FAs and n-6 FAs, as well as within the n-6 FAs, further supporting the argument that not
each n-6 FA may have its own unique role to play in metabolism. However, one important trend worth
noting is that, for 22 carbon FAs, associations with cardiovascular outcomes which were significant
even after adjusting for demographic variables, became non-significant after adjusting for n-3 FAs.
In these models (Table2c, fully adjusted model), n-3 FAs were significant, suggesting that the initial
n-6 associations with cardiovascular outcomes were better explained by variation in n-3 FAs. Further
work is needed to better understand the role of the full profile of fatty acids on disease risk.
The EDA finding in the present study was somewhat unexpected. EDA levels were adversely
associated risk for acute coronary syndromes in a case-control study from Kansas City [23]. On the
other hand, serum EDA levels were recently reported to be reduced in patients with inflammatory
bowel disease [25], and in a large prospective study of plasma phospholipid FAs and risk for type 2
diabetes, EDA was inversely associated with incident disease [26]. These findings—along with those
of the present study—would suggest that EDA participates in some manner in pathophysiology of
these conditions. EDA is an elongation product of LA (C18 to C20, both with 2 double bonds), and on
the biosynthetic path to DGLA and AA. These latter two n-6 FAs serve as substrates for the production
of a wide variety of active metabolites called oxylipins [27], but whether the beneficial/harmful effects
of EDA (if they indeed exist) are mediated by oxylipin metabolism is unknown. Complicating these
inconsistent observations is the fact that levels of EDA in these subjects were very low, averaging only
about 0.25% of total RBC FAs. Consequently, the ultimate meaning and impact of EDA in biology
is unclear.
Strengths and Limitations
Strengths of this study include the large sample size and number of events, the unambiguous
nature of the primary endpoint, the inclusion of community dwellers (instead of a patient population),
and the use of an objective biomarker of PUFA exposure with low biological variability [28].
The previous detection of clear inverse relations between the omega-3 index and outcomes in this same
cohort suggests that our failure to see associations with the n-6 FAs was not due to a lack of power,
but a lack of effect. The assessment of PUFA exposure at only one time point cannot capture PUFA
status changes throughout follow-up. Finally, the inability to rule out the possibility of residual or
unmeasured confounding also precludes inferences about causality [29].
In conclusion, we found no meaningful relationship between RBC levels of n-6 PUFAs and risk
for CVD or total mortality. Importantly, after adjustment for covariates, there was no increase in risk
for adverse outcomes with higher n-6 PUFA levels, with the possible exception of EDA. These findings,
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in the context of the totality of available evidence on this subject, provide no support for a harmful
role of n-6 PUFAs in these important clinical outcomes.
5. Conclusions
Higher circulating levels of marine n-3 FA levels are associated with reduced risk for incident
CVD and ischemic stroke and for death from CHD and all-causes; however, in the same sample little
evidence exists for association with n-6 FAs. Further work is needed to identify a full profile of FAs
associated with cardiovascular risk and mortality.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/10/12/2012/
s1, Table S1: Correlation between and among red blood cell n-3 and n-6 fatty acids, Table S2: Distribution of
outcomes (n = 2500), Table S3: Risk of events and mortality by individual n-6 fatty acids (n = 2500), Table S3a:
Linoleic Acid—Unadjusted, Adjusted for demographics (Table 1 variables), and further adjusted for the Omega-3
Index (5-groups), Table S3b: Gamma-linolenic Acid, Table S3c: Eicosadienoic Acid, Table S3d: Eicosatrienoic Acid,
Table S3e: Arachidonic Acid, Table S3f: Docosatetraenoic Acid, Table S3g: Docosapentaenoic Acid, Table S3h: n6
index (sum of all 7 n6’s).
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